A molecular analysis of the LPS resistance of the mouse species Mus spretus by Mahieu, Tina
        
 
Ghent University 
Faculty of Sciences 
Flanders Interuniversity Institute for Biotechnology 
Department for Molecular Biomedical Research 
Molecular Mouse Genetics Unit 
Academic year: 2005-2006 
 
 
 
 
A molecular analysis of the LPS resistance of the 
mouse species Mus spretus. 
 
 
 
Tina Mahieu 
 
 
 
Thesis submitted in partial fulfillment of the requirements for the degree of 
Doctor in Sciences: Biotechnology 
 
 
 
 
 
 
Promotor: Prof. Dr. Claude Libert 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted to fulfill the requirements for the degree of Doctor in Sciences: Biotechnology 
 
 
By Tina Mahieu 
Molecular Mouse Genetics Unit 
Department for Molecular Biomedical Research 
Flanders Interuniversity Institute for Biotechnology and Ghent University 
Technologiepark 927 
B-9052 Ghent 
 
 
Academic year: 2005-2006 
 
 
Promotor:    Prof. Dr. Claude Libert 
  Ghent University, Belgium 
 
 
 
Examination Committee: 
 
Chairman:   Prof. Dr. Anna Depicker 
 Ghent University, Belgium 
 
 
Reading committee:     Prof. Dr. Claude Libert      
  Ghent University, Belgium 
 
 Prof. Dr. Johan Grooten 
 Ghent University, Belgium 
 
 Prof. Dr. Rudi Beyaert 
 Ghent University, Belgium  
 
 Dr. Hilde Revets 
 Ablynx, NV, Belgium 
 
 
Other members:  Dr. Jody Haigh 
 Ghent University, Belgium 
 
 Dr. Anja Cauwels 
 Ghent University, Belgium 
 
 Dr. Jan Staelens 
 Ghent University, Belgium 
 
 Prof. Dr. Georges Leclercq 
 Ghent University Hospital, Belgium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The research described in this thesis was performed at the Department for Molecular Biomedical 
Research, Faculty of Sciences, Ghent University and Flemish Institute for Biotechnology. This work was 
supported by the Institute for the Development of Science and Technology in Flanders (IWT). 
 
 
 
Cover illustration: LPS resistant (BxS)F1 mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DANKWOORD 
 
Oef, ik ben er bijna….Het heeft vele (lastige) uren, dagen, weken en maanden werk gevergd, maar 
uiteindelijk ben ik bijna klaar met het schrijven van dit boekje! Nu enkel wachten op inspiratie om dit 
dankwoord te schrijven. Maar echt veel langer kan ik het niet meer uitstellen, aangezien het 
morgenvroeg naar de drukker moet…. Vanzelfsprekend wil ik een heleboel mensen bedanken die mij 
gedurende de afgelopen jaren gesteund en geholpen hebben om dit werk tot een goed einde te 
brengen. Zonder hen zou ik er waarschijnlijk nooit in geslaagd zijn. Anyway, ik zal mijn best doen om 
niemand te vergeten! 
 
Uiteraard wil ik mijn promotor Prof. Dr. Libert speciaal bedanken omdat hij mij de kans gaf om, in de eerste 
plaats, een IWT-beurs aan te vragen op zijn labo. Ik was dan ook dolgelukkig toen ik, na bang afwachten, op het 
net zag verschijnen dat ik toch mijn IWT-beurs behaald had! Claude, bedankt voor vele kleine en grote dingen: je 
geduld, je goede begeleiding en de leerrijke vergaderingen, de tijd die je steeds voor me vrijmaakte, je motivatie 
(je slaagde er steeds weer in om mij toch weer in het project te doen laten geloven, ook toen ik niet meer zo 
optimistisch was) en zeker ook bedankt omdat je het helemaal niet erg vond om me ook praktisch te helpen bij 
experimentjes. Ik wil natuurlijk ook Prof. Dr. Van Roy bedanken omdat hij in het begin van mijn IWT-beurs het 
promotorschap van mijn doctoraat heeft opgenomen. 
 
Toen ik ongeveer 5,5 jaar geleden toekwam op het labo, en ik ergens op een minibureautje (toen nog in 
de Ledeganck) werd gedropt, heb ik met goede hulp van Wim mijn eerste stapjes in de wereld van de 
biotechnologie gezet. Dit smaakte naar meer en daardoor is dit doctoraat er ook gekomen! 
Wie ik zeker en vast niet mag vergeten in dit dankwoord is Dr. Jan Staelens. Hij heeft me o.a. wegwijs 
gemaakt in de wereld van het ‘mappen’. Ondanks het feit dat hij het zelf op sommige momenten heel 
druk had, kon ik hem altijd lastig vallen met onnozele en minder onnozele vragen (zelfs nadat hij naar 
de ‘andere kant’ van het gebouw gaan werken is), was hij bereid om mij met een experimentje te helpen 
of om samen op jacht te gaan achter een ontsnapte Spretus muis (wat niet altijd even simpel is)!  
 
Natuurlijk mag ik mijn collega’s van U9 niet vergeten… Gedurende de 5,5 jaar op het labo is de sfeer er 
jaar na jaar enkel nog leuker op geworden. Jullie hebben me elk wel op de een of andere manier 
geholpen. Dankjewel! Leen, onze ‘bezige bij’, bedankt voor de vele PCRs die je hebt gedaan voor de 
‘backcross’ en natuurlijk ook omdat ik altijd op je kon rekenen voor praktische vragen zelfs al was je op 
die moment, zoals meestal, druk bezig! Heel veel succes met de studies en de thesis, en hopelijk kun je 
binnen enkele jaren zelf aan je doctoraat schrijven hé! Joke, bedankt om mij op het einde van mijn 
 doctoraat te verlossen van vele PCRs en om voor mijn ‘wilde’ muisjes te zorgen. Maarten, als het 
‘feestcomité’ van U9, bedankt om de leuke bowling, pretpark en andere uitjes te organiseren buiten het 
werk. Philippe, onze MMP-er en ‘computerspecialist’, die ik vooral de laatste tijd heb lastig gevallen met 
allerlei computerprobleempjes en vooral ‘berucht’ is omdat hij wel eens een vraag durft te stellen op een 
doctoraatsverdediging…Maarten en Philippe, allebei heel veel succes met het schrijven van jullie 
doctoraat, het zal er sneller aankomen als jullie denken of willen! Ineke, onze spring-in-’t-veld, altijd 
goedlachs en vol leuke verhalen over de ‘Slijpschijven’ (al durft ze wel al is met een blauw oog 
toekomen op het labo). Tom en Lien, de nieuwe aanwinsten van U9, veel geluk in de komende jaren. 
Jullie zijn alvast goed ingeburgerd! Lien blijkt ook een natuurtalent te zijn om de ‘wilde’ Spretus muizen 
aan te pakken: heel veel succes in het verderzetten van het Spretus project. De ex-U9 leden, Tino en 
Ben, ook bedankt dat ik steeds op jullie hulp kon rekenen en Tino, bedankt voor het organiseren van de 
gezellige ‘Ardennen’ weekendjes.  
 
Ten slotte wil ik ook enkel ander mensen uit het DMBR bedanken die mij in deze 5,5 jaar geholpen hebben. Ik 
mag zeker Myriam niet vergeten. Myriam heeft bijna heel de tijd voor mijn Spretus muisjes gezorgd 
zonder vrees en ‘met plezier’. Maar ze zal waarschijnlijk ook wel dikwijls gevloekt hebben. Dat kunnen 
de mensen die zich nu bezighouden met het verzorgen van de muizen zich wel voorstellen… Dus ook 
een speciale dank-je-wel voor de mensen die zich bezighouden met het animalarium en het verzorgen van de 
muizen. Ook veel dank aan de mensen van de weefselkweek (voor het uitvoeren van mijn IL-6, TNF en IFN-
assays), het secretariaat en het beheer van ons departement, de keuken, de IT, de sequenering, enz... En 
moest ik iemand vergeten zijn, bedankt voor alle hulp de vorige jaren! 
Natuurlijk moet ik ook het IWT bedanken voor de fondsen waardoor ik aan dit project kon werken. I also 
want to thank Dr. Jin Mo Park of the University of California for collaborating with us and providing us 
with interesting data. 
 
Gelukkig waren er ook buiten het labo vele mensen waarmee ik zowel over mijn ‘frustraties op het werk’ 
(als een of ander experiment weer eens niet lukte) als over mijn ‘plezier op het werk’ kon babbelen.  
Katrien, Kristof, Mich, Kobe, Bob en Imke als doctoraatsstudenten gingen onze gesprekken wel eens 
over ons doctoraat, maar gelukkig niet altijd! Bedankt allemaal voor de vriendschap en toffe momenten 
die we al samen beleefd hebben! En Katrien (maar ook de anderen) veel succes met je doctoraat! Ik 
denk dat jij de volgende in het rijtje bent… Barbara en Geert, bedankt voor de ‘De Pinte’ avonden, de 
café ruststraat en nu de Heerweg-Noord avonden….En veel succes met de nieuwe spruit. Philippe en 
Stijn, bedankt voor de vele filmavondjes, etentjes, en voor het mij meesleuren, of was het omgekeerd 
(?), naar de fitnesszaal of de badminton. Dieter, Jurgen en Koen, hoewel ik jullie niet meer zo vaak zie 
 als tijdens onze studententijd op Home Boudewijn, ben ik heel blij dat we af en toe nog eens gezellig 
kunnen bijpraten.  
 
Mijn grootste dank gaat natuurlijk naar mijn ouders voor hun onvoorwaardelijke steun. Mama en papa, 
jullie hebben mij niet alleen de kans gegeven om te studeren in Gent (en mij ook vrij te laten in mijn 
keuze), maar jullie hebben mij ook heel hard gesteund toen ik besloot een IWT beurs aan te vragen. 
Bedankt voor alles! Broer en Mayke, ook bedankt voor de interesse en broer, bedankt omdat ik je met al 
mijn vragen mocht lastigvallen. 
Mijn lieve lieve Wouter, bedankt om me die laatste maanden zo te steunen! Het was niet gemakkelijk 
om onze eerste maanden zo samen door te brengen aangezien ik niet al te veel tijd voor je vrij kon 
maken. Gelukkig begreep je dat en stond je altijd klaar om de verplaatsing Leuven-Gent te maken, mij 
met vanalles en nog wat te helpen en mij ook vooral ontspannende momenten te bezorgen door mij 
vanachter mijn computer weg te sleuren. Bedankt omdat je er altijd bent voor mij en voor alle steun!!  
 
 
Bedankt, 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
Table of contents 
TABLE OF CONTENTS 
 
Dankwoord 
Table of contents .......................................................................................................................................................i 
List of figures ............................................................................................................................................................v 
List of tables ........................................................................................................................................................... vii 
List of abbreviations.................................................................................................................................................ix 
 
Chapter I: GENERAL INTRODUCTION.................................................................................................. 1 
 
1. Innate immunity: regulating host response to pathogens .................................................................................... 3 
 1.1. History, chemical constitution and bioactivity of endotoxin. .......................................................................... 3 
 1.2. Sepsis, severe sepsis and septic shock: an enormous impact on society .................................................... 5 
 1.3. Pattern-recognition receptors (PRRs). .......................................................................................................... 8 
  1.3.1. Pattern-recognition receptors, important in innate and adaptive immunity. ........................................ 8 
  1.3.2. Toll/IL-1R family in mammals............................................................................................................ 10 
 1.3.2.1. Toll-like receptors, belonging to the Toll/IL-1R superfamily........................................................ 11 
  1.3.2.2. The IL-1R family, belonging to the Toll/IL-1R superfamily.......................................................... 19 
  1.3.3. Non-TLR pattern-recognition receptors recognizing PAMPs of different microorganisms ................ 20 
 1.4. Recognition of LPS ..................................................................................................................................... 23 
  1.4.1. Requirement of LBP, MD-2 and CD14.............................................................................................. 23 
  1.4.2. A receptor cluster as a model for TLR4 activation. ........................................................................... 25 
 1.5. References.................................................................................................................................................. 26 
2. TLR/IL-1R signallisation..................................................................................................................................... 34 
 2.1. TIR domain-containing adaptors. ................................................................................................................ 34 
 2.2. TLR signalling. ............................................................................................................................................ 37 
  2.2.1. The MyD88-dependent pathway....................................................................................................... 38 
2.2.1.1. Important molecules belonging to the MyD88-dependent pathway............................................ 38 
2.2.1.2. TLR-induced MyD88-dependent signalling (Figure I.2.2.). ......................................................... 40 
2.2.1.3. TLR7- and TLR9-induced MyD88-dependent signalling in pDCs (Figure I.2.3.) ........................ 42 
2.2.1.4. Other molecules involved in MyD88 signalling. .......................................................................... 44 
  2.2.2. TLR3- and TLR4-mediated MyD88-independent pathway................................................................ 45 
2.2.2.1. Some important molecules belonging to the MyD88-independent pathway............................... 45 
2.2.2.2. MyD88-independent signalling (Figure I.2.4. and I.2.5.)............................................................. 46 
2.2.2.3. Other signalling pathways: role of PI3K, RIP1 and RIP2 (Figure I.2.4.) ..................................... 49 
  2.2.3. IRF-5 in TLR signalling (Figure I.2.6).. .............................................................................................. 50 
 2.3. Negative regulation of TLR signalling. ........................................................................................................ 51 
 2.4. Importance of endotoxin tolerance. ............................................................................................................. 56 
 2.5. References.................................................................................................................................................. 59 
3. Type I IFNs ........................................................................................................................................................ 67 
 3.1. Overview of the IFN family .......................................................................................................................... 67 
 3.2. The IFN-β promoter .................................................................................................................................... 67 
  3.2.1. Sequence and regulatory domains. .................................................................................................. 67 
  3.2.2. Activation and termination of IFN-β gene expression. ...................................................................... 69 
  3.2.3. Regulatory mechanisms of the IFN-β promoter. ............................................................................... 71 
  3.2.4. Posttranscriptional regulation of IFN-β expression. .......................................................................... 73 
Tina Mahieu PhD thesis (2006) i
Table of contents 
 3.3. The IFN-α promoter.................................................................................................................................... 73 
 3.4. Type I IFN signalling. .................................................................................................................................. 75 
  3.4.1. The classical JAK-STAT pathway in type I IFN signalling and importance of IFN-β in  
 sepsis. .............................................................................................................................................. 75 
  3.4.2. Other pathways involved in type I IFN signalling. ............................................................................. 86 
  3.4.3. Regulation of IFNAR expression....................................................................................................... 86 
  3.4.4. Amplification of the type I IFN response and importance of IRF-7.................................................... 87 
 3.5. References.................................................................................................................................................. 89 
4. Mapping in the mouse. ...................................................................................................................................... 93 
 4.1. Mouse domestication. ................................................................................................................................. 93 
 4.2. Historical roots of inbred mice..................................................................................................................... 94 
 4.3. The mouse as a model organism................................................................................................................ 96 
 4.4. Use of wild-derived mouse strains .............................................................................................................. 96 
 4.5. Mapping of a trait ........................................................................................................................................ 99 
  4.5.1. Introduction: Linkage and recombination .......................................................................................... 99 
  4.5.2. Genetic markers.............................................................................................................................. 101 
  4.5.3. Mapping of a trait: initial crosses..................................................................................................... 102 
  4.5.4. Isolation of QTLs from a complex trait in CSS strains (Nadeau et al., 2000). ................................. 105 
  4.5.5. Some methods used in QTL mapping analysis............................................................................... 106 
 4.6. References................................................................................................................................................ 108 
 
Chapter II: AIM OF THE PROJECT. ................................................................................................... 111 
 
Chapter III: RESULTS......................................................................................................................... 115 
 
1. The wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-β production......... 117 
 1.1. PNAS article.............................................................................................................................................. 117 
2. Description of the LPS resistance of SPRET/Ei in vivo. .................................................................................. 124 
 2.1. Introduction ............................................................................................................................................... 124 
 2.2. Experimental procedures .......................................................................................................................... 124 
  2.2.1. Determination of TNF in the serum................................................................................................. 124 
  2.2.2. Histological analysis........................................................................................................................ 124 
  2.2.3. Gelatin zymography ........................................................................................................................ 125 
 2.3. Results ...................................................................................................................................................... 125 
  2.3.1. TNF-α induction after injection of a high dose LPS. ....................................................................... 125 
  2.3.2. Inflammation after a high dose LPS................................................................................................ 126 
  2.3.3. Response of C57BL/6 and (BxS)F1 mice to E.coli LPS. ................................................................. 128 
 2.4. Conclusion ................................................................................................................................................ 128 
3. In vitro data...................................................................................................................................................... 130 
 3.1. Introduction ............................................................................................................................................... 130 
 3.2. Experimental procedures .......................................................................................................................... 130 
  3.2.1. In vitro experiments: IL-6 concentration after LPS in supernatant .................................................. 130 
  3.2.2. Derivation of macrophages from bone marrow cells ....................................................................... 131 
  3.2.3. Real-time Q-PCR analysis .............................................................................................................. 131 
  3.2.4. Immunoblot analysis ....................................................................................................................... 132 
 3.3. Results ...................................................................................................................................................... 132 
  3.3.1. Response of peritoneal macrophages and MEFs to LPS ............................................................... 132 
  3.3.2. The MyD88-dependent pathway is normal in SPRET/Ei................................................................. 133 
Tina Mahieu PhD thesis (2006) ii
Table of contents 
  3.3.3. The MyD88-independent, TRIF-dependent pathway is defective in SPRET/Ei .............................. 135 
 
 3.4. Conclusion ................................................................................................................................................ 136 
4. Importance of IFN-β in the LPS resistance. ............................................................................................138 
 4.1. Introduction ............................................................................................................................................... 138 
 4.2. Results ...................................................................................................................................................... 138 
  4.2.1. The LPS-resistance can be reverted by administration of IFN-β .................................................... 138 
 4.3. Conclusion ................................................................................................................................................ 138 
5. What causes this defective IFN-β production?................................................................................................ 141 
 5.1. Introduction ............................................................................................................................................... 141 
 5.2. Experimental procedures .......................................................................................................................... 142 
  5.2.1. Sequencing..................................................................................................................................... 142 
  5.2.2. Immunoblot analysis ....................................................................................................................... 142 
  5.2.3. Real-time Q-PCR analysis .............................................................................................................. 143 
  5.2.4. In vitro: determining IL-6 concentration after IFN............................................................................ 143 
  5.2.5. Semi-quantitative RT-PCR.............................................................................................................. 143 
 5.3. Results ...................................................................................................................................................... 143 
  5.3.1. Defect in the IFN-β promoter? ........................................................................................................ 143 
  5.3.2. Defect in the TRIF-dependent pathway? ........................................................................................ 144 
  5.3.3. Defect in the JAK-STAT pathway?.................................................................................................. 148 
 5.4. Conclusion ................................................................................................................................................ 150 
6. Response of SPRET/Ei on different TLR/IL-1R ligands................................................................................... 151 
 6.1. Introduction ............................................................................................................................................... 151 
 6.2. Experimental procedures .......................................................................................................................... 151 
  6.2.1. Injections......................................................................................................................................... 151 
  6.2.2. In vitro experiments......................................................................................................................... 151 
 6.3. Results ...................................................................................................................................................... 152 
  6.3.1. Response of SPRET/Ei, in vivo and in vitro to IL-1......................................................................... 152 
  6.3.2. Response of SPRET/Ei, in vivo and in vitro to TLR2. ..................................................................... 153 
  6.3.3. Response of SPRET/Ei, in vivo and in vitro to TLR3. ..................................................................... 155 
 6.4. Conclusion ................................................................................................................................................ 156 
7. Genetic analysis of the LPS response of SPRET/Ei........................................................................................ 158 
 7.1. Introduction ............................................................................................................................................... 158 
 7.2. Experimental procedures .......................................................................................................................... 159 
  7.2.1. Setting up an interspecific backcross.............................................................................................. 159 
  7.2.2. Generation of consomic strains ...................................................................................................... 159 
 7.3. Results ...................................................................................................................................................... 160 
  7.3.1. Mapping to subchromosomal level.................................................................................................. 160 
  7.3.2. Chromosome substitution strains (CSS) or consomic mice ............................................................ 166 
  7.3.3. Chromosome 2 semi-consomic mice. ............................................................................................. 168 
  7.3.4. Chromosome 10 (semi)-consomic mice.......................................................................................... 169 
  7.3.5. Chromosome 13 semi-consomic  mice. .......................................................................................... 170 
 7.3.6. Chromosome X semi-consomic mice.............................................................................................. 171 
 7.4. Conclusion ................................................................................................................................................ 172 
8. References ...................................................................................................................................................... 174 
 
Chapter IV: SUMMARY OF THE RESEARCH ................................................................................... 177 
 
1. Summary of the research and discussion........................................................................................................ 179 
2. Samenvatting van het onderzoek en bespreking............................................................................................. 192 
3. References. ..................................................................................................................................................... 206 
Tina Mahieu PhD thesis (2006) iii
Table of contents 
Tina Mahieu PhD thesis (2006) iv
 
Chapter V: ADDENDUM ..................................................................................................................... 209 
 
List of figures 
LIST OF FIGURES 
 
Figure I.1.1.    Overall structure of the Gram-negative cell envelope ................................................................. 3 
Figure I.1.2.   General overview of LPS and chemical structure of lipid A......................................................... 4 
Figure I.1.3.  Contribution of the innate immune system to activation of adaptive immune responses ......... 9 
Figure I.1.4.   Toll/IL-1R superfamily ............................................................................................................... 10 
Figure I.2.1.   TIR domain-containing adaptor molecules................................................................................ 35 
Figure I.2.2.   TLR-mediated MyD88-dependent signalling pathway............................................................... 41 
Figure I.2.3.   TLR7 and TLR9 signalling pathways ........................................................................................ 43 
Figure I.2.4.   TLR3 signalling pathway ........................................................................................................... 47 
Figure I.2.5.   TLR4 signalling pathway ........................................................................................................... 48 
Figure I.2.6.    Role of IRF-5 in TLR signalling. ................................................................................................ 50 
Figure I.3.1.   DNA sequence and regulatory regions of the murine IFN-beta promoter ................................. 69 
Figure I.3.2. A model for the synergistic activation of transcription by the IFN-β enhanceosome................. 70 
Figure I.3.3.   A weak constitutive level of IFN-α/β is necessary for effective amplification  
of the IFN-α/β signal after stimulation ...................................................................................... 88 
Figure I.4.1.   Geographical distribution of the different subspecies of Mus musculus.................................... 93 
Figure I.4.2.   Origin of the inbred laboratory mouse strains ........................................................................... 94 
Figure I.4.3.   Picture of agouti SPRET/Ei (Mus spretus) and black C57BL/6 (Mus musculus)....................... 98 
Figure I.4.4.  Phylogenetic relationships in the genus Mus ............................................................................ 99 
Figure I.4.5.  Genotyping of microsatellite alleles......................................................................................... 101 
Figure I.4.6.  Illustration of a backcross experiment..................................................................................... 103 
Figure I.4.7.  The swept radius determining the number of markers needed in a whole genome screen .... 104 
Figure I.4.8.    Strategy for the construction of CSS strains ........................................................................... 105  
Figure III.2.1.   Concentration of TNF in serum after 250 µg S.a.e. LPS. ....................................................... 126 
Figure III.2.2.  Liver and lung inflammation after LPS .................................................................................... 127 
Figure III.2.3.   MMP-9 as a marker for inflammation ...................................................................................... 128 
Figure III.2.4.    Response of C57BL/6 and (BxS)F1 mice to 500 µg E.coli LPS .............................................. 128 
Figure III.3.1.    IL-6 induction in vitro after 24 hours of LPS stimulation .......................................................... 132 
Figure III.3.2.   TNF-α and IL-6 mRNA induction in BMDMs after LPS stimulation......................................... 133 
Figure III.3.3.   Early and late induction of IL-6 after LPS stimulation.............................................................. 134 
Figure III.3.4.   IFN-β mRNA induction after LPS and poly (I:C) stimulation and nuclear  
 translocation of STAT1 after LPS............................................................................................ 135 
Figure III.3.5. Candidate molecules at this stage. ......................................................................................... 137 
Figure III.4.1.   The LPS-resistance is reverted by exogenous IFN-β administration ...................................... 139 
Figure III.5.1.      The defect in IFN-β induction can be situated at three levels ................................................. 141 
Figure III.5.2.      IFN-β promoter elements........................................................................................................ 144 
Figure III.5.3.   Sequences of the C57BL/6 and SPRET/Ei IFN-β promoter region ........................................ 145 
Figure III.5.4.   Amino acid changes in SPRET/Ei in the serine/threonine cluster of IRF-3 ............................. 146 
Tina Mahieu PhD thesis (2006) v
List of figures 
Tina Mahieu PhD thesis (2006) vi
Figure III.5.5.   Phosphorylation of IRF-3 in BMDMs after LPS stimulation..................................................... 147 
Figure III.5.6.   Gene induction in IRF-3-knockout and SPRET/Ei macrophages after LPS stimulation ....... 148 
Figure III.5.7.   IFN-induced OAS mRNA expression and IL-6 induction in BMDMs ....................................... 149 
Figure III.6.1.   IL-6 concentration after an i.p. IL-1 injection ........................................................................... 152 
Figure III.6.2.   IL-6 induction in vitro after 24 hours of IL-1 stimulation........................................................... 153  
Figure III.6.3.   Swelling of the foot after injection of zymosan ........................................................................ 154  
Figure III.6.4.      TNF-α concentration in BMDMs after stimulation with PGN................................................... 154 
Figure III.6.5.      IL-6 concentration in BMDMs after poly (I:C) stimulation. ....................................................... 155  
Figure III.6.6.   Survival after a lethal injection of poly (I:C) and d-GalN.......................................................... 156 
Figure III.7.1. Steps to detect and localize QTL. ........................................................................................... 161 
Figure III.7.2.   Simple interval mapping analysis of BSB backcross............................................................... 164 
Figure III.7.3.   Simple interval mapping analysis of BSB backcross: a sensitivity gene on chromosome 6. .. 165 
Figure III.7.4.   Composite interval mapping.................................................................................................... 166 
Figure III.7.5.   IL-6 concentration after a low dose LPS. ................................................................................ 167 
Figure III.7.6. Difference between consomic and semi-consomic mice......................................................... 168 
Figure III.7.7.   Interval mapping analysis of chromosome 2 semi-consomic mice.......................................... 169 
Figure III.7.8.   Interval mapping analysis of chromosome 10 semi-consomic mice........................................ 170 
Figure III.7.9.   Interval mapping analysis of chromosome 13 semi-consomic mice........................................ 171 
Figure IV.1.1.      Possible mechanism to explain the role of IFN-β in LPS-induced lethality ............................. 188 
 
List of tables 
LIST OF TABLES 
 
Table I.1.1.   Therapeutic interventions for sepsis in clinical trials ....................................................................... 7 
Table I.1.2.   Comparison of the properties of innate and adaptive immune systems ......................................... 8 
Table I.1.3.   Toll-like receptors and their (synthetic) ligands ............................................................................ 13 
Table I.1.4.   Toll-like receptors and endogenous ligands ................................................................................. 18 
Table I.1.5.  Pattern-recognition receptors and their ligands ............................................................................ 22 
Table I.2.1.   Negative regulators of Toll-like receptor signalling ....................................................................... 55 
Table I.3.1  The IFNs and IFN-like molecules ................................................................................................. 68 
Table III.5.1.    Overview of amino acid changes found in the SPRET/Ei serine/threonine cluster of IRF-3....... 146 
Table III.7.1.   Linkage of genetic markers to the LPS-resistance ..................................................................... 162 
Table III.7.2.   Epistatic interactions in the LPS response of SPRET/Ei ............................................................ 165 
Table III.7.3.  Overview of linkage found between different traits and chromosome 2, 10, 13 or X .................. 173 
Tina Mahieu PhD thesis (2006) vii
List of tables 
Tina Mahieu PhD thesis (2006) viii
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Abbreviations 
LIST OF ABBREVIATIONS 
 
AA   amino acid 
AAF IFN-α activated factor 
AKT thymoma viral proto-oncogene 1 
AP-1  activator protein-1 
APC  antigen-presenting cell 
APC activated protein C 
ARE  AU-rich element 
ARM armadillo repeat motif 
AT antithrombin 
ATF  activating transcription factor 
B C57BL/6 
BC Before Christ 
BIR baculovirus inhibitor of apoptosis repeat 
BLP bacterial lipoprotein 
(BxS)F1 (C57BL/6xSPRET/Ei)F1 
BMDM bone marrow-derived macrophages 
BMP bone morphogenetic protein 
bp  basepairs 
BPI bactericidal permeability increasing protein 
C1 complement 1 
CAP cathelicidin antimicrobial peptide 
CARD caspase-recruitment domain 
CBP CREB-binding protein 
CCL5 chemokine (C-C motif) ligand 5 
CCR CC-chemokine receptor 
cDC conventional DC 
cDNA  complementary DNA 
C/EBP CCAAT/enhancer binding protein 
C.elegans Caenorhabditis elegans 
CHO Chinese hamster ovary 
CI confidence interval 
CIM  composite interval mapping 
CITED CBP/p300-interacting transactivators with E (glutamic acid)/D (aspartic acid)- 
 rich carboxyl-terminal domain 
CLP cecal ligation and puncture 
cM  centiMorgan 
CR complement receptor 
CRD carbohydrate recognition domain 
CRE cAMP response element 
CREB  cAMP responsive element binding protein 
CRF2 class II cytokine receptor family 
CRID coding region instability domain 
CSS  chromosome substitution strain 
C-terminal  carboxy-terminal 
CTL cytotoxic T lymphocyte  
CXCL10  CXC-chemokine ligand 10 
CXCR chemokine (C-X-C motif) receptor 
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1.   INNATE IMMUNITY: REGULATING HOST RESPONSE TO PATHOGENS 
 
1.1.   History, chemical constitution and bioactivity of endotoxin 
 
More than a century ago, endotoxin was discovered by Richard Pfeiffer as a heat-resistant, non-
proteinaceous, toxin that is associated with the insoluble part of the bacterial cell. Pfeiffer stated that 
endotoxins were components of both Gram-negative and Gram-positive bacteria (Pfeiffer, 1892). Mainly 
through the efforts of Mary Jane Osborn and Hiroshi Nikaido, it is recognized nowadays that endotoxin 
is the principal glycolipid component of the outer membrane of Gram-negative bacteria (Figure I.1.1.) 
(Rietschel and Westphal, 1999).  It took till the middle of the 20th century to purify endotoxin, which was 
then called lipopolysaccharide (LPS) because of the presence of lipid and polysaccharide components 
(Beutler and Rietschel, 2003), and this purification ultimately led to the characterization of the chemical 
structure of LPS (Rietschel et al., 1996). 
 
 
 
Figure I.1.1. – Overall structure of the Gram-negative cell envelope (Reprinted from textbook: Biology of 
Microorganisms, eighth edition, 1997). 
 
LPS is composed of 2 major structural regions: a hydrophilic polysaccharide and a hydrophobic complex 
glycophospholipid known as lipid A, which anchors the molecule to the outer leaflet of the outer 
membrane. The polysaccharide portion is divided into a highly variable core oligosaccharide containing 
10-12 sugars, which is further divided into outer and inner segments, and a more conserved O-specific 
chain, which contains dozens of identical oligosaccharide repeating units (Figure I.1.2.) (Caroff et al., 
2002; Ulevitch and Tobias, 1995). 
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The classical lipid A moiety is represented by Escherichia coli. It has a backbone consisting of a β-1’,6-
linked D-glucosamine (GlcN) disaccharide carrying ester- and amide-linked fatty acids, and phosphate 
groups at positions C-1 and C-4’ (Figure I.1.2). The hydroxyl groups in position 6' serve as the 
attachment site for the polysaccharide component (Ulevitch and Tobias, 1995). The lipid A moiety from 
other Gram-negative bacteria follows the same architectural principle, but might differ in structural 
details (Caroff et al., 2002). Thus, next to high variability in O-polysaccharides also lipid A heterogeneity 
is observed, even though lipid A is the most conserved region of LPS. Both can be achieved through 
variations at different levels. For example, O-polysaccharides can be modified with sugar moieties such 
as glucosyl and fucosyl residues, or they can vary in the number of repeating oligosaccharide units 
(Lerouge and Vanderleyden, 2002). Lipid A structures can be modified by, for example, the degree of 
acylation or the nature of fatty acids (Karibian et al., 1993; Zarrouk et al., 1997). In 1985, E.coli lipid A 
was chemically synthesized for the first time and it was found to be a molecule of about 1,2 kDa. 
Synthesized E.coli lipid A exhibited the same degree of biological activity as the wild-type lipid A 
(Galanos et al., 1985). In addition, it was demonstrated that any modification of the chemical structure of 
LPS does not lead to higher toxicity, but rather yields products of lower endotoxicity (Kotani et al., 
1985). Thus, minor to moderate changes in lipid A structures can have a tremendous impact on their 
biological activity.  
 
GluGalGlu
GalGlu-Nac
n
O-specific chain Core
KdoHepHep
KdoHep
Kdo
P
P
P
NH3+
Lipid A
GlcN
GlcN
P
P
Outer core            Inner core
Polysaccharide Glycophospholipid
 
 
Figure I.1.2. – General overview of LPS and chemical structure of lipid A. The left panel shows a schematic 
representation of the basic chemical structure of LPS of Gram-negative bacteria. Glu, glucose; Gal, galactose; GluNac, N-
acetylglucosamine; GlcN, glucosamine; Hep, Heptose; P, phosphate; Kdo, ketodeoxyoctonate; zig-zag lines, fatty acids. The 
right panel shows the chemical structure of lipid A from Enterobacteria such as E.coli and Salmonella (Reprinted from Caroff 
et al, Microbes and infection, 4, 915-926, 2002). 
 
LPS molecules vary considerably in structural motifs from one genus, species or strain to another 
(Caroff et al., 2002). Moreover, they can also vary within one bacterial strain (Hackstadt et al., 1985).  
Furthermore, bacteria can produce, either naturally or because of genetic defects, incomplete LPS 
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lacking the inner core sugars or the O-specific chain. This incomplete LPS is called ‘rough LPS’ 
because of the morphology of the colonies the organisms form. LPS composed of the O-specific chain, 
inner core oligosaccharides and lipid A is called ‘smooth LPS’, because the organisms grow as smooth 
colonies (Dixon and Darveau, 2005). 
 
Lipid A is known as the bioactive component of LPS (Ulevitch and Tobias, 1995). Bioactivity of lipid A is 
not only dependent on the composition of lipid A, but also on the molecular conformation determined by 
steric factors, negative charges and hydrophobic domains. These features determine the distinct shape 
of the molecule, which in turn leads to formation of larger multimeric aggregates. Endotoxin aggregates 
in a cubic conformation, with individual molecules within the aggregates having a conical shape, are 
biologically highly active, whereas lamellar aggregates, with individual molecules within the aggregates 
having a cylindrical shape, are not active (Schromm et al., 1998). LPS is one of the most potent 
bioactive molecules. Extremely small amounts (ng to pg range) of LPS are sufficient to initiate the innate 
host defense system (Rietschel and Westphal, 1999) by activating myeloid (neutrophils, monocytes, 
macrophages, platelets) and/or non-myeloid cells (fibroblasts) (Ulevitch and Tobias, 1995) to produce 
primary (e.g. TNF, IL-6, IL-12 and IFN-γ) and secondary (e.g. NO, thromboxanes and PAF) mediators. 
Then these primary and secondary mediators cause the activation of the coagulation cascade, the 
complement cascade and the production of prostaglandins and leukotrienes (Hsueh et al., 1990; Levi 
and Ten Cate, 1999). Immense differences in toxicity are observed between species and especially 
between vertebrate classes. For example, reptiles, amphibians, birds and fish are unresponsive to LPS, 
while mammals are very sensitive (Berczi et al., 1966). LPS is able to reproduce many of the features of 
a Gram-negative infection, including fever, shock and other features of sepsis.  
 
1.2.   Sepsis, severe sepsis and septic shock: an enormous impact on society 
 
Sepsis occurs when the body’s response to an overwhelming infection becomes uncontrolled. The 
immune response, necessary to clear the pathogen and its toxins, actually causes damage to the host’s 
own tissues when it becomes hyper-reactive. The response involves a complex network of circulating 
mediators such as pro-inflammatory cytokines and chemokines, the activation of plasma protein 
cascade systems, such as the complement system, the pathways of coagulation, and the fibrinolytic 
system (Tslotou et al., 2005). Hence, the immune response must be carefully controlled to prevent 
damage to the host.   
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The term SIRS (systemic inflammatory response syndrome) was developed to define a systemic clinical 
response to an inflammation or injury that can be infectious (bacterial, viral, fungal) or non-infectious 
(major surgery, burns, trauma, ischaemia/reperfusion, pancreatitis). SIRS is defined by having two of 
the following symptoms: hypothermia (<36°C) or hyperthermia (>38°C), tachycardia (>90 beats/min), 
tachypnea (>20 breaths/min or PCO2<32mm Hg) and the alteration of white blood cell count (<4 x 109 
cells/liter or >12 x 109 cells/liter) or the presence of >10% immature neutrophils. Sepsis is defined as the 
presence of SIRS associated with infection. Sepsis, severe sepsis and septic shock are commonly used 
terms. Sepsis associated with organ dysfunction, tissue/organ hypoperfusion, or hypotension is called 
severe sepsis. Septic shock is characterized by a persistent arterial hypotension, despite adequate fluid 
resuscitation. Later, multiple organ failure/dysfunction syndrome (MOF/MODS), characterized by the 
presence of altered function of two or more organs, is developed and often results in death (Karima et 
al., 1999; Tslotou et al., 2005).  
People at greatest risk of developing sepsis are those with a suppressed immune system due to cancer 
or immune deficiency diseases, but also neonates and elderly. Sepsis remains an important and life-
threatening problem. Sepsis affects approximately 750.000 people in the United States of America 
(USA) each year and an additional 1.2 million in Europe and Japan. The rate of severe sepsis is 
expected to rise to 1 million cases a year in the USA alone by 2020 as the population ages. Each year, 
approximately 215.000 people in the USA die from severe sepsis, more than breast, colon/rectal, 
pancreatic, and prostate cancer combined (Angus et al., 2001). Each year sepsis costs 7.6 billion dollar 
in Europe and 17.4 billion dollar in the USA (Angus et al., 2001; Bone et al., 1992). The overall mortality 
is approximately 30%, rising to 40% in the elderly and 50% or more in septic shock patients (Angus et 
al., 2001). 
There are three major types of sepsis characterized by the type of infecting organism. Gram-negative 
sepsis, the majority of these infections caused by Escherichia coli, Klebsiella species and 
Pseudomonas aeruginosa, and Gram-positive sepsis, caused mainly by staphylococci and streptococci, 
are the most common types of sepsis. The third major group includes fungi, most commonly Candida. 
Fungal infections cause a relatively small percentage of severe sepsis cases, but with a high mortality 
rate. Also mixed infections involving both Gram-negative and Gram-positive bacteria are common 
(Tslotou et al., 2005).  
Therapies for sepsis at this moment are antimicrobial therapy, fluid resuscitation, glucose control, use of 
corticosteroids and use of recombinant human activated protein C. Early initiation of antibiotics for 
sepsis improves survival, but both timing and adequacy of antibiotics are critical contributors to ultimate 
survival with sepsis (Houck et al., 2004). Antibiotic resistance among pathogens is a growing problem in 
hospitals. A common cause of hospital infections is the methicillin-resistant staphylococcus aureus 
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(MRSA).  Fluid resuscitation is used for patients with severe sepsis or septic shock. In the presence of 
acute organ dysfunction in case of severe sepsis, therapy with recombinant human activated protein C 
is considered.  However, despite all these therapies, sepsis and SIRS remain the main causes of death 
in intensive care units (Bone et al., 1992). Various clinical trials in sepsis have failed. For example, 
administration of anti-endotoxin antibodies, PAF (platelet activating factor) inhibitor and anti-TNF 
antibodies failed in sepsis therapy (Riedemann et al., 2003). So, extensive studies to find novel 
strategies for the treatment of sepsis are still indispensable. A summary of clinical trials in sepsis is 
given in Table I.1.1. 
 
 
 
Table I.1.1. - Therapeutic interventions for sepsis in clinical trials (Adapted from Riedemann et 
al., 2003). 
 
INTERVENTION TARGET SUCCESS 
Corticosteroids Inflammatory system + 
Anti-endotoxin antibodies 
BPI (bactericidal permeability increasing protein) 
LPS analogues 
Endotoxin - 
- 
- 
Anti-TNF antibodies 
Soluble TNF receptor 
TNF-α - 
- 
IL-1 receptor agonist IL-1 - 
PAF inhibitor/antagonist PAF - 
Prostaglandin E1  
Thromboxane (synthetase) inhibitors 
Cyclooxygenase inhibitor 
Arachidonic acid metabolites - 
- 
- 
Antioxidants (N-acetylcysteine, Selenium)  Oxygen radicals - 
Inhibitors of NO synthase (NOS, iNOS) NO - 
Inhibition of coagulation factors 
- tissue factor pathway inhibitor (TFPI) 
- antithrombin (AT)-III 
- activated protein C (APC) 
Coagulation/Inflammation  
- 
- 
+ 
IFN-γ 
G-CSF, GM-CSF  
Neutrophil activation - 
- 
Phosphodiesterase inhibitor Phosphodiesterase - 
Bradykinin antagonist Bradykinin - 
C1 (complement 1) inhibitor  Complement system - 
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1.3.   Pattern-recognition receptors (PRRs) 
 
1.3.1.  Pattern-recognition receptors important in innate and adaptive immunity 
 
Vertebrates possess two main intricate systems of host defense, termed the innate and adaptive 
immunity system (for an overview see Table I.1.2.). The adaptive immune system is unique to 
vertebrates, but the innate immune system is found in vertebrates, invertebrate animals and plants. This 
evolutionary ancient innate immunity system provides a first line of defense against infection. It uses 
sets of germ-line encoded receptors (pattern-recognition receptors or PRRs) to recognize highly 
conserved molecular structures shared by large groups of pathogens (pathogen-associated molecular 
patterns or PAMPs). PRRs can be secreted, located in intracellular compartments or expressed on the 
cell surface. The best known PRRs are the Toll-like receptors (TLRs) (see next section), but a lot of 
non-TLR PRRs such as proteins with leucine-rich repeat (LRR) domains, calcium-dependent lectin 
domains, or scavenger-receptor (SR) domains, are known at this moment (see further). PRRs are 
involved in performing specific tasks including opsonization, phagocytosis, apoptosis, activation of the 
complement cascade and the coagulation system and release of cytokines and chemokines (Medzhitov, 
2001; Medzhitov and Janeway, 2000). 
 
Table I.1.2. - Comparison of the properties of innate and adaptive immune systems (Adapted from Janeway 
and Medzhitov, 2002). 
 
Property Innate immune system Adaptive immune system 
Cells Macrophages, DCs, NK cells  T-cells, B-cells 
Receptors 
 
Germline-encoded 
Rearrangement not necessary 
Non-clonal distribution 
Encoded in gene segments 
Somatic rearrangement necessary 
Clonal distribution 
Type of Response Antigen-independent Antigen-dependent 
Response Cytokines 
Chemokines 
Co-stimulatory molecules 
Clonal expansion or anergy 
IL-2 
Effector cytokines 
Recognition Conserved molecular patterns 
Selected over evolutionary time 
Details of molecular structure 
Selected over lifetime of individual 
Immunologic Memory None 
 
Exposure results in immunologic  
memory 
Specificity Broad spectrum Antigen-specific 
Action time Immediate (hours) Lag between exposure and response 
(days) 
 
Evolution Vertebrates and invertebrates Only vertebrates  
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In vertebrates, a second line of defense, called the adaptive immune system, has evolved. The adaptive 
immune system is characterized by clonal selection of lymphocytes, specificity and memory. The 
system uses a diverse repertoire of antigen receptors on B- and T-cell lymphocytes. Each lymphocyte 
expresses a unique antigen receptor generated by random somatic gene rearrangements. Activation of 
a naïve lymphocyte is followed by clonal expansion to generate sufficient lymphocytes with relevant 
specificities, before differentiation into effector cells. This process, which is the basis of immunological 
memory, takes 3-5 days and is the reason why adaptive immune responses occur only after several 
days. Because there is a delay of 3-5 days, our body relies on the more general innate immune system 
to control infection during this period (Medzhitov and Janeway, 2000; Pasare and Medzhitov, 2004). 
 
 
 
Figure I.1.3. – Contribution of the innate immune system to activation of adaptive immune responses. Phagocytosis 
of pathogens by antigen-presenting cells (APCs) such as DCs and macrophages triggers both degradation and subsequent 
presentation of pathogen-derived peptides. In addition, TLRs recognize pathogen-derived components, inducing the 
expression of genes such as co-stimulatory molecules and inflammatory cytokines.  Antigen-presentation together with TLR-
mediated gene expression of co-stimulatory molecules and inflammatory cytokines drives naïve T-cells to differentiate, 
especially into TH1 cells (Reprinted from Takeda and Akira, 2005). 
 
The innate immune system significantly contributes to activation of adaptive immune responses. 
Detection of microbial presence by TLRs of the innate immune system leads to downstream signalling 
events that initiate the process of dendritic cell (DC) maturation. The maturation process includes up-
regulation of co-stimulatory molecules (CD40, CD80 and CD86) and major histocompatibility complex 
(MHC) molecules bearing pathogen-derived peptides, production of pro-inflammatory cytokines (e.g. IL-
12 and TNF-α) and altered expression of chemokine receptors (CCR2, CCR5 and CCR7). Mature 
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antigen-presenting cells (APCs) such as DCs signal T-cells and induce clonal expansion of antigen-
specific T-cells.  Antigen-presentation in the absence of co-stimulatory molecules results in a state of 
non-responsiveness to the antigen, termed anergy. In addition to its contribution to co-stimulatory 
molecule induction, the innate immune system is also responsible for induction of chemokines and 
cytokines, such as IL-12 and IL-18, by APCs. Production of IL-12 and IL-18 drives naïve T-cells to 
differentiate in TH1 cells (Akira et al., 2001) (Figure I.1.3.). Also, B-cells express receptors of the innate 
immune system and respond to their ligands by proliferation and expression of co-stimulatory molecules 
(Pasare and Medzhitov, 2004). 
 
1.3.2.  Toll/IL-1R family in mammals  
 
The Toll/IL-1R superfamily is a family of type I transmembrane receptors characterized by a common 
cytoplasmic region of about 200 amino acids, which is known as the Toll/IL-1 receptor (TIR) domain. 
Within this domain are three conserved boxes that are crucial for signalling (Slack et al., 2000). In 
contrast, the extracellular regions are quite distinct: whereas the extracellular region of the TLR family 
contains leucine-rich repeats (LRR) that of the IL-1 receptor family (IL-1R) possesses three 
immunoglobulin (Ig)-like domains (Fig. I.1.4). The extracellular region is involved in ligand recognition 
and contains 19-25 tandem copies of the LRR motif.  The LRR motif comprises 24-29 AAs containing 
the leucine-rich sequence XLXXLXLXX, where X denotes any AA. The LRR region is separated from 
the transmembrane region by a C-terminal domain characterized by a consensus motif 
CXC(X23)C(X17)C (Medzhitov, 2001). In spite of this conservation among LRR domains, TLRs can 
recognize the most diverse ligands, lacking any structural similarity (Bell et al., 2003).  
 
LRRs
TLR              IL-1R
Ig-like 
domains
TIR domain
 
Figure I.1.4. - Toll/IL-1R superfamily. The Toll/IL-1R superfamily comprises the TLR family and the IL-1R family. The TLR 
family is characterized by leucine-rich repeats (LRRs) in their extracellular domain, while the IL-1R family has three 
Immunoglobulin (Ig)-like domains in their extracellular region.  
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The TIR domain is also found in a number of mammalian cytoplasmic proteins such as MyD88 (see 
further). In addition, cytoplasmic plant-disease-resistance proteins involved in plant immunity contain 
both TIR and LRR domains (Medzhitov, 2001). Also in the nematode Caenorhabditis elegans two genes 
encoding TIR domain proteins, which have a function in host defense, are found (Liberati et al., 2004; 
Pujol et al., 2001). The first TIR domain-containing protein identified was ‘Toll’ in Drosophila.  
Toll was first identified in the early 1980s by Anderson, Jurgens and Nusslein-Volhard as an important 
factor in establishing the dorso-ventral axis in the early embryo of Drosophila (Anderson et al., 1985). 
The Toll gene was isolated and sequenced in 1988 (Hashimoto et al., 1988). In the 1990s, Toll was 
proved to be a type I transmembrane receptor containing blocks of LRRs in the ectodomain (Buchanan 
and Gay, 1996), flanked by characteristic cysteine-rich motifs and a cytoplasmic domain with similarities 
to that of the IL-1R, therefore referred to as the Toll/IL-1R (TIR) domain (Schneider et al., 1991). A study 
using Toll-mutant flies demonstrated that Toll is important in detecting fungal infection and 
demonstrated its important role in innate immune responses of Drosophila (Lemaitre et al., 1996). 
 
1.3.2.1.  Toll-like receptors, belonging to the Toll/IL-1R superfamily 
 
One year after the discovery of Drosophila Toll, a mammalian homologue of the Toll receptor, now 
termed TLR4, was found to induce the expression of genes involved in inflammatory responses 
(Medzhitov et al., 1997). After the characterization of the first mammalian TLR, several structurally 
related proteins, named Toll-like receptors, were identified (Rock et al., 1998). TLRs belong to the 
Toll/IL-1 receptor superfamily. To date, thirteen Toll-like receptors have been reported, ten in humans 
and twelve in mice (Tabeta et al., 2004) (Table I.1.3.). TLR1-9 are conserved between human and 
mouse. In contrast to human TLR10, mouse TLR10 is non-functional. Human TLR11 is not produced, 
because of a stopcodon in the Tlr11 gene. Mouse TLR11 is functional (Zhang et al., 2004). Mice 
express TLR12 and TLR13, but both TLRs are absent in humans (Tabeta et al., 2004). The TLR family 
is specialized for functioning in immune responses and comprises a family of cell-surface (TLR1, TLR2, 
TLR4, TLR5, TLR6, TLR11) and endosomally (TLR3, TLR7, TLR8, TLR9) expressed receptors.  
 
The TLRs are evolutionary conserved to recognize PAMPs ranging from bacteria (Hayashi et al., 2001; 
Poltorak et al., 1998a; Takeuchi et al., 1999; Zhang et al., 2004) to viruses (Diebold et al., 2004; Heil et 
al., 2004; Lund et al., 2003; Lund et al., 2004; Tabeta et al., 2004) to fungi (Meier et al., 2003) to 
parasites (Campos and Gazzinelli, 2004). The innate immune system uses not only TLRs for detecting 
infection, but also for detecting sterile inflammation, driven by ligands derived from damaged cells which 
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are usually not present in the extracellular environment. Examples are heat-shock proteins, β-defensins 
and oxidized lipids. Some TLRs are able to form heterodimeric complexes to activate innate immunity 
(Ulevitch, 2004).  
 
Toll-like receptors and their (synthetic) ligands 
 
TLR2. TLR2 recognizes a broad range of microbial components (see Table I.1.3.), but is primarily 
activated by PGN and lipoproteins. Its expression is regulated and seems to be restricted to APC and 
endothelial cells (Muzio et al., 2000). TLR2-deficient mice respond to LPS as wild-type mice, but are 
hypo-responsive to Gram-positive bacterial cell wall PGN and highly susceptible to Staphylococcus 
aureus infection (Takeuchi et al., 2000; Takeuchi et al., 1999). This is confirmed by a report showing 
that over-expression of human TLR2 in Chinese hamster ovary (CHO)/CD14 cells activated response to 
PGN from Staphylococcus aureus (Yoshimura et al., 1999). TLR2 can also recognize atypical LPS from 
Leptospira interrogans and Porphyromonas gingivalis, which differ from the typical LPS by the number 
of acyl chains. However, it was recently observed that LPS from P. gingivalis is only a poor activator of 
TLR2 (Hashimoto et al., 2004).  
The broad range of microbial components recognized by TLR2 can be explained by 2 mechanisms. The 
first explanation is that TLR2 cooperates with two other structurally related TLR family members: TLR6 
and TLR1 (Ozinsky et al., 2000; Takeuchi et al., 2001). Combinations of TLRs can recognize agonists 
not effectively recognized with individual TLRs. Both TLR1 and TLR6 are expressed constitutively on 
many cell types (Muzio et al., 2000). The second explanation of this broad range of ligands recognized 
by TLR2 is the functional cooperation of TLR2 with distinct types of receptors such as Dectin-1, a PRR 
recognizing the fungal cell wall component β-glucan (Gantner et al., 2003).  
 
TLR1/2. TLR1 and TLR2 are co-expressed in normal human monocytes and functionally cooperate with 
each other. Co-transfection of TLR1 and TLR2 into HeLa cells leads to enhanced responsiveness to 
soluble factors released from Neisseria meningitides, while expression of only TLR1 or TLR2 is not 
sufficient to confer responsiveness (Wyllie et al., 2000). Using TLR1-deficient mice, it became clear that 
TLR1 is involved in the recognition of triacylated lipopeptides as well as lipoproteins from mycobacteria. 
TLR1-deficient mice were most impaired in response to lipopeptides with an N-palmytoyl-S-dilauryl 
cysteine residue, demonstrating that TLR1 discriminates a subtle difference in the lipid moieties of 
lipopeptides (Takeuchi et al., 2002). In addition, it was shown that TLR1 is important in the recognition 
of the outer-surface lipoprotein (OspA) of the pathogen B. burgdorferi (Table I.1.3.) (Alexopoulou et al., 
2002). 
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Table I.1.3. - Toll-like receptors and their (synthetic) ligands (Adapted from Takeda et al., 2003). 
TLRs Ligands References 
TLR1 Triacyl lipopeptides (bacteria, mycobacteria) 
Soluble factors (Neisseria meningitides) 
Triacyl lipopeptides (synthetic) 
(Takeuchi et al., 2002) 
(Wyllie et al., 2000) 
(Ulevitch, 2004) 
TLR2 Pepidoglycan (G+) 
LTA (G+) 
Zymosan (yeast) 
Lipoproteins/lipopeptides (a variety of pathogens) 
LAM (Mycobacteria) 
A phenol-soluble modulin (Staphylococcus epidermis) 
Porins (Neisseria) 
LPS (Leptospira interrogans, Porphyromonas gingivalis) 
GPI (Trypanosoma cruzi) 
Glycolipids (Treponema maltophilum) 
Di- and triacyl lipopeptides (synthetic)  
(Schwandner et al., 1999; Takeuchi et al., 1999) 
(Schwandner et al., 1999) 
(Underhill et al., 1999) 
(Aliprantis et al., 1999; Brightbill et al., 1999) 
(Means et al., 1999) 
(Hajjar et al., 2001) 
(Massari et al., 2002) 
(Hirschfeld et al., 2001; Werts et al., 2001) 
(Coelho et al., 2002) 
(Opitz et al., 2001) 
(Ulevitch, 2004) 
 
TLR3 DsRNA (virus) 
Poly (I:C) (synthetic) 
(Alexopoulou et al., 2001) 
(Alexopoulou et al., 2001) 
TLR4  
 
LPS (G-) 
Taxol (plant)* 
Fusion protein (RSV) 
Envelope proteins (MMTV) 
Heat-sensitive cell-associated factor (M. tuberculosis) 
HSP60 (Chlamydia pneumoniae)* 
MPL, a mimetic of LPS/Lipid A (synthetic) 
E5564 (Synthetic lipid A) 
(Hoshino et al., 1999; Poltorak et al., 1998a)  
(Kawasaki et al., 2000) 
(Kurt-Jones et al., 2000) 
(Rassa et al., 2002) 
(Means et al., 1999) 
(Bulut et al., 2002) 
(Ulevitch, 2004) 
(Ulevitch, 2004) 
TLR5 Flagellin (bacteria) (Hayashi et al., 2001) 
TLR6 
 
Diacyl lipopeptides (mycoplasma) 
LTA (G+) 
Zymosan (yeast) 
Diacyl lipopeptides (synthetic) 
(Takeuchi et al., 2001) 
(Ozinsky et al., 2000; Schwandner et al., 1999) 
(Ozinsky et al., 2000) 
(Ulevitch, 2004) 
TLR7 (G+U)-rich ssRNA (virus)  
Imidazoquinoline (synthetic) 
Loxoribine (synthetic) 
Bropirimine (synthetic) 
(Diebold et al., 2004; Heil et al., 2004) 
(Hemmi et al., 2002) 
(Heil et al., 2003) 
(Heil et al., 2003) 
TLR8 (G+U)-rich ssRNA (virus) 
Imidazoquinoline (synthetic) 
(Heil et al., 2004) 
(Jurk et al., 2002) 
TLR9 Unmethylated bacterial CpG DNA (bacteria and virus)  
CpG oligodeoxynucleotides (synthetic) 
(Hemmi et al., 2000) 
(Ulevitch, 2004) 
TLR10(h) ND (Hasan et al., 2005) 
TLR11(m) Uropathogenic bacteria 
Profilin-like protein (Toxoplasma gondii) 
(Zhang et al., 2004) 
(Lauw et al., 2005) 
TLR12(m) ND (Tabeta et al., 2004) 
TLR13(m) ND (Tabeta et al., 2004) 
*It is possible that these ligand prepariations were contaminated with LPS and/or other potent microbial components.  
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TLR6/2. TLR2 and TLR6 physically interact in the cell, as demonstrated by co-immunoprecipitation of 
TLR2 and TLR6. Both receptors cooperate in the response to PGN of Gram-positive bacteria and 
zymosan of the yeast cell-wall (Ozinsky et al., 2000). Recognition of a phenol-soluble modulin from 
Staphylococcus epidermidis by TLR2 is enhanced by TLR6 (Hajjar et al., 2001). Using TLR6-deficient 
cells, it was proven that these cells are unresponsive to diacylated mycoplasmal macrophage-activating 
lipopeptide (MALP)-2, but retain their normal responses to triacylated lipopeptides of other bacterial 
origins. Reconstitution experiments in TLR2/TLR6 double-knockout embryonic fibroblasts demonstrated 
that both TLR2 and TLR6 are required for MALP-2 responsiveness. In conclusion, association of TLR6 
with TLR2 is necessary to discriminate between diacyl and triacyl lipopeptides (Table I.1.3.) (Takeuchi 
et al., 2001). 
 
TLR10. Human TLR10 is most closely related to TLR1 and TLR6 and is located in the Tlr6-Tlr1-Tlr10 
gene cluster. TLR10, primarily expressed on B-cells and pDCs, also heterodimerizes with TLR1 and 
TLR2 (Hasan et al., 2005). The specific ligands and functions of TLR10 are currently unknown. 
 
TLR3. TLR3 is located in the endosomal membranes (Matsumoto et al., 2003) and has unique features 
among the mammalian TLRs. First, TLR3 is different from other TLRs in its genomic organization and it 
also lacks the conserved proline residue at codon 712 common to other TLRs. A mutation in this proline 
residue in the Tlr4 gene of C3H/HeJ mice results in hypo-responsiveness to LPS (see further). Also, 
equivalent substitutions in some other TLRs abrogates their inflammatory responses (Ozinsky et al., 
2000; Underhill et al., 1999), suggesting that TLR3 signalling might differ from the signalling 
mechanisms of other TLRs. TLR3 indeed differs from the other TLRs in not requiring MyD88 for 
signalling, but recruiting TRIF as the critical adaptor protein (Yamamoto et al., 2002). Secondly, TLR3 is 
expressed in specific celtypes. It is expressed in specific myeloid cells, vascular endothelial cells and 
airway epithelial cells. Also, there are differences between mice and humans. Mouse TLR3 is highly 
expressed in macrophages, whereas human TLR3 is highly expressed in immature dendritic cells (DCs) 
(Muzio et al., 2000; Rehli, 2002). In mice, TLR3 expression is induced by LPS and IFNs, particularly 
IFN-β, while in human its expression is only induced by IFNs, and also particularly IFN-β (Heinz et al., 
2003). 
 
TLR3 is a major mediator of cellular response to certain viral infections, because it responds to dsRNA, 
produced as an essential intermediate in RNA synthesis or as a by-product of replication of some 
viruses. TLR3 activation leads to induction of type I IFN (IFN-α/β), which exerts anti-viral and 
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immunostimulatory activities, transcription of IFN-inducible genes and maturation of DCs. Alexopoulou 
et al. showed that some synthetic dsRNA molecules, such as poly (I:C), have similar activity as dsRNA. 
TLR3-/- mice showed reduced responses to poly (I:C), resistance to the lethal effects of poly (I:C) when 
sensitized with d-galactosamine (d-GalN), and reduced production of inflammatory cytokines 
(Alexopoulou et al., 2001). Enforced expression of human TLR3 in the dsRNA-non-responsive cell line 
HEK293, enables the activation of NF-κB and the IFN-β promotor in response to dsRNA and poly (I:C) 
(Alexopoulou et al., 2001; Matsumoto et al., 2002). 
TLR3 plays a role in clearing a mouse cytomegalovirus (MCMV) infection (Tabeta et al., 2004) and is 
important in the response to influenza virus infection (Guillot et al., 2005). On the other hand, Edelmann 
et al. claimed that TLR3 is not required for the generation of antiviral responses after MCMV, reovirus, 
vesicular stomatitis virus (VSV) and lymphocytic choriomeningitis virus (LCMV) infection (Edelmann et 
al., 2004). TLR3 can also recognize West Nile virus (WNV), a mosquito-borne ssRNA flavivirus. TLR3-
deficient mice were more resistant to lethality following WNV infection. Furthermore, TLR3-deficiency 
leads to impairment of inflammatory cytokine production and enhanced viral load in the periphery, 
whereas in the brain, viral load, inflammatory responses and neuropathology were reduced compared to 
wild-type mice (Wang et al., 2004).  
 
TLR4. In 1965, it was observed that mice of the C3H/HeJ strain were highly resistant to the lethal effect 
of LPS (Heppner and Weiss, 1965). Later it became clear that responses to LPS were impaired by a 
single mutation affecting a locus that was called Lps (Watson and Riblet, 1974). By the adoptive transfer 
of bone marrow cells from LPS-sensitive mice (C3H/HeN) to LPS-resistant mice (C3H/HeJ), it was 
demonstrated that C3H/HeJ mice can be rendered sensitive to LPS. So, this suggested that 
lymphocytes and/or macrophages play a primary role in responsiveness to LPS (Michalek et al., 1980). 
Also, C3H/HeJ mice showed enhanced susceptibility to infection by Gram-negative bacteria, suggesting 
that recognition of LPS is essential for clearing of the infection (O'Brien et al., 1980). In 1998, Tlr4 on 
mouse chromosome 4 has been identified as the gene encoded by Lps by positional cloning in the LPS-
non-responsive C3H/HeJ mouse (Poltorak et al., 1998b). A point mutation in the third exon of Tlr4 
modifies the protein within the TIR domain and creates a co-dominant inhibitory effect on LPS signal 
transduction. The mutation results in amino acid change from proline to histidine at position 712 
(Poltorak et al., 1998a). The role of TLR4 in LPS-induced responses was further supported by the 
demonstration that TLR4-null mice had a phenotype similar to that of C3H/HeJ mice (Hoshino et al., 
1999). In addition, a second spontaneous mutation that caused LPS susceptibility was identified. 
C57BL/10ScCr mice were shown to have a deletion of Tlr4, yielding a recessive loss of the LPS 
response. Also, polymorphisms in both the ectodomains and the cytoplasmic domains of human TLR4 
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have been identified and these are correlated with an increased susceptibility to Gram-negative 
infections (Agnese et al., 2002). In addition to LPS, TLR4 recognizes several other molecules (Table 
I.1.3.). TLR4 is expressed in a variety of cell types, most predominantly in myeloid cells, including 
macrophages and DCs (Medzhitov et al., 1997).  
 
TLR5. TLR5 is involved in recognition of flagellin, a conserved monomeric protein of bacterial flagella, 
which is a very complex structure that extends out from the outer membrane of certain Gram-negative 
bacteria. Recognition of an evolutionary conserved domain of flagellin is mediated through close 
physical interaction between TLR5 and flagellin (Smith et al., 2003). TLR5 can recognize bacterial 
flagellin from both Gram-positive and Gram-negative bacteria. Enforced expression of human TLR5 in 
CHO cells enables the response to bacterial flaggelin (Hayashi et al., 2001). Interestingly, TLR5 is 
expressed on the basolateral, but not the apical side of intestinal epithelial cells (Gewirtz et al., 2001), 
where it is able to recognize flagellin from pathogenic bacteria. Pathogenic, but not commensal, 
microorganism can cross the epithelial barrier, which enables the host to discriminate between 
commensals and pathogens. The intestinal endothelial cells of the subepithelial compartment also 
express TLR5 (Maaser et al., 2004). A common stop codon polymorphism in the ligand-binding domain 
of TLR5 unables flagellin signalling and is associated with susceptibility to pneumonia caused by 
Legionella pneumophila, a flagellated bacterium (Hawn et al., 2003). TLR5 forms homomeric complexes 
as well as heteromeric complexes with TLR4. Flagellin induces distinct patterns of inflammatory 
mediators depending on the nature of the TLR5 signalling complex. For example, the induction of NO by 
flagellin involves signalling via TLR5/TLR4 complexes (Mizel et al., 2003). 
 
TLR7, TLR8 and TLR9. TLR7, TLR8 and TLR9 compose a subfamily of TLRs based on phylogenetic 
analysis. TLR7 and TLR8 are the most closely related TLR family members (Du et al., 2000). TLR7/8/9 
are strongly expressed by pDCs (Liu, 2005) and primarily in the endosomal compartment (Ahmad-Nejad 
et al., 2002; Diebold et al., 2004). The endosomal location of TLR9 in a mouse macrophage cell line 
was revealed using a monoclonal antibody against TLR9 (Ahmad-Nejad et al., 2002). Signalling by 
TLR7/8/9 is inhibited by chloroquine, indicating the requirement for endosomal acidification in this 
process (Heil et al., 2003). Not only in pDCs, but also in other celtypes such as in immature B-cells and 
in macrophages expression is found of TLR7/9 (Applequist et al., 2002).  
 
By using TLR-deficient mice and genetic complementation, the natural ligand of murine TLR7 and 
human TLR8 was observed to be guanosine (G)- and uridine (U)-rich ssRNA oligonucleotides derived 
from viruses such as human immunodeficiency virus (HIV), VSV and influenza virus (Diebold et al., 
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2004; Heil et al., 2004; Lund et al., 2004). Mammalian DNA has a low frequency of CpG dinucleotides. 
Mammalian CpG dinucleotides are mostly methylated on their cytosine residues and therefore 
mammalian DNA does not have immuno-stimulatory activity. In contrast, bacteria lack cytosine 
methylation and thus, unmethylated CpG DNA might signal the presence of microbial infection. DNA 
containing unmethylated CpG motifs is common to both bacterial and viral genomes. Using TLR9-
deficient mice it was demonstrated that TLR9 is a receptor for unmethylated CpG DNA (Hemmi et al., 
2000). Signalling by CpG DNA requires its internalization into late endosomal or lysosomal 
compartments (Hacker et al., 1998). Another interesting aspect of CpG DNA recognition is that human 
and mouse cells are optimally activated by slightly different sequence motifs flanking CpG dinucleotides 
(Krieg and Wagner, 2000). This can be explained by species differences among TLR9s. Enforced 
expression of human or mouse TLR9 in the CpG DNA-unresponsive cell line HEK293, enabled the cells 
to respond respectively to the optimal human or mouse CpG sequences. Therefore, TLR9 can 
presumably recognize CpG DNA directly (Bauer et al., 2001). Also, it was shown that herpes simplex 
virus (HSV)-2 stimulates IFN-α production by pDCs through TLR9 (Lund et al., 2003). 
 
TLR7 and TLR8 can also detect synthetic compounds. Using TLR7 knockout mice it was demonstrated 
that TLR7 is able to respond to synthetic Imidazoquinolines (e.g Imiquimod and Resiquimod), which 
have structures similar to nucleic acids (Hemmi et al., 2002). Two other compounds, Loxoribine and 
Bropirimine, are also recognized by TLR7 (Heil et al., 2003). Stimulation with those synthetic 
compounds induces cytokine production and upregulation of co-stimulatory molecules and MHCI/II (Lee 
et al., 2003). Some of these compounds are in clinical use. For example, Bropirimin is being used 
against renal cell carcinoma (Sarosdy, 1993) and Imidazquinolines are used for treatment of genital 
warts associated with viral infection (Hemmi et al., 2002). This indicates that a screen for TLR-ligands 
can be useful for clinical applications. Human TLR8, but not murine TLR8, is also activated by an 
Imidazoquinoline (Jurk et al., 2002). 
 
TLR11. The first ligand for mouse TLR11 identified is a profilin-like protein from Toxoplasma gondii (Lauw 
et al., 2005). TLR11-null mice are highly susceptible to infection with uropathogenic Escherichia coli. 
TLR11 is expressed in bladder epithelial cells, liver, kidney and macrophages. There is no functional 
TLR11 protein in humans (Zhang et al., 2004). 
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Toll-like receptors and endogenous ligands 
 
An increasing number of studies implicate TLRs as being involved in the immune response to self-
molecules that have in some way been altered from their native state or accumulate in non-physiologic 
sites or amounts, although questions have been raised about possible contaminants in certain of these 
studies.  
 
It was suggested that TLR2 can interact with endogenous ligands such as high mobility group box 1 
protein (HMGB1) and HSPs, such as HSP60, HSP70 and GP96 (Asea et al., 2002; Park et al., 2005; 
Vabulas et al., 2001; Vabulas et al., 2002b). However, activation of TLR2 by HSPs has recently been 
determined to be due to contamination with pathogen-associated molecular patterns (Table I.1.4.). 
TLR3 is also involved in the recognition of endogenous RNA released from or associated with necrotic 
cells or generated by in vitro transcription and induces immune activation (Table I.1.4.) (Kariko et al., 
2004).  
 
        Table I.1.4. - Toll-like receptors and endogenous ligands. 
TLRs Endogenous ligands References 
TLR2 HSP60* 
HSP70* 
GP96* 
HMGB1 
(Vabulas et al., 2001) 
(Asea et al., 2002) 
(Vabulas et al., 2002b) 
(Park et al., 2005) 
TLR3 mRNA (Kariko et al., 2004) 
TLR4 HSP60* 
HSP70*  
GP96* 
Oligosaccharides or hyaluronic acid  
Fibrinogen   
Type III repeat extra domain A of fibronectin  
Polysaccharide fragments of heparan sulphate  
Surfactant protein-A 
β-Defensin 2 
HMGB1 
(Vabulas et al., 2001) 
(Asea et al., 2002) 
(Vabulas et al., 2002b) 
(Termeer et al., 2002) 
(Smiley et al., 2001) 
(Okamura et al., 2001) 
(Johnson et al., 2002) 
(Guillot et al., 2002) 
(Biragyn et al., 2002) 
(Park et al., 2005) 
*These putative endogenous ligands of TLR2 and TLR4 have recently been discovered to be due to contamination 
with pathogen-associated molecular patterns. Thus, more data are needed to conclude that TLRs recognize these 
endogenous ligands. 
 
 
Numerous studies have identified a role for TLR4 in endogenous ligand recognition (Table I.1.4.). For 
example, it has been suggested that TLR4 is involved in the recognition of HSP60 and HSP70 (Asea et 
al., 2002; Vabulas et al., 2001; Vabulas et al., 2002a). Also, a role for TLR4 in recognition of 
Tina Mahieu PhD thesis (2006) 18
Chapter I - General introduction 
extracellular matrix (ECM) components, including the type III repeat extra domain A of fibronectin, 
oligosaccharides of hyaluronic acid, and polysaccharide fragments of heparan sulfate has been 
demonstrated (Johnson et al., 2002; Okamura et al., 2001; Termeer et al., 2002). Fibrinogen is another 
endogenous ligand of TLR4 (Smiley et al., 2001). All of these components can be released upon 
inflammation, suggesting that TLR4 is also involved in inflammatory processes even in the absence of 
infection. However, to activate TLR4 very high concentrations of all of these ligands are necessary. 
Therefore the possibility remains that these preparations might be contaminated with LPS. Multiple 
studies have demonstrated that contamination of HSP preparations with LPS was the reason for TLR4 
activation (Bausinger et al., 2002; Gao and Tsan, 2003). In addition, TLR4-deficient C57BL/10ScCr 
mice still bind HSP60 on their macrophages, but do not demonstrate HSP60-induced production of 
inflammatory cytokines (Habich et al., 2002). Therefore, more studies have to be performed to confirm 
the ability of TRL4 to recognize endogenous ligands. 
  
1.3.2.2.  The IL-1R family, belonging to the Toll/IL-1R superfamily 
 
The IL-1R family comprises true receptors such as IL-1R1 and IL-18Rα, decoy receptors such as IL-
1R2 and accessory proteins such as IL-1R accessory protein (IL-1RAcP). Single Ig domain IL-1R 
related protein (SIGIRR or TIR8) and ST2  (IL-1RL1), both involved in negative regulation of IL-1 and 
LPS signalling, belong also to this family (Sims, 2002). The IL-1R1 is a receptor for IL-1, refering to both 
IL-1α and IL-1β molecules, and IL-1 receptor antagonist (IL-1Ra), while the IL-1R2 can only bind IL-1. 
IL-1α and IL-1β are agonists and IL-1Ra is a specific receptor antagonist. IL-1α, IL-1β and IL-1Ra 
belong to the large IL-1 gene family. Binding of IL-1Ra to the receptor complex prevents or disrupts the 
complex between IL-1 and the receptor (Dinarello, 1996). The IL-1R1 is an integral membrane protein 
containing a single membrane-spanning segment of 21 amino acid residues. The extracellular ligand-
binding domain of the receptor consists out of three Ig-like domains (319 amino acid residues). The 
intracellular domain contains 217 amino acid residues. The human and murine IL-1 receptors are very 
similar (Sims et al., 1989). Similar to the IL1-R1, the IL-1R2 has three extracellular Ig-like domains and a 
short transmembrane region. In contrast, the IL-1R2 has a truncated cytoplasmic domain of only 29 
intracellular amino acid residues. IL-1 mediated signalling occurs exclusively through IL-1R1 and the IL-
1R2 is not able to transduce signals (Sims et al., 1993). Instead, IL-1R2 acts as a decoy receptor, 
inhibiting IL-1 signalling by capturing and blocking IL-1 (Re et al., 1996). It is likely that 
heterodimerization of the intracellular domains of IL-1R1 and IL-1RAcP triggers IL-1 signal transduction. 
IL-1R1 is mainly expressed on endothelial cells, epithelial cells, fibroblasts, epidermal dendritic cells, 
and T lymphocytes, while IL-1R2 is predominantly present on B-cells, monocytes, bone marrow cells 
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and neutrophils (Dinarello, 1996). IL-1 is a proinflammatory cytokine that elicits its pleiotropic effects 
through activation of the transcription factors NF-κB and activator protein-1 (AP-1). IL-1 is involved in 
several inflammatory and autoimmune pathologies, such as in septic shock, rheumatoid arthritis, 
inflammatory bowel diseases, psoriasis, autoimmune diabetes, osteoporosis, leukemias and solid 
tumors and many other pathological conditions (Dinarello, 1996). 
Similar to IL-1, IL-18, another member of the IL-1 family, participates in both innate and acquired 
immunity. IL-18 activates the IL-18 receptor (IL-18R) complex. This IL-18R complex consist out of IL-
18Rα, a member of the IL-1R family, and a signalling chain, also a member of the IL-1R family. Binding 
of IL-1/IL-18 to their receptors results in recruitment of the adaptor protein MyD88 and activates a 
signalling pathway similar to that of TLRs (Dinarello, 1999).  
 
1.3.3.  Non-TLR pattern-recognition receptors recognizing PAMPs of different microorganisms 
 
Several non-TLR PRRs can recognize LPS. Among them are some members of the macrophage 
scavenger receptor (MSR) family. Scavenger receptors are integral membrane proteins expressed by 
mammalian monocytes/macrophages and certain endothelial cells. They play an important role in lipid 
transport, but also in host defence and in the regulation of adaptive immunity. They bind to bacterial cell 
walls and their products including Gram-negative bacteria (LPS), Gram-positive bacteria (lipoteichoic 
acid or LTA), intracellular bacteria and CpG DNA. They are essential in the clearing of bacteria from the 
circulation (Gordon, 2002; Peiser et al., 2002). The scavenger receptor family comprises at least eight 
different subclasses (A-H). The different subclasses bear little sequence homology to each other but 
recognize common ligands (Murphy et al., 2005). Macrophage scavenger receptor class A types I and II 
(MSR-A) knockout mice have smaller atherosclerotic lesions and are also more susceptible to infection 
with Listeria monocytogenes (Kobayashi et al., 2000; Suzuki et al., 1997). MARCO, a MSR-A family 
member, is a macrophage receptor with a collagenous structure encoded by a distinct gene. MARCO 
binds to a range of Gram-negative and Gram-positive bacteria to clear them of circulation (Gordon, 
2002).  
 
The macrophage mannose receptor (MMR), a member of the calcium-dependent lectin family, is an 
endocytic PRR expressed by macrophages, DCs and some endothelial cells. It functions as a secreted 
PRR and specifically recognizes microbial carbohydrates through its carbohydrate recognition domains 
(CRD) and mediates their phagocytosis by macrophages (Gordon, 2002). In addition, it recognizes LPS 
of Klebsiella pneumoniae (Zamze et al., 2002). Type 3 complement receptor (CR3), also known as Mac-
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1 or CD18/CD11b, is a β2 integrin expressed on cells of myeloid origin. It is mainly a phagocytic 
receptor for complement opsonised particles and contributes to the clearance of apoptotic cells 
(Gordon, 2002). It can also interact with LPS (Wright and Jong, 1986). Malhotra and colleagues showed 
that L-selectin on neutrophils (Malhotra et al., 1996) and P-selectin on platelets (Malhotra et al., 1998) 
are able to bind LPS. A receptor on the plasma membrane of rat hepatocytes can also bind with 
heptose residues in the inner core of LPS (Parent, 1990). 
 
LPS binding protein (LBP) is important in the LPS response by accelerating the binding of LPS to CD14, 
a glycerosylphosphatidylinositol (GPI)-anchored protein (see further) (Yu and Wright, 1996). Other LPS-
binding proteins such as bactericidal/permeability-increasing protein (BPI), cathelicidin antimicrobial 
peptide (CAP)18, CAP37, serum amyloid P (SAP), lactoferrin and lysozyme have been characterized 
(Van Amersfoort et al., 2003). 
 
The nucleotide-binding site and leucine-rich repeat (NBS-LRR) family of proteins, involved in 
intracellular recognition of microbes and their PAMPs, is characterized by a tripartite structure with a C-
terminal LRR domain, a central nucleotide binding site (NBS) domain and an N-terminal effector 
domain, such as a pyrin (PYD), a caspase-recruitment domain (CARD) or a baculovirus inhibitor of 
apoptosis repeat (BIR) domain. The LRR domain is necessary for sensing microbial motifs. The NBS 
domain is essential for the oligomerization of the molecule and its subsequent transactivation capacity. 
The N-terminal CARD and PYD signal through homophylic interactions with other CARD/PYD 
containing molecules. Nucleotide-binding oligomerisation domain  (Nod) molecules belong to this NBS-
LRR family of PRRs. Nod-1 and Nod-2, are cytoplasmic surveillance proteins. Structurally the Nod 
proteins are similar to the R proteins of plants, involved in disease-resistance against pathogens 
(Philpott and Girardin, 2004). Nod-1 and Nod-2 both recognize bacterial peptidoglycan (PGN) although 
distinct motifs of PGN. The core structure recognized by Nod-1 is d-Glu-meso-DAP, a naturally 
occurring PGN degradation product of Gram-negative bacteria (Chamaillard et al., 2003). In contrast, 
Nod-2 recognizes muramyl dipeptide (MDP), the minimal bioactive PGN motif common to both Gram-
positive and Gram-negative bacteria. Before, it was thought that Nod-1 and Nod-2 could recognize LPS, 
but recent reports have demonstrated that this was due to contamination of LPS preparations with PGN 
motifs (Girardin et al., 2003). 
 
TLR3-deficient mice are only partially impaired in dsRNA recognition (Alexopoulou et al., 2001). Various 
molecules for the TLR3-independent recognition of dsRNA and viruses are known. PKR or dsRNA-
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dependent protein kinase is an interferon-induced serine-threonine kinase implicated in dsRNA 
recognition. PKR stops protein synthesis by phosphorylating the alpha subunit of the translation 
initiation factor eIF2 (Taylor et al., 2005). Retinoic acid-inducible gene I (RIG-I) is a DexD/H box RNA 
helicase containing a caspase recruitment domain (CARD). It was demonstrated using RNAi knockdown 
experiments and ectopic expression of RIG-I, that RIG-I is important in dsRNA- and virus-induced type I 
IFN expression (Yoneyama et al., 2004). In fibroblasts and conventional dendritic cells (cDCs), RIG-I 
induces type I IFNs by activating IRF-3 via IκB kinase-related kinases. In contrast, plasmacytoid DCs 
(pDCs), which produce large amounts of IFN-α, use TLR3 rather than RIG-I for viral detection (Kato et 
al., 2005). Melanoma differentiation-associated gene (MDA) 5 is another CARD and helicase domain 
containing protein which senses viral RNA (Yoneyama et al., 2005). 
Table I.1.5. gives an overview of PRRs recognizing PAMPs of different microorganisms and some other 
of their endogenous and exogenous ligands. 
 
Table I.1.5. – Pattern-recognition receptors and their ligands.  
Receptor (Family) Example(s) Ligand(s) 
Scavenger receptors and 
related 
MSR-A I/II LPS, LTA, oxidized LDL, 
apoptotic cells 
 MARCO G-/G+ bacteria, LPS  
C-type lectins and related MMR Klebsiella LPS, 
lipoarabinomannan, 
mannosyl, fucosyl 
 
β2 Integrins CR3 (CD18/11b) LPS, C3bi, C3b, ICAM-1/2, 
zymosan 
 
L-selectin  LPS, LTA, GlyCAM-1, CD34, 
AdCAM-1 M 
P-selectin  LPS, PSGL-1 (sialyl Lewis-X 
oiety) m
 
Heptose receptor  LPS  
GPI-anchored proteins CD14 LBS, PGN, LBP, apoptotic 
cells, HDL, HSP, fibrinogen 
 
LPS binding molecules LBP, BPI, CAP18, 
CAP37, SAP, lactoferrin, 
lysozyme  
LPS 
NBS-LRR Nod-1 LPS(?), PGN of G-  
 Nod-2 LPS(?), PGN of G-/G+  
PKR  dsRNA 
RIG-I  dsRNA 
MDA5  dsRNA 
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1.4.   Recognition of LPS 
 
1.4.1.  Requirement of LBP, MD-2 and CD14  
 
 
TLR4 forms a complex with several proteins on the cell surface to recognize and respond to LPS. 
Overexpression of TLR4 in HEK293 cells is not sufficient for LPS-signalling, indicating the necessity for 
additional factors (Kirschning et al., 1998).  
 
LBP. Until the purification of LBP from rabbit serum in 1986, it was believed that LPS activates immune 
cells through spontaneous intercalation of lipid A into the mammalian lipid bilayer (Tobias et al., 1986). 
LBP was demonstrated to bind with the lipid A moiety of rough and smooth LPS (Tobias et al., 1989). It 
is constitutively synthesized in hepatocytes as a single polypeptide, glycosylated, and secreted into the 
bloodstream as a 60-kD glycoprotein (Grube et al., 1994; Ramadori et al., 1990). In all species, 
including human, LBP behaves as an acute phase protein (Schumann et al., 1996). Its synthesis is 
under control of cytokines (e.g IL-1β and IL-6) and steroid hormones (e.g. glucocorticoids) (Grube et al., 
1994; Schumann et al., 1996). Upon infection, the levels of LBP in serum greatly increases (Gallay et 
al., 1993). Besides the liver, LBP is also produced in the lung, kidneys and heart (Su et al., 1994). 
LBP is closely related to bactericidal/permeability-increasing protein (BPI), a protein found in the 
granules of polymorphonuclear neutrophils (PMN) and able to bind LPS with high affinity (Elsbach and 
Weiss, 1993). In contrast to LBP, BPI neutralizes the LPS activity (Gallay et al., 1993). LBP has opsonic 
activity, but its importance as a protein involved in LPS response lies with its abilities to accelerate the 
binding of endotoxin to either membrane or soluble CD14 (Yu and Wright, 1996). LPS bound to LBP is 
100-to 1000-fold more potent, as measured by the response of CD14+ cells (Martin et al., 1992). The C-
terminal part of LBP is necessary for interaction with CD14. A truncated form of human LBP comprising 
amino acid residues 1-197, binds LPS but does not transfer LPS to CD14 (Han et al., 1994). Residues 
91-108 of the N-terminal part of the molecule are necessary for LPS binding (Taylor et al., 1995), while 
the LPS binding site of LBP is localized in the N-terminal part.    
The importance of LBP in LPS signalling is obvious from studies with LBP knockout animals, which are 
hypersusceptible to invasion by otherwise harmless numbers of Gram-negative bacteria (Fierer et al., 
2002; Jack et al., 1997). This sentinel function of LBP is shared by CD14 (Moore et al., 2000). LBP has 
been shown to contribute to LPS toxicity in experimental endotoxemia. Blockade of LBP activity with 
polyclonal Abs was found to protect mice from lethal endotoxemia (Gallay et al., 1993; Gallay et al., 
1994). LBP contributes to the toxicity of high doses of LPS, and the transfer of LPS to HDL is not 
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sufficient to prevent the activation of cells via the LPS/LBP/CD14 pathway. LBP can transfer LPS also to 
high density lipoproteins and LPS is nearly biologically inactive when complexed to HDL (Vesy et al., 
2000). Since the affinity of CD14 for LPS-LBP is greater than that of HDL, it is not clear whether the 
trafficking of LPS to HDL is a major pathway in vivo. High ratios of LBP to LPS may also inhibit the 
binding of LPS to lipid membranes and decrease the stimulatory effects of LPS on mononuclear cells 
(Gutsmann et al., 2001). CD14 greatly enhances the formation of LPS-TLR4-MD-2 complexes. 
 
MD-2. Myeloid differentiation-2 (MD-2) is a 25-kDa secreted glycoprotein that exists on the cell surface in 
complex with transmembrane proteins. Following synthesis, MD-2 is either secreted directly into the 
medium as a soluble, active protein, or binds directly to TLR4 in the endoplasmic reticulum before 
migrating to the cell surface. MD-2 was first identified as a molecule similar to MD-1, a protein that binds 
with the B-cell specific receptor RP105. RP105 contains LRRs similar to Drosophila Toll and is involved 
in B-cell activation. It was thought that an analogous protein might associate with TLR4. Shimazu et al. 
identified that MD-2 physically associates with the extracellular leucine-rich repeats of TLR4 and 
augments TLR4-dependent LPS responses in vitro (Shimazu et al., 1999). MD-2-knockout mice do not 
respond to LPS, but are susceptible to Salmonella typhimurium infection. These phenotypes are 
identical to TLR4-knockout mice, demonstrating an absolute requirement for MD-2 in TLR4-dependent 
LPS responses in vivo (Nagai et al., 2002a). B-cells deficient for RP105 or MD-1 have also an impaired 
LPS response, revealing that B-cells require both TLR4/MD-2 and RP105/MD-1 clusters for intact LPS 
signalling (Nagai et al., 2002b). 
LPS binds directly to cell surface TLR4-MD2 (Akashi et al., 2003; da Silva Correia et al., 2001). 
Furthermore, other groups have indicated that MD-2 binds to LPS and that the soluble MD-2/LPS 
complex behaves as an active ligand for TLR4 (Kennedy et al., 2004; Viriyakosol et al., 2001; Visintin et 
al., 2003). The amino-terminal region of TLR4 seems to be crucial for its association with MD-2, which is 
essential for the cell surface expression of the receptor and hence the recognition of LPS (Fujimoto et 
al., 2004).  
 
CD14. CD14 belongs to the family of leucine-rich proteins. It is a 55-kDa glycerosylphosphatidylinositol 
(GPI)-anchored glycoprotein expressed on the plasma membrane of most cell types of the myeloid 
lineage (Tobias et al., 1995). Other LPS-responsive cells such as endothelial cells, smooth muscle cells, 
and some epithelial cell lines do not express this membrane-bound CD14 (mCD14), but contain the 
soluble form of CD14 (sCD14), which circulates in plasma without a GPI-tail (Pugin et al., 1993). 
Treatment with phosphatidylinositolphospholipase C (PI-PLC) cleaves CD14 between 
phosphatidylinositol and the diacylglycerol moiety and releases the protein from the cell surface. The 
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transfer of LPS from LBP-LPS complexes to mCD14 or sCD14 is catalyzed by LBP. Transgenic mice 
over-expressing CD14 are hypersensitive to LPS-induced endotoxin shock (Ferrero et al., 1993). In 
addition, CD14-deficient mice were found to be highly resistant to shock induced by either live Gram-
negative bacteria or LPS. Surprisingly, despite the inability to respond to LPS and Gram-negative 
bacteria, CD14-null mice have an accelerated clearance of Gram-negative bacteria from the blood and 
tissues (Haziot et al., 1996). This is due to an enhanced infiltration of neutrophils that is normally 
delayed in CD14-expressing mice (Haziot et al., 2001). However, at very high concentrations of LPS or 
bacteria, responses through non-CD14 receptors could be detected (Haziot et al., 1996). In CD14-null 
macrophages, CD11b/CD18 receptors can compensate for deficiency in CD14 in response to whole 
bacteria (Moore et al., 2000). Blocking of CD14 only partially inhibits LPS-binding (Lynn et al., 1993). 
Neutralization of CD14 prevents lethal shock by LPS. However, after blocking LBP and CD14, mice 
challenged with virulent Klebsiella pneumoniae or Salmonella typhimurium did not survive. Thus, host 
responses to Gram-negative bacteria are not identical to that of LPS (Heumann et al., 2003). Also, 
CD14 is important in the response on TLR2-mediated peptidoglycan signalling (Dziarski and Gupta, 
2005). CD14 lacks transmembrane and intracellular domains, which disables this molecule to transduce 
a signal inside the cell. So another molecule, namely TLR4, is necessary for signal transduction. 
 
1.4.2.  A receptor cluster as a model for TLR4 activation 
 
Different studies have suggested that LPS must interact with a complex of transmembrane receptors for 
signal transduction. An activation cluster comprising of TLR4, CD14, CD11b/CD18, CD55, Hsp70, 
Hsp90, growth differentiation factor 5 (GDF5) and chemokine receptor 4 (CXCR4) was formed in 
response to LPS. The composition of these supramolecular activation clusters may change with the 
activation state of the cell. Stimulation with penta-acyl lipid A, which is a known LPS antagonist, 
triggered the recruitment of hsp70, hsp90, CD55 and, to a lesser extent, TLR4. CD11b/CD18, CD81, 
GDF5 and CXCR4 were not recruited within the cluster of receptors, thus suggesting that different 
shapes of LPS promote different protein–protein receptor associations (Pfeiffer et al., 2001; Triantafilou 
and Triantafilou, 2002).  Another model described formation of an activator cluster composed of TLR4, 
CD14, CD11b/CD18, CD55, CD16a, Fcγ RIIIa, CD36 and CD81, Fcγ-receptors CD32 and CD16a after 
LPS or LTA stimulation (Pfeiffer et al., 2001).  
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2.   TLR/IL-1R SIGNALLING 
 
2.1.  TIR domain-containing adaptors 
 
The first TIR domain-containing adaptor characterized was MyD88. At this moment, four additional TIR 
domain-containing adaptors have been identified. These include TIRAP/Mal, TRIF, TRAM and SARM 
(Figure I.2.1.) and will be discussed next. 
 
MyD88. Myeloid differentiation factor 88 (MyD88) was originally identified as a myeloid differentiation 
primary response gene induced rapidly during IL-6-stimulated differentiation of M1 myeloleukaemic cells 
into macrophages (Lord et al., 1990). The protein contains a death domain (DD) in the N-terminal region 
and a TIR domain in the C-terminal region. Subsequently, MyD88 was cloned and proven to be an 
adaptor molecule involved in recruitment of IRAK to the IL-1R complex after IL-1 stimulation. MyD88 
associates with the TIR domain of TLRs/IL-1Rs and links them with downstream signalling molecules 
containing DDs, an event leading to NF-κB activation (Wesche et al., 1997). MyD88 forms homodimers 
through its DD domain (DD-DD interaction) or through its TIR domain (TIR-TIR interaction), and is 
recruited as a homodimer to the receptor complex (Dunne et al., 2003). It is a common adaptor for all 
TLRs, except TLR3 (Medzhitov et al., 1998). In response to several TLR ligands, MyD88-deficient mice 
show an impaired pro-inflammatory cytokine (TNF-α, IL-12 and IL-6) production (Akira et al., 2001). In 
addition, a role for MyD88 in apoptosis has been proposed. Bacterial lipoproteins induce apoptosis of 
monocytic cells through a TLR2- and MyD88-dependent pathway and it is demonstrated by co-
immunoprecipitation studies that Fas-associated death domain protein (FADD) and MyD88 interact 
through their DDs. Thus, an apoptotic signal is mediated via a MyD88 - FADD - caspase 8 pathway 
(Aliprantis et al., 2000). Also, a cellular splice variant of MyD88 (referred to as MyD88s), lacking only the 
short intermediate domain separating the DD and TIR domains, has been identified. MyD88s has been 
demonstrated to be involved in the regulation of IL-1R- and TLR4-mediated signalling. Over-expression 
of MyD88s inhibits IL-1- and LPS- induced NF-κB activation (Janssens and Beyaert, 2002; Janssens et 
al., 2002). 
 
TIRAP/Mal. MyD88-deficient mice fail to produce inflammatory cytokines in response to LPS. On the 
other hand, activation of NF-κB and mitogen-activated protein kinase (MAPK) was still able, although 
with delayed kinetics (Kawai et al., 1999). This study suggested a role for an additional adaptor in LPS-
induced signalling and led to the search for homologues of MyD88. Fitzgerald et al. discovered Mal 
(MyD88-adapter-like) during high-throughput sequencing of a human DC cDNA library as a gene with 
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sequence similarity to MyD88. Mal has a C-terminal TIR domain but lacks, in contrast to MyD88, a DD 
in its N-terminal region (Figure I.2.1.). Through their C-terminal TIR domains, Mal and MyD88 can form 
homo- and/or heterodimers. A dominant-negative form of Mal inhibits NF-κB activation by LPS, but it 
does not inhibit activation of NF-κB by IL-1RI or IL-18R. In addition, TLR4 has been shown to recruit 
Mal. Also, it was demonstrated that IRAK-2, but not IRAK-1, is necessary for NF-κB activation by Mal. 
Thus, Mal is a specific adaptor for TLR4 signalling (Fitzgerald et al., 2001). At the same time, another 
group also discovered Mal, but named it TIR domain-containing adaptor protein (TIRAP). They 
confirmed the important role for Mal/TIRAP in NF-κB activation by TLR4. In addition, they showed that 
Mal/TIRAP interacts with PKR, which is activated upon LPS-stimulation in a MyD88-independent 
manner (Horng et al., 2001). 
 
MyD88
TIRAP/Mal
TRIF/TICAM1
TRAM/TIRP/TICAM2
712
235
296
TIRDD
TIR
TIR
SARM TIR
735
SAM SAM
235
TIRPEST
 
 
Figure I.2.1. - TIR domain-containing adaptor molecules. A schematic representation of the TIR domain-containing 
adaptor molecules MyD88, Mal/TIRAP, TRIF/TICAM1, TRAM/TICAM2/TIRP, and SARM. MyD88 is an essential adaptor 
used by all TLRs except TLR3. Mal/TIRAP is restricted to TLR2- and TLR4-dependent signalling to NF-κB. TRIF is an 
adaptor for TLR3 and TLR4 signalling, which regulates both NF-κB and IRF-3. TRAM is specific for TLR4 signalling. A 
function for SARM has yet to be described. The AA lengths are indicated on the right side. 
 
Initially it was thought that TIRAP mediates the MyD88-independent signalling from TLR4. However, 
subsequent studies using TIRAP-deficient macrophages showed that expression of IFN-β and IFN-
inducible genes is intact (Yamamoto et al., 2002a). Also, TIRAP-deficient mice respond normal to 
ligands of TLR3, TLR5, TLR7 and TLR9, as well as to IL-1 and IL-18. In response to ligands of TLR2 
there’s a defect in NF-κB activation, MAPK activation and subsequent cytokine production, but not in 
expression of IFN-inducible genes (Horng et al., 2002). Even in mice lacking both MyD88 and 
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Mal/TIRAP, expression of IFN-inducible genes by LPS is not impaired. Thus, Mal/TIRAP is essential for 
the TLR2- and TLR4-mediated MyD88-dependent signalling pathway, but not for the MyD88-
independent signalling. 
 
TRIF. A third TIR domain-containing adaptor, (TIR domain-containing adaptor inducing IFN) TRIF, was 
identified by a database search (Yamamoto et al., 2002b). Another group identified the same adaptor as 
a molecule associated with TLR3 by a yeast two-hybrid screen and termed it TIR-containing adaptor 
molecule-1 (TICAM-1) (Oshiumi et al., 2003a). Over-expression of TRIF, but not MyD88 or TIRAP, in 
HEK293 cells led to activation of the IFN-β promoter. Therefore, this molecule was named TIR domain-
containing adaptor inducing IFN-β or TRIF. Furthermore, over-expression of TRIF, as well as MyD88 
and TIRAP, resulted in the activation of the NF-κB-dependent promoter. Also, a dominant-negative 
TRIF inhibited TLR3-dependent activation of the IFN-β promoter. These in vitro studies showed that 
TRIF is important in the MyD88-independent pathway to induce IFN-β.  
In TRIF-deficient mice, TLR3- en TLR4-mediated expression of IFN-β and IFN-inducible genes and 
activation of IRF-3 was severely impaired (Yamamoto et al., 2003a). Analysis of mutant Lps2 mice, 
generated by random germline mutagenesis using the alkylating agent N-ethyl-N-nitrosourea (ENU), 
also led to the conclusion that Trif is responsible for TLR3- and TLR4-mediated responses (Hoebe et al., 
2003). In addition, TRIF-deficient mice have a defective TLR4-mediated inflammatory cytokine 
production, although LPS-induced IRAK-1 phosphorylation and early phase NF-κB activation is normal. 
Therefore, the TLR4 signalling pathway requires activation of both the MyD88-dependent and MyD88-
independent components to induce inflammatory cytokines. 
 
TRAM. A fourth TIR domain-containing adaptor has been identified through sequence homology by 
different groups (Bin et al., 2003; Fitzgerald et al., 2003b; Oshiumi et al., 2003b; Yamamoto et al., 
2003b). This molecule was called TRIF-related adaptor molecule (TRAM), TIR-containing protein 
(TIRP), and TICAM-2. In vitro studies using RNAi-mediated knockdown of TRAM expression showed 
that TRAM is involved in the MyD88-independent pathway from TLR4, but not TLR3 (Fitzgerald et al., 
2003b; Oshiumi et al., 2003b). In addition, similar to TRIF-deficient mice, TRAM-deficient mice showed 
impaired activation of IRF-3 and diminished expression of IFN-β and IFN-inducible genes in response to 
LPS. However, TRAM-deficient mice showed normal responses to a TLR3 ligand. Also, TRAM-deficient 
mice are deficient in production of pro-inflammatory cytokines in response to LPS, although they show 
normal activation of IRAK-1 and early phase NF-κB activation (Yamamoto et al., 2003b). These data 
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prove that TRAM is specific for the TLR4-mediated MyD88-independent pathway and that TRAM is 
involved in the TLR4-mediated production of inflammatory cytokines (Yamamoto et al., 2003b). 
 
SARM. The fifth known TIR adaptor protein is also known as SARM (sterile α and HEAT/armadillo motif 
containing protein) (O'Neill et al., 2003). Human SARM consists of about 700 amino acids, with the TIR 
domain located in the C-terminal region. At present, its function is entirely unknown. SARM is the most 
distant of the TIR adaptors, displaced from the other members of the family by a great evolutionary 
distance. The TIR motif of SARM is most similar to a TIR motif observed in the Caenorhabditis elegans 
TIR domain-containing protein (TIR1). TIR1 mediates the expression of genes that encode antimicrobial 
peptides, but this response is independent of the C.elegans TLR (Couillault et al., 2004). Next to its TIR 
domain, SARM also contains two sterile α motif (SAM) domains and an armadillo repeat motif (ARM). 
 
2.2.   TLR signalling 
 
Stimulation of TLRs/IL-1Rs induces activation of signalling pathways. After ligand binding, TLRs/IL-1Rs 
form dimers and undergo a conformational change necessary to recruit downstream adaptor molecules. 
TLR2 can form heterodimers with TLR1 and TLR6 (Akira and Takeda, 2004). TLR10 can form 
heterodimers with TLR1 and TLR2 (Hasan et al., 2005). In other cases, TLRs form homodimers. MyD88 
was the first adaptor molecule proven to be important in the signalling pathways originating from the TIR 
domain of the TLRs/IL-1Rs. It was demonstrated that MyD88-deficient mice fail to produce inflammatory 
cytokines such as TNF, IL-1 and IL-6, but are able to activate NF-κB and JNK, although with delayed 
kinetics, in response to LPS (Kawai et al., 1999). In addition, MyD88-null mice still induce IFN-
dependent genes such as GARG16 (glucocorticoid-attentuated response gene 16), IRG1 
(immunoresponsive gene 1) and CXCL10 (CXC-chemokine ligand 10), co-stimulatory molecules and 
maturation of DCs in response to LPS (Kaisho et al., 2001; Kawai et al., 2001). This indicated that 
although MyD88 is important for LPS-induced production of inflammatory cytokines, there must be a 
pathway independent of MyD88. Four different TIR domain-containing adaptor molecules, including 
MyD88, TIRAP/Mal, TRAM and TRIF, determine the signalling specificity of the response. (Akira and 
Takeda, 2004; Fitzgerald et al., 2001; Kawai et al., 1999; Oshiumi et al., 2003a; Yamamoto et al., 
2003a; Yamamoto et al., 2002a; Yamamoto et al., 2003b; Yamamoto et al., 2002b). The MyD88-
dependent pathway is used by all TLRs, except TLR3 (Moynagh, 2005). However, there are some 
differences in the use of signalling molecules in the MyD88-dependent pathway from TLR7 and TLR9 in 
pDCs. To conclude, two main pathways can become activated upon TLR stimulation: a MyD88-
dependent pathway that promotes fast activation of NF-κB and induction of pro-inflammatory molecules 
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and a MyD88-independent pathway that mediates slow activation of NF-κB and activates IFN-regulatory 
factor (IRF-3), which leads to induction of IFN-β, IFN-inducible genes and co-stimulatory molecules. 
This MyD88-independent pathway is specific for the TLR3- and TLR4-signalling pathways (Akira et al., 
2001). 
2.2.1.    The MyD88-dependent pathway 
 
2.2.1.1.   Important molecules belonging to the MyD88-dependent pathway 
 
IRAK family. In mammals, four members of the IL-1R-associated kinase (IRAK) family have been 
identified: IRAK-1, IRAK-2, IRAK-3 or IRAK-M, and IRAK-4 (Li et al., 2002). IRAKs contain an N-
terminal DD and a central serine/threonine kinase domain. IRAK-1 and IRAK-4 are catalytically active 
since they harbour a critical aspartate residue in their kinase domain. IRAK-2 and IRAK-M lack this 
critical residue, which causes them to be catalytically inactive (Janssens and Beyaert, 2003). In contrast 
to IRAK-4-deficient mice which are completely defective in their response to ligands that stimulate 
TLR2, TLR3, TLR4 and TLR9 (Suzuki et al., 2002), IRAK-1-deficient mice show diminished but not 
abolished cytokine production in response to IL-1 and LPS (Swantek et al., 2000; Thomas et al., 1999). 
Introduction in 293RI cells of a dominant-negative IRAK-4 molecule results in an impaired IRAK-1 
degradation after IL-1 stimulation. Thus, IRAK-1 is a direct substrate of IRAK-4 but not vice versa (Li et 
al., 2002). In addition, the kinase activity seems not essential for signalling, as seen by strong NF-κB 
activation after over-expression of a kinase-defective IRAK-1 mutant (Li et al., 1999a). Also, children 
with an inherited IRAK-4 deficiency fail to respond to IL-1, IL-18, or stimulation of TLR2, TLR3, TLR4 
and TLR5, and as a consequence develop infections caused by pyogenic bacteria (Picard et al., 2003). 
IRAK-M is primarily expressed by monocytes and macrophages. IRAK-M-deficient mice show an 
increased production of pro-inflammatory cytokines in response to TLR ligands and an exaggerated 
inflammatory response to bacterial infection, demonstrating its role as a negative regulator in TLR 
signalling (Kobayashi et al., 2002a). 
 
TRAF6. TNFR-associated factor (TRAF) proteins belong to a family of evolutionary conserved proteins 
that mediate cytokine signalling pathways. This family contains seven members and is characterized by 
a N-terminal coiled-coil domain, called TRAF-N, and a conserved C-terminal domain, called TRAF-C. 
The TRAF-C domain is necessary for interaction with upstream molecules and for interaction with TRAF 
proteins. The TRAF-N domain contains a RING (really interesting new gene)-finger/zinc-finger region, 
essential for downstream signalling events (Bradley and Pober, 2001). TRAF6 was first identified as a 
protein binding to the N-terminal region of CD40, a member of the TNFR superfamily (Ishida et al., 
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1996). Next to its involvement in CD40 signalling, TRAF6 is important in TLR/IL-1R signalling through its 
interaction with IRAKs. The consensus sequence for the TRAF-6-binding domain is Pro-X-Glu-X-X-
aromatic/acidic residue, and is found three times in IRAK-1, two times in IRAK-2 and once in IRAK-M 
(Ye et al., 2002). In TRAF6 deficient mice, LPS-induced inflammatory cytokine production is reduced 
and NF-κB and MAPK activation is observed with delayed kinetics. In response to ligands for TLR2, 
TLR5, TLR7 and TLR9, NF-κB and MAPK activation or inflammatory cytokine production is impaired 
(Gohda et al., 2004). 
 
TAK1 and TABs. TGF-β-activated kinase 1 (TAK1), also called TRAF2-associated kinase (T2K), is a 
member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family, originally identified in 
the TGF-β signalling pathway (Yamaguchi et al., 1995). TAK1 binding proteins, TAB1 and TAB2 are two 
proteins involved in the activation of transcription factors NF-κB and activator protein 1 (AP-1) by 
TRAF6 (Deng et al., 2000; Shibuya et al., 1996). TAB2 functions as an adaptor molecule linking TRAF6 
and TAK1 and hereby facilitating activation of TAK1. However, TAB2 deficient embryonic fibroblasts 
show no impaired IL-1/LPS- or TNF-induced NF-κB activation. TAK1 becomes activated by the E2 
ligases Ubc13 and Uev1A, which interact with the E3 ubiquitin ligase TRAF6. The Ubc13 and Uev1A 
complex catalyzes the assembly of a lysine63-linked polyubiquitin chain of TRAF6, thereby inducing 
TRAF6-mediated TAK1 activation (Deng et al., 2000; Wang et al., 2001) (Figure I.2.2). Over-expression 
studies show that LPS and IL-1 can activate TAK1, which in turn activates the IKK complex (Deng et al., 
2000; Lee et al., 2000b). 
 
NF-κB. The NF-κΒ  family is composed of five members of the Rel transcription factor family: p65 
(RelA), RelB, cytoplasmic Rel (c-Rel), p50 (and its precursor p105) and p52 (and its precursor p100). 
Active NF-κB  transcription factors are composed of homodimeric or heterodimeric combinations of 
these members. Heterodimers of p50 and p65 are the most abundant (Akira and Takeda, 2004). B-cells 
from mice deficient in p50, RelA, c-Rel or RelB show an impaired growth response to LPS (Ghosh et al., 
1998). Mice deficient in p50, RelB or p52 were found to be highly susceptible to microbial infections 
(Caamano et al., 1999; Franzoso et al., 1998; Sha et al., 1995). Members of the inhibitory IκB family 
sequester NF-κΒ dimers in the cytosol in an inactive form, until they become phosphorylated on serine 
residues by the IκB kinase (IKK) complex. The IKK complex contains two catalytic subunits, IKK-α and 
IKK-β, as well as a regulatory subunit, IKK-γ or NF-κB essential modulator (NEMO). Phosphorylation of 
IκB leads to its polyubiquitinylation, followed by its degradation by the 26S proteasome. Degradation of 
IκB releases NF-κB and this is followed by translocation of NF-κB to the nucleus where it induces pro-
Tina Mahieu PhD thesis (2006) 39
Chapter I - General introduction 
inflammatory and co-stimulatory molecules (Akira and Takeda, 2004) (Figure I.2.2). Stimulation of a 
human monocytic cell line with LPS enhances IKK activity (O'Connell et al., 1998). In contrast to NF-κB 
activation in IKK-α-null mice, NF-κB activation in IKK-β- or IKK-γ-null mice  is impaired in response to 
LPS or IL-1 (Li et al., 1999b; Rudolph et al., 2000).  
 
MAPKKK/MAPKK/MAPK. Extracellular signal-regulated kinase (ERK1/2)/MAPK, c-Jun N-terminal kinase 
(JNK)/stress-activated protein kinase 1 (SAPK1) and p38/SAPK2 belong to the MAPK family. Activation 
of a MAPK involves a three-part intracellular signal transduction cascade. A MAP/ERK kinase kinase 
(MEKK) or Raf phosphorylates a MAP/ERK kinase (MEK) or MAP kinase kinase (MKK), which in turn 
phosphorylate a specific tyrosine and threonine residue on a MAPK (Figure I.2.2). MEKK3-deficient 
MEFs have an impaired IL-6 production and defective NF-κB, JNK and p38 MAPK activation in 
response to LPS. Stimulation with LPS also induces the association of MEKK3 with TRAF6 (Huang et 
al., 2004). Tumour-progression locus 2 (TPL2) is also involved in TLR4-induced ERK activation 
(Dumitru et al., 2000). MKK4 and MKK7 are involved in phosphorylation of JNK/SAPK1 (Kishimoto et 
al., 2003). MKK6 has been implicated in TAK1-induced JNK and p38 activation (Wang et al., 2001). 
MKK3 is involved in p38 activation in LPS-stimulated neutrophils (Nick et al., 1999).  
The AP-1 family of transcription factors contains c-Jun and c-Fos proteins which form homo- and 
heterodimers (Karin et al., 1997). Jun proteins can also form heterodimers with the cAMP responsive 
element binding protein/activating transcription factor (CREB/ATF) family of transcription factors, such 
as ATF-2, which enables them to bind to the cAMP response element (CRE). Phosphorylation of AP-1 
transcription factors by the MAPK JNK enhances its activity (Karin, 1995). LPS or PGN stimulation 
enhance the transcriptional activity of AP-1 and the CREB/ATF family (Mackman et al., 1991). Viral 
infection and dsRNA activate the transcriptional activity of AP-1 through induction of JNK (Chu et al., 
1999) and p38 (Moynagh, 2005). Recently it has been shown that p38 is needed for phagocytosis 
(Doyle et al., 2004).  
 
2.2.1.2.  TLR-induced MyD88-dependent signalling (Figure I.2.2.) 
 
The IL-1R complex and all TLRs, except TLR3, activate the MyD88-dependent pathway upon 
stimulation. It has been demonstrated that TLR7 and TLR9 use a slightly different MyD88-dependent 
pathway in pDCs. After ligand binding, MyD88 associates with the cytoplasmic TIR domain of TLRs/IL-
1Rs. TIRAP/Mal, a second TIR domain-containing adaptor, is involved in the MyD88-dependent 
signalling pathway through TLR2 or TLR4.  
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Figure I.2.2. - TLR-mediated MyD88-dependent signalling pathway. This pathway is used by all TLRs except TLR3. It is 
demonstrated that TLR7 and TLR9 use a slightly different MyD88-dependent pathway in pDCs. Upon stimulation, TLRs 
homodimerize and undergo conformational changes to recruit adaptor molecules. TLR2 can also form heterodimers with 
TLR1, TLR6 and probably also with TLR10. MyD88 binds to the cytoplasmic portion of TLRs through interaction between 
individual TIR domains. TIRAP/Mal, a second TIR domain-containing adaptor, is involved in the MyD88-dependent signalling 
pathway through TLR2 and TLR4. The MyD88-dependent pathway leads to NF-κB and MAPK activation to induce 
expression of inflammatory cytokines. Both AP-1 and CREB/ATF transcription factors as well as NF-κB are required for 
cytokine production. 
 
 
Next, MyD88 facilitates the binding of IRAK-4 with the receptor complex through interaction of the DDs 
of both molecules. Binding of IRAK-4 to the receptor complex leads to IRAK-4-mediated 
phosphorylation of IRAK-1. This triggers IRAK-1 autophosphorylation and enables IRAK-1/TRAF6 
interactions. TRAF6 is recruited to the receptor complex upon IRAK-1 phosphorylation. Then, the IRAK-
1/TRAF-6 complex dissociates from the receptor and associates with TAK1 and TAK1-binding proteins, 
TAB1 and TAB2, at the membrane portion, inducing phosphorylation of TAB2 and TAK1. IRAK-1 
mediates translocation of this complex (consisting of TRAF6, TAK1, TAB1 and TAB2) to the cytosol, 
while IRAK-1 itself stays at the plasma membrane and is degraded after ubiquitinylation. In the cytosol, 
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the TRAF6/TAK1/TAB1/TAB2 complex recruits other proteins such as the E2 ligases ubiquitin-
conjugating enzyme 13 (Ubc13) and ubiquitin-conjugating enzyme E2 variant 1 (Uev1A). These ligases 
catalyze the synthesis of a Lys63-linked polyubiquitin chain of TRAF6, leading to the activation of TAK1. 
TAK1, in turn, phosphorylates the IKK complex, which consists of IKK-α, IKK-β and IKK-γ, and also 
MAP/ERK kinases. The IKK complex induces phosphorylation of IκB, which sequesters the transcription 
factor NF-κB in the cytoplasm. Phosphorylation of IκB leads to its ubiquitinylation and subsequent 
degradation, triggering the nuclear translocation of NF-κB to induce expression of inflammatory 
cytokines (Takeda and Akira, 2004a; Takeda and Akira, 2004b). MAP/ERK kinases in turn 
phosphorylate specific tyrosine and threonine residues on MAPK. Concomitantly, members of the AP-1 
transcription factor family, such as c-Jun and c-Fos, and members of the CREB/ATF family of 
transcription factors, such as ATF-1 and ATF-2, are activated by MAPK JNK and p38. Both AP-1 and 
CREB/ATF transcription factors as well as NF-κB are required for cytokine production (Figure I.2.2.) 
(Guha and Mackman, 2001). TRAF6 also interacts with two other proteins, p62 and evolutionarily 
conserved signalling intermediate in toll pathways (ECSIT), which link TRAF6 respectively to protein 
kinase ζ and MEKK1 (Janssens and Beyaert, 2002). Also, TLR2 induces apoptosis through MyD88 via 
FADD and caspase 8 (Aliprantis et al., 2000). 
 
2.2.1.3.  TLR7- and TLR9-induced MyD88-dependent signalling in pDCs (Figure I.2.3.) 
 
TLR7 and TLR9 are strongly expressed by pDCs (Liu, 2005) and locate in the endosomal compartment 
(Ahmad-Nejad et al., 2002; Diebold et al., 2004). Also in other cell types such as in immature B-cells 
and in macrophages expression is found of TLR7 and TLR9 (Applequist et al., 2002). pDCs produce 
large amounts of type I IFN, especially IFN-α, in response to virus infection. Lund et al. demonstrated 
by using TLR7-deficient mice that ssRNA viruses, such as VSV or influenza virus, stimulate type I IFN 
responses through TLR7 (Heil et al., 2004; Lund et al., 2003). Furthermore, recognition of these ssRNA 
viruses requires endosomal acidification (Lund et al., 2004). In response to TLR9 ligands such as the 
DNA viruses MCMV and HSV-1/-2, and unmethylated CpG DNA motifs, pDCs also produce large 
amounts of IFN-α (Lund et al., 2003). In contrast to pDCs, macrophages and cDCs respond to TLR7/8 
and TLR9 stimulation by activating NF-κB to produce pro-inflammatory cytokines, but they produce less 
type I IFN (Asselin-Paturel et al., 2005; Heil et al., 2004). Within the endosomal compartment, TLR7 and 
TLR9 signalling is entirely dependent on MyD88 (Lund et al., 2004). MyD88 forms a complex with IRF-7, 
which is constitutively expressed in pDCs, to trigger its activation and induce type I IFN (Honda et al., 
2004; Kawai et al., 2004). IRF-7 seems to be phosphorylated by IRAK-1 (Honda et al., 2005). IRAK-4 
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and TRAF6 are also part of the complex and the ubiquitin ligase activity from the latter is necessary for 
IRF activation (Honda et al., 2004; Kawai et al., 2004) (Figure I.2.3.). 
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Figure I.2.3. - TLR7 and TLR9 signalling pathways. TLR7 and TLR9 are primarily expressed in the intracellular endosomal 
compartement of pDCs. Both TLR7 and TLR9 use a MyD88-dependent, but IRAK-1-independent pathway to induce NF-κB. 
This results in the phosphorylation, ubiquitination and degradation of the IκΒ proteins, allowing NF-κB to translocate to the 
nucleus and induce the expression of inflammatory proteins. TLR7 and TLR9 use also a MyD88- and IRAK-1-dependent 
pathway to phosphorylate IRF-7. Phosphorylation of IRF-7 leads to its translocation to the nucleus to induce type I IFN 
genes. 
 
In IRAK-1-deficient mice, TLR7- and TLR9-mediated IFN-α production is abolished, while inflammatory 
cytokine production is not impaired (Uematsu et al., 2005). In IRAK-1-deficient pDCs, IRF-7 is not 
activated by a TLR9 ligand, whereas NF-κB and MAPK activation is normal. This shows that the kinase 
activity of IRAK-1 is necessary for transcriptional activation of IRF-7 and that IRAK-1 is a specific 
regulator for TLR7- and TLR9-mediated IFN-α induction (Uematsu et al., 2005). Thus, IRAK-1 is not 
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involved in NF-κB-mediated induction of inflammatory genes. Also, it is still unclear whether other 
kinases, such as TBK1 and IKK-ι, might play a role in IRF-7 activation. 
 
2.2.1.4.  Other molecules involved in MyD88 signalling 
 
Pellino. Pellino was originally identified in Drosophila as a protein that interacts with Pelle, a homologue 
of mammalian IRAK. At this moment, three Pellino proteins have been identified. Pellino-1 and Pellino-2 
are observed to interact with IRAK-1 after IL-1 signalling, and in the case of Pellino-2 also after LPS 
signalling (Jiang et al., 2003; Yu et al., 2002). Pellino-3 physically interacts with IRAK-1, TRAF6, TAK1, 
and NF-κB-inducing kinase (NIK) in an IL-1-dependent manner, displaying its role as a scaffolding 
protein. Two alternatively spliced Pellino-3 mRNAs, Pellino-3a and Pellino-3b, are widely expressed 
(Jensen and Whitehead, 2003). Recently, it was found that Pellino-3 acts as a novel upstream regulator 
of the p38 MAPK pathway (Butler et al., 2005).  
 
ECSIT. Evolutionary conserved signalling intermediate in Toll pathways (ECSIT) was identified in a yeast 
two-hybrid screening of TRAF6-interacting molecules. A homologue of mammalian ECSIT is identified in 
Drosophila. ECSIT can interact with the MAP kinase kinase MEKK1, which can phosphorylate and 
activate the IKK complex (Kopp et al., 1999). ECSIT-deficient mice die on about embryonic day 7.5 
(Xiao et al., 2003). This adaptor protein plays not only a role in Toll/IL-1 signalling, but also in bone 
morphogenetic protein (BMP) signalling. Expression of a dominant-negative mutant and knock-down of 
ECSIT with short hairpin RNA inhibits both BMP and Toll signalling (Xiao et al., 2003).  
 
Bruton’s tyrosine kinase. Bruton’s tyrosine kinase (BTK) belongs to the SRC-related TEC-family of protein 
tyrosine kinases. BTK has an essential role in B-cell receptor mediated signalling and in B-cell 
development. It has been observed to interact with the TIR domain of TLRs, such as TLR4, TLR6, TLR8 
and TLR9 (Jefferies et al., 2003) and of signalling molecules such as TIRAP and MyD88. Also, BTK is 
tyrosine phosphorylated upon LPS stimulation. Expression of a dominant-negative form of BTK inhibits 
LPS-induced NF-κB activation (Meng and Lowell, 1997). 
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2.2.2.   TLR3- and TLR4-mediated MyD88-independent pathway 
 
2.2.2.1. Some important molecules belonging to the MyD88-independent pathway 
 
TRIF and TRAM. See section 2.1 
 
 
TBK1 and IKK-ε/IKK-i. Hiscott and colleagues tried to identify molecules that interact with IRF-3 by two-
hybrid screening, and found that IRF-3 was associated with two non-canonical IKKs, TANK-binding 
kinase 1 (TBK1) and IKK-ε/-i (Sharma et al., 2003). TBK1, also called NF-κB-activating kinase (NAK), 
and IKK-ε/IKK-i have distinct kinase activities compared with the canonical IKKs, IKKα and IKK-
β (Takeda and Akira, 2004b). McWhirter and colleagues showed that purified recombinant IKK-ε and 
TBK1 directly phosphorylate the critical serine residues in IRF-3. In response to LPS, mouse embryonic 
fibroblasts (MEFs) derived from TBK1-deficient mice show impaired production of type I IFN and IFN-
inducible genes, but not of pro-inflammatory cytokines (McWhirter et al., 2004). However, IKK-ε 
knockout mice show normal production of these genes. MEFs from IKK-ε/TBK1-doubly deficient mice 
were completely defective in the induction of IFN-β as well as IFN-inducible genes in response to poly 
(I:C) stimulation. Activation of IRF-3 in response to LPS and poly (I:C) was abolished in IKK-ε/TBK1 
double deficient cells (Hemmi et al., 2004). These observations demonstrate that IKK-ε/TBK1 signalling 
is essential for LPS and dsRNA-induced IFN responses (Fitzgerald et al., 2003a; Sharma et al., 2003). 
 
IRF-3. IRF-3 was identified through a search of an expressed sequence tag (EST) database for IRF-1 
and IRF-2 homologues (see further). IRF-3 is constitutively expressed in all tissues and is not induced 
by viral infection or IFN treatment (Au et al., 1995). It is present in the cytoplasm due to a continuous 
nuclear export mediated by a nuclear export signal (NES). IRF-3 also contains a nuclear localization 
sequence (NLS), an IRF association domain (IAD) and a DNA binding domain (DBD) (Yoneyama et al., 
1998). The C-terminal regulatory domain is activated upon phosphorylation of specific serine residues 
by TBK1 and IKK-ε. The serine residues, which become phosphorylated, differ between the TLR3 and 
TLR4 pathways. The serine residue 396 (Ser396) in the C-terminal portion of IRF-3 is only 
phosphorylated after stimulation with dsRNA, while Ser386 is phosphorylated both upon LPS and 
dsRNA stimulation (Mori et al., 2004; Servant et al., 2003). However, the critical serine residue in IRF-3 
seems to be Ser386 (Mori et al., 2004). Phosporylation of IRF-3 causes a change in conformation, 
revealing the IAD and DBD domains. This allows IRF-3 to form dimers, to translocate rapidly to the 
nucleus and to bind to IRF-3 elements in relevant promoters (Yoneyama et al., 1998). The prominent 
phosphorylation sites have been mapped to Ser385, Ser386 and the distal region; the mutations of 
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these residues abolish virus-induced activation (Lin et al., 1998; Yoneyama et al., 1998). Stimulation 
with LPS activates IRF-3 in a MyD88-independent manner, as observed using MyD88-deficient cells 
(Hoshino et al., 2002). Expression of a dominant-negative form of IRF-3 in a macrophage cell line 
interferes with the LPS-mediated induction of the IFN-β gene. Also, DCs of IRF-3 deficient mice show a 
defect in LPS-mediated IFN-β gene induction. Moreover, IRF-3-deficient mice show resistance to LPS-
induced endotoxin shock (Sakaguchi et al., 2003).  
 
2.2.2.2.   MyD88-independent signalling (Figure I.2.4. and I.2.5.) 
 
TRIF and TRAM, two TIR domain-containing adaptors, are used in the MyD88-independent pathway. 
TRAM is specific for TLR4-signalling, while TRIF can be recruited by both TLR3 and TLR4. Recruitment 
of TRAM and TRIF to the TLR4 receptor leads to activation of the kinases TBK1 and IKK-ε, followed by 
phosphorylation of the transcription factor IRF-3 and thereby inducing IFN-β (Moynagh, 2005). The N-
terminal portion of TRIF is needed for its association with TBK1 and IKK-ε (Sato et al., 2003). A recent 
study suggested that NAK-associated protein 1 (NAP1) might facilitate the interaction of both kinases 
with TRIF (Sasai et al., 2005). It is also shown that TRIF recruits TRAF6-TAK1-TAB2 through its 
TRAF6-binding site lying in the N-terminal portion of TRIF (Sato et al., 2003). Recruitment of TRAF6 is 
required for late phase NF-κB activation, but not for IRF-3 activation (Jiang et al., 2004). The IRF-3 
transcription factor is ubiquitously expressed and resides in the cytoplasm in an inactive state (Au et al., 
1995). Upon activation through phosphorylation of critical serine residues in the C-terminal regulatory 
domain of IRF-3, IRF-3 molecules form a dimer, which is transported to the nucleus where it activates 
transcription of type I IFN genes by recruiting co-activators p300 and CREB-binding protein (CBP). This 
complex of IRF-3, CBP and p300 is called ‘dsRNA-activated factor 1’ or DRAF1. The serine residues 
phosphorylated in IRF-3 differ between the TLR3 and TLR4 pathways. The IRF-3 activation following 
TLR3 stimulation is more rapid and potent then following TLR4 stimulation. This correlates with the 
higher IFN-β production after TLR3 stimulation (Doyle et al., 2003). 
The gene induction is primarily due to transcriptional activation of the IFN-α/β promoter sequences, 
termed virus-inducible enhancers (referred to as PRDI and III for IFN-β) (Fan and Maniatis, 1989), to 
which IRF-3 (and IRF-7) binds. Transcription of IFN-β is dependent on transcriptional activator proteins 
such as IRF-3, but also on NF-κB (p50/p65) and ATF-2/c-jun and they induce IFN-β promoter activation 
in a synergistic manner. They bind co-operatively and form the enhanceosome on the IFN-β promoter 
(Thanos and Maniatis, 1995). The secreted type I IFN activates the expression of IFN-inducible genes 
such as CXCL10 and IRG-1 through a JAK-STAT signalling pathway (see further).  
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Figure I.2.4. - TLR3 signalling pathway. TLR3 is located in the intracellular endosomal membranes and is the only TLR not 
able to recruit the adaptor molecule MyD88. Upon TLR3 stimulation the adaptor molecule TRIF is recruited to the membrane. 
Non-typical IKKs, TBK1 and IKK-i, mediate phosphorylation of the transcription factor IRF-3 downstream of TRIF. Activated 
TLR3 can also recruit PI3K through its phosphotyrosines. Recruitment of PI3K activates the PI3 kinase-Akt pathway, leading 
to further phosphorylation and maximal activation of IRF-3 by an unknown mechanism. Phosphorylation of IRF-3 leads to its 
dimerization and translocation to the nucleus where it induces IFN-β, IFN-dependent genes and co-stimulatory molecules. 
TRIF can activate through a TRAF6-dependent mechanism three classes of kinases (JNK, p38 and IKK), which in turn 
activate their corresponding transcription factor to initiate gene induction. In addition, TRIF can activate NF-κB through a 
TRAF6-independent mechanism, involving the recruitment of RIP1. 
 
In addition, the proteins of the CITED family show nuclear or nucleocytoplasmic localization and bind to 
CBP/p300 transcriptional integrators through their conserved C-terminal acidic domain (Shioda et al., 
1997; Yahata et al., 2000). CITED proteins do not appear to bind to DNA directly but function as 
transcriptional co-activators. CITED stands for CBP/p300-interacting transactivators with E (glutamic 
acid)/D (aspartic acid)-rich carboxyl-terminal domain (Shioda et al., 1997; Yahata et al., 2000). CITED1, 
or MSG1, and CITED2 (splice isoforms known as MRG1 or p35srj) belong to this family (Sun et al., 
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1998). Because their expression is regulated by cytokines and stress, they are predicted to have a 
possible role in modifying CBP/p300-dependent transcription in a variety of biological events. For 
example, it has been demonstrated that CITED1 directly binds to CBP and p300, which in turn bind to 
the Smads and enhances Smad-mediated transcription (Yahata et al., 2000). 
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Figure I.2.5. - TLR4 signalling pathway. Stimulation of TLR4 facilitates the activation of two main pathways: the MyD88-
dependent and MyD88-independent pathways. The MyD88-dependent pathway involves the early activation of inflammatory 
proteins through early phase NF-κB activation. The MyD88-independent pathway involves the recruitment of two adaptor 
molecules, TRAM and TRIF. TRAM is specific for the TLR4-mediated MyD88-independent (TRIF-dependent) pathway. TRIF 
is essential for both TLR4 and TLR3-mediated signalling pathways (see Figure I.2.4. for TLR3-mediated signalling).The 
MyD88-independent pathway activates IRF-3 and is involved in NF-κB late phase activation. Both transcription factors are 
needed for production of IFN-β, co-stimulatory molecules and the expression of IFN-inducible genes. For details of the 
MyD88-dependent pathway see Figure I.2.2. and for details of the TRIF-dependent pathway see Figure I.2.4. 
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2.2.2.3.  Other signalling pathways: role of PI3K, RIP1 and RIP2 (Figure I.2.4.) 
  
The phosphatidylinositol 3-kinase (PI3K) p85 regulatory subunit can directly interact with TLRs through 
its SRC homology 2 (SH2) domain. The subsequent association of the p110 catalytic subunit of PI3K is 
important for its complete activation and results in the activation of its downstream target Akt (Koyasu, 
2003). By using LY294002 and wortmannin, two PI3K inhibitors, it was demonstrated that ISG56 
induction by dsRNA was abolished. Dominant-negative mutants of PI3K or its downstream target kinase 
Akt, inhibited ISG56 induction. Thus, PI3K is required for TLR3 signalling. However, PI3K activity is not 
sufficient for TLR3 signalling, as seen by a non-induction of ISG56 after over-expression of a 
constitutively active mutant of PI3K (Sen and Sarkar, 2005). Upon stimulation by dsRNA, TLR3 is 
phosphorylated by an unknown kinase on two specific tyrosine residues at the cytoplasmic domain. 
Phosphorylation of TLR3 is essential for initiating two distinct signalling pathways. One involves 
activation of TBK1 via TRIF and the other recruits and activates PI3K and the downstream kinase, Akt. 
Both are involved and necessary for the complete phosphorylation of IRF-3. Incompletely 
phosphorylated IRF-3 fails to bind the promoter of the target genes in dsRNA-stimulated cells (Sarkar et 
al., 2004). 
 
Also, a role for PI3K in LPS signalling has been suggested. In macrophages, lauric acid-induced TLR4 
signalling is inhibited by blocking PI3K/Akt (Lee et al., 2003). In the absence of PI3K, TLR4-induced NF-
κB release and nuclear translocation is observed, but no gene induction (Ojaniemi et al., 2003). In 
human neutrophils, JNK activation and induction of some genes in response to LPS is dependent on the 
PI3K pathway (Arndt et al., 2004). TLR2 signalling is also dependent on PI3K. PI3K is needed for both 
TLR2-induced NF-κB activation and receptor tyrosine phosphorylation (Arbibe et al., 2000). TLR2-
induced ERK1/2 activation, but not JNK1/2 or p38, requires PI3K (Martin et al., 2003). In neutrophils, 
PI3K is important for TLR2-induced Ser536 phosphorylation of the p65 subunit of NF-κB (Strassheim et 
al., 2004). Also, PI3K plays an important role in shuttling CpG DNA to TLR9 (Ishii et al., 2002). 
 
RIP1-knockout MEFs have an impaired NF-κB activation in response to a TLR3 ligand. In its C-terminal 
domain, TRIF has a RIP homotypic-interaction motif, thus RIP1 binds with the C-terminal domain of 
TRIF (Meylan et al., 2004). RIP1 mediates NF-κB activation through TRIF after TLR3 stimulation. RIP2 
was originally identified as a kinase that associates with TRAFs and with TNFR family members to 
induce NF-κB activation and apoptosis (McCarthy et al., 1998). RIP2-deficient mice are partially 
impaired in their response to LPS, PGN and dsRNA (Chin et al., 2002; Kobayashi et al., 2002b). 
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2.2.3.   IRF-5 in TLR signalling (Figure I.2.6.) 
 
IRF-5 is structurally most related to IRF-6 and is induced after stimulation with IFN-α/β. Cells from IRF-
5 knockout mice show a diminished pro-inflammatory cytokine production (e.g. TNF-α, IL-6 and IL-12) 
after stimulation with TLR3, TLR4, TLR5, TLR7 and TLR9 ligands. However, IFN-α is still induced upon 
TLR9 stimulation in IRF-5 -/- pDCs. In addition, IRF-5 -/- mice are more resistant to lethal shock induced 
by LPS or unmethylated DNA than wild-type mice. IRF-5 interacts with MyD88 and TRAF6, becomes 
phosphorylated and translocates to the nucleus to cooperate with NF-κB to induce pro-inflammatory 
cytokines (Takaoka et al., 2005). 
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Figure I.2.6. - Role of IRF-5 in TLR signalling. All TLRs, except TLR3, use a MyD88-dependent pathway to activate NF-
κB. This involves phosphorylation of the inhibitory IκB proteins, which leads to translocation of NF-κB to the nucleus and 
induction of inflammatory proteins. Recently, it has been demonstrated that TLRs can induce IRF-5 phosphorylation through 
a MyD88-dependent pathway involving IRAK-1 and TRAF6. Activation of IRF-5 leads to its translocation to the nucleus and 
co-operation with NF-κB in the induction of inflammatory genes.The mechanism underlying the possible TLR3-mediated 
activation of IRF-5 still awaits further clarification.  
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Putative IRF-5-binding sites are found in the promoters of several pro-inflammatory cytokines. The 
kinase responsible for phosphorylation of IRF-5 is not yet clear at this moment. TBK1 and IKK-ε can 
phosphorylate IRF-5, but this phosphorylation does not lead to nuclear localization or activation of IRF-5 
(Lin et al., 2005). IRF-5 becomes activated primarily after TLR7, TLR8 and TLR9 stimulation. Recently, 
Schoenemeyer and colleagues showed a role for IRAK-1 and TRAF6 in TLR7-induced IRF-5 activation 
(Schoenemeyer et al., 2005). They claim that IRF-5 is not activated upon TLR3 stimulation, which is in 
contrast to data from other groups. All TLRs, except TLR3, use a MyD88 dependent pathway to activate 
IRF-5 and NF-κB to induce pro-inflammatory cytokine production, such as TNF, IL-6 and IL-12 
(Napolitani et al., 2005) (Figure I.2.6).  
Napolitani and co-workers show a synergistic effect between TLR agonists to optimize transcriptional 
regulation of particular target genes important in immune response to pathogens. By giving suboptimal 
doses of TLR agonist, unable to induce IL-12p70 when given alone, it was demonstrated that 20- to 50-
fold more IL-12p70 is induced when TLR agonists are given together than when a single agonist is 
given (Napolitani et al., 2005). However, another study showed that the co-operation between different 
TLR pathways is explained through synergistic action of TLRs and type I IFN receptors (Gautier et al., 
2005). Using cells from IFNAR- and STAT1-knockout mice it was shown that an autocrine and/or 
paracrine loop of type I IFN, induced after stimulation of TLR3 or TLR4, is necessary for production of 
IRF-7. Next, IRF-7 can be activated by engagement of TLR7/8 or TLR9, leading to secretion of bioactive 
IL-12p70 and optimal type I IFN (Gautier et al., 2005). 
 
 
2.3.  Negative regulation of TLR signalling 
 
TLRs serve to recognize PAMPs of different microorganisms to clear the invasion of these organisms in 
the body. The TLR-mediated response needed to clear the infection also leads to production of 
inflammatory cytokines. When those inflammatory cytokines are released in excess, this can induce 
serious systemic disorders such as endotoxin shock associated with a high mortality rate. Thus it is not 
surprising that TLR signalling is under tight negative regulation. There are different layers of negative 
regulation of TLR signalling, going from soluble decoy receptors to intracellular inhibitors, membrane-
bound suppressors, degradation of TLRs, and TLR-induced apoptosis (Table I.2.1.).  
 
Soluble decoy receptors. Naturally produced soluble decoy TLRs provide powerful negative regulatory 
mechanisms, reminiscent of soluble chemokines and cytokine receptors. They might provide a first-line 
defense by preventing a direct contact between TLRs and their PAMPs. So far, only soluble decoy 
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TLR4 and TLR2 have been identified. The mechanism by which they attenuate TLR2 and TLR4 function 
remains obscure (Liew et al., 2005). 
 
Intracellular negative regulators. The most studied group of regulators are the intracellular negative 
regulators. Some of them are constitutively expressed to regulate TLR activation at a physiological level, 
whereas others are upregulated and attenuate TLR signalling in a negative-feedback loop. At this 
moment this group includes MyD88s, IRAK-M, IRAK2c, IRAK2d, SOCS-1, Nod-2, PI3K, TOLLIP, A20, 
RIP3, IRF-4, β-arrestin, IκBNS and FLN29. They function at various stages of the TLR signalling 
cascade but concentrate principally on the MyD88-dependent pathway. 
MyD88s. MyD88 short (MyD88s), an alternatively spliced form of MyD88 that lacks only the short 
intermediate domain separating the DD and TIR domains, is induced upon LPS stimulation and is 
primarily expressed in the spleen (Janssens et al., 2002). Expression of MyD88s leads to shutdown of 
IL-1/LPS-induced NF-κB activation. MyD88s is not able to interact with IRAK-4, which disables IRAK-1 
phosphorylation and subsequent NF-κB activation (Burns et al., 2003).  
IRAK-M, IRAK2c and IRAK2d. Whereas other IRAKs are expressed ubiquitously, IRAK-M expression is 
restricted to monocytes/macrophages and is induced upon TLR stimulation. IRAK-M inhibits the 
dissociation of the IRAK1-IRAK4 complex from MyD88, thereby preventing the formation of an IRAK1-
TRAF6 complex. IRAK-M-knockout mice show increased cytokine production to bacterial infection and 
lack of endotoxin tolerance (Kobayashi et al., 2002a). The mouse Irak2 gene has four splice variants: 
Irak2a, Irak2b, Irak2c, Irak2d. Over-expression of IRAK2c and IRAK2d, lacking the DD of fullength 
IRAK2, inhibits LPS-induced NF-κB activation in fibroblast cells. LPS-stimulated mouse macrophages 
show an increased level of IRAK2c, but not IRAK2a (Liew et al., 2005). 
SOCS-1. Suppressor of cytokine signalling 1 (SOCS-1) belongs to the SOCS family involved in the 
negative regulation of signal transduction by a variety of cytokines (Yasukawa et al., 2000). SOCS-1 is 
found to be rapidly induced by LPS or CpG-DNA stimulation in macrophages (Crespo et al., 2000; 
Dalpke et al., 2001). Furthermore, SOCS-1 knockout mice are more sensitive to LPS-induced shock. In 
addition, over-expression of SOCS-1 suppressed LPS-induced NF-κB activation, showing that SOCS-1 
plays an important role in the down-regulation of LPS signal transduction (Kinjyo et al., 2002; Nakagawa 
et al., 2002). Previously it was thought that the mechanism of SOCS-1 inhibition of TLR4- and TLR9-
signalling occurred by targeting IRAK-1. It was also demonstrated that SOCS-1, induced by TLR 
stimulation, limits the extent of TLR signalling by inhibiting type I IFN signalling, but not the main NF-κB 
pathway (Baetz et al., 2004). In addition, recently it was reported that SOCS-1 mediates Mal 
degradation. Mal is specifically involved in TLR2 and TLR4 signalling. Mal becomes phosphorylated by 
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Btk. Phosphorylation of Mal leads to its interaction with SOCS-1, which results in Mal polyubiquitination 
and degradation (Mansell et al., 2006). 
NOD-2. The role of Nod-2 as a negative regulator of TLR2 signalling is probably not universal. Watanabe 
and co-workers showed a Nod-2-induced suppression of TLR2-ligand-induced TH1-cell responses in 
wild-type mice, but not in Nod2-deficient mice (Watanabe et al., 2004). However, a recent report failed 
to confirm Nod-2 as a negative regulator in TLR2 signalling (Kobayashi et al., 2005). 
PI3K.  PI3K functions at the early phase of TLR signalling and modulates the magnitude of the primary 
activation (Fukao and Koyasu, 2003). Also, PI3K inhibits IL-12 synthesis and prevents the over-
expression of a TH1 response. The exact mechanism by which PI3K inhibits TLR signalling remains 
unknown, but might involve the suppression of p38, JNK, ERK1/2 and NF-κB (Fukao et al., 2002). 
TOLLIP. Toll-interacting protein (TOLLIP) was first described for its role in IL-1 signalling (Burns et al., 
2000). After IL-1 stimulation, a membrane-proximal signalling complex is formed consisting out of two 
different IL-1Rs, IL-1RI and IL-1RAcP, MyD88, IRAK and TOLLIP (Burns et al., 2000). Later, it was 
discovered that TOLLIP not only interacts with the IL-1Rs, but also with TLR2 and TLR4 through their 
cytoplasmic TIR domain. TOLLIP act as a negative regulator in IL-1 and TLR-signalling by inhibiting the 
phosphorylation and kinase activity of IRAK-1. In quiescent cells, TOLLIP pre-associates with IRAK, 
thus preventing it from being phosphorylated and activated on the TLR receptor complex. Once 
activated on the receptor, TOLLIP-IRAK1 complexes are recruited to the receptor and IRAK1 
phosphorylates TOLLIP. Phosphorylation of TOLLIP might then lead to the dissociation of TOLLIP from 
IRAK and the receptor complex, allowing IRAK to bind to downstream TRAF6. Thus, TOLLIP is thought 
to maintain immune cells in a quiescent state (Zhang and Ghosh, 2002). 
A20. Mice deficient for A20, a cytoplasmic zinc finger protein, develop severe inflammation and are 
hypersensitive to both LPS and TNF, and die prematurely (Lee et al., 2000a). A20 is a negative inhibitor 
of TLR4 signalling as showed by the fact that full length A20 inhibits the ability of TLR4 to activate NF-
κB and AP-1 (O'Reilly and Moynagh, 2003). A20 interacts with several proteins including ABIN-1, ABIN-
2, TRAF6 and IKK-γ, and its expression is controlled by NF-κB itself (Heyninck et al., 1999; Van Huffel 
et al., 2001). The effect of A20 is mediated by its deubiquitinating activity. A20 is a deubiquitinating 
enzyme that cleaves ubiquitin chains from TRAF6, thereby terminating TLR-induced NF-κB signalling 
(Boone et al., 2004). 
RIP3. RIP3 acts by down-regulating TLR3-induced TRIF-mediated NF-κB activation. RIP3 and TRIF 
compete which each other for binding with RIP1. RIP3 acts as a negative inhibitor of TRIF-dependent 
NF-κB activation (Meylan et al., 2004). 
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IRF-4. Another recently identified negative regulator of TLR signalling is IRF-4. IRF-4 mRNA is induced 
upon TLR stimulation and competes with IRF-5 for interaction with MyD88. In IRF-4-knockout 
macrophages, TLR-dependent induction of pro-inflammatory cytokines is enhanced. Moreover, IRF-4-
deficient mice show hypersensitivity to DNA-induced shock, with elevated serum pro-inflammatory 
cytokine levels. Thus, IRF-4 is an important factor in the negative-feedback regulation of TLR-induced 
pro-inflammatory cytokine production (Negishi et al., 2005). 
β-arrestins. β-arrestins, a family of multifunction proteins, directly interact with TRAF6 in response to LPS 
or IL-1β stimulation in vivo and in vitro. Formation of a β-arrestin-TRAF6 complex prevents TRAF6 
autoubiquitination and oligomerization to negatively regulate the TLR-IL-1R signalling pathways. As a 
consequence, β-arrestins negatively regulate activation of NF-κB and AP-1. β-arrestin 2-knockout mice 
produce higher levels of pro-inflammatory cytokines and are more susceptible to endotoxic shock than 
are wild-type mice (Wang et al., 2006). 
IκBNS. IκBNS, a TLR-inducible nuclear IκB protein, is involved in termination of NF-κB activity and 
thereby it inhibits a subset of TLR-dependent genes that are induced late such as IL-6, IL-12p40 and IL-
18. Termination of NF-κB activity is caused by the degradation of p65 by IκBNS. IκBNS-deficient mice 
are highly susceptible to LPS-induced endotoxic shock and to intestinal inflammation (Kuwata et al., 
2006). 
FLN29. Recently another TLR signalling inhibitor, FLN29, was discovered. FLN29 is an IFN- and LPS-
inducible gene, which contains a TRAF6-related zinc finger motif and TANK-related sequences. By 
interacting with TRAF6, FLN29 attenuates NF-κB activation and TLR signalling (Mashima et al., 2005). 
 
Transmembrane regulators. Transmembrane protein regulators include ST2L, SIGIRR, TRAILR and 
RP105. These proteins inhibit TLR functions either by sequestration of adaptor proteins (ST2L) or 
transcription factors (TRAILR), or by interfering with the binding of TLR agonists to their respective TLRs 
(RP105). 
ST2L. It was demonstrated that the membrane bound form of ST2 (ST2L) negatively regulates IL-1RI 
and TLR4, but not TLR3, signalling by sequestrating the adaptors MyD88 and Mal. In contrast to wild-
type mice, ST2-deficient mice fail to develop endotoxin tolerance and show increased inflammatory 
cytokine production. 
SIGIRR. SIGIRR negatively modulates TLR and IL-1R signalling. The mechanism of inhibition is not yet 
clear but it is shown that SIGIRR can bind with TLR4, IRAK and TRAF6. SIGIRR does not affect the 
MyD88-independent pathway (Liew et al., 2005). Cells from SIGIRR-null mice show enhanced activation 
in response to either IL-1 or certain Toll ligands (Wald et al., 2003). SIGIRR-deficient mice are hyper-
responsive to IL-1 injection or LPS challenge. 
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Table I.2.1. - Negative regulators of Toll-like receptor signalling (Adapted from Liew et al.). 
Negative Regulator Possible mechanism  Affected TLR 
sTLR2 Antagonist of TLR2 TLR2 
sTLR4 Blocks interaction of TLR4 and 
MD2 
TLR4 
MyD88s Inhibits IRAK-4 recruitment TLR4 
IRAK-M Prevents the formation of IRAK1-TRAF6 complex TLR4, 9 
IRAK2c Suppression of IRAK function TLR4 
IRAK2d Suppression of IRAK function TLR4 
SOCS-1 Supresses IRAK  TLR4, 9 
 Indirect: inhibition of type I IFN signalling  TLR2, 3, 4, 9 
 Degradation of Mal TLR2, 4 
NOD-2 Supresses NF-κB TLR2 
PI3K Inhibition of p38, JNK and NF-κB TLR2, 4, 9 
TOLLIP Autophosphorylates IRAK TLR2, 4 
A20 Deubiquitinylation of TRAF6 TLR2, 3, 4, 9 
RIP3 Inhibition of RIP1/TRIF interaction TLR3 
IRF-4 Compete with IRF-5 for MyD88 TLR4, 7, 9 
β-ARRESTINS Prevents TRAF6 oligomerization TLR4 
IκBNS Terminates NF-κB activity TLR2, 4, 9 
FLN29 Sequesters TRAF6 TLR4 
ST2L Sequesters MyD88 and Mal TLR2, 4, 9 
SIGIRR Interacts with TLR4, TRAF6 and IRAK TLR4, 9 
TRAILR Stabilizes IκBα TLR2, 3, 4 
RP105 Inhibiting binding of LPS to TLR4  TLR4 
TRIAD3A Ubiquitylates TLRs TLR4, 9 
 
 
 
 
 
 
TRAILR. TNF-related apoptosis-inducing ligand receptor (TRAILR) belongs to the TNF superfamily and 
does not have a TIR domain. Stimulation of macrophages with ligands for TLR2, TLR3 and TLR4, but 
not TLR9, results in TRAIL up-regulation and enhanced cytokine production in TRAILR-deficient cells. 
The TRAILR seems to inhibit TLR signalling by stabilizing IκBα and decreases in this way the nuclear 
translocation of NF-κB (Diehl et al., 2004). 
RP105. RP105 is a TLR4 homologue and is not only expressed in B cells as originally proposed, but is 
widely expressed on APCs as this is the case for TLR4. RP105 is a specific inhibitor of TLR4 signalling 
in HEK 293 cells and DCs. Moreover, RP105 and its helper molecule, MD-1, interact directly with the 
TLR4 signalling complex, disabling its binding to LPS (Divanovic et al., 2005). 
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Reduction in TLR expression. A reduction in TLR expression can be realized by ubiquitination 
(TRIAD3A) promoting the proteolytic degradation of TLRs, or through inhibition of the transcription or 
stability of TLR-encoding mRNAs by anti-inflammatory cytokines such as IL-10 and TGF-β. TRIAD3A is 
a RING finger protein, which act as an E3 ubiquitin ligase. It enhances ubquitination and proteolytic 
degradation of TLR4 and TLR9, but not TLR3 or TLR2 (Chuang and Ulevitch, 2004). 
 
Apoptosis. The last level of negative regulation is self-destruction. TLR-induced apoptosis might be 
important in the control of excessive TLR activation. Association of MyD88 and FADD through their DD 
domains might trigger the recruitment of caspase-8 and subsequent caspase-dependent apoptosis. The 
MyD88-independent signalling pathway can trigger caspase-independent apoptosis. The MyD88-
dependent pathway will also enhance cell survival through NF-κB activation. Thus, TLR signalling can 
be regulated by the balance of apoptosis and anti-apoptosis signals induced by TLR (Liew et al., 2005). 
 
 
2.4.   Importance of endotoxin tolerance 
 
 
LPS activates monocytes and macrophages to produce pro-inflammatory cytokines and other 
mediators. This inflammatory response is critical to control the growth of pathogenic microorganisms. 
However, excessive and uncontrolled production of these inflammatory cytokines and mediators in 
response to LPS is regarded as the cause of sepsis and septic shock. Gram-negative sepsis is a major 
cause of death throughout the world (see section 1.2.).  
Beeson (1946) first defined ‘endotoxin tolerance’ as a reduced endotoxin-induced fever following 
repeated injections of typhoid vaccine in humans (Beeson, 1947a). He described the same 
phenomenon in experimental animals (Beeson, 1947b). ‘Endotoxin tolerance’, also called ‘LPS 
desensitisation’ or ‘deactivation’ or ‘reprogramming’, is now defined as a transient state of cellular hypo-
responsiveness towards a second stimulation with a high dose LPS after a preceding stimulation with a 
sub-lethal dose of LPS. As a consequence of endotoxin tolerance, the host is protected from developing 
a shock syndrome caused by hyper-activation of macrophages and other immune cells, and has a 
significant survival advantage (Zeisberger and Roth, 1998). On the other hand, it has been 
demonstrated that suppressed IL-12 expression by monocytes and DCs, associated with endotoxin 
tolerance, may result in an inability to respond appropriately to secondary infections in survivors of 
sepsis (Karp et al., 1998). Thus, endotoxin tolerance can be a huge problem in the treatment of patients 
with Gram-negative sepsis. Patients recovering from Gram-negative septic shock are often hypo-
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responsive to LPS, but have a reduced response to opportunistic pathogens leading to high mortality 
(Docke et al., 1997).  
 
Using animal models, it became clear that macrophages/monocytes are the principal mediators in 
tolerance (Cavaillon, 1995). In addition, both macrophage cell lines (RAW 264.7, Mono-Mac-6 cells) and 
ex vivo isolates of macrophages can be tolerized for LPS (Haas et al., 1990; Li et al., 1994; Virca et al., 
1989). One of the main characteristics of endotoxin tolerance is a change (up- or down-regulation) in 
production of pro-inflammatory (e.g. TNF-α, IL-1, IL-12 and IL-6), anti-inflammatory (e.g. IL-10) and 
other mediators (e.g. peroxisome proliferator-activated receptor-gamma (PPARγ), NO, TNFRII and IL-
1Ra) in cells of the myeloid lineage. Also, alterations to the LPS-induced activation of signalling 
cascades have been noticed. So, endotoxin tolerance does not totally inhibit cellular functions, but 
rather represents a reprogramming of cells, possibly, as a means of adaptation to bacterial infection 
(Schade and E. Dominguez-Fernandez, 1999; Shnyra et al., 1998). 
In animal models, an early and a late stage of endotoxin tolerance has been demonstrated. The later 
stage of endotoxin tolerance depends on specific O-antigen antibodies, whereas the initial stage of 
endotoxin tolerance has not been elucidated yet (Flohe et al., 1999; West and Heagy, 2002). The early 
stage of endotoxin tolerance is associated with low levels of inflammatory mediators. Endotoxin-tolerant 
animals fail to induce IL-6 and TNF-α after LPS treatment. In contrast, IFN and IL-1 synthesis were only 
partially inhibited (Erroi et al., 1993; Flohe et al., 1999). In LPS-tolerized rats there was a diminished 
iNOS production due to the elevation of endogenous glucocorticoid levels (Szabo et al., 1994). In vitro 
studies demonstrated that sometimes IL-1 and IL-6 levels are augmented and sometimes they are 
decreased. These contrasting results may be due to differences in potential LPS treatment and 
differences in the cellular phenotype and genotype. TNF-α expression is inhibited during endotoxin-
tolerance (Peck et al., 2004; West and Heagy, 2002).  
The cytokine IL-12 was also suppressed in endotoxin-tolerant monocytes (Karp et al., 1998). The CC 
chemokines MIP-1α, MIP-1β and RANTES are permanently down-regulated in endotoxin-tolerant 
monocytes. In contrast, the chemokine IL-8 is unaffected (Kaufmann et al., 2000). Other possible 
mechanisms of endotoxin tolerance are a decreased Gi protein content and activity (Makhlouf et al., 
1998), and a diminished activation of protein kinase C leading to a diminished TNF-α secretion (West et 
al., 1997). 
 
Endotoxin tolerance has been widely investigated, but to date, the mechanism underlying this 
phenomenon remains poorly understood. One of the proposed molecular mechanisms of LPS tolerance 
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is the down-regulation of the LPS receptor complex. It has been demonstrated that TLR4 is down-
regulated on the surface of LPS-tolerant macrophages (Nomura et al., 2000). During tolerance, the 
expression of LBP, CD14 and MD-2 is unchanged or up-regulated (Labeta et al., 1993). However, a 
down-regulation of the surface expression of the TLR4/MD-2 complex has been demonstrated in LPS-
tolerant macrophages (Fujihara et al., 2003). In contrast, in CD14-expressing CHO cells that over-
express human TLR4/MD-2, LPS pre-treatment caused a reduction of NF-κB activation while there was 
no reduction of TLR4/MD-2 cell surface expression (Medvedev et al., 2001). Also in HEK293T cells that 
over-express CD14, TLR4 and MD-2, reduction of NF-κB activation was demonstrated (Medvedev and 
Vogel, 2003). Thus, down-regulation of the surface expression of the TLR4/MD-2 complex alone is not 
sufficient for endotoxin tolerance, and other mechanisms must be involved. 
 
Another possible molecular mechanism behind the endotoxin tolerant phenomenon is an alteration to 
the LPS intracellular signalling pathway. This can be an impaired activation of the MyD88-dependent 
and/or MyD88-independent pathway. A diminished quantity of the IRAK-1 signalling protein is seen in 
LPS-tolerant THP-1 cells, and as a consequence interaction of IRAK-1 with MyD88 is abolished (Li et 
al., 2000). Furthermore, a reduction in LPS-induced MAPK, SAPK1, and p38 kinase activation is noticed 
(Kraatz et al., 1999). Medvedev and colleagues also showed that MAPK phosphorylation, NF-κB and 
AP-1 activation was inhibited in endotoxin-tolerized murine macrophages stimulated with LPS. In 
addition, a suppressed activation of IKK and decreased degradation of IκB isoforms is demonstrated. 
The LPS-inducible IκB kinase activity is not detectable in endotoxin-tolerant cells. IκB remains in the 
cytoplasm where it sequesters NF-κB. Thus, the IκB kinase may play an important role in endotoxin 
tolerance (Kohler and Joly, 1997). At the nuclear level, accumulation of p50/p50 NF-κB homodimers, 
which lack trans-activation activity, instead of the transcriptionally active p50-p65 heterodimer leads to 
less TNF and a decrease in the levels of NO release (Goldring et al., 1998; Ziegler-Heitbrock et al., 
1994).  
 
Another mechanism to regulate the endotoxin tolerant phenomenon is the induction of specific anti-
inflammatory proteins and signalling pathways. The anti-inflammatory proteins TGF-β and IL-10 are 
mediators of endotoxin tolerance. IL-10 is up-regulated and is involved in the down-regulation of pro-
inflammatory cytokines (Cavaillon et al., 2003). Although, some studies have shown a down-regulation 
of the IL-10 protein (Randow et al., 1995). Prostaglandins and glucorticoids are also mediators of 
endotoxin tolerance (Cavaillon et al., 2003). Also, increased activation of peroxisome proliferator-
activated receptor-gamma (PPARγ) has been linked to the tolerance phenotype (Fan and Cook, 2004).  
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It has also been demonstrated that IRAK-M (Escoll et al., 2003), SOCS-1 (Crespo et al., 2000), and 
PI3K signalling (Bowling et al., 1995) are induced in the endotoxin tolerant phenomenon. IRAK-M 
becomes rapidly up-regulated in tolerant monocytes and its expression is regulated by PI3K (Escoll et 
al., 2003).  Experiments with SH2-containing inositol 5-phosphatase (SHIP) -/- mice show a correlation 
between the duration of endotoxin tolerance and elevated SHIP levels. In SHIP -/- mice, inhibition of 
both NF-κB activation and STAT1 activation, two of the principal end points of LPS signalling, is not 
observed in contrast to wild-type SHIP +/+ mice. Thus, SHIP is also an important molecule in endotoxin 
tolerance (Beutler, 2004).  
 
Cross-tolerance is also an interesting phenomenon. In RAW264.7 macrophages, LTA, LPS and CpG-
DNA induce tolerance towards a second stimulation with the same stimulus used for priming, as well as 
cross-tolerance towards a second stimulation with other stimuli. In an in vivo model of dGalN-induced 
liver damage, CpG-DNA does not induce cross-tolerance towards LTA or LPS. In contrast, LTA/LPS 
can induce cross-tolerance in the same model (Dalpke et al., 2005). Also, tolerance induced by bacterial 
lipoprotein (BLP) protects mice against BLP-induced lethality, but also LPS-, live bacteria- sepsis-
induced lethality (Wang et al., 2003). 
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3.   TYPE I IFNs 
 
3.1.   Overview of the IFN family 
 
About fifty years ago interferon (IFN) was discovered as a soluble factor that served to inhibit viral 
replication (Isaacs and Lindenmann, 1957). For a long time, it was believed that this was the only 
function of IFN. Recently a lot of progress has been made in understanding the mechanisms and 
signalling pathways of IFN. The IFNs were initially classified as classical or type I IFN and immune or 
type II IFN (Ho and Armstrong, 1975). The type I IFNs, predominantly α and β (IFN-α/β) belong to the 
class II family of α-helical cytokines. This family consists out of 6 cytokines of the IL-10 family (IL-10, IL-
19, IL-20, IL-22, IL-24 and IL-26), multiple type I IFNs, 1 type II IFN, 3 IFN-λs and IL-22BP, which is the 
soluble receptor which can neutralize the action of one of the cytokines of the IL-10 family (Kotenko and 
Langer, 2004).  
The mouse type I IFN multi-gene family comprises 14 IFN-α genes, single IFN-β, IFN-κ, IFN-ζ (limitin) 
and IFN-ε genes (Hardy et al., 2004; Kelley and Pitha, 1985; Takahashi et al., 2001; van Pesch et al., 
2004; Vassileva et al., 2003). Based on sequence similarity and their anti-viral activity IFN-λ1 (IL-29), 
IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B) are called IFN-like molecules. However, because IL-29, IL-28A 
and IL-28B use a different receptor, have another chromosomal location and gene structure they form a 
new cytokine family (Kotenko et al., 2003; Sheppard et al., 2003). In addition to these IFNs, IFN-
δ in pigs, IFN-τ in ruminants and IFN-ω in mammals with placenta (eutherian mammals) have been 
identified (Table I.3.1.) (Pestka et al., 2004). 
 
3.2.   The IFN-β promoter 
 
3.2.1.  Sequence and regulatory domains 
 
The functional IFN-β promoter is contained within a 170-bp DNA fragment located 5' of the coding 
sequence. The murine IFN-β promoter has a virus-responsive element (VRE) containing the four 
positive regulatory domains (PRDs I to IV) of the IFN-β promoter. The VRE region corresponds to the 
minimal region necessary for virus-induced activation of the promoter. Also, two negative regulatory 
domains, NRDI and NRDII, are found in the promoter. Within NRDI a negative regulatory element, 
called the NRE, is identified (Nourbakhsh et al., 1993). PRDI and III are related sequence elements that 
bind members of the IRF family. PRDII and PRDIV are composite regulatory units binding NF-κB/Rel 
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family members (PRDII) and ATF-2 homodimers or c-Jun/ATF-2 heterodimers (PRDIV). All PRD 
elements act in a synergistic manner to induce IFN-β promoter activation (Du et al., 1993). The high 
mobility group protein HMGI(Y) enhances binding of c-Jun/ATF-2 and NF-κB to the IFN-β promoter 
through binding in the minor grooves of the DNA helix in the proximity of PRDII and PRDIV (Figure 
I.3.1.) (Du and Maniatis, 1994; Thanos and Maniatis, 1992). 
 
Table I.3.1. - The IFNs and IFN-like molecules (Adapted from Pestka et al., 2004). 
                           Gene number Receptor Species (mammals) 
Type I IFN IFN-αR1, IFN-αR2  
IFN-α Multiple  All 
IFN-β One (except cows)  All 
IFN-δ Multiple   Pigs 
IFN-ε One  Eutherian mammals 
IFN-κ One  All (?) 
IFN-τ Multiple  Ovine 
IFN-ω One (primates) 
Multiple (cat, pig, cow) 
 Eutherian mammals 
IFN-ζ (limitin) Multiple  Mouse 
Type II IFN  IFN-γR1,IFN-γR2  
IFN-γ One  All 
IFN-like molecules  IL-28RI, IL-10R2  
IL-28A (IFN-λ2) One  All (?) 
IL-28B (IFN-λ3) One  All (?) 
IL-29 (IFN-λ1) One  All (?) 
 
First, it was demonstrated that IRF-1 binds to PRDI and PRDIII (Reis et al., 1992). Later, it was 
suggested that both IRF-3 and IRF-7 are involved in the transcriptional induction of IFN-β (Lin et al., 
1998; Sato et al., 1998b; Wathelet et al., 1998). Another IRF family member, IRF-2, can also bind with 
the IFN-β promoter (see further) (Harada et al., 1989). The NRDI domain physically overlaps with PRDII 
and acts as a constitutive and position-independent silencer of PRDII (Nourbakhsh et al., 1993). Using 
co-immunoprecipitation assays, two transcriptional co-activators CBP and p300 were found to associate 
with IRF-3. CBP and p300 molecules do not have the ability to bind DNA directly but can recruit the 
histone acetyltransferase (HAT) p300/CBP-associated factor (PCAF) (Bannister and Kouzarides, 1996) 
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that is important in histone acetylation, chromatin conformation, and acetylation of specific transcription 
factors. 
 
AACTGTACAAGATTTTATAAATCCTTAGTTTGTATATATTTTAACCCAGTACATAGCATATAAAATAGCCAGGAGCTTGAATAAAATGAATATTAGAAG
NRDII-200 -150
100 50
CTGTTAGAATAAGAGAAAATGACAGAGGAAAACTGAAAGGGAGAACTGAAAGTGGGAAATTCCTCTGAGGCAGAAAGGACCATCCCTTATAAATAGCAC
NRDI
ATF-2 IRF IRF p50 p65c-Jun
PRDIV PRDIII-I PRDII
VRE
 
 
Figure I.3.1. - DNA sequence and regulatory regions of the murine IFN-beta promoter. The DNA sequence of the 
murine IFN-β promoter is spanning from the TATA box to position –210. The DNA binding sites of transcription factors NF-
κB (p50 and p65), IRF proteins, and ATF-2/c-Jun are indicated.  Positions of the VRE and NRDs are also indicated 
(Reprinted from Bonnefoy et al., Mol Cell Biol, 19, 2803-2816, 1999). 
 
3.2.2.  Activation and termination of IFN-β gene expression 
 
Virus infection activates multiple transcriptional activator proteins such as NF-κB (p50/p65), ATF-2/c-jun 
and IRF proteins. In the presence of the architectural protein HMGI(Y), they bind co-operatively and 
form the enhanceosome on the IFN-β enhancer (Thanos and Maniatis, 1995). HMGI(Y) is the essential 
architectural component for the assembly and stability of the IFN-β gene enhanceosome (Du et al., 
1993; Thanos and Maniatis, 1992; Thanos and Maniatis, 1995). Two molecules of HMGI(Y) bind to four 
sites within the enhancer in a highly co-operative fashion by employing both intra- and intermolecular 
co-operativity (Yie et al., 1997). 
In the inactive state, the enhancer is nucleosome-free but is flanked by two nucleosomes. One of these 
nucleosomes (nucleosome II) masks the TATA box and the initiation site necessary for transcriptional 
activation, whereas the other lies upstream of the enhancer (Agalioti et al., 2000). Following the 
enhanceosome assembly, the activation domains of all the activators form a novel surface that 
constitutes a high-affinity binding site and thus function co-operatively to recruit the GCN5/PCAF 
complex, which acetylates the nucleosomes. PCAF has an intrinsic HAT activity and acetylate histones 
of nearby nucleosomes. Hyper-acetylation of histone tails in nucleosomes upon virus infection is an 
important mechanism by which transcription of IFN-β is induced (Parekh and Maniatis, 1999). 
Recruitment of this GCN5/PCAF complex is followed by recruitment of CBP/p300, which has also 
intrinsic HAT activity, and CBP-associated proteins. Recruitment of CBP by the enhanceosome tethers 
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the PolII holoenzyme via its interaction with the carboxyl terminus of CBP. In turn, the nucleosome 
acetylation facilitates interaction of CBP with the Swi/SNF complex resulting in nucleosome modification. 
By binding of another molecule, TBP, DNA bending is induced and nucleosome II slides to a new 
position, unmasking the TATA box and enabling transcription from the IFN-β promoter (Agalioti et al., 
2000; Bode et al., 1986; Lomvardas and Thanos, 2001). At the same moment of recruitment of the PolII 
holoenzyme complex, other components of the basal transcription machinery, such as transcription 
factor (TF) IID, TFIIA, TFIIB and USA of the TFIID/A/B complex are recruited (Figure I.3.2.) (Agalioti et 
al., 2000; Merika et al., 1998). The treatment of cells with trichostatin A (TSA), an inhibitor of histone 
deacetylases, induced strong, constitutive derepression of the murine IFN-β gene promoter stably 
integrated into a chromatin context (Shestakova et al., 2001). 
 
IFN-β 
TRANSCRIPTION
II
I
p50
p65
IRF
IRF
TATA
IIDIIA IIB
USA
SRBs
III
IV ATF-2
c-Jun
CBP
TFIIF TFIIE
TFIIH
POLII holoenzyme
POLIICN
Swi/SNF
TBP
 
 
Figure I.3.2. – A model for the synergistic activation of transcription by the IFN-β enhanceosome. The IFN-β gene 
requires the assembly of a higher order nucleoprotein complex, the enhanceosome, which consists of the transcriptional 
activators NF-κB (p50/p65), ATF-2/c-jun, IRF proteins, architectural protein HMGI(Y), and the coactivator CBP. HMGI(Y) 
helps them to bind co-operatively to the enhancer to form an enhanceosome HMGI(Y) organizes the enhanceosome into a 
structure that optimally interacts with chromatin-modifying activities and general transcription factors (Adapted from (Kim and 
Maniatis, 1997). 
 
Termination of IFN-β gene expression depends on the recruitment of CBP that acetylates HMGI(Y) at 
distinct lysine residues. Both PCAF and CBP can acetylate HMGI(Y), but the lysine residues acetylated 
by CBP and PCAF differ. Acetylation of HMGI(Y) by CBP, but not by PCAF, disrupts the HMGI/NF-κB 
complex and thus the enhanceosome stability (Munshi et al., 2001; Munshi et al., 1998). 
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3.2.3.  Regulatory mechanisms of the IFN-β promoter 
 
The production of IFN-β is considered to be subject to stringent control, and essentially IFN-β is 
maintained in a constitutive transcriptional silent state in the absence of external stimuli. This silent state 
is controlled through the inhibitory effects of an NF-κB regulating factor (NRF). NRF, an active 
transcription repressor that binds to NRE, abolishes the transcriptional activity of the bordering NF-κB- 
binding sites by a direct protein-protein interaction between NRF and proximal bound NF-κB preventing 
the transcriptional activation (Nourbakhsh and Hauser, 1997). The promoters of human IL-8 and human 
inducible nitric oxide synthetase (hiNOS) contain also such a NRE site overlapping partially with the NF-
κB response element. NRF is involved in transcriptional silencing of the human IL-8 and hiNOS 
promoters, but it plays an additional role acting as an activator of IL-1-induced IL-8 gene expression 
(Feng et al., 2002; Nourbakhsh et al., 2001). 
 
YY1 is a transcription factor that binds the IFN-β promoter at positions -90 and -122 through the 
recognition of a specific consensus sequence. YY1 has been shown to bind to transcriptional co-
repressors such as histone deacetylases (HDACs) or co-activators such as HATs, and a wide variety in 
transcription factors, such as c-Myc, SP1 (Seto et al., 1993) and E1A (Lewis et al., 1995). In vivo YY1 
binds to HDAC2 and in vitro to HDAC1, HDAC2, and HDAC3 (Davie and Chadee, 1998). YY1 also 
interacts with HATs p300 and CBP (Yao et al., 2001). YY1 has a dual activator/repressor role in the 
transcriptional capacity of the IFN-β promoter depending on its posttranslational modifications through 
HATs and HDACs, its binding site and on the moment after virus infection (Weill et al., 2003). 
 
IRF-1 and IRF-2 are functionally distinct factors, but they show a high degree of structural similarity in 
their N-terminal DNA-binding domains. Both factors bind to the same DNA element, called IRF-E 
(consensus sequence: G(A)AAAG/C T/CGAAA G/C T/C). The IRF-E element resembles the interferon-
stimulated response element (ISRE; consensus sequence: A/G NGAAANNGAAACT) in IFN-dependent 
genes (Tanaka et al., 1993). Both factors are constitutively expressed at low levels in a variety of cell 
types. Upon virus infection or IFN stimulation both IRF-1 mRNA and IRF-2 mRNA are induced, and 
particularly IRF-1 mRNA. The IRF-1 promoter has binding sites for STAT and NF-κB transcription 
factors (Harada et al., 1994; Pine et al., 1994). In STAT1-deficient cells, no induction of IRF-1 mRNA 
was seen after IFN stimulation (Meraz et al., 1996). IRF-2 is also inducible by IFN-α/β and this is 
mediated by an NF-κB and ISRE element in its promoter region (Harada et al., 1994). 
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IRF-1 can activate IFN-α/β promoters as shown by IRF-1 cDNA expression experiments. High level 
expression of the cloned mouse Irf-1 gene in monkey COS cells and mouse ECs resulted in the 
induction of endogenous IFN-α and IFN-β without viral stimulation (Fujita et al., 1989; Harada et al., 
1989; Harada et al., 1990). In contrast, IRF-2 represses IRF-1 induced transcription of IFN-
α/β promoters (Harada et al., 1990). Thus, IRF-1 and IRF-2 act as transcriptional activator and 
repressor for the IFN-α/β genes. 
IRF-1-/- and IRF-2-/- mice are resistant to LPS-induced lethality (Cuesta et al., 2003; Senaldi et al., 
1999). Using IRF-1-/- macrophages, it was demonstrated that IRF-1 is necessary for iNOS production 
(Kamijo et al., 1994).  However, IRF-1 is not essential for type I IFN production in vivo, because virus- or 
dsRNA-induced type I IFN was unimpaired in IRF-1-/- mice (Reis et al., 1994). IRF-2-/- mice develop a 
CD8+ T-cell mediated-inflammatory skin disease and show elevated expression of IFN-dependent genes 
(e.g. Irf-7 and Oas) (Hida et al., 2000). IFN induction after viral infection is more efficient in IRF-2-
deficient fibroblasts than in wild-type fibroblasts (Matsuyama et al., 1993). IRF-2 and IFN-stimulated 
gene factor 3 (ISGF3) compete with each other for the ISRE sites on IFN-inducible genes and loss of 
IRF-2 leads to a continuing expression of IFN-dependent genes (Hida et al., 2000). IRF-2 can also act 
directly on the IFN-β promoter to inhibit its induction (Senger et al., 2000). To conclude, in contrast to 
IRF-1, which is a positive factor, IRF-2 does not function as an activator but suppresses the function of 
IRF-1 under certain circumstances (Harada et al., 1989). 
 
Another regulator of the IFN-β promoter is IRF-7, which is most closely related to IRF-3 in terms of the 
primary structure (for IRF-3, see section 2.2.2.1.) (Nguyen et al., 1997). IRF-7 was first described to bind 
and repress the Qp promoter region of the Epstein–Barr Virus (EBV)-encoded gene EBNA-1, which 
contains an ISRE-like element. IRF-7 is ubiquitously expressed, but unlike IRF-3 its expression is 
dependent of IFN-α/β signalling (Zhang and Pagano, 1997). Upon IFN-α/β stimulation, IRF-7 becomes 
phosphorylated in its C-terminal domain, which is highly homologous to the IRF-3 C-terminal end, and 
undergoes nuclear translocation. Sato and colleagues expressed a deletion mutant of IRF-7, in which 
the region containing the potential sites of inducible phosphorylation between amino acids 411 and 453 
was truncated. The mutant IRF-7 is incapable of translocation upon virus infection of the cells, 
demonstrating an essential role of this region in nuclear translocation. In addition, de novo synthesis of 
IRF-7 is important for positive-feedback regulation of IFN-α/β gene induction (Sato et al., 1998a). For a 
more extensive explanation of IRF-7 and its importance in amplification of the type I IFN response see 
section 3.3.4. 
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3.2.4.   Posttranscriptional regulation of IFN-β expression 
 
IFN-β mRNA is transiently expressed after virus infection or poly(I:C) stimulation (Hayes et al., 1979). 
The down-regulation of IFN-β mRNA synthesis is due to both transcriptional repression and rapid 
mRNA degradation. Degradation of transiently expressed mRNAs involves two steps. First, the mRNAs 
are deadenylated and this is followed by a rapid degradation of the deadenylated mRNA, which is 
facilitated by the presence of an AU-rich element (ARE) in the 3’ untranslated region (UTR) (Raj and 
Pitha, 1993). ARE motifs are found in many transiently expressed mRNAs such as in proto-oncogenes 
(e.g. c-fos, c-myc and c-jun), and in cytokine/lymphokine mRNAs (e.g. TNF-α). IFN-β has two 
destabilizing sequences: an AU-rich element in the 3’ UTR, and the coding region instability domain 
(CRID) in the 3’ end of the coding region. The AU-rich element in the 3’UTR of the IFN-β mRNA is 
highly homologous to the ARE region of other transiently expressed mRNAs. It targets the mRNA for 
rapid degradation and affects its translatability. AREs are classified into distinct categories based on the 
number and distribution of AUUUA pentamers. IFN-β ARE belongs to class II AREs, which are 
characterized by the accumulation of poly(A)- intermediates. The CRID region is also found in other 
unstable mRNAs such as c-fos and c-myc. The degradation of the IFN-β mRNA is under the control of 
these two cis-acting elements, which act independently (Paste et al., 2003; Raj and Pitha, 1993). 
The posttranscriptional regulation of the IFN-β mRNA is also mediated by a 65 kDa cytoplasmic protein 
that binds on three AU-rich domains of 19, 20 and 29 nucleotides long. One of these binding sites is the 
CRID domain, and the two other sites are in the 3’UTR. The deadenylation and degradation of IFN-
β mRNA is not coupled to its translation or to viral infection but requires a nuclear event (Raj and Pitha, 
1993). 
 
3.3.  The IFN-α promoter  
 
In humans and mice, multiple functional IFN-α gene subtypes exist. All IFN-α subtypes interact with the 
same receptor complex, termed the IFNAR complex. The PRDII and PRDIV elements, which are found 
in the IFN-β promoter and are activated by NF-κB and ATF-2/c-jun, are not identified in the IFN-α 
promoters (Nakaya et al., 2001). On the other hand, PRDI- and III-like elements (PRD-LEs), which bind 
members of the IRF family, have been identified in IFN-α promoters (Braganca et al., 1997). The murine 
IFN-α4 gene contains a VRE element located in the promoter proximal (-120 to -43) region comprising 
four PRD-LE elements (A-D). Cooperation among these binding sites is required for maximal IFN-α4 
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gene trans-activation. The AB elements bind preferentially IRF-7, while the C element is preferentially 
recognized by IRF-3. On the other hand, in the IFN-α11 gene there are point mutations in the C and D 
elements. This causes weaker activation of the IFN-α11 subtype and explains the molecular basis for 
differential expression of IFN-α genes following virus infection (Morin et al., 2002). At this moment it is 
still not clear whether or not other transcription factors are involved in the induction of these genes.  
 
Next to IRF-3 and IRF-7, IFN-α promoters can also bind IRF-1, IRF-2 and IRF-5 proteins. IRF-5 can 
synergize with the virus-mediated induction of IFN-α genes. It has also been demonstrated that human 
IRF-5 can activate IFN-α genes after virus infection in the absence of IRF-7 and that this is virus-
specific. IRF-5 can form heterodimers with IRF-3 and IRF-3/IRF-5 heterodimers can induce IFN-α 
genes in virus-infected cells (Barnes et al., 2001). Barnes and colleagues showed that also IRF-5/IRF-7 
heterodimers can be formed that modulate the expression profile of IFN-α subtypes (Barnes et al., 
2003). In addition, the functions of IRF-5 and IRF-7 are not redundant, since they each induce distinct 
IFN-α subtypes (Barnes et al., 2001). 
 
It seems that in vitro (monocytes) no IFN-α is induced after LPS stimulation (Bogdan et al., 2004; Hayes 
et al., 1991). Also in vivo it was demonstrated that LPS-induced IFN-α4 expression is very low 
(Karaghiosoff et al., 2003). In contrast, IFN-α is induced after TLR3 stimulation. The mechanisms of 
TRIF-mediated IFN gene induction via TLR4 and via TLR3 are not the same. While TLR3 activation 
results in the induction of IFN-α4 as well as IFN-β, TLR4 induces only IFN-β (Doyle et al., 2002).  
IFN-α is also strongly induced upon activation with TLR7 and TLR9 ligands in pDCs (Asselin-Paturel et 
al., 2005; Krug et al., 2001). To efficiently induce IFN-α production a signalling complex, consisting of 
IRF-7, is formed. 
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3.4.  Type I IFN signalling 
 
3.4.1.  The classical JAK-STAT pathway in type I IFN signalling and importance of IFN-β in sepsis 
 
Manuscript submitted by Tina Mahieu and Claude Libert 
 
‘Must we inhibit type I IFNs in endotoxemia and sepsis?’ 
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Type I interferons (IFNs) are well-known potent antiviral 
cytokines, but our knowledge about their roles in the host 
response to bacterial lipopolysaccharides (LPS) has 
increased rapidly only over the last few years. Bacterial 
infections, if they succeed in deregulating host responses, 
can lead to sepsis, severe sepsis or septic shock, and 
possibly high mortality rates. Here, we revisit the available 
data that suggest that type I IFNs are absolutely essential 
in LPS induced endotoxemia. This review will discuss the 
importance of the molecules involved in the induction of 
type I IFNs, the IFNs themselves, the IFN-responsive JAK-
STAT molecules, and the downstream genes in 
endotoxemia. We also discuss the potential advantages 
and disadvantages of treating septic patients with 
antibodies that block type I IFNs or their receptors. 
 
Introduction 
Infectious agents (viruses, bacteria, lower eukaryotes, worms 
etc.) are omnipresent, posing a continuous threat to 
vertebrates, including humans. Many examples of disastrous 
outbreaks of plague or viral epidemics colour our history books, 
for example the plague of the 1340s, which killed one third of 
the European population, and the Spanish flu of 1918. Many 
infectious agents have come under strict control, but many 
others that remain unchecked cause many casualties, e.g. HIV, 
SARS, Influenza and malaria.  
 Sepsis is defined as a systemic inflammatory response 
syndrome (SIRS) resulting from infection. Every year, more 
than 750,000 people in the U.S. and the E.U. develop sepsis, 
severe sepsis (sepsis associated with acute organ failure) or 
septic shock (severe sepsis with a dependency on 
vasopressors). All three syndromes are characterized by an 
overwhelming systemic response to infection that can rapidly 
lead to organ dysfunction and eventually death. Severe sepsis 
and septic shock strike hard and kill quickly. Each year, 
approximately 215,000 people in the U.S. die from severe 
sepsis/septic shock, which exceeds those dying from breast, 
colon/rectal, pancreatic, and prostate cancer combined (1). 
Over the recent decades, mortality rates due to severe sepsis 
have remained constant or decreased slightly, but incidence 
rates have grown steadily. Despite advances in our knowledge 
of infectious diseases and critical care, and despite numerous 
attempts to develop new treatments, the rate of mortality from 
severe sepsis and septic shock remains unacceptably high (2). 
Gram-negative sepsis, the leading cause of sepsis, has a case 
fatality rate of about 35%. Gram-positive pathogens are the 
second major cause of sepsis. 
 Vertebrates, as well as invertebrates and plants, have 
developed mechanisms to detect and respond to intruders (3, 
4). Clearly, inflammation and innate and adaptive immune 
responses are aimed at destroying the intruders. Gram-negative 
bacteria contain lipopolysaccharides (LPS) in their outer 
membranes (5). LPS, which has been studied extensively, is 
considered as the prototypic activator of innate immunity. 
Picomolar concentrations of LPS are sufficient to stimulate cells 
of the immune, inflammatory and vascular systems (6). LPS 
belongs to the group of molecules produced by pathogens and 
containing so-called “pathogen-associated molecular patterns” 
(PAMPs). PAMPs are recognized by one or more members of a 
family of transmembrane signalling receptors known as the Toll-
like receptor family (TLR), as well as by intracellular PAMP-
detecting molecules, such as nucleotide-binding oligomerization 
domain (Nod)-1, Nod-2, and retinoic acid inducible gene I (RIG-
I). (7-10). To date, 13 different mammalian TLRs have been 
recognized and cloned. (11). Activation of TLRs induces 
intracellular signalling pathways that lead to the production of 
specific sets of pro-inflammatory cytokines and chemokines, as 
well as type I IFNs and IFN-inducible gene products (12). 
Tina Mahieu PhD thesis (2006) 76
Chapter I - General Introduction 
TLR4-mediated type I IFN production Interferon (IFN) was discovered about 50 years ago as a 
soluble factor that inhibited viral replication upon induction of 
specific anti-viral genes, such as Oas and Mx, in infected cells. 
IFNs are classified in two distinct types. Type I IFNs consist of 
multiple IFN-α proteins, and single IFN-β, ε, κ, ζ (also called 
limitin), and ω subtypes, as well as δ and τ subtypes found in 
pig and ovine, respectively (13). IFN-λ1 (IL-29), IFN-λ2 (IL-
28A) and IFN-λ3 (IL-28B) function somewhat like type I IFN, but 
belong to a new cytokine family (14).  
Bacterial lipopolysaccharide (LPS) is an important structural 
component of the outer membrane of Gram-negative bacteria. It 
is considered as the principal active agent in the pathogenesis 
resulting from infection with Gram-negative bacteria. Indeed, 
injection of LPS leads to endotoxemia and endotoxic shock, 
which closely resemble sepsis and septic shock (23). We will 
briefly review the major factors involved in induction of type I 
IFNs upon LPS stimulation, and describe the major factors 
involved in responding to these IFNs.   The last few years of research have not only led to a much 
better characterization of the classical antiviral activities of IFN, 
but have also revealed a number of surprises concerning other 
biologically important immune regulatory functions of type I 
IFNs. Together, these results led to the conclusion that type I 
IFNs are essential links between the early innate responses and 
the subsequent, more specific adaptive immune responses (15, 
16). Type I IFNs induce MHC class I expression and have 
important effects on maturation and function of dendritic cells 
(DCs). They also lead to amplification of their own induction, as 
well as that of IL-15 and a high-affinity form of the IL-12 
receptor, and activate natural killer (NK) cell cytotoxicity (17-21). 
Indeed, recent studies have shown that a clear connection 
exists between type I IFN and antigen-presenting DCs at two 
levels. First, a specific DC precursor, the plasmacytoid pre-DC 
(p-preDC), was identified as a cell type that, following 
stimulation with infectious agents, can secrete very large 
amounts of type I IFNs. Second, type I IFNs have been shown 
to act as differentiation and maturation factors for DCs.  The 
signal for up-regulation of co-stimulatory surface molecules, 
including CD40, CD80 (B7-1) and CD86 (B7-2), is initiated by 
LPS, but it is mediated by IFN-β  and the type I interferon 
receptor (IFNAR) signalling axis (21). Furthermore, type I IFNs 
are crucial in inducing cytotoxic activity and proliferation of NK 
cells (17), and may also play key roles in induction of effective 
B-cell responses (22). Taken together, the available data 
suggest that type I IFNs serve as a link between the innate 
immune response to infection and the adaptive immune 
response. 
Beutler and co-workers demonstrated that the genetic defects in 
two LPS hyporesponsive strains of mice are linked to TLR4 (24, 
25). C3H/HeJ mice have a point mutation in the coding region 
of the Tlr4 gene, resulting in a substitution of a highly conserved 
proline at codon 712 by histidine, whereas in C57BL/10ScCr 
mice the Tlr4 gene is deleted. These mutations render these 
strains resistant to endotoxin (24). It has been demonstrated 
that activation of macrophages by LPS results in the release of 
a variety of inflammatory cytokines, such as tumor necrosis 
factor (TNF), interleukin (IL)-1, IL-6, IL-8, IL-12 and interferon 
(IFN)-β, in addition to smaller mediators such as prostaglandins 
and nitric oxide (NO) (26).  
 After binding to LPS, TLR4 dimerizes and undergoes a 
conformational change required for the recruitment of 
downstream TIR domain-containing adaptor molecules (see 
Figure 1). These include myeloid differentiation primary-
response protein 88 (MyD88), TIR-domain-containing adaptor 
protein (TIRAP), TRIF-related adaptor molecule (TRAM) and 
TIR-domain-containing adaptor protein inducing IFN-β (TRIF), 
which together determine the signalling specificity of the 
response (12). All TLRs, except TLR3, recruit MyD88 in order to 
activate both NF-κB and the mitogen-activated protein kinases 
(MAPKs), such as extracellular signal-regulated kinase (ERK), 
p38 and c-Jun N-terminal kinase (JNK) (12). MyD88 recruits IL-
1 receptor-associated kinases (IRAKs) through interaction of 
the death domains. IRAKs are activated by phosphorylation, 
after which they associate with TRAF6, leading to activation of 
the IκB kinase (IKK) complex, degradation of IκB, nuclear 
translocation of NF-κB, and expression of inflammatory 
cytokines (10, 27).  
 In this review, we discuss the importance of type I IFNs in 
LPS-induced lethal endotoxemia and sepsis, and the rationale 
for treating endotoxemia and sepsis by blocking type I IFN 
production or activity.  
 Stimulation with LPS also leads to recruitment of TRIF to 
the TLR4 receptor complex, and consequently to activation of 
IFN-regulatory factor (IRF)-3. This transcription factor induces 
expression of the IFN-β  encoding gene (12). Hiscott and 
colleagues identified the kinases responsible for activation of 
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IRF-3. Using two-hybrid screening, they found that IRF-3 was 
associated with two IKKs (28, 29), namely TANK-binding kinase 
1 (TBK1) and IKK-ε/IKK-i, whose activities are distinct from 
those of the canonical IKK-α and IKK-β (10). In response to 
LPS, mouse embryonic fibroblasts (MEFs) derived from TBK1-
deficient (TBK1-/-) mice are impaired in the production of type I 
IFNs and IFN-inducible gene products, but not of pro-
inflammatory cytokines (Table 1) (30). IKK-ε-/- mice show 
normal expression of these genes, but MEFs from IKK-ε/TBK1-
double deficient mice, upon specific TLR3 stimulation with 
poly(I:C), were unable to produce IFN-β and IFN-inducible 
proteins (note that the TLR3 receptor does not use the MyD88 
pathway, but only the TRIF pathway). Moreover, in IKK-ε/TBK1 
double deficient cells, LPS failed to activate IRF-3 (31). It was 
also shown that after TLR4 stimulation TRIF can recruit TRAF6-
TAK1-TAB2 through its TRAF6-binding site, which is different 
from its IRF-3 activating site (32). Upon LPS stimulation, 
phosphorylated IRF-3 dimerizes and translocates to the 
nucleus. IRF-3 dimers become transcriptionally active after 
association with p300/CBP co-activators. Activated IRF-3, along 
with NF-κB, induce the expression of the IFN-β gene (33).  
 
The JAK-STAT pathway 
Once produced, type I IFNs bind to the interferon-alpha 
receptor (IFNAR) 1 and IFNAR2 and initiate a signalling 
cascade mediated by the tyrosine kinases janus kinase (JAK) 1 
and tyrosine kinase (TYK) 2, which activate the signal 
transducer and activator of transcription (STAT) 1 and STAT2 to 
form a STAT1/STAT2 heterodimer (34). Other pathways, most 
notably the p38 MAPK and phosphatidylinositol 3-kinase (PI3K) 
pathways, are also induced (35). STAT1/STAT2 complexes 
associate with a p48 protein, identified as IRF-9, to form the 
interferon-stimulated gene factor-3 (ISGF-3). This factor 
recognizes interferon stimulated response elements (ISREs) in 
promoter regions of interferon responsive genes (ISGs) 
encoding proteins such as PKR (double-stranded RNA-
dependent protein kinase), OAS (2’,5’-oligoadenylate 
synthetase), Mx1 (myxovirus (influenza) resistance 1) and IRF-
7 (34). In addition to being part of ISGF-3, STAT1 also forms 
homodimers that bind to a distinct promoter element, the IFN-γ-
activated site (GAS). STAT1 homodimers, called the AAF (IFN-
α activated factor) complex, induce the IRF-1 gene, another 
transcriptional activator (36, 37). When IRF-7 is induced by 
ISGF3, it becomes phosphorylated and is translocated to the 
nucleus (38), where it activates the IFN-α/β promoters (20, 39). 
Induction of serum IFN-α/β  by viruses is severely impaired in 
IRF-7 knockout mice, which shows that IRF-7 is essential for 
the induction of type I IFN after virus infection (40). IFN-
α/β gene induction is more severely impaired by blocking IRF-7 
expression than by introducing an IRF-3 null mutation (41). 
Thus, IRF-7 plays a crucial role in the massive IFN-α/β 
production through a positive feedback loop (see Figure 1) (20, 
38, 42).   
 The JAK-STAT pathway is negatively regulated by distinct 
regulatory proteins, including the suppressors of cytokine 
signalling (SOCS)-1 and SOCS-3, which inhibit the kinase 
activity of JAK1. STAT1 tyrosine phosphorylation following TLR 
triggering is severely impaired by SOCS-1, and to a lesser 
extent SOCS-3. Thus, SOCS proteins, which can be induced by 
cytokines as well as by TLR ligands such as LPS and CpG, limit 
the extent of TLR signalling by inhibiting the type I IFN 
signalling pathway but not the main NF-κB pathway (43).  
 JAK1 phosphorylation is also negatively regulated by 
protein tyrosine phosphatases (PTPs), such as SRC homology 
2 (SH2)-domain-containing PTP1 (SHP1), SHP2, CD45 and T-
cell PTP (TCPTP) (44).  
 STAT1 is not only regulated by the PTPs SHP2 and 
TCPTP, but also by protein inhibitor of activated STAT (PIAS). 
STAT1-mediated gene activation is regulated by PIAS1 and 
PIASY. PIAS1 blocks the DNA-binding activity of STAT dimers 
and inhibits STAT1-mediated gene activation in response to 
IFN-γ (45). PIASY acts as a transcriptional co-repressor of 
STAT by recruiting co-repressor proteins such as histone 
deacetylase (HDAC) (46). 
 SH2-containing inositol 5-phosphatase (SHIP) is a negative 
regulator of the PI3K-pathway, which stimulates a number of 
other pathways, including the MyD88-dependent (47) and the 
TRIF-dependent pathways (48). Phosphorylation of STAT1 has 
recently been shown to be PI3K dependent (49).  
 
IFN-β as a critical mediator in lethal endotoxemia 
Type I IFNs have long been known as potent antiviral 
molecules. In the last few years, however, a critical role for 
these interferons in LPS-induced endotoxemia has been 
elucidated. It has become clear that non-viral PAMPs, such as 
LPS, induce expression of the type I IFN genes. The essential 
molecules involved in inducing type I IFNs and in responding to 
them have also become known. The role of these molecules in 
endotoxemia, as well as that of the IFNs themselves, is now 
being investigated in knockout mice and in cells. Table 1 lists 
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the phenotypes relevant to this review. Figure 1 depicts 
molecules whose knockout affects LPS responsiveness.  
 A mutant mouse, called Lps2 and generated by random 
mutagenesis with ENU in the laboratory of Dr. B. Beutler, 
appears to contain a distal frameshift error in a Toll/interleukin-1 
receptor/resistance (TIR) adaptor protein, now known as TRIF 
or TICAM-1. TrifLps2 homozygote mice are markedly resistant to 
endotoxemia, and fail to produce type I IFNs in response to 
LPS. LPS-induced STAT1 phosphorylation and IRF-3 
dimerization are also impaired in these mice (50). TRIF-
deficient mice, generated in the laboratory of Dr. S. Akira, are 
also defective in TLR4- and TLR3-induced expression of IFN-β 
and activation of IRF-3. Furthermore, TRIF-deficient 
macrophages are impaired in the production of inflammatory  
cytokines in response to the TLR4 ligand, but not in response to 
ligands of TLR2, TLR7 and TLR9. Poly (I:C)-induced NF-κB 
activation was severely impaired. In contrast, induction of NF-
κB and MAPK JNK by LPS was almost normal. This might be 
due to an intact MyD88-dependent early NF-κB activation (51). 
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Figure 1. Representation of TLR4-signalling through the MyD88-dependent and MyD88-independent pathways. The MyD88 
independent/TRIF-dependent pathway leads to induction of IFN-β. IFN-β then binds to the IFNAR complex in an autocrine or 
paracrine way, leading to activation of ISGF3 and AAF. The former binds to ISRE elements of IFN-inducible genes, such as 
those encoding IRF-7, OAS  and  PKR. IRF-7  can bind  to promoter  elements of the genes encoding IFN-β and IFN-α. The 
molecules in color are those whose deletion in mice leads to resistance to endotoxemia.
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 TRAM-deficient mice, also generated by Dr. Akira and his 
colleagues, are defective in LPS-induced cytokine production 
(TNF-α and IL-6). In TRAM-deficient macrophages (52) LPS 
failed to induce IFN-β and IFN-stimulated genes (Ifit2, Cxcl10, 
Ccl5), and to activate STAT1.  
 TBK1 deficiency resulted in TNF-mediated liver 
degeneration and consequent embryonic mortality (53). In 
TBK1-/- macrophages, the LPS induced activation of IRF-3 and 
STAT1 was absent or greatly diminished. Also, in response to 
LPS, TBK1-/- macrophages failed to up-regulate transcription of 
IFN-β and IFN-mediated transcription of genes encoding 
CXCL10, CCL5, IFN-α5, IRF-7, IL-15 and Mx1. However, they 
activate NF-κB normally in response to LPS (54).  
It was also shown recently, using IRF-3 knockout mice, that 
IRF-3 is indeed essential for LPS-mediated IFN-β gene 
Embryonic fibroblasts from IKK-ε-/- mice responded normally to 
LPS with respect to IRF-3 activation and induction of type I IFN. 
However, expression of IRG-1 and CXCL10 mRNA in IKK-ε-/-
TBK1-/- cells was severely impaired, and induction of IFN-β, 
IFN-α, and ISG54 mRNA after stimulation with poly (I:C) was 
abolished (31).  Loss of IRF-3 also affects the expression profile 
of other genes, such as some IFN-α subtypes, CXCL10 and IL-
15. As would be expected, IRF-3-deficient mice are resistant to 
LPS-induced endotoxic shock (55). 
As described above, the JAK-STAT pathway is involved in 
transduction of the signal induced by the IFNAR1 and leading to 
expression of IFN-responsive genes as well as massive up-
regulation of IFN-α/β genes. Absence of several molecules of 
the JAK-STAT pathway causes resistance to LPS-induced 
endotoxemia. In addition, over-expression of negative 
regulators of the JAK-STAT pathway (see above) can shut 
down IFN signalling and hence are expected to protect against 
endotoxemia. 
 
 
Table 1: Summary of the biological effects, relevant to endotoxemia, observed in mice or cells deficient in genes that are 
centrally involved in induction of type I IFNs, downstream signaling molecules or the IFNs themselves. 
 LPS stimulation   
-/- IFN-β IFN-dependent 
genes  
(e.g. IFNα) 
Pro-inflammatory 
Cytokines  
(e.g. TNF) 
Lethality Gram – 
Sepsis 
References 
TLR4 ND ND  R Sensitive 23, 52, 53 
TRIF(m) 
TRIF (c) 
↓↓ 
 
↓↓ 
↓↓ 
↓↓ 
↓↓ 
R ND 54, 55 
TRAM (c) ↓↓ ↓↓ ↓↓ ND ND 56 
TBK1 (c) ↓↓ ↓↓ √ (NF-κB) ND ND 58 
IKK-ε/ι (c) ↓↓ ↓↓ ND ND ND 30 
IRF-3 ↓↓ ↓↓ √  R ND 59 
IFNAR1 ND ↓↓ ND R ND 60 
TYK2 ↓↓ ↓↓ √ (IκB degrad.) R ND 62 
STAT1 ↓↓ ND ND R (±) ND 62 
STAT2 ND ↓↓ ND ND ND 63 
IRF-7 ND ND? ND ND ND 42 
IFN-β ↓↓ ND √ R ND 62 
SOCS-1 ND ND √ (IκB) Sensitive ND 64 
Legend: ↓↓ mRNA strongly decreased; √ : Inflammatory cytokine production OK; R: resistant to LPS ; m: mice; c: cells; ND: not done.
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 IFNAR1 -/- mice are highly susceptible to viral infection. In 
cells from IFNAR1 -/- mice, no signalling in response to type I 
IFN was detectable as measured by induction of OAS. Also, 
bone marrow macrophages from IFNAR1 -/- mice respond 
abnormally to LPS (56). We indeed found that IFNAR1-deficient 
mice completely resist LPS-induced lethal endotoxemia 
(Mahieu et al., 2006). In addition, using macrophages from 
IFNAR1-/- mice, Hertzog and colleagues found that type I IFNs 
mediate the induction of cyclin D2 by LPS (58).   
  Tyk2 knockout mice are resistant to shock induced by high 
doses of LPS. Induction of IL-1β, IL-6, IL-12, TNF and NO in 
serum were comparable in wild-type and Tyk2 null mice. LPS-
induced MyD88-dependent signalling in vitro was intact, as 
shown by normal TNF-secretion, IκB degradation and 
phosphorylation of p38, ERK1/2 and JNK. In Tyk2 null 
macrophages, LPS-induced expression of IFN-β and IFN-α4 
mRNA was diminished, and induction of IFN-γ mRNA was low. 
Moreover, phosphorylation of IRF-3 was normal, but induction 
of IRF-1 and IRF-7 mRNA was reduced (59).  
 Mice defective in STAT1 are resistant to LPS, but not as 
much as Tyk2 knockout mice. As would be expected, LPS-
induced expression of IFN-β mRNA was reduced in the 
absence of STAT1. But, in contrast to Tyk2 null macrophages, 
STAT1 null macrophages were not impaired in IFN-
γ expression (59). 
 STAT2 null mice also show a loss of the type I IFN 
autocrine/paracrine loop, which afffects several aspects of the 
immune response (60). Furthermore, it was shown in IRF-7 
knockout mice that the transcription factor IRF-7 is essential for 
the induction of IFNα/β genes after virus infection (40). The 
most solid evidence that type I IFNs are central mediators in 
endotoxemia was provided by Karaghiosoff and co-workers, 
who showed that IFN-β knockout mice are resistant to lethal 
endotoxemia induced by high doses of LPS, and that they have 
less serum TNF, NO and IFN-γ  after LPS challenge compared 
to WT animals (59). 
 Deficiency in SOCS-1 leads to early-onset fatal disease. 
Experiments on cells from SOCS-1 knockout mice 
demonstrated that SOCS-1 is necessary for inhibition of IFN-
α/β receptor signalling through effects on Tyk2. As expected, 
SOCS-1-/- mice did not resist LPS, nor did SOCS1-/- IFN-γ-/- 
mice (61). On the contrary, SOCS-1 is strongly induced by LPS 
and is an essential protective molecule since SOCS-1-/- mice 
were found to be supersensitive to LPS (62, 63). In fact, SOCS-
1--/- mice develop severe inflammatory disease, which appears 
to be solely the result of overactivity of the type I IFN signaling 
cascade and not due to enhanced type II IFN activity (64). 
Overexpression of SOCS-1 or SOCS-3 down-regulated the IFN-
induced phosphorylation of STAT1 and STAT3. Overexpression 
of SOCS-1 in cells abolished mRNA expression of both OAS 
and Mx1 and overexpression of SOCS-3 inhibited mainly OAS 
mRNA expression. Thus, SOCS-1 and SOCS-3 have important 
negative regulatory effects on the type I IFN-induced activation 
of the JAK-STAT pathway (65). In macrophages for example, 
overexpressing SOCS-1 or SOCS-3, induction of the IFN-β-
dependent gene CXCL10 was defective, and LPS-induced 
STAT1 phosphorylation was abolished (43).  Interestingly, 
recent data suggest that protein therapy using cell permeable 
SOCS-3 has a curative effect in mouse models of endotoxemia 
(66). 
 Not much is known about the potential role of the other 
JAK-STAT inhibitory molecules SHP1, SHP2, CD45, TCPTP, 
the PIAS proteins and SHIP in endotoxemia. It was shown that 
SHIP-/- macrophages are hyper-responsive to LPS, that they 
are not endotoxin tolerant, and that their STAT1-
phosphorylation is not diminished after a second exposure to 
LPS (67). 
 
IFN-α/β as a therapeutic tool and target 
Almost 50 years of intense research have made it clear that 
type I IFNs are absolutely essential in the defence of 
vertebrates against many viruses. First, the IFN genes are 
strongly conserved, and their orthologues have been found in 
different species, e.g. fish and birds. Second, deficiency of IFN 
receptor genes leads to dramatically increased sensitivity for 
many viruses (56, 68). Third, exogenously added IFNs have 
antiviral effects, such as the curative effects on hepatitis C 
infected patients (69). However, type I IFNs are also important 
in controlling other diseases and pathologies. In leishmaniasis, 
low doses of IFN-β protect mice from progressive cutaneous 
and fatal visceral disease after infection with Leishmania major 
parasites (70).  Also, IFN-β is the most commonly used therapy 
for relapsing Multiple Sclerosis (71) and it can also inhibit 
collagen-induced arthritis in mice (72). Finally, type I IFNs inhibit 
proliferation of several human cancers, a therapy that has been 
evaluated in clinical trials, e.g. for renal cancer (73-75). From 
the above, one can conclude that type I IFNs are molecules that 
should certainly not be absent from the body and that should be 
given to patients under certain pathological conditions.  
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 It is now also clear that resistance to endotoxemia can be 
induced by deletion of genes encoding IFN-β, IFNAR1, Tyk2 or 
other genes involved in the induction of, or in the response to, 
type I IFNs. The data support the idea that type I IFNs have to 
be considered as mediators in endotoxemia. The mechanism by 
which they mediate LPS, is still an open question. However, 
several studies have clearly shown that type I IFNs are able to 
induce the expression of genes encoding other inflammatory 
molecules, such as NF-IL6 and a large set of chemokines (76, 
77). Hence, one would also like to block type I IFNs or their up-
stream or down-stream mediators. A recent study clearly shows 
that this idea can have therapeutic application in the treatment 
of endotoxemia (66). Two central questions, however, need to 
be addressed.  
  First, to what extent will an inhibitory molecule, such as a 
neutralizing antibody to IFN-β or an IFNAR1 antagonist, 
compromise the anti-viral status of the organism? Studies using 
IFNAR1-knockout mice indeed indicate that these mice may be 
resistant to endotoxemia (Mahieu and Libert, unpublished data) 
and supersensitive to viral infections (68). Further studies with 
experimental animals or clinical trials will have to provide an 
answer this first question, but possibilities can be contemplated. 
Firstly, e.g. in the case of the IFNAR1, an inhibition of 90% 
could suffice to protect against endotoxemia, but that the 
remaining 10% of receptor activity could be enough to mount an 
adequate anti-viral response. Whether a sufficiently strong 
inhibition of the IFNAR1 will be possible has to be evaluated 
first. Inhibition of ligand could be problematic too, as many type 
I IFNs may play a role in endotoxemia. Luckily, the resistance of 
IFN-β deficient mice to endotoxemia resembles that of IFNAR1-
knockouts, indicating that IFN-β is the type I IFN playing the 
predominant role in endotoxemia. Moreover, IFN-β is the major 
type I IFN induced by LPS (56), though also induction of IFN-α4 
by LPS was observed in macrophages (59). Furthermore, septic 
patients may be treated with IFN-blocking agents over a short 
time interval in strictly contained conditions to prevent viral 
infection.  
 Second, do type I IFNs also play a mediating role in real 
sepsis and not just in endotoxemia? To our knowledge, no 
studies endorsing this hypothesis in the case of Gram-negative 
sepsis have been published. However, it was clearly 
demonstrated that type I IFNs are an essential component in 
the lethal response of mice to a Gram-positive Listeria 
monocytogenes infection, probably because macrophages are 
sensitized to cell death by production of type I interferon 
induced by Listeria monocytogenes (78). Although our 
knowledge of the role of type I IFNs in endotoxemia indicates 
that they also play a mediating role in sepsis, experimental 
evidence is needed to confirm this hypothesis. 
 Finally, endotoxemia (and probably sepsis) are not the only 
disorders in which type I IFNs play a detrimental role, and in 
which the type I IFN system should be blocked. Given the 
diverse and potent effects of type I IFNs in the innate and 
adaptive immune systems, it is not surprising that they play a 
pivotal pathogenic role in several autoimmune diseases. 
Increased serum levels of IFN-α were found to correlate with 
exacerbation of systemic lupus erythematosus (SLE) (79, 80) 
and insulin-dependent diabetes mellitus (IDDM) (81, 82) in 
humans and rodents, and IFN-α over-expression in beta cells 
at the onset of diabetes has been reported in human patients 
(83). 
 
Conclusion 
 Many recent data suggest that type I IFNs as well as 
several molecules involved in inducing these cytokines and in 
responding to them play essential mediating roles in 
endotoxemia induced by Gram-negative cell wall components, 
and in several autoimmune disorders. These data suggest that 
key molecules, such as IFN-β and the IFNAR1, may be 
considered as new therapeutic targets in endotoxemia and 
sepsis, provided that their essential role in antiviral defence and 
in activation of the immune system are not compromised. 
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3.4.2. Other pathways involved in type I IFN signalling 
 
Next to the classical JAK-STAT pathway, it has been demonstrated that other pathways such as the p38 
and PI3K pathways are involved in responses to type I IFN (for review see Platanias, 2005). The p38 
MAPK seems to play an important role in type I IFN signalling. After activation of p38 MAPK through a 
cascade of kinases, p38 may subsequently activate downstream molecules such as MAPK-activated 
protein kinase 2 (MAPKAPK2), MAPKAPK3, mitogen- and stress-activated kinase 1 (MSK1) and MAPK-
interacting protein kinase 1 (MNK1). These molecules have a possible role in respectively Isg15 gene 
induction, posttranscriptional regulation of expression of various genes, histone H3 phosphorylation and 
phosphorylation of the eukaryotic translation-initiation factor 4E (EIF4E) in IFN-mediated signalling. 
Other MAPK-signalling pathways, such as the MEK-ERK pathway, seem to have a role in type I IFN 
signalling. PI3K has a role in IFN-dependent transcriptional activation by STAT1, apoptosis, mRNA 
translation and regulation of IFN-β-dependent phosphorylation of the p65 subunit of NF-κB. 
Furthermore, instead of the classical STAT1-STAT2 and STAT1-STAT1 complexes, other STAT 
complexes are formed upon type I IFN stimulation. This includes the formation of STAT3-STAT3, 
STAT4-STAT4, STAT5-STAT5 and STAT6-STAT6 homodimers, as well as, STAT-1-STAT3, STAT1-
STAT4, STAT1-STAT5, STAT2-STAT3 and STAT5-STAT6 heterodimers. All these complexes bind to 
the IFN-γ-activated site (GAS) element in some genes (Platanias, 2005).  
 
3.4.3.  Regulation of IFNAR expression 
 
The type I IFNs bind to a receptor consisting of two sub-units, IFNAR1 and IFNAR2. There is a single 
form of the IFNAR1 subunit and there are three forms of the IFNAR2, namely one transmembrane 
(muIfnar-2c) and two soluble isoforms (muIfnar-2a/2a’). IFNAR2 has ligand-binding capacity, but is not 
able to transduce signals (Owczarek et al., 1997). Hardy and colleagues proposed a model by which 
stimulation of cells with IFN-γ leads to activation of ISGF3. Then, the increased level of ISGF3 can allow 
up-regulation of muIfnar-2c in response to type I IFN via ISRE and GAS elements in the promoter of the 
muIfnar-2 gene. At first, muIfnar-2c is upregulated on the cell surface, leading to increased biological 
activity in response to type I IFN. Later, soluble muIfnar-2a mRNA is induced, acting as an inhibitor of 
type I IFN signalling (Hardy et al., 2002). 
Down-regulation of activated receptors is important for retaining the duration of the signal. At this 
moment, there is still little information on the modulation of IFN receptor expression. Recently, some 
data on IFNAR1 down-regulation have been published. In the distal cytoplasmic tail of the IFNAR1 is a 
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motif that can be recognized by homologue of Slimb (HOS) F-box-containing protein, which acts as a 
receptor for SCFHOS E3 ubiquitin ligase that has been demonstrated to be essential for ubiquitination, 
internalization, proteolysis and down-regulation of IFNAR1 in response to IFN-α (Kumar et al., 2003). It 
has also been reported that TYK2 slows down IFNAR1 degradation, a process that is at least partly due 
to inhibition of IFNAR1 endocytosis (Ragimbeau et al., 2003).  
  
3.4.4.   Amplification of the type I IFN response and importance of IRF-7 
 
After virus infection, IFN-α/β and many IFN-inducible genes are expressed to elicit anti-viral responses. 
These genes contain similar cis-acting IRF-binding elements: interferon-stimulated response element 
(ISRE), PRD and PRD-like (PRD-LE) elements. ISREs reside usually in the promoters of IFN-inducible 
genes; PRDI and PRDIII elements are found in the IFN-β promoter and PRD-LE elements in the IFN-α 
promoters. A complex of IRF-3 and co-activators CBP/p300 can directly induce some IFN-inducible 
genes. This complex is called DRAF1. Also, the IFN-α/β-induced ISGF3 complex, composed of STAT1, 
STAT2 and IRF-9, can induce IFN-inducible genes and the Irf-7 gene by binding the ISRE elements in 
their promoters. IRF-7 can induce IFN-α genes by binding the PRD-LE sites and IFN-β by binding PRD 
elements. Thus, ISRE, PRD and PRD-LE elements differentially utilize IRF family members. IFN-α/β 
and IFN-inducible genes are classified into different groups in terms of their activation. The first group is 
the ‘ISGF3 only’ group of genes totally dependent on IFN-α/β-induced ISGF3 formation. OAS, PKR and 
IRF-7 belong to this group. The second group is called the ‘ISGF3/IRF-3’ group and comprises ISG15, 
ISG54, guanylate binding protein (GBP) and IP10. The third group is called the ‘IRF-3/IRF-7’ group, to 
which IFN-β belongs. IFN-α belongs to the ‘IRF-7 only’ group (Nakaya et al., 2001). 
 
Type I IFNs are expressed rapidly after infection and plays a key role in innate defence against 
pathogens. The regulation of IFN-α/β expression is through a two-step activation model. In uninfected 
cells, IRF-3 is constitutively expressed. IRF-3 becomes activated upon virus infection and translocates 
to the nucleus to induce IFN-β, but not IFN-α genes (except IFN-α4), resulting in the initial production 
of IFN-β (and IFN-α4). Type I IFN can act in an autocrine or paracrine manner through binding to the 
IFNAR1/IFNAR2 complex and induces Irf-7 gene expression via activation of ISGF3. The expression of 
IRF-7 is ubiquitous, however, it is totally dependent on IFN-α/β. IRF-7 can bind on the PRD and PRD-
LE elements in the IFN-β and IFN-α promoters. Thus, secreted IFN-α4 and IFN-β proteins can bind on 
their common receptor to induce activation of IRF-7, which will lead to the induction of a set of delayed 
IFN-α genes which includes IFN-α2, -α5, -α6 and -α8 genes (Marie et al., 1998; Taniguchi and 
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Takaoka, 2002). The de novo synthesis of IRF-7 is crucial for the up-regulation of IFN-α/β production by 
a positive feedback mechanism. The induced IRF-7 resides in the cytoplasm, but undergoes 
phosphorylation in its carboxy-terminal region on two distinct sets of Ser/Thr residues. The C-terminal 
region of IRF-7 is highly homologous to the corresponding region of IRF-3. Phosphorylation of IRF-7 
leads to its dimerization, nuclear accumulation, DNA binding, and transcriptional activation (Taniguchi 
and Takaoka, 2002; Wathelet et al., 1998). Thus, IRF-7 is induced upon type I IFN stimulation and 
further enhances the production of IFN-α/β through a positive feedback loop (Sato et al., 1998a). The 
IRF-7 protein is short-lived, and must be continuously produced (Sato et al., 2000). 
 
IRF-7-knockout mice are more susceptible to viral infection than IRF-3- or MyD88-knockout mice. In 
IRF-3-knockout cells IFN-α/β is still present, although in diminished levels, because of the weakly 
activated ISGF3 through spontaneously produced IFN-α/β. So, in uninfected cells spontaneously 
produced IFN-α/β maintains the level of IRF-7 expression at an appropriate level, so that the positive 
feedback loop can be initiated immediately upon viral infection (Sato et al., 1998a; Sato et al., 2000). 
The spontaneous production of IFN-α/β in absence of viral infection is observed both in vitro and in vivo 
(Gresser, 1990; Gresser et al., 1995). The mechanism of spontaneous IFN-α/β production is not known 
(Figure I.3.3.). Even in the absence of both IRF-3 and -7, there is a low constitutive level of IFN-α/β 
(Sato et al., 2000). 
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Figure I.3.3. – A weak constitutive level of IFN-α/β is necessary for effective amplification of the IFN-α/β signal after 
stimulation. The presence of a low constitutive level of IFN-α/β sustaines a weak activated ISGF3 and IRF-7 expression. 
This is important for a robust response of the cells to stimuli like viral infection. Upon viral infection the positive feedback loop 
can be rapidly initiated because of this sustained IRF-7 expression. The mechanism of the spontaneously produced IFN-α/β 
remains unknown. 
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Using cells lacking IRF-9, an essential component of ISGF3, it was shown that ectopic expression of 
IRF-7 but not IRF-3 can rescue IFN-α gene expression (Sato et al., 1998a). Using IRF-7-knockout mice, 
it was demonstrated that IRF-7 is important in type I IFN induction after virus-activated MyD88-
independent signalling, but also in TLR9-induced MyD88-dependent signalling (Honda et al., 2005b). 
IRF-7 is also important in co-operation between TLRs and IFNAR for optimal induction of IL-12p70 
(Gautier et al., 2005). There is also an important role for IRF-7 in the TLR9-mediated induction of the 
antigen-specific CD8+ T-cell response in pDCs. Spatiotemporal regulation of MyD88-IRF-7 signalling is 
critical for type I IFN induction in response to TLR9 activation. The TLR9 ligand, CpG-A, is retained 
together with MyD88-IRF7 in the endosomal vesicles of pDCs for a long time, making it possible to 
activate this signalling pathway. In cDCs, CpG-A localizes to lysosomes and is not able to induce IFN 
(Honda et al., 2005a). 
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4.   MAPPING IN THE MOUSE 
 
4.1.   Mouse domestication  
 
At the dawn of civilization, humans developed the ability to farm, to build store grain and foodstuffs. The 
mouse was attracted by this environment with unlimited food and was well adapted to steal food from 
granaries. Thus, humans needed to protect their food-storages from the ‘bad mouse’. So it is not at all a 
surprise that the word mouse comes originally from the Sanskrit mush meaning to steal, which became 
mus in Latin and mys in Greek. 
The ancestral Mus musculus followed human migration to all corners of the world (Figure I.4.1.). Several 
distinct subspecies of Mus musculus have evolved to dominate non-overlapping segments of the world. 
The wild house mouse, Mus musculus (M.m.) musculus, lives in Eastern Europe and Asia and M.m. 
domesticus is common in Western Europe, Africa and the near-East and is transported by man to the 
Americas and Australia. Asian musculus and European domesticus mice dominate the world but have 
evolved separately over about 1 million years (Ferris et al., 1983). These subspecies are not separated 
by a major geographical boundary and only live together in a small stroke of land in Eastern Europe. 
The subspecies M.m. castaneus lives from Sri Lanka to South East Asia.  
 
 
 
Figure I.4.1. - Geographical distribution of the different subspecies of Mus musculus (Reprinted from Silver, Mouse 
Genetics, concepts and applications, 1995). 
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In nature, those different subspecies are not completely isolated genetically. As a consequence, there is 
genetic exchange between subspecies in the regions where they meet. In Japan, the two subspecies 
M.m. castaneus and M.m. musculus have hybridized extensively, giving rise to a unique population 
referred to as M.m. molossinus (Guenet and Bonhomme, 2003; Silver, 1995). 
 
4.2.   Historical roots of inbred mice 
 
In 1664, the mouse was used for the first time as a laboratory animal. Robert Hooke used the first 
laboratory mice in a study on the properties of air (Morse, 1978). By the 1700s, many varieties of mice 
were domesticated as pets in China and Japan. They were the first to raise unusual mice, in particular 
mice with coat-colour mutations (e.g. albino, yellow and dominant-spotting) and waltzing mutants.  
Already in 1100 B.C. the spotted mouse was mentioned in a Chinese lexicon. Europeans imported 
these ‘fancy mice’, so that by the 19th century ‘fancy mouse breeding’ became a popular hobby and it 
spread to the USA by the beginning of the 20th century. Abbie Lathrop, a retired schoolteacher, started 
to collect and breed these fancy mice at Granby, Massachusetts in 1900. Thousands of years of fancy 
mouse breeding resulted in highly homogeneous versions of these wild mice being traded and ending 
up in Lathrop’s schoolhouse (Figure I.4.2.). A number of mouse colonies were generated, including 
some of which develop tumours.  
 
Ancestral 
Mus musculus
species
domesticus
subspecies 
group
West Europe
castaneus
subspecies 
group
West Asia
Southeast Asia
South China
musculus
subspecies 
group
East Europe
Russia
North China
molossinus
subspecies
group
Japan
European
Fancy Mouse
Laboratory
mouse
East Asian 
Fancy Mouse
100 years
2000 years
1 million
years
 
 
Figure I.4.2. – Origin of the inbred laboratory mouse strains. The genome of inbred strains is a mosaic from segments 
derived from both European (domesticus) and Asian (musculus and castaneus) subspecies because the mice were derived 
from a few mouse breeders in Asia or Europe who originally bred ‘fancy’ mice (Wade et al., 2002). 
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In 1900, with the rediscovery of Mendel's laws of inheritance, a rush to verify these genetic theories in 
other animals was created. It was shown that the variation of ‘fancy’ mice was analogous to that of 
Mendel's peas. From 1902 on, William Castle of the Harvard University, a customer of Abbie Lathrop, 
started studying inheritance in mice. Mating programs were established to create inbred strains that 
resulted in many of the modern, well-known strains used in medical research. Clarence C. Little 
established the first inbred strains by brother-sister mating. Castle, Little and others formed the most 
commonly used inbred strains from the Lathrop stock (Silver, 1995). The DBA mouse (which has the 
coat-colour alleles, dilute, d, brown, b, and non-agouti, a) was the first real inbred strain produced by 
Little in 1909. Other inbred strains were generated over the next decade, including C57BL, C3H, CBA 
and BALB/c (Staats, 1966). Abbie Lathrop also conducted her own experimental breeding program, 
giving rise to strains such as C57BL/6 and C57BL/10. This hybrid breeding between M.m. domesticus, 
M.m. musculus and other subspecies led to the creation of progenitors of modern laboratory mice. 
 
The gene pools of most inbred laboratory mouse strains are small, as they were derived from a mixed, 
but limited founder population in a few laboratories (Beck et al., 2000). The genomes of these inbred 
strains are mosaics with the vast majority of segments derived from both European (domesticus) and 
Asian (musculus and castaneus) subspecies because the mice were derived from Asian or European 
‘fancy’ stocks collected by a few mouse suppliers. So the genome represents a mosaic with unequal 
contributions of several Mus musculus subspecies (Figure I.4.2.). The pattern of genetic variation in the 
genome of classical inbred strains has a mosaic structure, with regions of low levels of polymorphism 
and regions of high levels of polymorphism (Wade et al., 2002). Most of the inbred strains carry a 
musculus Y chromosome (Bishop et al., 1985) and domesticus mitochondrial DNA (Ferris et al., 1982). 
An inbred strain is defined as a strain that has been maintained for more than 20 generations of brother-
sister mating and is essentially homozygous at all genetic loci, except for mutations arising 
spontaneously. The inbreeding coefficient achieved is at least 0.99. After breeding 20 generations about 
98.6% of the loci in each mouse are homozygous. Many strains have been bred for more than 150 
generations and thus are essentially homozygous at all loci. Many of these inbred mice are bred for a 
specific phenotype. For example, the C57BL/6 mice have a preference for alcoholics and narcotics 
(Peirce et al., 1998). Some mouse strains are useful in transgenic and ES cell technology: FVB/N mice 
because of their large pronuclei which facilitate microinjection of DNA (Taketo et al., 1991) and 129/Sv 
mice because of successful contribution of ES cells to the germline. BALB/c and C3H mice are very 
sensitive to mutagenesis and useful in ethyl nitrosourea (ENU) projects, for example the large-scale 
ENU-mutagenesis screen in the German Human Genome Project. 
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Over 450 inbred strains of mice have been described. Ninety years after the generation of the first 
inbred strain, a chart of the origin and relationship of all the known inbred strains was constructed (Beck 
et al., 2000). In 1929, the Jackson Laboratories were established to serve as a repository for inbred 
stocks and mutant lines for experimental purposes. 
 
4.3.   The mouse as a model organism 
 
The mouse is the model organism most closely related to humans. The mouse and human genomes are 
approximately the same size (2.5 Gb compared with 2.9 Gb), contain the same number of genes (about 
30.000) and show extensive synteny (conserved gene order). Most mouse genes have human 
counterparts (about 99%), and the functions of these genes are closely related. Mutations that cause 
diseases in humans often cause similar diseases in mice. Importantly, mice have genes that are not 
represented in other animal models (the fruit fly and nematode), including the genes of the immune 
system. 
The similarities discussed above probably apply to most mammals, but the mouse has further properties 
that make it an ideal model organism. Mice do not pose a significant threat (non-aggressive) and there 
are fewer ethical issues associated with mice. With nonhuman primates, there are greater restrictions 
that must be followed. Mice are small, easy to maintain and breed in the laboratory and they have, 
compared to most mammals, a short breeding cycle of about 2 months. They can produce 10-15 
offspring per litter and approximately one litter every month. Furthermore, the breeding of mice is 
relatively inexpensive.   
All these properties make the mouse suitable for genetic analysis. Many mutants are available and new 
mutations can be introduced easily by irradiation, feeding with chemical mutagens or inserting DNA 
fragments into the genome to interrupt genes. In the early 1980s researchers began to produce 
transgenic animals by inserting human genes into fertilized mouse eggs. Now, the technique of 
homologous recombination is been used to target human genes into the mouse genome.   
 
4.4.  Use of wild-derived mouse strains 
 
The mouse is the model organism most closely related to humans and so the common laboratory inbred 
strains of mice are extensively used in genetic and biomedical research. However, genetic diversity 
between the different inbred laboratory mouse strains is very low, as they were derived from a mixed, 
but limited ancestral pool as shown by single nucleotide polymorphisms (SNP) analysis (Beck et al., 
2000; Wade et al., 2002). The common laboratory strains have limited levels of genetic variation when 
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compared with human populations, making it a serious disadvantage. Mouse inbred strains may be 
divided into two groups, classical and wild-derived. Wild-derived mouse inbred strains are inbred strains 
that have been derived from wild mice trapped at different times and locations, from different 
populations (Bonhomme and Guenet, 1996). Interspecific hybrids generated by crossing wild-derived 
Mus spretus and the classical laboratory strain Mus musculus are viable and have a high level of 
genetic diversity (Bonhomme et al., 1978). The usefulness of these wild-derived strains in genetic 
research stems from the high level of diversity, introducing new allelic variants at genes that might code 
for functional or non-functional variant enzymes. The levels of variation between wild-derived and 
common laboratory strains are significantly higher than among common laboratory strains (Wiltshire et 
al., 2003). For a good review about laboratory and wild mice, see Bonhomme (Bonhomme and Guenet, 
1996). 
Wild-derived strains are frequently used for genetic research in immunology (Bagot et al., 2002a; Bagot 
et al., 2002b; Campino et al., 2005; Jin et al., 1999; Kozak, 1985; Kozak et al., 1984; Sangster et al., 
1998; Sebastiani et al., 2002; Sebastiani et al., 1998; Urosevic et al., 1999; Velupillai et al., 1999) and 
oncology (Ewart-Toland et al., 2003; Manenti et al., 1994; Manenti et al., 1996; Nagase et al., 1995; 
Nagase et al., 1999; Nagase et al., 2003; Nagase et al., 2001; Pataer et al., 1996; Santos et al., 2002). 
When looking at the size variability of microsatellites between Mus spretus and common laboratory 
strains, 70-90% of the sequences show size variations (Cornall et al., 1991; Hearne et al., 1991; Love et 
al., 1990; Montagutelli et al., 1991; Santos et al., 1995). Only about 50% of the sequences is 
polymorphic among different laboratory strains (Hearne et al., 1991; Love et al., 1990; Montagutelli et 
al., 1991). When compared to the classical inbred strains, inbred strains derived from Mus spretus have 
a SNP in every 80-100 basepairs (Guenet and Bonhomme, 2003). This high degree of genetic 
polymorphism made strains derived from Mus spretus (the most popular being SEG/Pas and SPRET/Ei) 
the species of choice to conduct a mapping experiment. In 1994, a large Mus spretus/C57BL/6 
backcross of 982 progeny was set up. This was constructed to create a high-resolution genetic map of 
the mouse genome achieving a resolution of 0.1 centimorgan (cM) at the 95% confidence level 
(approximately 200 kb in the mouse genome) (Group, 1994; Rhodes et al., 1998).  
 
However, some practical difficulties occur using Mus spretus-derived strains. SPRET/Ei mice are very 
poor breeders and litters are mostly very small. In addition, F1 hybrid males are sterile and only hybrid 
females are fertile (Guenet et al., 1990). This sterility of F1 hybrid males is concordant with Haldane’s 
rule (Haldane, 1922). This rule states that when two different animal races are crossed and one of the 
sexes of the F1 offspring is absent, rare or sterile, this sex is the XY or heterozygous sex.  This F1 male 
sterility makes it impossible to do intercross-experiments. Also a considerably large amount of 
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backcross males are sterile due to the segregation of hybrid sterility factors (Bonhomme et al., 1982; El-
Nahas et al., 2002; Fossella et al., 2000; Hemberger et al., 1999; Matsuda et al., 1991; Olds-Clarke, 
1997; Redkar et al., 1998). In addition, sometimes there are difficulties in generating consomic mice or 
interspecific recombinant congenic strains starting from Mus spretus. Wild-derived strains belonging to 
the Mus musculus species (e.g. M.m. castaneus (CAST/Ei) or M.m. musculus (PWK/Ph)) also show a 
high level of diversity compared to the classical laboratory strains (Montagutelli et al., 1991), but suffer 
much less from these problems. Intersubspecific consomic and semi-consomic mice have been 
successfully generated from CAST/Ei (Iakoubova et al., 2001) and PWK/Ph.  
 
Agouti SPRET/Ei (Figure I.4.3.) was made inbred in 1988 by Eva Eicher. The wild-derived inbred strain 
SPRET/Ei is an inbred strain derived from Mus spretus. Other wild-derived strains are CAST/Ei 
(castaneus) and CzechII/Ei (musculus). Mus spretus and Mus musculus are diverged from each other 
about 1,5 million years ago (Figure I.4.4.) and this has led to a great amount of genetic polymorphisms, 
which allow mapping to the subcM level of resolution (Bonhomme et Guénet, 1996). Other subspecies 
belonging to the Mus spretus group are SEG/Pas and STF/Pas (originating from the Institut Pasteur). 
The Mus spretus-derived inbred strains SPRET/Ei, SEG/Pas, STF/Pas are frequently used in crosses 
with common inbred strains (e.g. C57BL/6) to create highly polymorphic panels for genetic mapping. 
 
 
 
Figure I.4.3. - Picture of agouti SPRET/Ei (Mus spretus) and black C57BL/6 (Mus musculus) (Photograph by Jan 
Staelens). 
 
 
Three independently derived strains of Mus spretus, SPE/Pas, SEG/Pas and SPR/Smh, were analysed 
by microsatellites for polymorphisms. SPE/Pas and SEG/Pas are very close (3% polymorphism), 
whereas the third one, SPR/Smh, is very different from the other two strains (33% polymorphism) 
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(Montagutelli et al., 1991). Staelens and colleagues from our group published that SPRET/Ei mice are 
resistant against high doses of TNF-α (Staelens et al., 2002). In addition, (C57BL/6 x SPRET/Ei)F1 
mice are resistant against TNF-induced arthritis and partially resistant against ovalbumin-induced 
asthma (Staelens et al., 2004). 
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Figure I.4.4. – Phylogenetic relationships in the genus Mus (Reprinted from Guénet and Bonhomme, Trends in Genetics, 
19, 24-31, 2003). 
  
 
4.5.   Mapping of a trait 
 
4.5.1.  Introduction: Linkage and recombination 
 
Mendel’s first law, also called ‘the law of segregation’, states that each individual has two copies of 
every gene and that only one copy is transmitted to the next generation. Cells or individuals with two 
copies of each gene, controlling a certain phenotype, are called ‘diploid’. A germ cell can transform from 
the diploid state to the haploid state through a process called meiosis. At the end of meiosis the two 
copies of each gene are segregated from each other and the germ cell contains only one copy of each 
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gene. The probability to receive either allele is equal and one allele is dominant to the other which is 
said to be recessive. 
Mendel’s second law or ‘the law of independent assortment’ states that the segregation of alleles is 
independently from each other. For example, when we look at two genes (gene with alleles ‘A’ and ‘a’ 
and gene with alleles ‘B’ and ‘b’), the possibility that a gamete will be AB, ab, Ab or aB is 25%. Today 
we know that Mendel’s second law applies only to two genes that are located on different 
chromosomes. 
 
Walter Sutton and Theodore Boveri demonstrated in the beginning of the 20th century that 
chromosomes segregate following Mendel’s law. Then, Morgan and Brides showed that genes are 
located on chromosomes. In 1905 it became clear that the law of independent assortment applies only 
to chromosomes and not genes (Bateson et al., 1905). 
When genes are located on the same chromosome they are ‘linked’. Two allele combinations will be 
transmitted at a frequency different from 25%. In the case of extreme linkage, when the genes are very 
close to each other, only the ‘parental combinations’ of alleles will be transmitted, each at a frequency of 
50%. At intermediate levels of linkage, termed ‘incomplete linkage’, the parental combinations of alleles 
will be transmitted at a frequency greater than 50%, but less than 100% because recombination events 
or ‘crossovers’ occur during meiosis. Crossovers occur at random sites across the chromosomes. The 
recombination frequency is related to the genetic distance between the two genes. Genetic distance is 
measured in cM and 1cM, which is about 2000kb in the mouse, is defined as the distance between two 
loci recombining with a frequency of 1%. In addition, when the distance between two loci increases, the 
probability increases to have double crossovers. Double or an even number of crossovers are not 
detectable from the original parental combination, while by an odd amount of crossovers a recombinant 
genotype can be detected. As a consequence, the observed recombination frequency will be less than 
the actual recombination frequency. The chance that a double crossover will happen between two loci 
that are separated by 20 cM is the product of the predicted frequencies for each locus alone, which is 
0.20 (20%). So for this example, the probability to miss recombination events in gametes is 0.2 x 0.2 = 
0.4 or 4%.  
Also one recombination on a certain location on a chromosome can influence the initiation of other 
recombination events. This event is called interference and restricts the resolution of a linkage map. The 
resolution is calculated with the formula 100/N, where N is the number of meiotic events that are typed. 
For example, when 1000 backcross animals are analysed, the theoretical map will be 0.1 cM or 200kb. 
Linkage analysis can be used for the genetic mapping of a distinct phenotype. 
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4.5.2.  Genetic markers 
 
Mapping of a phenotype demands the cross of two parental strains that are phenotypically and also 
genetically distinct. Of course, tools are needed to detect what parts of the genome are from which 
parent. Any variation in sequence can be used to distinguish between strains. Two individuals of the 
same species have variations in about 1bp per 200-500bp. The frequency of variations between two 
individuals of different species is much higher.  
 
The markers used to screen need to be abundantly present, to be easily genotyped and to have a high 
level of polymorphism. Some examples of molecular markers used in mapping are restriction fragment 
length polymorphisms (RFLPs), single stranded conformation polymorphisms (SSCPs), single 
nucleotide polymorphisms (SNPs) and simple sequence length polymorphisms (SSLPs) or 
microsatellites. Microsatellites have much of the requirements for a good screening system. Because of 
the high level of polymorphism associated with microsatellites, they are frequently used a genetic 
marker. Microsatellites are PCR-based DNA markers that can be rapidly typed in high amount of 
animals and are abundant throughout the genome. These are repeats of one till 4 nucleotides with the 
most common being CA-dinucleotide repeats. In the mouse genome, CA repeats are found once every 
18kb on average. The length of these microsatellites can vary between 80 and 270bp. The flanking 
sequences of the microsatellites are quite conserved, making it possible to design PCR primers for 
amplification to determine the length of microsatellites in various mouse strains. The products can be 
visualized by gel electrophoresis or by RP-HPLC (Figure I.4.5.).  
 
 
 
Figure I.4.5.  – Genotyping of microsatellite alleles. The figure shows a microsatellite locus with 3 different alleles. PCR 
amplification of the locus results in 3 fragments of different lengths. The products can be visualized by gel electrophoresis as 
shown below (Reprinted from Silver, Mouse Genetics, concepts and applications, 1995). 
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About 14.000 microsatellites have been positioned on the genome, implying that every 0.1 cM a genetic 
marker can be found assuming that the mouse genome is about 1.500cM. About 50% of the 
microsatellites are polymorphic between the strains of the Mus musculus group, while the percentage 
can be as high as 90% between C57BL/6 and wild-derived inbred mouse strains such as M.m. spretus 
and M.m. castaneus (Love et al., 1990; Montagutelli et al., 1991).  
 
Other popular genetic markers are SNPs, which are characterized by variation in a single nucleotide. 
SNPs are also abundantly scattered throughout the genome and are detected using PCR techniques, 
making it a technique that can be easily upscaled such as microsatellites (Syvänen, 2001). 
Approximately every 80-100 nucleotides a SNP is found between M. spretus and the common 
laboratory strains (Guenet and Bonhomme, 2003). 
 
4.5.3.  Mapping of a trait: initial crosses 
 
The subject of my thesis is the hypo-responsiveness of SPRET/Ei mice to LPS. In contrast, C57BL/6 
mice are susceptible to the toxic effect of LPS. The LPS-resistant phenotype is a dominant trait, 
because (BxS)F1 mice are also hypo-responsive to LPS. To map a phenotype you have essentially the 
choice between two crosses: a backcross or an intercross. However, C57BL/6 and SPRET/Ei mice can 
only produce fertile female hybrids making it impossible to intercross male F1 and female F1 mice.  
 
In a backcross (Figure I.4.6.) the first step is to outcross the homozygous mutant mice (S/S) with the 
homozygous wild-type mice (B/B). Their (BxS)F1 progeny will be heterozygous for all loci (B/S) and, as 
mentioned before, are also resistant to LPS demonstrating the dominant character of the phenotype. 
Next, the (BxS)F1 progeny is crossed back to the wild-type strain (B). The N2 progeny, which are the 
result of one meiosis, are unique and can be homozygous (B/B, 50%) or heterozygous (B/S, 50%) for 
each locus. The mice that are still resistant to LPS shall be heterozygous for the locus responsible for 
the LPS-resistant phenotype. By determining the amount of LPS-sensitive and LPS-resistant mice a 
prediction can be made of the amount of loci linked with the LPS-resistant phenotype. The phenotype 
will be monogenic when 50 out of 100 mice are sensitive and the other 50 are resistant. When the 
number of resistant mice is lower than 50, the trait is complex (see further). 
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C57BL/6 (B/B) X SPRET/Ei (S/S)
X C57BL/6 (B/B)F1 (B/S)
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Screening (B/B or B/S) for each locus
……..
 
 
Figure I.4.6. – Illustration of a backcross experiment. The backcross mice (N2) have two possible genotypes for each 
locus (homozygous B/B or heterozygous B/S). 
  
 
The swept radius can determine the number of markers that are necessary for an initial whole genome 
screen. The swept radius is the distance (in cM) that linkage can be observed between two loci and is 
related to the number of progeny tested. The smaller the number of progeny, the smaller the swept 
radius and the more markers are needed to ensure detection of linkage. Thus, the more mice are tested 
in a backcross, the less markers per chromosome are needed to span a whole chromosome. For 
example, when 72 backcross mice are tested the swept radius will be 20 cM. For a chromosome of 100 
cM, 4 or 3 markers will be needed at a distance of 30 or 40 cM of each other to scan a whole 
chromosome (Figure I.4.7.). However, at a certain moment increasing the number of progeny does not 
lead to a reduction of markers needed for genotyping. An initial genome scan will be typically done on 
50 to 100 animals with 75 markers spaced evenly over the whole genome. This will give an idea about 
the region, typical a 20 cM region, where the mutated gene is located.  
 
For a monogenic trait, this region can be simply narrowed down by typing more genetic markers 
between the two genetic markers surrounding the mutated locus, and by analysing more (e.g. 1000) 
mice. This large amount of mice is necessary to find crossovers really close to the gene of interest. With 
a backcross of 1000 mice a resolution of 0.1 cM can be achieved (Silver, 1995). Next, the gene of 
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interest can be easily identified because the full sequence of the mouse genome is now available on the 
web. 
 
 
 
 
Figure I.4.7. – The swept radius determining the number of markers needed in a whole genome screen. Each circle 
represents the swept radius around a locus. With 72 backcross animals, three marker loci are necessary to cover mouse 
chromosome 2 (Reprinted from Silver, Mouse Genetics, concepts and applications, 1995). 
 
 
However, most of the traits or diseases (e.g. asthma, diabetes, hypertension,…) are caused by multiple 
genes and this is called a complex trait. The term ‘complex trait’ is defined as any phenotype with no 
one-to-one relationship between genotype and phenotype. Often genes work together in an additive or 
epistatic way meaning that interactions between QTLs result in an effect on the trait that would not be 
predicted from the sum of the individual QTL effects. Traits can be qualitative or quantitative (e.g. 
temperature, IL-6 concentration, …), but qualitative traits can often be considered as quantitative traits. 
In this case, the quantitative trait (QT) has to reach a certain threshold to give rise to the qualitative trait 
(e.g. the development of a disease). The term ‘quantitative trait locus’ or QTL is used to define a locus 
that affects a complex trait in a strictly quantitative way or not (Nature review genetics, 4, 911-916, 
2003). 
A way to map QTLs in a complex trait is first to perform an initial backcross or intercross experiment to 
map at a subchromosomal level. Next, the QTLs will be isolated using consomic mice (or as Nadeau 
proposed ‘chromosome substitution strains’ or CSS strains). Nadeau and colleagues described this 
technique and it will be discussed in the next section. When the location of the QTL is confirmed using 
CSS strains, an additional cross can be done to allow fine mapping of the trait. 
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4.5.4.  Isolation of QTLs from a complex trait in CSS strains (Nadeau et al., 2000) 
 
CSS strains or consomic mice are homozygous inbred strains that are identical to strain ‘B’ except that 
1 chromosome has been replaced by the corresponding chromosome of strain A (Figure I.4.8.). CSS 
strains are a very interesting tool in multigenic trait analysis. There are advantages and limitations of this 
approach over classical approaches. Advantages are that there is no need to perform a lot of crosses 
and that an unlimited amount of genetically identical mice are available. A limitation of CSS strains is 
that QTLs are assigned to an entire chromosome instead of a 20cM region as in a cross. However, the 
QTL can be narrowed by an additional backcross or intercross. In addition, CSS strains do not 
distinguish between multiple QTLs on the same chromosome.  
 
1        2       3…..
Inbred strain A Inbred strain B
Chr.
X
X(N1)
(N2)
(N3).
.
.
.
(N7)
1        2       3…..
1        2       3
1     2      3
1      2       3
1      2       3
X
X
X
1      2       3
B.A – Chr. 2 
 
 
Figure I.4.8.  – Strategy for the construction of CSS strains. The first step is the construction of F1 mice (AxB) which are 
then backcrossed to the recessive strain B. The progenies are screened for a specific chromosome, for example 
chromosome 2, using microsatellite markers. The mice that contain the entire chromosome of interest from the donor strain 
A are selected to cross back to strain B. For different generations, a selection is made for the mice containing the entire 
chromosome of interest. Each generation 50% of the donor genome is lost. After 7 generations mice are created that are for 
99% donor strain, except for the chromosome for which a selection was performed. These mice are still heterozygous for the 
selected chromosome, so a brother-sister mating is necessary to receive a CSS strain homozygous for all loci and one 
chromosome from strain A. Expected is that for larger chromosomes such as chromosome 1, 2, 4 and 11, there will be less 
progenies that contain a whole chromosome because of the higher chance of a crossover.  
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Another advantage is that it is easy to investigate epistatic interactions between QTLs by crossing 
different CSS mice. It can give more information about the nature of the trait, but also about the 
combinations that are required. In the case of epistatic interactions between genes, the phenotype will 
not be fully present or even be completely absent in the consomic mice. In the absence of epistatic 
effects, it is also possible that the one QTL present has only a subphenotype of the original complex 
phenotype because of the absence of additive effects from the other QTL(s). By crossing different 
consomic mice it is possible to reconstitute the original QTL combination and phenotype or to determine 
which QTL combination is sufficient to obtain the parental phenotype. The creation of CSS strains goes 
as described in Figure I.4.8.  
 
4.5.5.   Some methods used in QTL mapping analysis 
 
The following can be said about QTL mapping: ‘Crossing two inbred lines creates associations between 
genetic marker loci and traits to allow localization of QTL’. Different methods can be used for QTL 
mapping. One method used in QTL mapping is the simple ‘single-locus association’ test (e.g using t-
test, ANOVA and simple linear regression statistics). This test is used to evaluate the association 
between the genotype of each locus and a trait value. Each locus is analysed separately, so there is no 
requirement for mapping the loci relatively to each other. The marker locus being tested is called the 
target locus. Another level of QTL mapping is simple interval mapping (SIM). SIM does require the 
mapping of the loci relatively to each other. It evaluates the possibility of a hypothetical QTL at multiple 
analysis points across each inter-marker interval.  
Results of these tests can be expressed by giving a LOD or LRS score. To give an example, a LOD-
score of 4 means that there is 104 more chance that there is a QTL on the indicated location than that 
there is no QTL present. The likelihood ratio statistic (LRS) score is a value given to each association 
and follows an asymptotically χ2 distribution. The logarithm of the odds (LOD) and LRS scores are 
effectively the same statistic. The correlation between the LOD and LRS scores is a factor 4.6 
(LRS=LOD*4.6). 
 
Although SIM is better for complex trait analysis than the single-locus association’ test, because SIM 
can localize possible QTLs more accurately, both are still single-QTL methods. Because these tests 
cannot detect epistatic interactions between loci, other tests have been developed. The computer 
program (see below) we used in this work to analyze the data contains an algorithm, which detects 
epistatic interactions. Composite interval mapping (CIM) or multiple QTL mapping is like SIM but takes 
additional marker loci into account that have been shown to be associated with the trait. This test is 
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even better for complex trait analysis, but still cannot detect epistatic interactions between QTLs that by 
themselves do not show any linkage. 
 
The terms for statistical significance levels such as ‘point-wise significance’ and ‘genome-wide 
significance’ were introduced by Lander and Kruglyak. A point-wise significance is the probability that 
one can find by chance a LOD or LRS at a certain locus. The genome-wide significance is the 
probability that one can encounter a specific LOD somewhere in a genome scan, and is obviously a 
more stringent significance level. A permutation test analysis is a method calculating the genome-wide 
significance of the LRS generated by one of the tests described above. It is a method where the 
phenotypic trait data are randomly distributed among the progeny, while the genetic map is kept intact. 
This breaks the relationship between the phenotypic trait data and the genotypes of the marker loci. 
This procedure can be repeated multiple times (e.g. 1.000 or 10.000 times). For each permutated 
dataset the maximal LRS is recorded at regular intervals throughout the genome. Values at appropriate 
percentile points of this empirical distribution are used as a threshold value above which the observed 
LRS is significant. The accepted levels for significance nowadays are: highly significant (p<0.001), 
significant (p<0.05) and suggestive (p<0.63). The suggestive level is the level at which on average one 
false positive is found per genome scan. At this level, the detected QTLs are not strong QTLs. The 
highly significant level is the level at which strong QTLs, or in large crosses the strongest moderate 
QTLs, will be detected. 
To analyze the data obtained from large crosses a specific computer program containing these methods 
for QTL mapping, called Mapmanager QTX made by Dr. Manly, was used. This program, which is freely 
available, is used in this work to analyse the data (Manly et al., 2001). First, the genetic and phenotypic 
data obtained from a backcross are analysed using the simple ‘single-locus association’ test to predict 
the amount of loci linked with the LPS-resistant phenotype of SPRET/Ei. In a second step, the SIM test 
searches intervals defined by two adjacent markers at multiple analysis points and a permutation test is 
used to evaluate if a QTL is present at the location or not. For a monogenic trait, a trait caused by (a) 
mutation(s) in a single gene, this region can be simply narrowed down by setting up a large backcross 
and typing more genetic markers between the two genetic markers surrounding the mutated locus. The 
mapping of a complex trait (e.g. the LPS resistance of SPRET/Ei), generally caused by mutations in 
numerous genes, consists of several phases. After the initial genome scan, QTLs are isolated in 
consomic/congenic mice to confirm the location of the QTL. Congenic mice are mice where only a part 
of the chromosome is introgressed from the donor strain into the acceptor strain. Finally, when the 
location of the QTL is confirmed, a second cross involving the consomic/congenic mice will be set up to 
fine map the trait. 
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We have found that SPRET/Ei, an inbred strain derived from Mus spretus, can easily survive injection of 
500 µg LPS, while C57BL/6 mice succumb to 50 µg LPS. SPRET/Ei mice exhibit an extreme, but also 
dominant resistance ((BxS)F1 mice also survive a dose of 500 µg LPS) to LPS. This clearly 
demonstrates the presence of LPS resistance genes in SPRET/Ei. In addition, (BxS)F1 mice are 
relatively resistant to a Gram-negative Klebsiella pneumoniae infection. Hence, SPRET/Ei is a very 
important new tool, because, in contrast to the LPS-resistant C3H/HeJ and C57BL10/ScCr strains, it not 
only resists the toxic effects of LPS, but can also clear infection of a Gram-negative pathogen. We 
reason that identifying the molecular basis of the LPS hypo-responsiveness might lead to new 
therapeutic possibilities for the treatment of sepsis, because SPRET/Ei mice are unresponsive to the 
toxicity of LPS and preserve the recognition and destruction of pathogens. 
To identify the genes that are responsible for the LPS resistance of SPRET/Ei, we followed two different 
approaches.  
A first approach was to map and clone the LPS resistance genes of SPRET/Ei. To map a trait, two 
parental strains are needed that are significantly different for a trait and that show significant genetic 
polymorphism. Thus, SPRET/Ei mice are ideal for mapping experiments due to the high degree of 
genetic polymorphism between SPRET/Ei and the common laboratory strains (e.g. C57BL/6). In 
addition, C57BL/6 and SPRET/Ei are significantly different in their response to LPS, since SPRET/Ei 
mice can resist a 10 times higher dose of LPS than C57BL/6 mice. First, we did an initial genome scan 
to detect the QTL(s) linked with the LPS resistance. To confirm the importance of the loci found in the 
initial backcross we started making consomic mice. 
A second approach was to identify the molecular basis of the LPS resistance in vitro. Hypo-
responsiveness of SPRET/Ei to LPS was also evident in vitro and the signalling pathways activated by 
LPS are well known. So, we were able to use an in vitro model to identify the molecular basis the LPS 
resistance of SPRET/Ei.  
  
Tina Mahieu PhD thesis (2006) 113
Chapter II - Aim of the project 
Tina Mahieu PhD thesis (2006) 114
 
Chapter III - Results 
 
 
 
 
 
 
 
 
 
 
 
 
 III.  RESULTS  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Tina Mahieu PhD thesis (2006) 115
Chapter III - Results 
Tina Mahieu PhD thesis (2006) 116
Chapter III - Results 
1.   THE WILD-DERIVED INBRED MOUSE STRAIN SPRET/Ei IS RESISTANT TO LPS  
 AND DEFECTIVE IN IFN-β PRODUCTION 
 
1.1.   PNAS article 
 
Tina Mahieu, Jin Mo Park, Hilde Revets, Bastian Pasche, Andreas Lengeling, Jan Staelens, Andy 
Wullaert, Ineke Vanlaere, Tino Hochepied, Frans van Roy, Michael Karin and Claude Libert (2006) 
Proceedings of the National Academy of Sciences of the USA (PNAS) 203: 2292-2297. 
Tina Mahieu PhD thesis (2006) 117
Chapter III - Results 
 
 
Tina Mahieu PhD thesis (2006) 118
Chapter III - Results 
 
 
Tina Mahieu PhD thesis (2006) 119
Chapter III - Results 
 
 
Tina Mahieu PhD thesis (2006) 120
Chapter III - Results 
 
 
Tina Mahieu PhD thesis (2006) 121
Chapter III - Results 
 
 
Tina Mahieu PhD thesis (2006) 122
Chapter III - Results 
 
 
 
Tina Mahieu PhD thesis (2006) 123
Chapter III - Results 
2.   DESCRIPTION OF THE LPS RESISTANCE OF SPRET/Ei IN VIVO 
 
2.1.   Introduction 
 
Compared to the commonly used laboratory strain C57BL/6, SPRET/Ei and (BxS)F1 mice easily survive 
a dose of 500 µg, which also shows that the hypo-responsiveness to LPS is a dominant trait. C57BL/6 
mice die from a dose of 50 µg LPS. Also, SPRET/Ei and (BxS)F1 mice are significantly protected to 
LPS-induced hypothermia. In addition, IL-6 concentrations in serum of SPRET/Ei and (BxS)F1 mice 
remain significantly lower than those in C57BL/6 mice, especially 3 and 9 hours after LPS (PNAS 
article). To describe the LPS-resistance phenotype of SPRET/Ei more in detail, we also looked at TNF-
α induction in serum and inflammation after LPS. 
 
2.2.   Experimental procedures 
 
Injections, preparation of serum, determination of IL-6 in the serum (7TD1 assay) and measurement of 
body temperature is as described in Mahieu et al. (PNAS article). 
 
2.2.1.  Determination of TNF in the serum 
 
TNF was measured by using the sensitive cell line WEHI 164 cl 13 (Espevik and Nissen-Meyer, 1986). 
In the presence of serially diluted serum or recombinant TNF as a standard, 50.000 cells per well were 
cultured and stimulated with 1 µg/ml Actinomycin D in flat-bottom, 96-well microtiter plates. Next, the 
number of surviving cells was determined after 18 hours of incubation with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Mosmann, 1983; Niks and Otto, 1990). The assay has a 
detection limit of about 0.5 pg/ml.   
 
2.2.2.  Histological analysis 
 
Lungs and liver were fixed overnight in 4% formalin. Fixation is followed by dehydration with a mounting 
percentage of alcohol and by clearing with histo-clear.  After clearing, the tissues are infiltrated with 
paraffin wax (making a paraffin block). A tissue paraffin block is cut in sections of 4-5 µm with a 
microtome. The advantage from paraffin embedding is that it is easy to cut a paraffin block into thin 
serial tissue sections: once embedded tissue sections can be preserved for a long time at room 
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temperature. Inflammation, as observed by the infiltration of inflammatory cells, was examined in 
haematoxylin/eosin stained lung and liver sections (5µm).  
 
2.2.3. Gelatin zymography 
 
A 10% gel was prepared according to the standard procedure. When preparing the running gel, 1 mg/ml 
gelatin was added. One part sample is mixed with one part sample buffer (2x) and the mix is incubated 
for 10 min at room temperature (RT). Samples were applied (typically 10-25 µl) and the gel is runned 
with 1x tris-glycine running buffer according to the standard running conditions (~125V, constant 
voltage). After running, the gel is incubated in zymogram renaturing buffer with gentle agitation for 30 
min at RT. The zymogram renaturing buffer is decanted and replaced with 1x zymogram developing 
buffer. The gel is equilibrated for 30 min. at RT with gentle agitation and then replaced with fresh 1x 
zymogram developing buffer and incubated at 37°C for at least four hours. Next, the gel is stained with 
0.5% coomassie blue R-250 for 30 min. Gels are destained with coomassie R-250 destaining solution. 
Areas where the protease has digested the substrate (protease activity) will appear as clear bands 
against a dark blue background. 
 
2.3.  Results 
 
2.3.1.  TNF-α induction after injection of a high dose LPS 
 
LPS acts on myeloid and non-myeloid cells to express pro-inflammatory proteins such as IL-6 and TNF-
α (Ulevitch and Tobias, 1995). We looked at TNF-α induction after an intraperitoneal (i.p.) injection of 
250 µg S.a.e. LPS.  
 
Besides a defective IL-6 gene induction, SPRET/Ei mice demonstrate also a defective TNF-α induction 
after LPS injection (Figure III.2.1.). So, SPRET/Ei mice have a defect in pro-inflammatory cytokine gene 
induction after LPS. However, it is possible that the SPRET/Ei TNF-α molecule is not active on the 
WEHI 164 cl 13 cell line. To exclude this possibility, we should test a serum sample in both an ELISA- 
and TNF-assay, and compare the data. In contrast to the defective gene induction in SPRET/Ei at early 
time points after LPS in vivo, we observe a normal IL-6 and TNF-α mRNA induction at early time points 
after LPS in vitro in BMDMs (PNAS article). It should be kept in mind that the in vivo situation is much 
more complex. LPS can activate myeloid (neutrophils, monocytes, macrophages, platelets) and/or non-
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myeloid cells (fibroblasts) to produce pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-6 and IL-1. 
These cytokines (e.g. IL-1) might activate other cells to produce also IL-6 and TNF-α. 
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Figure III.2.1. – Concentration of TNF in serum after 250 µg S.a.e. LPS. A dose of 250 µg S.a.e. LPS was given i.p. to 
C57BL/6 (n = 10) and SPRET/Ei mice (n = 6). 1 hour after injection TNF was measured in serum (*p<0,05 C57BL/6 vs 
SPRET/Ei). 
 
 
2.3.2.      Inflammation after a high dose LPS 
 
Sepsis is characterized by an acute systemic inflammatory response and frequently dysfunction of 
lungs, liver, kidneys and gastrointestinal channel are observed (Tracey et al., 1986). LPS can mimic 
much of the devastating effects of bacterial sepsis (Ulevitch and Tobias, 1995). Nine hours after an i.p. 
injection of 250 µg LPS, lungs and livers were removed from C57BL/6 and SPRET/Ei mice. Histological 
analysis showed that in the blood vessels of the liver of C57BL/6 mice leukocytes are attached to the 
endothelium. Also, in the lung of C57BL/6 we note that leukocytes are attached to the endothelium and 
that leukocytes migrate to the alveoli. In SPRET/Ei lungs and livers much less leukocytes attach to the 
endothelium and leukocytes do not migrate to the alveoli (Figure III.2.2.). Recently, it has been 
demonstrated that IFN-β can induce the expression of a large set of chemokines (Coelho et al., 2005). 
In addition, we have performed a differential expression study (in collaboration with Dr. J. Grooten), 
using macroarray filters containing about 500 macrophage specific genes, which demonstrated that 
different chemokines are not or less induced in SPRET/Ei BMDMs after LPS stimulation. However, 
these data are still preliminary because we have tested only one RNA sample of LPS-stimulated 
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BMDMs (C57BL/6 vs SPRET/Ei). Possibly, the defective IFN-β induction in SPRET/Ei causes a 
diminished chemokine expression leading to a defective migration of leukocytes.  
 
 
 
Figure III.2.2. – Liver and lung inflammation after LPS. C57BL/6 and SPRET/Ei mice were i.p. injected with 250 µg LPS. 
Inflammation (attachement of leukocytes to the endothelium of blood vessels) in the liver (upper panel, left) and lung (lower 
panel, left) of C57BL/6 mice, but not in the liver (upper panel, right) and lung (lower panel, right) of SPRET/Ei mice.  In the 
lung of C57BL/6, leukocytes migrate to the alveoli. 
  
Another marker for the progression of inflammation is the induction of matrix metalloproteinase (MMP)-
9. Monocytes/macrophages are prominent at inflammation sites, and activation of these cells by LPS 
leads to the production of significant amounts of MMP-9 (Lu and Wahl, 2005). We looked at the 
induction of MMP-9 in serum after LPS by gelatin zymography.  
MMP-9 expression in serum of SPRET/Ei and (BxS)F1 mice is reduced compared to MMP-9 expression 
in serum of C57BL/6 mice after injection of 250 µg S.a.e. LPS (Figure III.2.3). To conclude, SPRET/Ei 
mice show a reduced LPS-induced inflammatory state as seen by less inflammatory cells in the lung 
and liver, and reduced expression of serum MMP-9, a marker for the progression of inflammation. 
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Figure III.2.3. – MMP-9 as a marker for inflammation. After an i.p. 
injection of 250 µg LPS, we examined the MMP-9 expression by 
gelatine zymography. MMP-9 expression is observed in serum of 
C57BL/6 mice, but much less in serum of (BxS)F1 and SPRET/Ei 
mice.  
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2.3.3.  Response of C57BL/6 and (BxS)F1 mice to E.coli LPS 
 
SPRET/Ei and (BxS)F1 mice can resist high doses of S.a.e. LPS. In order to confirm that the LPS-
resistance of SPRET/Ei is not specific for S.a.e. LPS, we tested the response of (BxS)F1 mice to LPS 
derived from Eschericiae coli. We investigated the response of (BxS)F1 mice to an i.p. injection of 500 
µg E.coli LPS, a 100% lethal dose to C57BL/6 mice. (BxS)F1 mice resist also E.coli LPS-induced lethal 
shock and hypothermia, in contrast to C57BL/6 mice. In addition, significantly less IL-6 was found 3 
hours after LPS injection in serum of (BxS)F1 mice compared to the IL-6 concentration in serum of 
C57BL/6 mice. Thus, hereby we confirmed the LPS hypo-responsiveness of SPRET/Ei (Figure III.2.4.). 
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Figure III.2.4. -  Response of C57BL/6 and (BxS)F1 mice to 500 µg E.coli LPS. Lethality (left panel), body temperature 
(middle panel) and IL-6 induction (right panel) after an i.p. injection of 500 µg E.coli LPS in C57BL/6 and (BxS)F1 mice. 
(Triangles: (BxS)F1 (n = 6) and squares: C57BL/6 (n = 6);  line bars: (BxS)F1 (n = 9) and black bars: C57BL/6 (n = 4)) 
(**p<0,01 and ***p<0,001 C57BL/6 vs (BxS)F1). 
 
2.4.   Conclusion 
 
LPS is able to reproduce many of the features of a bacterial infection, including hypothermia, induction 
of circulating mediators such as pro-inflammatory cytokines and (lethal) shock (Glauser et al., 1991). 
We have identified a third LPS-resistant mouse strain, SPRET/Ei, next to the two known LPS-resistant 
Tina Mahieu PhD thesis (2006) 128
Chapter III - Results 
mouse strains C3H/HeJ and C57BL/10ScCr. SPRET/Ei exhibits an extreme resistance against LPS. In 
response to LPS, SPRET/Ei mice show a stable body temperature (in contrast to hypothermia observed 
in C57BL/6 mice), reduced production of pro-inflammatory cytokines such as IL-6 and TNF, reduced 
inflammation in the lungs and livers, and reduced expression of the inflammatory marker MMP-9 in 
serum. The trait is dominant, because (BxS)F1 mice also resist a high dose of LPS. In addition, we have 
confirmed the hypo-responsiveness of SPRET/Ei to LPS by testing the response of (BxS)F1 to LPS 
derived from E.coli.  
We think that this extreme phenotype of SPRET/Ei mice could be very relevant in the search for new 
therapeutic interventions for sepsis. Therefore, it is first needed to identify the SPRET/Ei LPS-resistance 
genes. 
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3.   IN VITRO DATA  
 
3.1.   Introduction 
 
Macrophages and DCs are the first target cells of LPS and respond by expressing many inflammatory 
cytokines (Guha and Mackman, 2001). Mouse embryonic fibroblasts (MEFs) also express high levels of 
TLR4 mRNA. Fibroblast cells participate in inflammatory processes and non-specific immunity by 
producing cytokines and mediators in response to bacterial LPS (Kurt-Jones et al., 2004). Through bone 
marrow transplantation experiments (see PNAS article) we demonstrated that white blood cells (WBCs), 
and most likely macrophages, are the relevant cell type in the LPS-resistance of SPRET/Ei. Lethally 
irradiated (BxS)F1 mice were reconstituted with bone marrow from C57BL/6 or (B x S)F1 mice. Due to 
transplant rejection, we could not reconstitute lethally irradiated C57BL/6 mice with (BxS)F1 bone 
marrow. (BxS)F1 mice reconstituted with C57BL/6 bone marrow were sensitive to 250 µg LPS, a 100% 
lethal dose for C57BL/6 mice. 
Next to the LPS-resistance in vivo, we could demonstrate the LPS hypo-responsiveness of SPRET/Ei in 
vitro in macrophages and MEFs. LPS activates both the MyD88-dependent pathway and the MyD88-
independent TRIF-dependent pathway to induce pro-inflammatory cytokines. MyD88 induces early NF-
κB activation, while TRIF induces late NF-κB activation. Recruitment of the adaptor protein TRIF leads 
also to induction of IFN-β and IFN-dependent genes (Akira and Takeda, 2004). In order to examine the 
MyD88-dependent pathway in SPRET/Ei we looked at the degradation of IκBα, which leads to release 
of the transcription factor NF-κB, and the phosphorylation of MAPK p38 and JNK, which activate the 
transcription factor AP-1. Pro-inflammatory gene induction depends on both NF-κB and AP-1. To 
investigate if the TRIF-dependent pathway is normal in SPRET/Ei, we measured the induction of IFN-
β mRNA. 
 
3.2.   Experimental procedures 
 
3.2.1.  In vitro experiments: IL-6 concentration after LPS in supernatant 
 
Thioglycolate-elicited peritoneal macrophages from C57BL/6 and SPRET/Ei mice were seeded at 
50.000 cells per 24-well in RPMI medium 1640 containing 10% foetal calf serum (FCS), 100 U/ml 
penicillin, 100 µg/ml streptomycin, 5 10-5 M β-mercaptoethanol, 1 mM sodium pyruvate and 2 mM L-
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glutamine. LPS was added to the cultures to a final concentration of 1 µg/ml. After 24 hours of 
stimulation, supernatant was harvested and IL-6 was measured by using the 7TD1 assay. 
 
MEFs were isolated from 18-day old embryos and cultured in RPMI 1640 supplemented with 10% FCS, 
penicillin, streptomycin, gentamycin and L-glutamine. MEFs were seeded at 100.000 cells per 24-well in 
supplemented RPMI medium 1640. LPS was added to the cultures to a final concentration of 1 µg/ml. 
After stimulation, supernatant was harvested and IL-6 was measured by using the 7TD1 assay. 
 
3.2.2.  Derivation of macrophages from bone marrow cells  
 
To derive macrophages from bone marrow cells we carried out the next protocol. Bone marrow cells 
were isolated from tibias and femurs of 3 month old C57BL/6 and SPRET/Ei mice. Cells from one 
mouse are collected in 50 ml DMEM medium (high glucose) supplemented with 10% heat-inactivated 
FCS, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 1mM sodium pyruvate and 20 ng/ml mouse 
recombinant M-CSF. M-CSF is a potent hematopoietic factor and is a key regulator of cellular 
proliferation, differentiation, and survival of blood monocytes, tissue macrophages and their progenitor 
cells. Bone marrow cells collected in 50 ml medium were grown in two bacterial Petri dishes. Cells were 
kept in culture for 7 days and every 2 days the medium, supplemented with growth factors, was 
changed. After 7 days cells could be used for experiments. For C57BL/6 up to 20 million bone marrow-
derived cells could be obtained, while for SPRET/Ei a maximum of 10 million bone marrow-derived cells 
was counted. 
 
3.2.3.  Real-time Q-PCR analysis 
 
The IL-6, TNF-α and IFN-β mRNA levels were analyzed by real-time Q-PCR in triplicate cultures 
(500.000 cells per 6-well) after stimulation of BMDMs with 100 ng/ml LPS. In addition, the IFN-β mRNA 
level was also analyzed after stimulation with 10 µg/ml poly (I:C), a TLR3 ligand. Total RNA was 
isolated using the RNAwiz reagent (Ambion). Complementary DNAs (cDNAs) were synthesized using 
the Superscript II reverse transcriptase system (Invitrogen). The cDNA equivalent of 0.2 µg of total RNA 
was amplified through 40 cycles of 15 sec at 95 °C and 1 min at 60 °C. Output was monitored using 
SYBR Green core reagents and the ABI Prism 7700 System (PE Applied Biosystems). The results were 
normalized to the level of cyclophilin mRNA. 
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3.2.4.  Immunoblot analysis 
Whole cell, cytoplasmic, and nuclear extracts for immunoblot analysis were prepared and subjected to 
SDS-PAGE. Proteins transferred to nitrocellulose membrane were probed with rabbit antiserum against 
NF-κB p65, phospho-Stat1 and Stat1, and the immune complexes were visualized with the ECL 
Western blot reagent (Pierce). 
 
3.3.  Results 
 
3.3.1.  Response of peritoneal macrophages and MEFs to LPS 
 
Bone marrow transplantation experiments revealed the importance of WBCs, and most likely 
macrophages, in the LPS-resistance of SPRET/Ei. To test the response of macrophages in vitro to LPS, 
we stimulated thioglycolate-elicited peritoneal macrophages with 1 µg/ml LPS and we measured IL-6 
concentration in supernatant. In addition, the response of immortalized (with SV40 LargeT) MEFs to 
LPS was also tested.  
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Figure III.3.1. –  IL-6 induction in vitro after 24 hours of LPS stimulation. Thioglycolate-elicited peritoneal macrophages 
(left figure; n = 3) and MEFs (right figure; n = 5) from C57BL/6 and SPRET/Ei were seeded at respectively 50.000 and 
100.000 cells/well and were stimulated with 1 µg/ml LPS. 24 hours after stimulation, supernatant was harvested and IL-6 
was measured using the 7TD1 assay (*p<0,05 and ***p<0,001 C57BL/6 vs SPRET/Ei). 
 
Both thioglycolate-elicited peritoneal macrophages and MEFs from SPRET/Ei induce significantly less 
IL-6 compared to thioglycolate-elicited peritoneal macrophages and MEFs from C57BL/6 (Figure 
III.3.1.). This reduced IL-6 induction is in line with the reduced IL-6 serum levels after injection of LPS in 
SPRET/Ei and with the elevated IL-6 levels after LPS injection in (BxS)F1 mice reconstituted with 
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C57BL/6 bone marrow. However, relatively high basal levels of IL-6 were measured in thioglycolate-
elicited macrophages and MEFs from both C57BL/6 and SPRET/Ei mice. Probably, the thioglycolate 
already stimulates macrophages to induce IL-6. In contrast, in non-stimulated BMDMs from C57BL/6 
and SPRET/Ei no IL-6 was detectable. For that reason, and also the fact that it was very difficult to 
isolate thioglycolate-elicited macrophages from SPRET/Ei mice, we decided to use BMDMs for our in 
vitro experiments. 
 
3.3.2.   The MyD88-dependent pathway is normal in SPRET/Ei 
 
To investigate the mechanism of the LPS-resistance, we used BMDMs as an in vitro model. LPS 
stimulation leads to recruitment of the adaptor molecule MyD88 to the TIR domain of TLR4 and is 
followed by the activation of NF-κB, which induces pro-inflammatory genes such as Il6 and Tnf. To 
release NF-κB, first the IκB protein sequestering NF-κB in the cytoplasm has to be phosphorylated by 
the IKK complex and degraded (Akira and Takeda, 2004). LPS also induces MAPK p38 and JNK, which 
activate the transcription factor AP-1 (Akira and Takeda, 2004; Guha and Mackman, 2001). Both IL-6 
and TNF induction are dependent on NF-κB, but also on other transcription factors such as nuclear 
factor IL-6 (NF-IL6) and AP-1 (Akira et al., 1990; Dendorfer et al., 1994; Guha et al., 2001).  
 
 
 
 
Figure III.3.2. – TNF-α and IL-6 mRNA induction in BMDMs after LPS stimulation. BMDMs of C57BL/6 and SPRET/Ei 
mice were stimulated with 100 ng/ml LPS for 1 and 4 hours. TNF-α and IL-6 mRNA levels were analyzed by real-time Q-
PCR in triplicate cultures (Black squares, C57BL/6; white squares, SPRET/Ei). 
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IκBα degradation and phosphorylation of MAPKs p38 and JNK1/2 was shown to occur with 
approximately the same kinetics in SPRET/Ei BMDMs as in C57BL/6 BMDMs after stimulation with 100 
ng/ml LPS (see PNAS article). Furthermore, the intact MyD88 signalling was confirmed by studying the 
induction of TNF-α and IL-6 mRNA. BMDMs from C57BL/6 and SPRET/Ei mice were stimulated with 
100 ng/ml LPS for 1 and 4 hours. Induction of IL-6 and TNF-α mRNA after LPS was comparable 
between SPRET/Ei and C57BL/6 BMDMs (Figure III.3.2.). Also, no significant differences were 
observed between SPRET/Ei and C67BL/6 with respect to LPS-induced mRNA expression of Il1a, Il1b, 
Il12a, Il12b, Bcl2, Birc4 (encoding XIAP) and Tnfaip3 (encoding A20). 
 
TLR4 can induce an early phase NF-κB induction through activation of the MyD88-dependent pathway, 
but it can also induce a late phase NF-κB activation by the TRIF-dependent pathway (Akira and 
Takeda, 2004). TRAF6 and TBK1/IKK-ε compete with each other for binding with the N-terminal portion 
of TRIF. When TRIF recruits TRAF6 this leads to a second wave of pro-inflammatory cytokine 
production. When TRIF recruits TBK1/IKK-ε this leads to expression of IFN-β and IFN-dependent genes 
(Sato et al., 2003). We also wanted to investigate the production of pro-inflammatory cytokines at an 
early (4 hours) and at a late (24 hours) time point after LPS stimulation. It has been demonstrated that 
TRIF knockout macrophages have diminished TNF-α, IL-6 and IL-12p40 production after 24 hours of 
LPS stimulation (Yamamoto et al., 2003). 
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Figure III.3.3. – Early and late induction of IL-6 after LPS stimulation. MEFs from C57BL/6 and SPRET/Ei mice were 
stimulated with 1 µg/ml LPS for 4 and 24 hours. IL-6 induction was analyzed by a 7TD1-bioassay, and expressed as relative 
induction compared to non-stimulated control cells (black bars: C57BL/6  (n = 3) and white bars: SPRET/Ei (n = 3)) (**p<0,01 
C57BL/6 vs SPRET/Ei). 
 
Tina Mahieu PhD thesis (2006) 134
Chapter III - Results 
MEFs were used instead of BMDMs because during my work SPRET/Ei mice were not easily available 
since they are very poor breeders. MEFs were stimulated with 1µg/ml LPS. IL-6 was measured in 
supernatant after 4 and 24 hours stimulation. As demonstrated before, IL-6 fold induction is significantly 
different between C57BL/6 and SPRETEi MEFs 24 hours after LPS stimulation. In contrast, early pro-
inflammatory cytokine production is comparable between C57BL/6 and SPRET/Ei (Figure III.3.3.). Thus, 
the early MyD88-dependent pro-inflammatory cytokine production seems intact in SPRET/Ei, while late 
MyD88-independent, TRIF-dependent pro-inflammatory cytokine is defective. These results show that 
early IL-6 release is normal in SPRET/Ei, and indirectly confirm the data obtained from the BMDM. 
 
3.3.3.   The MyD88-independent, TRIF-dependent pathway is defective in SPRET/Ei      
 
To investigate if the MyD88-independent, TRIF-dependent pathway in SPRET/Ei is intact, BMDMs from 
C57BL/6 and SPRET/Ei were stimulated with LPS for 1 and 4 hours to analyze IFN-β mRNA induction. 
IFN-β mRNA induction is defective in SPRET/Ei BMDMs (see PNAS article). In addition, the IFN-β 
mRNA level was also analyzed by real-time Q-PCR after stimulation of BMDMs with 100 ng/ml LPS and 
10 µg/ml poly (I:C), a TLR3 ligand, for 4 hours. TLR3 is the only TLR, which does not use the adaptor 
protein MyD88, but only recruits TRIF to induce IFN-β and IFN-dependent genes (Moynagh, 2005). 
BMDMs of SPRET/Ei induce significantly less IFN-β mRNA in response to poly (I:C) compared to 
C57BL/6 BMDMs. IFN-β stimulation after poly (I:C) is stronger than after LPS stimulation (Figure 
III.3.4.).  
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Figure III.3.4. – IFN-β mRNA induction after LPS and poly (I:C) stimulation and nuclear translocation of STAT1 after 
LPS. Left figure: The IFN-β mRNA level in C57BL/6 and SPRET/Ei BMDMs was analyzed by real-time Q-PCR in triplicate 
cultures after stimulation with 100 ng/ml LPS and 10 µg/ml poly (I:C) for 4 hours (Black bars, C57BL/6; white bars, 
SPRET/Ei). Right figure: Western Blot to look at STAT1α and NF-κB p65 translocation to the nucleus 2 hours after 
stimulation with 100 ng/ml LPS. 
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As a consequence of a defective IFN-β production in SPRET/Ei, less STAT1α is phosphorylated (PNAS 
article). The phosphorylation of STAT1 results in dimerization and translocation to the nucleus to 
activate gene transcription (Imada and Leonard, 2000). Thus, because of this lack of phosphorylated 
STAT1α, there is also a defect in nuclear translocation of STAT1α. Nuclear translocation of NF-κB p65 
is normal in SPRET/Ei (Figure III.3.4). 
 
3.4.  Conclusion 
 
The hypo-responsiveness of SPRET/Ei to LPS is not only evident in vivo, but also in vitro in 
macrophages and MEFs. By using BMDMs we demonstrated that the MyD88-dependent pathway 
leading to IκB degradation and phosphorylation of MAPK p38 and JNK1/2 is intact in SPRET/Ei. This 
was confirmed by comparable induction of IL-6 and TNF-α mRNA after LPS. However, the TRIF-
dependent late IL-6 induction and the IFN-induction are defective in SPRET/Ei. Thus, early pro-
inflammatory gene induction seems intact, while IFN-β and late pro-inflammatory gene induction is 
defective. The recruitment of TRAF6 to TRIF leads to activation of NF-κB and AP-1 and subsequently a 
second wave of pro-inflammatory cytokine production. On the other hand recruitment of TBK1/IKK-ε to 
TRIF leads to induction of IFN-β and IFN-dependent genes (Figure III.3.5.). 
 
So, our results suggest a defect in the adaptor molecule TRIF. However, we have only demonstrated 
that degradation of IκB is normal in SPRET/Ei and this only at early time points after LPS stimulation. 
IκB degradation and phosphorylation of MAPK does not prove that NF-κB and AP-1 activation is intact. 
Therefore, we must do an electrophoretic mobility shift assay (EMSA). In addition, it is also still possible 
that other dimers, such as p50/p50 NF-κB homodimers lacking transactivation activity, are formed in 
SPRET/Ei instead of the transcriptionally active p50-p65 heterodimer. Formation of p50/p50 
homodimers leads to less TNF and a decrease in the levels of NO after LPS (Goldring et al., 1998). The 
transcription factors that are known to be involved in the control of the IL-6 and TNF transcription rate 
are AP-1, nuclear factor IL-6 (NF-IL6) or CCAAT/enhancer binding protein (C/EBP), and NF-κB 
(Dendorfer et al., 1994). Thus, another possibility is a defect in the transcription factor NF-IL-6. In 
addition, at this stage there remain several candidate molecules for the defect in IFN-β production and 
in late phase NF-κB activation (see Figure III.3.5.). 
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Figure III.3.5. – Candidate molecules at this stage. TLR4 activates the TRIF-dependent pathway to induce late induction 
of inflammatory proteins and to induce IFN-β. At this stage there are still multiple candidate molecules that can cause a 
defect in IFN-β induction and in late phase NF-κB activation. 
 
 
 
 
 
 
 
 
 
 
 
Tina Mahieu PhD thesis (2006) 137
Chapter III - Results 
4.    IMPORTANCE OF IFN-β IN THE LPS RESISTANCE 
 
4.1.    Introduction 
 
SPRET/Ei not only has a defective IFN-β induction in vitro, but also in vivo the induction of IFN-β by 
LPS or Influenza virus is very low. Probably due to the defective induction of IFN-β, SPRET/Ei mice are 
completely resistant to Listeria monocytogenes and highly sensitive to Leishmania major infection (see 
PNAS article). Deletion of the Ifnb gene (Karaghiosoff et al., 2003) or genes involved in the induction of 
(e.g. IRF-3) (Sakaguchi et al., 2003), or in the response to (e.g. Tyk2) (Karaghiosoff et al., 2003), type I 
IFNs can induce resistance to endotoxemia. These observations indicate that type I IFN is essential in 
LPS-induced endotoxemia. Next, we wanted to investigate the importance of IFN-β in the LPS-
resistance of SPRET/Ei. 
 
4.2.  Results 
 
4.2.1.  The LPS-resistance can be reverted by administration of IFN-β  
 
SPRET/Ei mice are extremely resistant to the lethal effects of LPS, and are defective in IFN-β induction 
in vitro and in vivo. We reasoned that pre-treatment with IFN-β would restore LPS sensitivity to 
SPRET/Ei mice. Indeed, we found that (BxS)F1 mice can be sensitized for LPS by pre-treatment with 
IFN-β. Two hours before injection of a lethal dose of 200 µg LPS, we pre-treated (B x S)F1 mice with 20 
µg IFN-β.  All of the pre-treated (B x S)F1 mice died, but all of the control  (B x S)F1 mice survived. All of 
the control C57BL/6 mice also died after injection of 200 µg of LPS (Figure III.4.1.). So, this suggests 
that IFN-β is a critical factor in the resistance of SPRET/Ei mice to LPS.   
 
4.3. Conclusion 
 
Non-viral PAMPs, such as LPS, induce expression of the Ifnb gene through a TRIF-dependent pathway 
(Yamamoto et al., 2002). Although IFN-β has been known as a potent antiviral molecule for a long time, 
IFN-β also mediates a variety of immune regulatory effects and may be considered as an important link 
between innate and adaptive immune responses (Smith et al., 2005). In the last few years, a critical role 
for IFN-β has been observed in LPS-induced endotoxemia. The mechanism by which IFN-β mediates  
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Figure III.4.1. – The LPS-resistance is reverted by exogenous IFN-β administration. Two hours before an i.p. injection 
of 200 µg LPS, we pre-treated (BxS)F1 mice with 20 µg IFN-β.  All of the pre-treated (BxS)F1 mice died, but all of the control 
(BxS)F1 mice survived. All of the control C57BL/6 mice also died after injection of 200 µg of LPS. (Squares: (C57BL/6 (n = 
10), triangles: (BxS)F1 (n = 6) and circles: (BxS)F1/IFN (n = 4))  (**p<0,01 (BxS)F1 vs (BxS)F1/IFN). 
 
LPS is still an open question, but several studies have clearly shown that IFN-β is able to induce the 
expression of a large set of chemokines and genes encoding other inflammatory molecules such as NF-
IL6 (Coelho et al., 2005; Der et al., 1998). So, a possible mechanism by which IFN-β mediates LPS, is 
the induction of chemokines. Expression of chemokines attracts leukocytes to the inflammatory sites. 
The defective IFN-β induction in SPRET/Ei might cause a defect in chemokine production and 
subsequently in migration of leukocytes to the inflammatory sites. Indeed, in lungs of LPS-injected 
SPRET/Ei mice leukocytes do not migrate to the alveoli and in lungs and livers of LPS-injected 
SPRET/Ei mice less leukocytes are attached to the endothelium. Also, preliminary data from a 
differential mRNA expression study demonstrated that several chemokines are not or less induced in 
SPRET/Ei BMDMs compared to C57BL/6 BMDMs after LPS stimulation. 
 
We found that the resistance of SPRET/Ei to LPS can be reverted by administration of exogenous IFN-
β, suggesting that IFN-β is an important factor in the LPS-induced lethality. However, IFNAR1 knockout 
mice, protected against a lethal dose of LPS, show a drop in body temperature (less than 32°C 22 h 
after LPS injection). In contrast, SPRET/Ei and (BxS)F1 mice are protected against LPS-induced 
hypothermia. Therefore, to explain the extreme LPS-resistance of SPRET/Ei we assume that other 
genes than the Ifnb gene play a role in the LPS-resistance of SPRET/Ei mice. These results confirm the 
data from the backcross demonstrating that the LPS-resistance of SPRET/Ei is a complex trait, involving 
multiple genes. To find these other LPS-resistance genes, we will first repeat the differential expression 
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study to investigate the differential expression of macrophage specific genes between C57BL/6 and 
SPRET/Ei after LPS stimulation. In addition, we will also perform a differential expression study after 
poly (I:C) stimulation since SPRET/Ei mice have also a defect in IFN-β production in response to poly 
(I:C). We will also study more than one time point after LPS and poly (I:C) stimulation. We hope to 
decrease the amount of candidate genes by combining the data from the differential expression studies. 
Also, we intend to use the bioinformatica program ‘Difference Distance Matrix Analysis’ to find a limited 
amount of transcription factors/genes that might be responsible for the differential expression of 
SPRET/Ei genes. 
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5.   WHAT CAUSES THIS DEFECTIVE IFN-β PRODUCTION? 
 
5.1.  Introduction  
 
IFN-β is induced upon TLR4 stimulation using the MyD88-independent, but TRIF-dependent pathway. 
Two kinases, TBK1 and IKK-ε, are recruited to TRIF to phosphorylate and activate the transcription 
factor IRF-3 (Sharma et al., 2003). IRF-3 can induce IFN-β expression, but need co-activators 
CBP/p300 to induce transcription (Taniguchi and Takaoka, 2002). On the other hand, IFN-β can 
stimulate, in an autocrine or paracrine way, the IFNAR receptor complex to produce massive IFN-β 
through a positive-feedback loop involving IRF-7 (Sato et al., 1998). In addition, the IFN-β promoter is 
post-transcriptionally regulated by two destabilizing sequences - AU-rich element in the 3’ UTR and the 
coding region instability domain (CRID) - as well as regulated by various positive and negative 
regulators (Harada et al., 1989; Nourbakhsh and Hauser, 1997; Paste et al., 2003; Weill et al., 2003). 
The defective IFN-β induction can be situated at level of the IFN-β promoter or its regulators (1), the 
TRIF-dependent pathway (2) or the positive-feedback loop induced after IFN-β signalling (3) (see Figure 
III.5.1). 
 
1
2 3
 
 
Figure III.5.1. – The defect in IFN-β production can be situated at three levels. TLR4 stimulation activates the TRIF-
dependent pathway to activate the transcription factor IRF-3 which induces IFN-β. IFN-β stimulates, in an autocrine or 
paracrine way, the IFNAR receptor to induce IFN-dependent genes and co-stimulatory molecules (Reprinted from (Sato et 
al., 1998). 
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First, we wanted to sequence the IFN-β promoter of SPRET/Ei and C57BL/6 to find possible nucleotide 
changes between these two strains. If no nucleotide changes are found in the promoter of SPRET/Ei, 
the defect can be due to a defective activation of the IRF-3 transcription factor. IRF-3 is activated by the 
kinases TBK1 and IKK-ε, which are recruited to the adaptor molecules TRIF and TRAM after LPS 
stimulation. IFN-β mRNA induction by poly (I:C), a TLR3 ligand, is also compromised, indicating that 
TRIF-dependent, but not TRAM-dependent, responses can be defective in SPRET/Ei BMDMs. In case 
of a defective IRF-3 phosphorylation, molecules of the TRIF-dependent pathway such as TRIF, 
TBK1/IKK-ε and IRF-3 should be investigated at sequence and expression level. If the activation of IRF-
3 is normal in SPRET/Ei, we wanted to investigate if the positive-feedback loop after IFN stimulation is 
still intact in SPRET/Ei by looking at the mRNA levels of the IFN-dependent gene Oas and the IFNAR1 
receptor. 
 
5.2.   Experimental procedures 
 
5.2.1.  Sequencing 
 
For the sequencing of the IFN-β promoter from SPRET/Ei and C57BL/6, genomic DNA was extracted 
from tail and the region encoding the IFN-β promoter was PCR amplified, isolated from gel using the 
‘QIAEX II Agarose Gel Extraction’ kit (Qiagen, Germany) and ligated into pGEM-T vector for 
sequencing. The sequences were assembled and analyzed using the DNAstar software program. 
 
For the sequencing of the serine/threonine cluster in IRF-3 of SPRET/Ei and C57BL/6, total RNA was 
extracted from snap-frozen livers using the ‘Qiagen RNeasy Mini’ kit and was reverse transcribed 
using the ‘Superscript first-strand synthesis for RT-PCR’ kit (Invitrogen N.V.). The cDNA encoding the 
serine/threonine cluster of IRF-3 was PCR amplified, isolated from gel using the ‘QIAEX II Agarose Gel 
Extraction’ kit (Qiagen, Germany) and ligated into pGEM-T vector for sequencing. The sequences were 
assembled and analyzed using the DNAstar software program. 
 
5.2.2.  Immunoblot analysis 
 
Cytoplasmic extracts for immunoblot analysis were prepared and subjected to SDS-PAGE. Proteins 
transferred to nitrocellulose membrane were probed with rabbit antiserum against IRF-3 (Zymed) and 
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the immune complexes were visualized with the ECL Western blot reagent (Pierce). 
To analyze the phosphorylation of IRF-3, BMDMs were stimulated with 100 ng/ml LPS for 30 min.  
 
5.2.3.  Real-time Q-PCR analysis 
 
The TNF-α, IL-6, IFN-β, CXCL10, ISG15 and RANTES mRNA levels were analyzed by real-time Q-
PCR in triplicate cultures (500.000 cells per 6-well) after stimulation of BMDMs with 100 ng/ml LPS. 
Total RNA was isolated using the RNAwiz reagent (Ambion). Complementary DNAs (cDNAs) were 
synthesized using the Superscript II reverse transcriptase system (Invitrogen). The cDNA equivalent of 
0.2 µg of total RNA was amplified through 40 cycles of 15 sec at 95 °C and 1 min at 60 °C. Output was 
monitored using SYBR Green core reagents and the ABI Prism 7700 System (PE Applied Biosystems). 
The results were normalized to the level of cyclophilin mRNA. 
 
5.2.4.  In vitro: determining IL-6 concentration after IFN  
 
BMDMs were seeded at 100.000 cells per 24-well in supplemented DMEM medium. IFN was added to 
the cultures to a final concentration of 100 U/ml. The supernatant was harvested after 6 hour of 
stimulation and IL-6 was measured by using the 7TD1 assay. 
 
5.2.5.  Semi-quantitative RT-PCR 
 
Total RNA was isolated from BMDMs using the RNeasy Mini Kit (Qiagen). cDNAs were synthesized 
using the Superscript II reverse transcriptase system (Invitrogen). The cDNA equivalent of 0.1 µg of 
total RNA was amplified using primers for OAS. The results were normalized to the level of β-actin. 
 
5.3.   Results 
 
5.3.1.  Defect in the IFN-β promoter? 
 
The murine IFN-β promoter, spanning from the TATA box (at position –34) to position –210, contains 
four positive regulatory units binding NF-κB/Rel family members (PRDII), ATF-2 homodimers or c-
Jun/ATF-2 heterodimers and IRF family members, and contains also two negative regulatory units (Du 
et al., 1993) (Figure III.5.2.). In addition to these negative regulatory units, two destabilizing sequences 
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are found in the IFN-β promoter: an AU-rich element (ARE) in the 3’ UTR, and a second element called 
CRID in the 3’ end of the coding region.  
 
 
 
Figure III.5.2. – IFN-β promoter elements. The DNA sequence of the murine IFN-β promoter is spanning from the TATA 
box to position –210. The DNA binding sites of transcription factors NF-κB (p50 and p65), IRF proteins, and ATF-2/c-Jun are 
indicated.   
 
We wanted to sequence the IFN-β promoter to find possible nucleotide changes between the C57BL/6 
and SPRET/Ei IFN-β promoter. A lot of polymorphisms are found between SPRET/Ei and C57BL/6, 
because they diverged from each other about 1,5 million years ago (Guenet and Bonhomme, 2003). 
Therefore, frequently nucleotide changes are found between SPRET/Ei and C57BL/6.  
We sequenced the 210 bp region of the IFN-β promoter and some additional nucleotides before and 
after this 210 bp region. The sequences do not show any nucleotide change between SPRET/Ei and 
C57BL/6 (Figure III.5.3). So, it demonstrates that the IFN-β promoter is a conserved part of the 
genome.  
 
5.3.2.    Defect in the TRIF-dependent pathway? 
 
The defective IFN-β induction in SPRET/Ei can be caused by a defect in the TRIF-dependent pathway 
leading to activation of the transcription factor IRF-3. The IFN-β promoter contains IRF-binding sites and 
its induction is dependent on functional cooperation between IRF-3, NF-κB and ATF-2 homodimers or 
c-Jun/ATF-2 heterodimers (Du et al., 1993). The activation domains of all the activators are necessary 
to form a novel surface that constitutes a high-affinity binding site for the recruitment of a complex, 
namely GCN5/PCAF, important in the induction of the IFN-β promoter. IRF-3 is present in the cytoplasm 
of non-stimulated cells. Intramolecular association between the C terminus and the DNA-binding domain 
(DBD) maintains IRF-3 in a latent state by masking both DBD and (IRF association domains) IAD 
regions. 
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B   TTTGAGAGTTCTTTTATCTTCAGGGCTGTCTCCTTTCTGTTCTTCTCTCCTGGATATTCT   60 
S   TTTGAGAGTTCTTTTATCTTCAGGGCTGTCTCCTTTCTGTTCTTCTCTCCTGGATATTCT   60 
 
B   CTTCCTTTGCTCCAGCAATTGGTGAAACTGTACAAGATTTTATAAATCCTTAGTTGTATA 120 
S   CTTCCTTTGCTCCAGCAATTGGTGAAACTGTACAAGATTTTATAAATCCTTAGTTGTATA 120 
 
B   TATTTTAACCCAGTACATAGCATATAAAATAGCCAGGAGCTTGAATAAAATGAATATTAG   180 
S  TATTTTAACCCAGTACATAGCATATAAAATAGCCAGGAGCTTGAATAAAATGAATATTAG   180 
 
B   AAGCTGTTAGAATAAGAGAAAATGACAGAGGAAAACTGAAAGGGAGAACTGAAAGTGG   238 
S   AAGCTGTTAGAATAAGAGAAAATGACAGAGGAAAACTGAAAGGGAGAACTGAAAGTGG   238 
 
B   GAAATTCCTCTGAGGCAGAAAGGACCATCCCTTATAAATAGCACAGGCCATGAAGGAA   296 
S   GAAATTCCTCTGAGGCAGAAAGGACCATCCCTTATAAATAGCACAGGCCATGAAGGAA   296 
 
B   GATCATTCTCACTGCAGCCTTTGACAGCCTTTGCCTCATCTTGCAGGTAGCAGCCGAC   354 
S   GATCATTCTCACTGCAGCCTTTGACAGCCTTTGCCTCATCTTGCAGGTAGCAGCCGAC   354 
 
B   ACCAGCCT  362 
S     ACCAGCCT      362 
 
Figure III.5.3. – Sequences of the C57BL/6 and SPRET/Ei IFN-β promoter region. No nucleotide changes between the 
C57BL/6 and SPRET/Ei IFN-β promoters. In blue is the promoter region containing all the PRD and NRD elements of the 
IFN-β promoter.  
 
 
Stimulation of TLR3 or TLR4 leads to phosphorylation of the serine/threonine cluster in the C-terminal 
region of IRF-3, which leads to conformational changes of IRF-3 that relieve C-terminal autoinhibition 
and exposes the DBD and IAD domains. IRF-3 can now homodimerize, translocate to the nucleus and 
bind to the IFN-β promoter. The presence of a nuclear export signal (NES) shuttles IRF-3 back to the 
cytoplasm and terminates the response (Moynagh, 2005). Recently, Ser386 was recognized as the 
primary phosphorylation-site. This study provides an explanation for the TRIF activation of IRF-3, 
because both TBK1 and IKK-ε can phosphorylate IRF-3 at Ser386. Stimulation of TLR3 and TLR4 by 
dsRNA and LPS eventually leads to phosphorylation of this residue. The first serine of the 2S-site is 
important in the recognition of the IRF-3 kinases TBK1 en IKK-ε, while the second serine is the critical 
phosphorylation-site of IRF3. The 5ST-site might have a helping role with the phosphorylation of IRF-3 
(Mori et al., 2004). We sequenced the serine/threonine cluster in the C-terminal region of the irf3-gene.  
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At the same moment we had data demonstrating that IRF-3 activation was intact in SPRET/Ei. We tried 
to visualize IRF-3 phosphorylation after 30 minutes 100 ng/ml LPS stimulation in SPRET/Ei and 
C57BL/6 BMDMs through Western Blot. IRF-3 phosphorylation after LPS stimulation in BL6 BMDMs is 
not so clear due to a blot artefact, but IRF-3 becomes phosphorylated in SPRET/Ei BMDMs after LPS 
as seen by the higher band (Figure III.5.5.). In the future, we will surely repeat this experiment. 
 
 
 
Figure III.5.5. – Phosphorylation of IRF-3 in BMDMs after LPS stimulation. Western Blot to look at IRF-3 phosphorylation 
in C57BL/6 and SPRET/Ei BMDMs 30 minutes after stimulation with 100 ng/ml LPS. 
 
In addition, Jin Mo Park, with whom we closely collaborated, showed that IRF-3 knockout BMDMs have 
a broader gene defect than SPRET/Ei BMDMs. IRF-3-knockout macrophages are defective in their 
production of IFN-β, CCL5/RANTES, CXCL10/IP10 and ISG15 mRNA, while SPRET/Ei BMDMs are 
only defective in their IFN-β and RANTES/CCL5 mRNA production (Figure III.5.6.). Thus, the gene 
induction in SPRET/Ei macrophages after LPS does not reflect the gene induction in the IRF-3 knockout 
macrophages.  
However, an intact IRF-3 phosphorylation does not provide the certainty that IRF-3 dimers are formed 
and that the nuclear translocation and DNA-binding capacity of IRF-3 is intact. Also, IRF-3 needs co-
activators such as CBP and p300 to activate the IFN-β promoter (Taniguchi and Takaoka, 2002). In 
addition, trans-activators CITED1 and CITED2 can bind with CBP/p300 through their conserved C-
terminal acidic domain (Shioda et al., 1997; Yahata et al., 2000). CITED proteins do not appear to bind 
to DNA directly but function as transcriptional co-activators (Yahata et al., 2000). Cited1 and Cited2 lie 
respectively on chromosome X and chromosome 10, which are linked with the LPS-resistance of 
SPRET/Ei. Since their expression is regulated by cytokines and stress, they are predicted to have a 
possible role in modifying CBP/p300-dependent transcription in a variety of biological events. So, further 
research is needed to clarify the role of the IRF-3 complex in IFN-β activation. We have the intention to 
sequence the IRF-3 gene, but also to look at dimerization of IRF-3 molecules after stimulation with LPS 
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or poly (I:C). CBP/p300, CITED1 and CITED2 co-activators will also be sequenced and their expression 
will be investigated at mRNA and/or protein level.  
Also, RANTES and IFN-β contain both an NF-κB and an IRF-3 element in their promoter region. IRF-3 
and NF-κB need to cooperate to induce IFN-β, so possibly IRF-3 and NF-κB fail to cooperate with each 
other in SPRET/Ei to induce the Ifnb and Rantes genes. Using a bioinformatica tool we will identify other 
genes with both an NF-κB and an IRF element in their promoter region. These genes will be 
investigated at their expression after LPS and/or poly (I:C). 
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Figure III.5.6. – Gene induction in IRF-3-knockout and SPRET/Ei macrophages after LPS stimulation. BMDMs from 
C57BL/6, SPRET/Ei, IRF-3-knockout and IRF-3 wild-type mice were stimulated with 100 ng/ml LPS (triplicate cultures, 6-
well). Via Q-PCR, mRNA induction of TNF-α, IL-6, IFN-β, CXCL10, ISG15 and RANTES was investigated. 
 
5.3.3.   Defect in the JAK-STAT pathway? 
 
Preliminary data of a differential mRNA expression study, using BMDMs stimulated with LPS for 6 
hours, demonstrated that SPRET/Ei IFNAR1 mRNA was relatively low compared to the C57BL/6 
IFNAR1 mRNA after LPS stimulation. This interesting result led us to the investigation of the IFNAR1 
mRNA expression by semi-quantitative RT-PCR. Via RT-PCR we were able show that the basal 
expression of IFNAR1 mRNA was identical in SPRET/Ei and C57BL/6 BMDM, but that it was down-
regulated in SPRET/Ei cells very soon after LPS or IFN-β stimulation. In addition, we could demonstrate 
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that induction of OAS mRNA, which is dependent on ISGF3 complex formation after IFNAR stimulation, 
is significantly lower in SPRET/Ei BMDMs after LPS or IFN stimulation (see Figure III.5.7).  
In addition, significantly less IL-6 is induced upon IFN stimulation in SPRET/Ei BMDMs compared to 
C57BL/6 BMDMs (Figure III.5.7.). The mechanisms of IFN-induced IL-6 expression is not known yet, but 
these results confirm the defect in the positive-feedback loop after IFN stimulation. Also in another 
experiment using BMDMs from SPRET/Ei and C57BL/6 (in triplicate cultures, 100.000 cells per 24-well), 
IL-6 concentration was significantly lower in SPRET/Ei BMDMs compared to C57BL/6 BMDMs after 
stimulation with 250 and 125 U/ml IFN-β. 
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Figure III.5.7. – IFN-induced OAS mRNA expression and IL-6 induction in BMDMs. BMDMs from C57BL/6 and 
SPRET/Ei were seeded at 100.000 cells/well and were stimulated with 100 U/ml IFN-β for 1 hour (Oas mRNA, left figure) 
and 6 hours (IL-6 induction, right figure). RNA was isolated 1 hour after IFN-β stimulation and supernatant was collected 6 
hours after IFN-β stimulation. IL-6 was measured using the 7TD1 assay. (black bars: C57BL/6 (n = 3) and white bars: 
SPRET/Ei; n = 3) (***p<0,001 C57BL/6 vs SPRET/Ei). In non-stimulated BMDMs, expression of IL-6 is not detectable. 
 
 
These data suggest that hypo-responsiveness to IFN-β in SPRET/Ei may be due to rapid 
downregulation of the IFNAR1 by IFN-β or LPS. Nevertheless, IFNAR1 knockout mice, resistant to a 
lethal dose LPS, show a huge drop in body temperature after LPS injection. In contrast, SPRET/Ei mice 
are protected against LPS-induced hypothermia. This indicates that besides IFNAR1, other genes are 
involved in the LPS-resistance of SPRET/Ei. In the differential expression study using BMDMs 
stimulated with LPS for 6 hours, several MMPs, chemokines and interleukines (or their receptors) were 
differentially expressed between SPRET/Ei and C57BL/6 after LPS. The data of this experiment need to 
be confirmed, and by using the bioinformatica program ‘Difference Distance Matrix Analysis’ we hope to 
find a limited amount of transcription factors/genes that might be responsible for the differential 
expression of SPRET/Ei genes. 
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5.4.  Conclusion 
 
No nucleotide changes are found in the IFN-β promoter sequence of SPRET/Ei. In addition, IRF-3 
activation seems fine in SPRET/Ei as demonstrated by its phosphorylation after LPS and the broader 
gene defect of IRF-3-knockout mice. However, we did not look yet at its dimerization after LPS and 
neither at the expression of its co-activators CBP/p300, or at the trans-activators of CBP/p300 CITED1 
and CITED2. Also, IFN-β mRNA stability is regulated at the post-transcriptional level by 2 elements: an 
AU-rich element in the 3’ UTR and the coding region instability domain (CRID) in the 3’ end of the 
coding region. Thus, first the Ifnb gene itself should be sequenced. We must also investigate if IFN-β 
mRNA of SPRET/Ei mice is more rapidly degraded compared to IFN-β mRNA of C57BL/6 after LPS 
stimulation. We will do this by adding Actinomycin D to LPS-stimulated cell cultures to inhibit RNA 
synthesis and subsequently measure IFN-β mRNA expression at certain time points. Also, regulators 
such as YY1, IRF-1 and IRF-2 are known to be involved in IFN-β activation or shutdown and need to be 
investigated.  
 
Furthermore, it is interesting to know that the Ifnb and Ccl5 genes have both an NF-κB and IRF-3 PRD 
element. So, perhaps the induction of the Ifnb gene is defective because of a bad transactivation 
between the NF-κB and IRF-3 transcription factors. It is also still possible that p50/p50 homodimers, 
lacking transcriptional activity, are formed instead of p50/p65 dimers and that NF-κB or AP-1 activation 
is defect. We demonstrated that the early MyD88-dependent IκBα degradation and MAPK 
phosphorylation after LPS stimulation is intact in BMDMs from SPRET/Ei. This was confirmed by 
comparable induction of IL-6 and TNF-α mRNA after LPS in SPRET/Ei and C57BL/6 BMDMs. In 
contrast, late phase pro-inflammatory gene induction is defective in SPRET/Ei. So, we should look at all 
these elements (IRF-3 dimerization; NF-κB and AP-1 activation, NF-κB dimers) both at early and at late 
time points after LPS stimulation.   
We have demonstrated that IFNAR1 mRNA becomes rapidly downregulated in SPRET/Ei after IFN and 
LPS stimulation. The mechanism and significance of this phenomenon needs further investigation. It 
would also be interesting to look at the other molecules of the JAK-STAT pathway. Since the LPS-
resistance of SPRET/Ei is a dominant phenotype, the over-expression of a negative regulator would 
correlate with the dominant phenotype. Therefore, it would also be interesting to investigate the 
negative regulators of the JAK-STAT pathway such as SOCS, SHP and PIAS molecules. 
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6.  RESPONSE OF SPRET/Ei ON DIFFERENT TLR/IL-1R LIGANDS 
 
6.1.  Introduction 
 
The Toll/IL-1R family signals to downstream transcription factors using common signalling molecules 
and signalling pathways (Moynagh, 2005). We already demonstrated that SPRET/Ei is hypo-responsive 
to LPS in vivo and in vitro and that significantly less IFN-β is produced after LPS (in vivo and in vitro) 
and poly (I:C) (in vitro) stimulation. TLR4 is the only TLR using both TRIF and MyD88 to induce a variety 
of molecules, which makes it a very complicated pathway to analyze. TLR3 only recruits the adaptor 
molecule TRIF for signalling. We already knew that significantly less IFN-β is produced after poly (I:C) 
stimulation. We also tested the response of SPRET/Ei and (BxS)F1 mice to poly (I:C)/d-GalN-induced 
lethality. If we could use poly (I:C) instead of LPS to investigate the mechanism of the IFN-β defect, we 
only have to take the TRIF-dependent pathway into consideration. We also tested the response of 
SPRET/Ei to ligands for the IL-1R and TLR2. The IL-1R recruits only the adaptor molecule MyD88, 
while TLR2 recruits the adaptor molecules MyD88 and TIRAP. The Myd88-dependent pathway leading 
to early pro-inflammatory gene induction is intact in SPRET/Ei. Thus, we assumed a normal response of 
SPRET/Ei to IL-1R and TLR2 ligands. 
 
6.2.   Experimental procedures 
 
6.2.1.  Injections 
 
IL-1 was diluted in endotoxin-free PBS immediately before injection. All injections were given i.p. in a 
volume of 250 µl and with a with a dose of 1µg/25g bodyweight. Zymosan was injected in the footpad  
(20 µl). Swelling was measured and was compared to the PBS- injected foot. Poly (I:C) and d-GalN 
were diluted in endotoxin-free PBS immediately before injection. Injections were given i.p. in a volume of 
500 µg and with a dose of 10 µg poly (I:C) and 20 mg d-GalN per mouse. 
 
6.2.2.  In vitro experiments 
 
Thioglycolate-elicited macrophages and MEFs were seeded at 100.000 cells per well in supplemented 
RPMI medium 1640. IL-1 was added to the cultures to a final concentration of 1 µg/ml. After 24 hours of 
stimulation, supernatant was harvested and IL-6 was measured using the 7TD1 assay. 
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BMDMs were seeded at 100.000 cells per well in supplemented DMEM medium. PGN was added to the 
cultures to a final concentration of 2 µg/ml. Poly (I:C) was added to a final concentration of 25 µg/ml. 
After 6 hours of stimulation, supernatant was harvested and TNF was measured by using the sensitive 
cell line WEHI 164 cl 13 and IL-6 was measured using the 7TD1 assay. 
 
6.3.   Results 
 
6.3.1.  Response of SPRET/Ei, in vivo and in vitro to IL-1 
 
IL-1 binds to the IL-1R complex to stimulate the MyD88-dependent pathway to activate NF-κB and 
MAPK inducing pro-inflammatory cytokines such as IL-6. The adaptor molecule MyD88 is the only 
adaptor molecule which is recruited by the IL-1R complex (Janssens and Beyaert, 2002).  
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Figure III.6.1. – IL-6 concentration after an i.p. IL-1 injection. C57BL/6 (n = 3), (BxS)F1 (n = 2) an SPRET/Ei mice (n = 3) 
were i.p. injected with a dose of  1 µg IL-1. 3 hours after injection, IL-6 concentration was measured in serum using the 7TD1 
assay. 
 
 
To investigate the response to a ligand activating only the MyD88-dependent pathway SPRET/Ei, 
(BxS)F1 and C57BL/6 mice were i.p. injected with a dose of 1µg/25g bodyweight IL-1. IL-6 was 
measured in serum 3 hours after injection using the 7TD1 assay (Figure III.6.1). IL-1-induced IL-6 
expression is lower in SPRET/Ei mice compared to C57BL/6 mice, while (BxS)F1 mice have an 
intermediate phenotype. 
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This phenotype was also evident in vitro. Significantly less IL-6 was induced in SPRET/Ei macrophages 
and fibroblasts compared to C57BL/6 macrophages and fibroblasts (Figure III.6.2.). These data indicate 
that the MyD88-dependent pathway leading to IL-6 gene induction is defective.  
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Figure III.6.2. – IL-6 induction in vitro after 24 hours of IL-1 stimulation.  Thioglycolate-elicited peritoneal macrophages 
(left picture) and MEFs (right picture) from C57BL/6 and SPRET/Ei were seeded at 100.000 cells/well and were stimulated 
with 1 or 10 ng/ml IL-1. 24 hours after stimulation, supernatant was harvested and IL-6 was measured using the 7TD1 assay  
(black bars: C57BL/6 (n = 3) and white bars: SPRET/Ei; n = 3) (**p<0,01; ***p<0,001 C57BL/6 vs SPRET/Ei). 
 
 
6.3.2.  Response of SPRET/Ei, in vivo and in vitro to TLR2 
 
 
TLR2 activates the MyD88-dependent pathway, but not the TRIF-dependent pathway, to activate NF-
κB and MAPK to produce pro-inflammatory cytokines such as IL-6 and TNF. The IL-1R and TLR2 use 
many, but not all, of the same signalling components. For example, the adaptor molecule TIRAP is used 
by TLR2, but not by the IL-1R (Fitzgerald et al., 2001). TLR2 and TLR6 physically interact in the cell and 
both receptors cooperate in the response to zymosan derived from the cell-wall of yeast (Ozinsky et al., 
2000). Injection of zymosan in the footpad of mice induces inflammation, which can be seen as a 
swelling of the foot. When injected in the footpad of C57BL/6 mice, zymosan induced swelling of the 
foot, while in SPRET/Ei mice there was no swelling of the foot at all (Figure III.6.3.). In (BxS)F1 mice 
some swelling of the foot was seen. 
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Figure III.6.3. – Swelling of the foot after injection of zymosan. C57BL/6 (n = 8), (BxS)F1 (n = 8) and SPRET/Ei mice (n = 
5) were injected in the footpad with 20 µl zymosan. Swelling was measured and was compared to the PBS- injected foot 
(*p<0,05; ***p<0,001). 
 
In addition, we looked in vitro to stimulation with the TLR ligand peptidoglycan (PGN), a component of 
Gram-positive bacteria. PGN is recognized by the functional cooperation between TLR2 and TLR6. 
TLR2 needs a partner, demonstrated to be TLR6, to activate cytokines like TNF-α in macrophages 
(Ozinsky et al., 2000). PGN-induced TNF-α production is significantly less in C57BL/6 BMDMs 
compared to SPRET/Ei BMDMs (figure III.6.4.). Hence, also these data indicate a defect in the MyD88-
dependent pathway. After stimulation with PGN, IL-6 concentration in supernatants of C57BL/6 and 
SPRET/Ei BMDMs was very low. 
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Figure III.6.4. – TNF-α concentration in BMDMs after stimulation with PGN. BMDMs from C57BL/6 and SPRET/Ei were 
seeded at 100.000 cells/well and were stimulated with 2 µg/ml PGN for 6 hours (triplicate cultures). Concentration of TNF-α 
in supernatant was measured using the sensitive cell line WEHI 164 cl 13 (**p<0,01 C57BL/6 vs SPRET/Ei). 
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6.3.3.  Response of SPRET/Ei, in vivo and in vitro to TLR3 
 
TLR3 is the only TLR that does not activate the MyD88-dependent pathway (Moynagh, 2005). Instead it 
uses the TRIF-dependent pathway, mainly to induce IFN-β and IFN-dependent genes, but also to 
induce pro-inflammatory cytokines (Sato et al., 2003). TLR3 recognizes dsRNA and some synthetic 
dsRNA molecules, such as poly (I:C) (Alexopoulou et al., 2001).  
 
We decided to investigate pro-inflammatory gene induction after stimulation with poly (I:C). Significantly 
less IL-6 is produced upon poly (I:C) stimulation in SPRET/Ei BMDMs compared to C57BL/6 BMDMs 
(Figure III.6.5.). After poly (I:C) stimulation, TNF-α concentration in supernatants of C57BL/6 and 
SPRET/Ei BMDMs was very low. 
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Figure III.6.5. – IL-6 concentration in BMDMs after poly (I:C) stimulation. BMDMs from C57BL/6 and SPRET/Ei were 
seeded at 100.000 cells/well and were stimulated with 25 µg/ml poly (I:C) for 6 hours (triplicate cultures). Concentration of IL-
6 in supernatant was measured using the 7TD1 assay (***p<0,001 C57BL/6 vs SPRET/Ei). 
 
 
TLR3 knockout mice show a reduced response to poly (I:C). In addition, they are resistant to the lethal 
effects of poly (I:C) when sensitized with d-GalN and show reduced production of inflammatory 
cytokines (Alexopoulou et al., 2001). To test the response of SPRET/Ei mice to a TLR3 ligand, we 
injected mice with poly (I:C)/d-GalN and looked at survival. There is a significant difference in survival 
between (BxS)F1 or SPRET/Ei and C57BL/6 mice (Figure III.6.6 ). So, SPRET/Ei is hypo-responsive to 
poly (I:C) in vivo. In addition, SPRET/Ei has a defect in IFN-β mRNA induction and in IL-6 gene 
induction after poly (I:C) in vitro. 
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Figure III.6.6. – Survival after a lethal injection of poly (I:C) and d-GalN. C57BL/6, (BxS)F1 and SPRET/Ei mice were i.p. 
injected with 10 µg poly (I:C) and 20 mg d-GalN. Survival was monitored for 5 days. (Squares: C57BL/6 (n = 16), triangles: 
(BxS)F1 (n = 11) and circles: SPRET/Ei (n = 3))  (**p<0,01). 
 
 
6.4.   Conclusion 
 
Next to a defective pro-inflammatory cytokine induction in vivo and in vitro after LPS stimulation, also 
after stimulation with ligands for IL-1R, TLR2 and TLR3 a defective pro-inflammatory cytokine induction 
in SPRET/Ei in vitro is observed. SPRET/Ei mice are also hypo-responsive to IL-1 induced IL-6 
induction, zymosan-induced swelling of the foot and poly (I:C)/dGalN-induced lethality. We have shown 
that IκB degradation and MAPK p38 and JNK phosphorylation after LPS is intact at early time points, 
suggesting that the MyD88-dependent pathway in SPRET/Ei is intact. The intact MyD88 signalling was 
confirmed by studying the induction of TNF-α and IL-6 mRNA at early time points after LPS stimulation. 
However, MyD88, the adaptor molecule recruited by IL-1R and TLR2, is responsible for the activation of 
NF-κB and MAPK leading to pro-inflammatory cytokine production. Nevertheless, MyD88-dependent 
pro-inflammatory cytokine induction after IL-1R and TLR2 induction is defective in SPRET/Ei. Possible 
explanations could be the defective activation of NF-κB and MAPK or the formation of other NF-κB 
dimers, such as the p50-p50 homodimers lacking transactivation activity, instead of the transcriptionally 
active p50/p65 heterodimers. Also, CBP and p300 are identified as co-activators of the NF-κB 
component p65 (Gerritsen et al., 1997). Perhaps a defect in CBP/p300 is responsible for the defective 
pro-inflammatory cytokine induction. Recently, it was also shown that all TLRs use IRF-5, next to NF-
κΒ,  to induce production of pro-inflammatory cytokines such as TNF, IL-6 and IL-12 (Napolitani et al., 
2005). There are still contradictory results about the induction of IRF-5 in TLR3 signalling. So, the 
Tina Mahieu PhD thesis (2006) 156
Chapter III - Results 
defective pro-inflammatory cytokine (IL-6 and TNF) induction in SPRET/Ei can still be caused by 
multiple factors and requires further investigation. 
 
SPRET/Ei is hypo-responsive to poly (I:C) in vitro, as seen by defective IFN-β mRNA and IL-6 induction 
in BMDMs, and can resist the poly (I:C)/dGalN-induced lethality. For future work, we can use poly (I:C) 
instead of LPS to search for the mechanism causing the defective IFN-β expression. By using poly (I:C) 
we only have to take the TRIF-dependent pathway into consideration but not the MyD88-dependent 
pathway, which makes the response more complicated. A differential expression study of macrophage 
specific genes already showed us that about 50 genes are ≥ 2 times higher expressed in SPRET/Ei and 
about 50 genes are ≥ 2 times less expressed in SPRET/Ei BMDMs compared to C57BL/6 BMDMs after 
6 hours LPS stimulation. However, data are still preliminary because only one RNA sample of LPS-
stimulated BMDMs of SPRET/Ei and C57BL/6 was tested. The experiment will be repeated and we will 
also investigate the differential expression of macrophage specific genes in BMDMs of SPRET/Ei and 
C57BL/6 after poly (I:C) stimulation. By comparing the genes that are differentially expressed after both 
LPS and poly (I:C) stimulation we can reduce the amount of candidate genes, which might be 
responsible for the differential expression of SPRET/Ei genes. 
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7. GENETIC ANALYSIS OF THE LPS RESPONSE OF SPRET/EI  
 
7.1.  Introduction 
 
To identify and isolate the LPS protection genes in SPRET/Ei causing this LPS-resistance phenotype, 
we started a positional cloning experiment. To map a gene, two inbred strains are needed that are 
significantly different for a phenotype and that show significant genetic polymorphism. Firstly, SPRET/Ei 
and C57BL/6 are significantly different in their response to LPS. Secondly, Mus spretus diverged from 
Mus musculus about 1,5 million years ago. Because of this long period of evolutionary divergence, 
strains belonging to Mus musculus (C57BL/6) and Mus spretus (SPRET/Ei) demonstrate a high degree 
of genetic polymorphisms (Guenet and Bonhomme, 2003). It has been shown that 70-90% of the 
microsatellites between Mus spretus and common laboratory strains show size variations (Cornall et al., 
1991; Hearne et al., 1991). In addition, a dense genetic microsatellite-map is known. A backcross 
between Mus spretus and C57BL/6 of about 1000 progeny can achieve a resolution of 0.1 cM 
(approximately 200 kb). This made SPRET/Ei very popular for genetic mapping experiments (Group., 
1994; Rhodes et al., 1998). Also, SPRET/Ei can generate fertile female F1 animals with Mus musculus. 
These F1’s can be used to cross back to one of the parentals. Thus, SPRET/Ei and C57BL/6 are ideal 
partners for mapping of LPS-resistance genes.  
 
Nevertheless, the use of SPRET/Ei in mapping experiments has also some disadvantages. First, the 
degree of polymorphism between SPRET/Ei and C57BL/6 can be a disadvantage in gene identification. 
Due to this high degree of polymorphisms, almost in any gene a variation is found between SPRET/Ei 
and C57BL/6, making it difficult to identify the gene(s) causing the LPS-resistance of SPRET/Ei.  
Second, SPRET/Ei has very poor breeding performances. Third, since only fertile female F1 animals 
can be generated it is only possible to set up a backcross, but not an F2 intercross. In an F2 intercross 
25% of the genome of the F2 progeny will be BB, 25% SS and 50% BS. In contrast, in a backcross 50% 
of the genome will be BB and 50% will be BS. Hence, backcross mice have no homozygous SPRET/Ei 
loci. However, since the LPS-resistance of SPRET/Ei is a dominant trait this is not a real problem. 
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7.2.   Experimental procedures 
 
7.2.1.  Setting up an interspecific backcross  
 
To map the genes responsible for the LPS-resistance of SPRET/Ei, an interspecific backcross between 
female (BxS)F1 mice and male C57BL/6 mice (BSB backcross) was performed. Backcross mice were 
injected with 250 µg LPS at the age of 8 weeks. A genome scan was conducted by using microsatellite 
markers evenly spread across the genome. Primer sequences were obtained from the Massachusetts 
Institute of Technology (Cambridge) and primers were custom made by Invitrogen Life Technologies 
(Paisley, UK). The PCR reactions were performed on 100 ng of genomic tail DNA, as followed: DNA 
was denatured at 94°C for 4 minutes; 35 cycles of 30 seconds denaturation at 94°C, annealing of 
primers for 30 seconds at 55°C and elongation for 30 seconds at 72°C; elongation for 6 minutes at 
72°C. PCR products are separated by electrophoresis on 3% Nusieve agarose and visualized by 
ethidium bromide staining. Survival data and genotyping data were analyzed by using MapManager 
QTX B17 (Manly et al., 2001). 
 
7.2.2.  Generation of consomic strains 
 
To make a consomic strain homozygous for all loci and 1 chromosome from SPRET/Ei it is necessary to 
do brother-sister matings for different generations. Consomic strains were generated by first making a 
backcross between a fertile female (BxS)F1 mouse and a C57BL/6 male. The progenies are screened 
for a specific chromosome (chromosome 2, 10, 13 and X) using microsatellite markers. The mice that 
contain an entire chromosome 2, 10, 13 or X from SPRET/Ei are selected to cross back to C57BL/6. For 
different generations, a selection is made for the mice containing the entire chromosome of interest. 
Each generation 50% of the donor genome is lost. After 7 generations mice are generated that contain 
less than 1% SPRET/Ei genes (called passenger DNA), except for the chromosome one performed a 
selection for. Males and females with the non-recombinant chromosome from SPRET/Ei can be 
intercrossed to create progeny homozygous for the chromosome of interest. It is not possible to make 
homozygous consomic strains for chromosome X because of the hybrid sterility of males having a 
C57BL/6 Y chromosome and a SPRET/Ei X chromosome.  
Consomic strains were injected with high dose of LPS (100 µg/25g bodyweight) or low dose of LPS (10 
µg/25g bodyweight). PCR reactions on genomic tail DNA was done like in section 7.2.1. Survival data 
and genotyping data were analyzed by using MapManager QTX B17 (Manly et al., 2001). 
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7.3.   Results 
 
7.3.1.  Mapping to subchromosomal level 
 
An interspecific backcross between C57BL/6 and SPRET/Ei was set up to identify the genes conferring 
resistance to LPS. Female (BxS)F1 mice were crossed back with C57BL/6 males. A total of 141 BSB 
backcross mice were generated. At the age of 8 weeks the offspring was injected with a dose of 250 µg 
LPS, a dose of at least 5 times the LD100 for C57BL/6, but not lethal for SPRET/Ei. Out of 141 mice 
tested, 90 mice (64%) survived the injection of 250 µg LPS, while 51 mice (36%) died. When the trait 
follows a simple Mendelian inheritance pattern, 50% of the mice should be resistant and 50% should be 
sensitive for LPS. However, in the N2 backcross population only 36% of the mice is sensitive, which 
suggests that the LPS-resistance is a complex trait, controlled by multiple loci.   
A genome scan was performed by using microsatellite markers evenly spread across the genome. 
Genomic DNA was prepared from BSB mice and mice were PCR genotyped at marker loci. The 
genome scan was performed on 90 BSB mice. Afterwards, an additional 51 BSB mice were generated. 
These mice were only genotyped at marker loci on the 4 chromosomes found to be linked with the LPS-
resistance (see further). Also, some additional marker loci on these 4 chromosomes were genotyped.  
Subsequently, survival data and genotyping data were inserted into MapManager QTX B17 (Manly et 
al., 2001). To detect and localize QTLs the following steps need to be performed. First, putative QTLs 
are detected with tests like the ‘single-locus association’ test or simple interval mapping (SIM). Next, 
possible quantitative trait loci (QTLs) are more accurately localized with SIM. The significance of the 
putative QTLs is established with permutation tests. When multiple QTLs are present, also composite 
interval mapping (CIM) can be performed (Fig. III.7.1.) 
 
First a linkage analysis was performed using the simple ‘single-locus association’ test of Map Manager 
QTX. This test is used to evaluate the association of trait values with the genotypes of single loci (Table 
III.7.1). A lethal response to LPS was fixed as zero and a surviving response as hundred. A permutation 
test was used to determine empirically the likelihood ratio statistic (LRS) values corresponding to 
suggestive linkage (genome-wide type I error probability of 0.63), significant linkage (genome-wide type 
I error probability of 0.05) and highly significant linkage (genome wide type I error probability of 0.001). 
At the suggestive level on average one false positive is found per genome scan. At this level, the 
detected QTLs are not strong QTLs. At the significant level moderate QTLs and at the highly significant 
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level strong QTLs will be detected. The suggestive level corresponded to an LRS value of 6.6, the 
significant level to an LRS value of 12.9, and the highly significant level to an LRS value of 21.9. 
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Figure III.7.1. – Steps to detect and localize QTL. First homozygous mutant mice (S/S) are crossed with the homozygous 
wild-type mice (B/B). The (BxS)F1 progeny will be heterozygous for all loci (B/S).  Next, the (BxS)F1 progeny is crossed back 
to the wild-type strain (B). Following this steps, we generated 141 BSB mice. Survival data (lethality after LPS) and 
genotyping data (microsatellite markers) were introduced into Mapmanager QTX B17. Next, the following tests are 
performed to detect and localize QTL: ‘Single-locus association test’, SIM and CIM. 
 
 
These LRS values are less stringent than those of the genome-wide significance from Lander and 
Kruglyak determining the chance that a deviation will be found in a whole genome scan. The equivalent 
LRS needed for significance is about 20 for an F2 and about 15 for a backcross (Lander and Kruglyak, 
1995). The p-value is the probability of obtaining the observed LRS value by chance, the probability of a 
‘false positive’. This p-value is calculated by interpreting the LRS as a χ2 statistic. This p-value applies 
to one point in the genetic map. However, the probability of a false positive anywhere in the genome is 
much greater (Lander and Kruglyak, 1995). The p-value for a single point must be far below 0.001 to 
obtain a genome-wide p-value of 0.05 (Table III.7.1.) 
The best method to determine genome-wide significance is a permutation test to estimate an empirical 
genome-wide probability for observing a given LRS score by chance (Churchill and Doerge, 1994) 
(Table III.7.1.). 
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Following the empirical determined significance levels, loci on chromosome 10 and 13 reach suggestive 
linkage to LPS-resistance. A locus on chromosome 2 reaches significant linkage and a locus on 
chromosome X is significantly linked with the LPS-resistance (Table III.7.1.). In addition, a locus on 
chromosome 6, containing a sensitivity gene for LPS, was approaching the suggestive level (Table 
III.7.1.).  
 
 
 
Table III.7.1. -  Linkage of genetic markers to the LPS-resistance. 
Chr. Marker^ Position*  N° LRS %§ P value# 
 
95% CI†  
D2Mit89 32.0 119 7.9 5 0.00507 69 
D2Mit510 65.0 134 10.0 7 0.00155 55 2 
D2Mit52 87.4 115 6.1 5 0.01324 89 
        
6 D6Mit311 40.0 121 6.2 4 0.01251 87 
        
10 D10Mit253 23.0 113 7.4 5 0.00658 74 
        
D13Mit24 43.0 124 8.9 7 0.00286 62 
D13Mit145 52.0 117 8.9 7 0.00279 61 13 
D13Mit76 61.0 122 7.4 6 0.00649 74 
        
DXMit225 16.1 133 9.5 7 0.00205 58 
DXMit146 29.75 90 11.4 8 0.00072 48 
DXMit60 30.8 95 13.2 9 0.00028 42 
DXMit130 55.0 127 10.2 7 0.00144 54 
X 
DXMit135 69.0 123 13.4 10 0.00025 42 
 
^ Microsatellites 
* Expressed in cM 
° Population size 
§ Amount of total trait variance, explained by a QTL at this locus, as a percent 
# Point-wise P-values: The probability of obtaining the observed LRS value by chance 
† Confidence interval according to (Darvasi and Soller, 1997) 
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When we look at the corresponding 95% confidence intervals in Table III.7.1., which are data obtained 
by the simple ‘single-locus association’ test, we can see that the localizations of QTL (expressed in cM) 
are rather poor. The confidence interval for a QTL location determined by interval mapping is inversely 
proportional to the strength of the QTL and the square number of progeny. Even with a strong QTL, the 
confidence interval is unlikely to be less than 10 cM. A weak QTL may have a confidence interval, which 
covers the entire chromosome. For example, microsatellite DXMit135 on chromosome X is strongly 
linked with the LPS-resistance (high LRS value) and has a corresponding CI of 42 cM. In contrast, 
microsatellite D2Mit52 only reaches the suggestive level (low LRS value) and has a CI of 89 cM, which 
covers almost the entire chromosome.  
 
To obtain a more detailed location of a putative QTL another test is needed, namely SIM. SIM analysis 
calculates the association between phenotype and the expected contribution of hypothetical QTL at 
multiple analysis points between each pair of adjacent marker loci. The location of the putative QTL is 
given by that analysis point yielding the most significant association (Manly et al., 2001). A SIM analysis 
was performed using Map Manager QTX B17. Using this test, we observed: suggestive linkage of the 
LPS-resistance with loci on chromosome 10 and 13, a locus on chromosome 2 reaching the significant 
level and a locus on chromosome X highly significantly linked with the LPS-resistance (Figure III.7.2.) A 
locus on chromosome 6 (Figure III.7.3.) reaches the suggestive level. Suggestive (*), significant (**) and 
highly significant levels (***) are empirically determined using a permutation test as described before. 
 
We reanalyzed some of the data after our experiments with the consomic mice (see point 4.3). In Table 
III.7.1. we can learn that the effect of an individual locus on the overall trait variation ranges from 4 to 
10%, which is rather small. The combined effects of the detected loci on chromosome 2, 10, 13 and X 
account for approximately 30% of the total trait variation (LPS-resistance trait). This suggests that 
epistatic interactions exist between the detected QTLs or that additional QTLs were not detected. The 
power to detect QTL, defined as the probability of detecting a QTL at a given level of statistical 
significance, depends upon the strength of the QTL and the number of progeny in the population and is  
inversely proportional to the square of the strength of the QTL. If the strength of the QTL is considered 
in terms of the fraction of the total trait variation, three categories of QTLs can be defined. A strong QTL, 
is a QTL which explains 20% of the variance. At the other extreme are weak QTLs which only explain 
1% or less of the trait variance. Weak QTLs require at least a thousand progeny to detect them and it is 
not routinely feasible. Between these extremes are moderate QTLs, which can be detected with crosses 
of reasonable size.  This means that probably additional weak QTLs were not detected and a lot more 
mice are needed to detect all of the loci determining the LPS-resistance trait. 
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Figure III.7.2. – Simple interval mapping analysis of BSB backcross. *, suggestive level (genome wide type I error 
probability of 0.63); **, significant level (genome wide type I error probability of 0.05); ***, highly significant level (genome 
wide type I error probability of 0.001). Loci on chromosome 10 and 13 show suggestive linkage with LPS-resistance. A locus 
on chromosome 2 reaches significant linkage and a locus on chromosome X shows highly significant linkage with the LPS-
resistance.  
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Figure III.7.3. - Simple interval mapping analysis of BSB backcross: a sensitivity gene on chromosome 6. *, 
suggestive level (genome wide type I error probability of 0.63). In addition to the loci, which contain possible resistance 
genes, on chromosome 2, 10, 13 and X, a locus on chromosome 6 was found containing a sensitivity gene for LPS.  
 
We tested the possible epistatic interactions by analyzing the genome scan using an algorithm 
specifically aimed at detecting epistatic interactions.  This algorithm is the ‘interactions’ function of Map 
Manager QTX (Manly et al., 2001). Multiple loci are possibly involved in epistatic interactions (Table 
III.7.2.). In Table III.7.2. the LRS values for the individual  effect of locus 1 (Main 1) and locus 2 (Main 
2), and the LRS values for the interaction between locus 1 and locus 2 are given.  Above all, significant 
interactions between chromosomes 13 and X and between chromosomes 2 and X are detected. Some 
suggestive interactions are also detected.  Most notably, DXMit135 lying on the distal part of 
chromosome X is involved in epistatic interactions with chromosome 2 and 13, detected using the SIM 
analysis. Thus, probably there is key role for a locus on chromosome X in the overall phenotype. This is 
easily comprehensible, since chromosome X and 2 were strongest linked with the LPS-resistance. 
 
 Table III. 7.2 – Epistatic interactions in the LPS response of SPRET/Ei. 
Locus1 Locus2 LRS  Main1 Main2 
D13Mit145 DXMit135 32.3 ** 7.8 13.7 
D2Mit472 DXMit135 27.0 ** 4.4 12.8 
D13Mit24 DXMit225 21.6 * 3.9 9.2 
D12Mit88 D13Mit285 21.2 * 3.5 5.2 
D12Mit118 D15Mit255 20.3 * 0.7 1.7 
LRS, likelihood ratio statistic for the interaction; Main 1 and Main 2: individual effects of 
locus 1, respectively locus 2 (* suggestive, ** significant). 
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If more than one QTL is detected, another test, called composite interval mapping (CIM), can be 
performed (Jansen and Stam, 1994). SIM localizes a single QTL without regard to other QTLs affecting 
the trait, while CIM uses a marker near the first QTL to explore the effect of QTL combinations. Based 
on the assumption of epistatic interactions between QTLs, we performed CIM using markers DXMit135 
and D2Mit510, the two markers with the highest LRS values for chromosome X and chromosome 2, to 
control for background QTL. By doing so, linkage at the suggestive level became apparent on proximal 
chromosome 12 (Figure III.7.4.). However, this region was negatively linked with the LPS-resistance, 
meaning that a sensitivity gene might be located around D12Mit88, lying on proximal chromosome 12. 
D12Mit88 was also found as a marker involved in epistatic interaction with D13Mit285. 
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Figure III.7.4. – Composite interval mapping. Composite interval mapping was performed using DXMit135 and D2Mit510 
to control for background QTL. Linkage at the suggestive level with proximal chromosome 12 was found. This locus might 
contain a sensitivity gene for LPS. (*, suggestive level). 
 
7.3.2.  Chromosome substitution strains (CSS) or consomic mice 
 
To confirm the importance of the loci found in the initial backcross we started making consomic mice, 
also called chromosome substitution strains (CSS strains). At the ‘Institut Pasteur’ in Paris (Dr. J.-L. 
Guénet) consomic strains derived from Mus spretus are available. However, these consomic strains are 
derived from STF/Pas en SEG/Pas, 2 other inbred strains derived from Mus spretus individuals. 
STF/Pas and SEG/Pas were tested for their response to LPS and it was demonstrated that both strains 
are not resistant to LPS-induced lethal shock. We wanted to make consomic strains that are totally 
C57BL/6, except for one (pair of) chromosome(s) (in our case chromosome 2, 10, 13 or X) derived from 
SPRET/Ei (Nadeau et al., 2000). The complex trait has been turned into a monogenic trait if the trait is 
still (partially) evident in such consomic mice. 
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SPRET/Ei mice are also hyporesponsive to lethal shock induced by TNF (Staelens et al., 2002). By 
testing chromosome 2 or 6 consomic mice for their response to TNF, it became clear that the extreme 
TNF-resistance phenotype of SPRET/Ei cannot be reproduced by isolating loci lying on chromosome 2 
or 6 into a C57BL/6 background. Consomic mice heterozygous for the region between D6Mit104 and 
D6Mit194 are very significantly protected to TNF compared to their littermate controls. However, the 
protection conferred by the chromosome 6 locus is only to a very low dose of TNF (12.5 µg/25g mouse) 
compared to the dose which SPRET/Ei and (BxS)F1 resist (500 µg/25g mouse). Since the LPS-
resistance phenotype is - as the TNF-resistance - a complex trait involving multiple genes, we wanted to 
test if we could screen with a low dose of LPS. One advantage of working with a low dose of LPS is the 
more subtle approach meaning that we can look at quantitative traits such as body temperature and IL-6 
concentration. In contrast, after a high dose LPS (as in the backcross) mice are scored as either dead 
or alive. Bleeding of mice to measure IL-6 concentration in serum and measuring body temperature can 
stress them and influence lethality.  So, a mouse with a dramatically drop in body temperature that 
survives the high dose LPS injection is scored as alive. Another advantage is that most mice survive a 
low dose of LPS. So, they can be used to cross back to C57BL/6. In addition, a high dose of LPS 
induces not only lethality but also causes sterility problems. However, a disadvantage of this approach 
is the possibility that the IL-6 concentration and the LPS response in terms of lethality might not be 
linked to each other. C57BL/6 and (BxS)F1 mice were injected with a low dose (10 µg/25g mouse) LPS 
and IL-6 was measured 3 hours after injection. (BxS)F1 mice barely produce IL-6, while C57BL/6 mice 
still produce high amounts of IL-6 (Figure III.7.5.). Thus, we can also use a low dose of LPS to screen 
consomic mice for their response to LPS. 
 
C57BL/6 (BxS)F1
0
5000
10000
15000
IL
-6
 (n
g/
m
l)
 
 
Figure III.7.5. – IL-6 concentration after a low dose LPS. C57BL/6 and (BxS)F1 mice (n = 2) were injected i.p. with a low 
dose of 10 µg/25 g bodyweight LPS and IL-6 was measured in serum 3 hours after LPS injection. 
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7.3.3.   Chromosome 2 semi-consomic mice  
 
For chromosome 2, mice heterozygous for marker loci D2Mit32, D2Mit295, D2Mit472, D2Mit160, 
D2Mit510 and D2Mit109 (Figure III.7.7.) were selected for backcrossing to C57BL/6. In our initial 
interspecies backcross experiment, we found that a LPS-resistance locus is located on distal 
chromosome 2 between markers D2Mit516 and D2Mit109. Some chromosome 2 semi-consomic mice 
were injected with a high dose of LPS to look at lethality, while others were injected with a low dose LPS 
to look at body temperature and IL-6 in serum. 
In total, we injected 54 semi-consomic offspring of intercrossed consomic mice at generation N7 (see 
Figure III.7.6.) with a high dose of LPS (100 µg/25g bodyweight). Mice were typed and can be 
heterozygous (B/S) or homozygous (B/B or S/S) for marker loci op chromosome 2. For mice at 
generation N7, the remaining heterozygous SPRET/Ei fraction - except for chromosome 2 - is less than 
1%. Out of 54 mice, 13 mice survived. There was no linkage between a locus on chromosome 2 and 
lethality after LPS. For example, a mouse homozygous B/B for all the marker loci survived the LPS 
injection, while a mouse S/S or B/S for all the marker loci died.  
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Figure III.7.6. – Difference between consomic and semi-consomic mice. Chromosome 2 is used as an example. An 
intercross between two chromosome 2 consomic mice (N7) generates consomic mice (homozygous (S/S) for all marker loci) 
or semi-consomic mice (heterozygous (B/S) or homozygous (B/B or S/S) for marker loci). 
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Also, 37 semi-consomic offspring of intercrossed consomic mice at generation N7 were injected with a 
low dose LPS (10 µg/25g bodyweight). Concerning the IL-6 concentration, no linkage at all is found with 
chromosome 2. Also, no significant linkage can be found between body temperature 2, 6 and 24 hours 
after the LPS injection and chromosome 2 (Figure III.7.7.). Most semi-consomic mice show low body 
temperature even after a low dose of 10 µg/25g mouse. 
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Figure III.7.7. – Interval mapping analysis of chromosome 2 semi-consomic mice. Interval mapping analysis using body 
temperatures and IL-6 concentration after a low dose LPS as trait.  
 
 
7.3.4.   Chromosome 10 (semi)-consomic mice 
 
We decided to generate consomic mice for chromosome 10 (and 13), despite the fact that only 
suggestive linkage is found with the LPS-resistance. In each QTL experiment, a QTL can be 
underestimated and a QTL can be overestimated. For chromosome 10, mice heterozygous for marker 
loci D10Mit16, D10Mit186, D10Mit309, D10Mit233 and D10Mit238 were selected for backcrossing to 
C57BL/6 (Fig III.7.8.). In our initial interspecies backcross experiment, we found that a LPS-resistance 
locus is located on proximal chromosome 10 between markers D10Mit 16 and D10Mit253. 
Chromosome 10 consomic mice were injected with a high dose of LPS to look at lethality, while 
chromosome 10 semi-consomic mice were injected with a low dose LPS to look at body temperature 
and IL-6 in serum. In total, 12 consomic mice at the N5 and N6 generation, heterozygous for all marker 
loci, were injected with a high dose of LPS (100 µg/25g bodyweight). At generations N5 and N6, the 
remaining heterozygous SPRET/Ei fraction - except for chromosome 10 - was 6.25% and 3.125%. All 
mice died, except one. There was no linkage between a locus on chromosome 10 and lethality. The 
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impressive resistance that SPRET/Ei mice display towards the lethal effects of LPS is lost in the 
chromosome 10 consomic mice.   
Also, 66 chromosome 10 semi-consomic mice were injected with LPS at generations N4 and N5. At 
generations N4 and N5, the remaining heterozygous SPRET/Ei fraction - except for chromosome 10 - 
was 12.5% and 6.25%. Semi-consomic mice were injected with a low dose LPS (10 µg/25g bodyweight) 
and we looked at body temperature and IL-6 induction. We did find significant linkage between the IL-6 
concentration and a region between markers D10Mit16 and D10Mit186 (significant level; LRS = 6.9). 
Thus, the peak LRS score comprises not the same region as identified by the initial backcross. Also, 
significant linkage was found between body temperature 3 hours after LPS and a region between 
markers D10Mit186 and D10Mit309 (significant level; LRS = 7.4). Nevertheless, there was no significant 
linkage anymore between body temperature 7 hours after LPS and genotype (Figure III.7.8.). Thus, 
chromosome 10 semi-consomic mice show linkage with a region between D10Mit16 and D10Mit186 
and the IL-6 concentration after a low dose LPS.  
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Figure III.7.8. -– Interval mapping analysis of chromosome 10 semi-consomic mice. Interval mapping analysis using 
body temperatures and IL-6 concentration after LPS as trait.  
 
7.3.5.  Chromosome 13 semi-consomic mice 
 
For chromosome 13, mice heterozygous for marker loci D13Mit198, D13Mit24, D13Mit285, D13Mit145 
and D13Mit76 were selected for backcrossing to C57BL/6. In total, 33 semi-consomic mice for 
chromosome 13 were used at generations N3, N4 and N5. At generations N3, N4 and N5, the remaining 
heterozygous SPRET/Ei fraction, except for the selected chromosome, was 25%, 12.5%, 6.25%. In our 
initial interspecies backcross experiment, we found that a possible LPS-resistance locus is located on 
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distal chromosome 13. At different generations, semi-consomic mice were injected with a low dose LPS 
(10 µg/25g bodyweight) and we looked at body temperature. We did not find significant linkage between 
body temperature after LPS and chromosome 13 (Figure III.7.9.). 
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Figure III. 7.9 - Interval mapping analysis of chromosome 13 semi-consomic mice. Interval mapping analysis using 
body temperatures after LPS as trait. 
 
 
7.3.6. Chromosome X semi-consomic mice 
 
Mice heterozygous for marker loci DXMit50, DXMit60, DXMit130, DXMit135 and DXMit160 were 
selected for backcrossing to C57BL/6. 
Only 15 chromosome X semi-consomic mice at generations N4 and N5 could be generated. At 
generations N3, N4 and N5, the remaining heterozygous SPRET/Ei fraction, except for chromosome 13, 
was 25%, 12.5% and 6.25%. In our initial interspecies backcross experiment, we found very significant 
linkage with chromosome X with a peak between markers DXMit130 and DXMit135. Almost the entire 
chromosome X was significantly linked with the LPS-resistance. At different generations, semi-consomic 
mice were injected with a high dose LPS (100 µg/25g bodyweight) to investigate body temperature and 
IL-6 induction. No significant linkage between body temperature, lethality and IL-6 after LPS was found. 
6 mice out of 15 survived an injection of 100 µg LPS. Because we had breeding problems, only few 
consomic mice for chromosome X were generated. We did not have a group large enough to confirm 
the role for chromosome X in the LPS-resistance. 
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7.4.  Conclusion 
 
In an initial backcross experiment using ‘the single-locus association’ and SIM tests we found that loci 
on chromosome 2, 10, 13 and X are linked with the LPS-resistance of SPRET/Ei mice. On chromosome 
6 we found a locus containing a sensitivity gene for LPS. Chromosome X is highly significantly linked 
with the LPS-resistance. However, because of the breeding problems that we encountered we were not 
able to generate a high amount of consomic mice, especially chromosome X consomic mice. By using 
(semi-) consomic mice we could not turn the LPS-resistance phenotype into a monogenic trait. We only 
found a region in the proximal part of chromosome 10 with some linkage with the IL-6 concentration 
after injection of a low dose LPS. However, this region is not the same region as found in the initial 
backcross and consomic mice for chromosome 10 do not survive a dose of 100 µg LPS, which is a 
dose 5 times less than the 500 µg dose that SPRET/Ei and (BxS)F1 mice can resist (Table III.7.3.). 
Also, although the use of a low dose LPS (score for quantitative traits such as IL-6 and body 
temperature) is a more subtle approach than the use of a high dose LPS (score for dead or alive), the 
IL-6 concentration and the LPS response in terms of lethality might not be linked to each other. Hence, 
it looks that we are dealing with epistatic interactions between the different loci. 
 
Indeed, we reanalyzed the data of the backcross and found that the cumulative effect of the detected 
QTLs is about 30% of the total trait variance. This suggests that epistatic interactions between the 
detected QTLs or additional QTLs were not detected. We found possible interactions, using the 
‘interactions’ function of Map Manager QTX, between chromosomes 13 and X and between 
chromosomes 2 and X. This is not surprising since these are the most powerful QTL identified in the 
genome scan. So, a lack in this work is the generation of double consomic mice for chromosome 2 and 
chromosome X. However, after 3,5 years of trying to generate chromosome X consomic mice we 
decided to abandon this strategy and use an in vitro approach to identify the LPS-resistance genes of 
SPRET/Ei. Also, during this work we demonstrated that SPRET/Ei mice are defective in IFN-β induction 
after LPS and that this defective IFN-β production is a critical factor in the resistance of SPRET/Ei mice 
to LPS. So, probably it would have been better to measure the IFN-β concentration in serum of 
consomic mice instead of measuring IL-6 and body temperature. However, most of our experiments with 
consomic mice were already done and no serum was left. 
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Table III.7.3. – Overview of linkage found between different traits and chromosome 2, 
10, 13 or X.  
(Semi-) consomic High dose LPS Low dose LPS 
 Lethality Body temperature IL-6 
Chr. 2 - - - 
Chr.10 - + (∆3h) + 
Chr.13 ND - - 
Chr.X - ND ND 
 
 
We think that the loss of the LPS-resistance phenotype in the consomic mice is due to the absence of 
epistatic interactions (the function of one gene is dependent on the function of another gene) between 
different QTL or due to the absence of cooperation between the different loci (a threshold has to be 
crossed before becoming fully resistant to LPS). Also, additional QTL might be missed in the backcross 
experiment. The power of a QTL detection experiment is dependent on the strength of the QTL and the 
amount of mice. Thus, a backcross of 90 mice is not sufficient to detect weak QTL. A minimum of 1000 
backcross mice are needed to detect very weak QTL, suggesting that loci contributing only a small 
effect are not detected in a simple genome scan. Only the loci having the strongest effects, in our case 
on chromosome 2, 10, 13 and X, are detected in this way.  
 
To reduce complexity and to identify in this way the less powerful QTLs, we also tried to generate ‘blind 
congenic’ mice. Therefore, (BxS)F1 mice (LPS resistant) are crossed back to C57BL/6 mice (LPS 
sensitive)  and offspring are injected with a high dose LPS. Depending on the number of resistance 
genes present, a certain number of offspring will survive a high dose of LPS. This is repeated for a 
number of generations. After 5 generations C57BL/6 mice are generated containing only a fraction 
(6.25%) SPRET/Ei genome. However, because of sterility after a high dose LPS we were not able to 
generate ‘blind congenic’ mice. 
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1. SUMMARY OF THE RESEARCH AND DISCUSSION 
  
A first part of this work involved the detailed description of the LPS resistance of SPRET/Ei mice. 
Therefore we injected mice with high doses LPS. Compared to the commonly used laboratory strain 
C57BL/6, SPRET/Ei mice resist 10 times the LD100 for C57BL/6. C57BL/6 mice die from a dose of 50 µg 
LPS. SPRET/Ei and (BxS)F1 mice easily survive a dose of 500 µg, which shows that the hypo-
responsiveness to LPS is a dominant trait. Even at this high dose, SPRET/Ei mice do not show any sign 
of illness. A number of pathological parameters were examined. In C57BL/6 mice, LPS induced 
hypothermia, liver and lung inflammation (as observed by attachment of leukocytes to the endothelium 
of blood vessels and migration of leukocytes to the alveoli) and MMP9 expression (a marker for the 
progression of inflammation). In SPRET/Ei and (BxS)F1 mice, LPS induced no hypothermia and 
expression of MMP9 in serum was lower than MMP9 expression in serum of C57BL/6 mice. In 
SPRET/Ei lungs and livers much less leukocytes attach to the endothelium and leukocytes do not 
migrate to the alveoli. By bone marrow transplantation experiments we could demonstrate that the LPS-
resistant phenotype of (BxS)F1 mice depends critically on bone marrow-derived cells, likely 
macrophages.  
 
In vivo gene induction was measured by studying the IL-6 and TNF-α concentrations in the serum after 
LPS. SPRET/Ei induces IL-6 and TNF-α after LPS injection, but at significantly lower levels than in 
C57BL/6. Especially 3 and 9 hours after LPS injection IL-6 levels are significantly different between 
SPRET/Ei and C57BL/6. IL-6 induction in (BxS)F1 mice was as low as in SPRET/Ei mice. In addition, to 
confirm that the LPS resistance of SPRET/Ei is not specific for S.a.e. LPS, we also tested the response 
of  (BxS)F1 mice to LPS derived from E.coli. (BxS)F1 mice resist 500 µg E.coli LPS, a dose 100% lethal 
to C57BL/6 mice. In (BxS)F1 mice, LPS did not induce hypothermia or high levels of IL-6.  
In vitro gene induction was determined in thioglycolate-elicited macrophages and in mouse embryonic 
fibroblast (MEF) cells. Again, we used IL-6 expression to look at gene induction. SPRET/Ei 
macrophages and immortalized MEFs produced significantly lower amounts of IL-6 compared to 
C57BL/6 macrophages and MEFs. These reduced IL-6 levels in SPRET/Ei are in line with the reduced 
IL-6 serum levels after injection of LPS. However, we measured high basal levels of IL-6 in both 
C57BL/6 and SPRET/Ei thioglycolate-elicited macrophages and in MEFs. So, probably due to the 
thioglycolate and the immortalization with SV40 Large T, respectively macrophages and MEFs are 
already activated to express IL-6. In contrast, in BMDMs obtained from both C57BL/6 and SPRET/Ei we 
did not detect basal IL-6 levels. Hence, BMDMs are far more reliable to use as an in vitro model.  
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Since we were pleasantly surprised of the spectacular nature of the LPS resistance of SPRET/Ei, we 
wanted to identify the genes conferring resistance to LPS. We have followed two different approaches to 
identify the LPS resistance genes: a genetic approach and an in vitro approach using BMDMs. 
Considering this extreme resistance of SPRET/Ei, very strong protective genes are supposed to be 
present. SPRET/Ei is not only known for its extreme and dominant resistance to LPS, but also for its 
resistance against arthritis, partial resistance against asthma and extreme and dominant resistance to 
TNF (Staelens et al., 2004; Staelens et al., 2002). Nevertheless, the LPS resistance is probably not due 
to the same genes causing the TNF resistance. This assumption is based on following arguments: 
• TNF-deficient mice and TNF-receptor-deficient mice show increased susceptibility to high-dose 
LPS lethality (Marino et al., 1997; Rothe et al., 1993).  
• The TNF-resistant mouse strain DBA/2 is not resistant to LPS (Dr. Ben Wiellockx and Dr. 
Claude Libert, unpublished data).  
• LPS-resistant C3H/HeJ mice are totally responsive to TNF.  
• The loci linked with the TNF resistance are different from those linked with the LPS resistance.  
• 30% of the TNF-resistant backcross mice are sensitive to LPS (Dr. Jan Staelens, unpublished 
data).  
These arguments demonstrate that probably other genes than those genes providing hypo-
responsiveness to TNF account for the extreme resistance to LPS. 
 
We first performed an interspecific backcross (n = 90). After analysis of the data from the backcross we 
generated an additional 51 BSB mice and these mice were genotyped only at marker loci lying on the 4 
chromosomes detected in the ‘genome scan’ (see further). At the age of 8 weeks BSB backcross mice 
were injected with 250 µg LPS, a dose 100% lethal for C57BL/6, but not lethal for SPRET/Ei. Of the 
141 mice challenged, 90 mice (64%) survived and 51 mice (36%) died. In case of a monogenic trait, 
50% of the mice should die and 50% should survive. However, only 36% of the BSB mice are sensitive 
to LPS suggesting that the LPS resistance of SPRET/Ei is a complex trait, controlled by multiple loci. 
Survival data and genotyping data were inserted into MapManager QTX B17 and a ‘genome scan’ was 
performed. Using ‘the single-locus association’ and ‘simple interval mapping’ tests of MapManager we 
found that the LPS resistance of SPRET/Ei is linked to loci on chromosomes 2, 10, 13 and X. 
Suggestive linkage was found with loci on chromosome 10 and 13, almost significant linkage with a 
locus on chromosome 2 and highly significant linkage with a locus on chromosome X. On chromosome 
6 we found a locus containing an LPS sensitivity gene.  
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By using (semi-) consomic mice we tried to confirm the importance of the detected loci in the LPS 
resistance of SPRET/Ei. We used both a low and a high dose LPS to screen the consomic mice for 
their response to LPS. One advantage of using a low dose LPS is that quantitative traits such as IL-6 
and body temperature can be measured. The use of a low dose LPS is a more subtle approach than 
the use of a high dose LPS. Using a high dose of LPS, mice are scored as either dead or alive. For 
example, a mouse with a significant drop in body temperature that survives the high dose LPS injection 
will be scored as alive. However, a disadvantage of using a low dose LPS is that the IL-6 concentration 
and the LPS response in terms of lethality might not be linked to each other. It was necessary to make 
our own consomic strains, because STF/Pas and SEG/Pas - 2 other inbred strains derived from Mus 
spretus individuals and from which consomic strains are available in the Institut Pasteur, Paris, France - 
are not resistant to LPS-induced lethality. So, our own consomic strains were generated. However, we 
were not able to turn the LPS resistance phenotype into a monogenic trait by isolating the individual 
QTLs: using (semi-) consomic mice we only found a region between markers D10Mit16 and D10Mit186 
- a region that is different from the region found on chromosome 10 in the initial backcross – which 
showed some linkage with the IL-6 concentration after injection of a low dose LPS. The chromosome 
10 consomic mice did not survive a dose of 100 µg LPS, a dose 5 times smaller than the 500 µg dose 
that SPRET/Ei and (BxS)F1 mice can resist. So, maybe a gene is present in the proximal region of 
chromosome 10 positively influencing the response to LPS. This region is still very large and by looking 
at the public Mouse Genome we could not find genes known to be involved in the LPS response. 
Taken the data of the consomic mice together, it looks that the presence of only one of the resistance 
QTLs is not sufficient to explain the extreme resistance of SPRET/Ei to LPS and hence that we are 
dealing with a case of complex genetics, on top of that depending on epistatic interactions between the 
different loci. I have to stress that, because of the breeding problems that we encountered, we were not 
able to generate a high amount of consomic mice. Especially the generation of chromosome X 
consomic mice went very bad, which was frustrating because this was precisely the chromosome we 
wanted to investigate in detail as much as possible using consomic mice.  
By further analyzing the linkage data of the backcross, it became clear that the combined effects of 
chromosome 2, 10, 13 and X account for ± 30% of the total variation (effect of individual loci ranges 
from 4 to 10%). This suggests that epistatic interactions between the QTL - found in the backcross - or a 
number of additional QTLs, were not detected. Possibly, 2 or more loci are acting together in an additive 
fashion. This means that the one QTL present has only a sub-phenotype of the original complex 
phenotype because of the absence of additive effects from the other QTL(s) and that a threshold has to 
be reached to obtain full LPS resistance. Another explanation could be that QTLs are working in an 
epistatic fashion, meaning that interactions between QTLs result in an effect on the trait that would not 
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be predicted from the sum of the individual QTL effects. It is also possible that other loci involved in the 
resistance were not detected since a backcross of minimum 1000 mice is needed to detect a very weak 
QTL. Given the poor breading performance we had to deal with, expansion of the backcross was not 
considered as a valid option. By using the ‘interactions’ function of Map Manager QTX, we tested 
possible epistatic interactions (Manly et al., 2001). Multiple loci are possibly involved in epistatic 
interactions, but most notably DXMit135, located on the distal part of chromosome X, is involved in 
epistatic interactions with loci on chromosomes 2 and 13, both also detected using the SIM analysis. 
Knowing that there are probably epistatic interactions between QTLs, we performed composite interval 
mapping (CIM) to control for background QTLs. We found suggestive linkage with a locus on 
chromosome 12. The locus on chromosome 12 seems to contain a sensitivity gene and is also found as 
a locus involved in epistatic interaction with a locus on chromosome 13. A shortage in this work is the 
generation of double consomic mice for chromosome 2 and X. These two chromosomes are the 
strongest ones which are linked with the LPS resistance phenotype and possible epistatic interactions 
between loci on chromosome 2 and chromosome X indeed were clearly detected by MapManager QTX. 
However, after 3,5 years of problematic generation of consomic mice we decided to abandon this 
genetic approach to identify the LPS resistance genes and not to generate chromosome 2-X-double 
consomic mice and to focus on another strategy instead. 
 
Because of the spectacular resistance of SPRET/Ei to LPS and the great amount of genetic 
polymorphisms between C57BL/6 and SPRET/Ei, we thought that the identification of the LPS 
resistance genes would be quite simple. We believed that based on the backcross data, we would 
easily find the QTL linked with the LPS resistance and that this extreme phenotype of SPRET/Ei would 
be (partly) present in consomic mice. Indeed, when this would have been the case, it would have been 
possible to fine map the region by setting up a second and larger backcross between an LPS-resistant 
consomic mouse and C57BL/6, to end up with a small critical region with a limited amount of candidate 
genes.  Nevertheless, the backcross experiment was an interesting experience and at least learned 
that extreme phenotypes may be entirely depending on interaction between loci, just as was found 
earlier by Jan Staelens during his attempts to clone the SPRET/Ei TNF resistance genes. 
 
In a second approach, I tried to identify the molecular basis of the LPS resistance using an in vitro 
system. The SPRET/Ei LPS hypo-responsiveness in vitro in macrophages was used to investigate the 
mechanism of the LPS resistance. The LPS-induced response involves a complex network of signalling 
molecules, which end up in inducing expression of a variety of genes. The binding of LPS to TLR4 
causes the activation of the MyD88-dependent pathway leading to early NF-κB and MAPK activation 
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and the TRIF-dependent pathway leading to late NF-κB and MAPK activation and IRF-3 activation 
(Kawai et al., 1999; Yamamoto et al., 2003). LPS-induced pro-inflammatory gene induction (e.g. IL-6 
and TNF) is dependent on the NF-κB pathway, but also on the activation of other transcription factors 
such as AP-1, which is dependent on the activation by MAPK p38 and JNK (Akira et al., 1990; 
Dendorfer et al., 1994; Guha and Mackman, 2001; Guha et al., 2001). A key event in the activation of 
NF-κB is the nuclear translocation of NF-κB after phosphorylation and subsequent degradation of the 
IκB protein (Akira and Takeda, 2004). We showed that the MyD88-dependent pathway leading to 
transient degradation of IκBα was normal in SPRET/Ei BMDMs at early time points. We also 
demonstrated that phosphorylation of p38 MAPK and JNK1/2 was intact. Furthermore, the intact MyD88 
signalling was confirmed by the absence of a significant difference between SPRET/Ei and C57BL/6 
BMDMs in LPS-induced early TNF-α and IL-6 mRNA expression. Furthermore, LPS-induced mRNA 
expression of, e.g. Il1a, Il1b, Il12a, Il12b, Bcl2, Birc4 (encoding XIAP) and Tnfaip3 (encoding A20) was 
not significantly different between C57BL/6 and SPRET/Ei.  
So, IL-6 and TNF-α mRNA expression in vitro is normal in SPRET/Ei 1 hour and 4 hours after LPS. In 
contrast, IL-6 levels (3 hours after LPS) and TNF-α levels (1 hour after LPS) in serum of SPRET/Ei in 
vivo are significantly lower compared to IL-6 and TNF-α levels in serum of C57BL/6 mice. However, an 
in vivo situation is much more complex than an in vitro system. LPS can activate various cell types such 
as macrophages, DCs, neutrophils and fibroblasts to produce pro-inflammatory cytokines such as TNF-
α, IFN-γ, IL-6 and IL-1. Subsequently, these cytokines (e.g. IL-1) might activate other cells to produce 
also IL-6 and TNF-α. 
Next to an early phase NF-κB induction, TLR4 can also induce a late phase NF-κB and AP-1 activation 
by the TRIF-dependent pathway (Akira and Takeda, 2004). The adaptor molecule TRIF can recruit both 
TRAF6 and TBK1/IKK-ε to its N-terminal domain and recruitment of TRAF6 leads to a second wave of 
pro-inflammatory cytokine production. TRIF -/- macrophages are defective in their TNF-α, IL-6, and IL-
12p40 production 24 hours after LPS stimulation (Yamamoto et al., 2003). We found that 24 hours after 
LPS stimulation IL-6 expression in SPRET/Ei MEFs was strongly impaired compared to IL-6 expression 
in C57BL/6 MEFs.  In the same experiment it was confirmed that IL-6 induction was normal at an early 
time point, namely 4 hours after LPS stimulation. Thus, the (TRIF-dependent) late pro-inflammatory 
gene induction is defective in SPRET/Ei cells, while the early pro-inflammatory gene induction is intact. 
However, it should be stressed that normal, transient IκB degradation and normal phosphorylation of 
MAPK p38 and JNK does not mean that NF-κB and AP-1 activation is intact in SPRET/Ei, but it 
demonstrates that the signalling components upstream are intact. In the future, in vitro experiments 
should be performed to analyze activation of these transcription factors by means of electrophoretic 
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mobility shift assays. In addition, a possible explanation for the defect in late IL-6 induction might be that 
an anti-inflammatory mechanism is overactive in SPRET/Ei. In endotoxin tolerance, which is a transient 
state of hypo-responsiveness towards a second stimulation by LPS after a preceding stimulation, one 
mechanism is the induction of specific anti-inflammatory mechanisms such as accumulation of p50-p50 
NF-κB homodimers and the induction of signalling pathways such as PI3K. It is still possible that in 
SPRET/Ei p50-p50 NF-κB homodimers, lacking transactivation activity, are formed instead of the 
transcriptionaly active p50-p65 heterodimers. It has been observed that in endotoxin tolerance, 
formation of p50-p50 homodimers leads to a decrease in TNF levels (Goldring et al., 1998). Another 
mechanism to regulate the endotoxin tolerant phenomenon is the induction of PI3K signaling (Bowling et 
al., 1995). PI3K, found on mouse chromosome 13, can inhibit TLR signalling. The underlying 
mechanism remains unknown, but seems to involve the suppression of p38, JNK, ERK1/2 and NF-κB 
(Fukao et al., 2002). Thus, maybe an anti-inflammatory mechanism, such as the formation of p50-p50 
homodimers or the induction of the signalling pathway PI3K, that blocks pro-inflammatory gene 
induction is overactive in SPRET/Ei. This anti-inflammatory mechanism could be induced by NF-κB or 
AP-1 themselves since at early time points IL-6 and TNF-α are perfectly induced in SPRET/Ei.  
 
LPS induces expression of the Ifnb gene through a MyD88-independent TRIF-dependent pathway 
(Yamamoto et al., 2002). Poly (I:C), a TLR3 ligand, also induces the TRIF-dependent pathway to induce 
IFN-β. The TRIF-dependent pathway leads to activation of the transcription factor IRF-3, resulting in 
IFN-β induction, STAT1 phosphorylation and translocation, and the induction of STAT1 dependent 
genes, such as IRF-7 (Yamamoto et al., 2003). We showed that the induction of IFN-β mRNA by LPS, 
but also by poly (I:C), was largely impaired in SPRET/Ei-derived BMDMs. As a consequence of the 
defective IFN-β induction, LPS-induced STAT1 phosphorylation and subsequent nuclear translocation 
were impaired, and this in turn impaired the induction of IRF-7. The defect in IFN-β production is also 
observed in vivo in SPRET/Ei mice treated with LPS or Influenza virus.  
IFN-β was discovered as a potent antiviral molecule (Isaacs and Lindenmann, 1957). For a long time, it 
was believed that this was the only function of type I IFNs, but in the last few years a more extensive 
role for IFNs in immunity has been demonstrated. We determined the role of IFN-β in the LPS 
resistance of SPRET/Ei and also the consequences of this defective IFN-β induction. Since the 
resistance of SPRET/Ei mice can be reversed by administration of exogenous IFN-β, this suggests that 
IFN-β is an important factor in the LPS-induced lethality. Deletion of genes encoding IFN-β or genes 
involved in the induction of or in the response to IFN-β can induce resistance to endotoxemia 
(Karaghiosoff et al., 2003; Sakaguchi et al., 2003). In our hands, IFNAR1 knockout mice are resistant 
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against a lethal dose LPS (we are the first group to publish this), but they do show a serious drop in 
body temperature. In contrast, SPRET/Ei mice have a stable body temperature after injection of the 
same dose of LPS. Therefore, it seems that other genes besides Ifnb determine the complete LPS-
resistant phenotype of SPRET/Ei. Hereby the data of the genome scan demonstrating that the LPS 
resistance is a complex trait is confirmed. In collaboration with Dr. J. Grooten, we can use macro-array 
filters containing about 500 macrophage specific genes to study the differential mRNA expression in 
BMDMs of SPRET/Ei and C57BL/6. We have demonstrated that macrophages are the relevant cell type 
in the LPS resistance of SPRET/Ei. We already did a first differential expression study using these filters 
and observed that 6 hours after LPS stimulation about 50 genes are ≥ 2 times higher expressed in 
SPRET/Ei BMDMs and about 50 genes are ≥ 2 times less expressed in SPRET/Ei BMDMS compared 
to C57BL/6 BMDMs. This differential expression analysis has to be repeated, and we hope to lower the 
high number of differentially expressed genes by comparing data after LPS and poly (I:C) stimulation 
and studying more than one time point. Using the bioinformatics program ‘Difference Distance Matrix 
Analysis’ we hope to find transcription factors/genes that might be responsible for the differential 
expression of SPRET/Ei genes. 
 
The defect in IFN-β has its consequences. It has been demonstrated that IFN-β can sensitize 
macrophages for cell death induced by Listeria monocytogenes and that it can protect against 
progressive leishmaniasis (Mattner et al., 2004; Stockinger et al., 2002).  Probably due to the defective 
induction of IFN-β, SPRET/Ei mice indeed are completely resistant to Listeria monocytogenes and 
(BxS)F1 mice are highly sensitive to Leishmania major infection. We also plan to study the response of 
SPRET/Ei mice to viral infections. Since IFN-β is a well-known potent antiviral cytokine, we assume that 
SPRET/Ei mice will be very vulnerable for viral infections. Several studies suggest that IFN-β is 
essential in LPS-induced endotoxemia, but its importance in Gram-negative sepsis has yet to be 
investigated. The advantages and disadvantages of blocking IFN-β or its receptors in the treatment of 
septic patients are discussed in depth in the review: ‘Must we inhibit type I IFNs in endotoxemia and 
sepsis?’ (Mahieu and Libert). 
 
Another part of this work was to unravel the mechanism of the defective IFN-β induction. The defect can 
be situated at different levels: there can be a defect in the IFN-β promoter or in one of its regulators, in 
one of the molecules of the TRIF-dependent pathway or in the positive feedback loop induced after IFN-
β signaling. First, we studied the sequence of the IFN-β promoter region but found no variations 
between C57BL/6 and SPRET/Ei. Second, we investigated the activation of IRF-3 as an endpoint of the 
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TRIF-dependent pathway. IFN-β induction is dependent on the phosphorylation/activation of the 
transcription factor IRF-3. Therefore, we sequenced the serine/threonine cluster in the C-terminal region 
of IRF-3. No variations were found in the important serines of this region, but we did find some other 
unique amino acid changes, which might have an influence on the phosphorylation of IRF-3. However, 
about the same time we demonstrated that IRF-3 becomes phosphorylated in SPRET/Ei BMDMs, our 
collaborator Dr. Jin Mo Park could show that IRF-3 BMDMs had a broader gene defect (Ifnb, Rantes, 
Isg15 and Cxcl10) compared to SPRET/Ei BMDMs (Ifnb and Rantes) after LPS stimulation. Of course, 
normal phosphorylation of IRF-3 does not necessarily mean that the IRF-3 molecules dimerize or that its 
co-activators CBP/p300, or the trans-activators of CBP/p300 CITED1 and CITED2, found on mouse 
chromosome X and 10, are normal in SPRET/Ei. Interestingly, these two chromosomes are linked with 
the LPS resistance phenotype. Possibly, abolished or changed activation of these co-factors can 
change the IRF-3 dependent induction of IFN-β.  In addition, CBP/p300 are co-activators of the NF-κB 
component p65 (Gerritsen et al., 1997). Thus, perhaps a defect in CBP/p300 or its trans-activators 
CITED1 and CITED2 can be responsible for both defective IL-6 induction and defective IFN-β induction. 
In addition, we will also look at IRF-3 dimerization, NF-κB and AP-1 activation, and NF-κB dimers at 
early and late time points after LPS stimulation. 
Another interesting fact is that the IFN-β mRNA stability is regulated at the posttranscriptional level by 
an AU-rich element in the 3’ UTR, and a second element called CRID in the 3’ end of the coding region. 
So far, we have not sequenced the entire Ifnb gene and we have not looked at the sequence and 
expression of positive/negative regulators of the IFN-β promoter such as YY1, IRF-1 and IRF-2 (NRF-
knockout mice are susceptible to LPS-induced lethality). Clearly, these elements require further 
investigation. Furthermore, it is interesting to know that the promoters of the Ifnb and Ccl5 (encoding 
RANTES) genes both contain an NF-κB and an IRF-3 PRD element. In that case, the defective 
induction of both the Ifnb gene and the ccl5 gene can be caused by a defective transactivation between 
NF-κB and IRF-3 transcription factors. So, an anti-inflammatory mechanism inhibiting NF-κB activation, 
such as formation of p50-p50 homodimers, or a defect in co-factors of IRF-3, such as CPB/p300 and 
CITED1/2, can be responsible for both defective late pro-inflammatory gene induction and defective 
IFN-β induction. Using a bioinformatics tools we will search for other genes that contain both an NF-κB 
and IRF element in their promoter and investigate their expression after LPS. 
The defect can also be situated in the positive feedback loop after IFN-β signaling. We demonstrated 
that OAS mRNA induction, which is dependent on the formation of a STAT1/STAT2/IRF9 complex after 
IFNAR stimulation, is significantly lower in SPRET/Ei BMDMs after IFN or LPS stimulation We also 
showed that IFNAR1 mRNA becomes rapidly down-regulated in SPRET/Ei after IFN-β stimulation. The 
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mechanism and significance of this event is not yet known. The same was demonstrated after LPS 
stimulation. In addition, significantly less IL-6 is induced upon IFN stimulation in SPRET/Ei BMDMs. If 
these defective gene inductions after IFN are mediated by the down-regulation of the IFNAR1 has yet to 
be shown. Future work will need to address which mechanism exactly is responsible for the 
phenomenon of IFNAR1 down-regulation. Furthermore, sequence and expression analysis of several 
other molecules of the JAK-STAT pathway should be performed. The over-expression of a negative 
regulator would correlate with the dominance of the LPS resistance phenotype. Therefore, it would also 
be interesting to investigate the negative regulators of the JAK-STAT pathway such as SOCS, SHP and 
PIAS molecules. 
As suggested clearly other genes are involved in the LPS resistance of SPRET/Ei. It has been 
demonstrated that IFN-β is able to induce the expression of a large set of chemokines (Coelho et al., 
2005). Expression of chemokines leads to migration of leukocytes to the inflammatory sites. 
Interestingly, we have seen that in LPS-injected SPRET/Ei mice leukocytes do not migrate to the alveoli 
and in lungs and livers of LPS-injected SPRET/Ei mice fewer leukocytes were found attached to the 
endothelium. In addition, preliminary data from a differential mRNA expression study using blots with 
macrophage specific genes taught us that several chemokines are not or much less induced in 
SPRET/Ei BMDMs compared to C57BL/6 BMDMs after LPS stimulation. So, a possible mechanism to 
explain the importance of IFN-β to the LPS resistance is the following (see also Figure IV.1.1.). The 
defective IFN-β induction in SPRET/Ei might lead to a defect in chemokine production. The defective 
chemokine induction leads to a defect in migration of leukocytes to the inflammatory sites and a 
diminished tissue destruction. Also, IL-6 is produced upon stimulation of the IFNAR1 receptor by IFN-β. 
The mechanism of IFN-induced IL-6 is also not known at this moment. Hence, a combination of a defect 
in the MyD88-independent late IL-6 gene induction and a defect in the IFN-β induced IL-6 gene 
induction leads to significantly diminished IL-6 levels. Pro-inflammatory cytokines such as IL-6 can also 
act directly on tissue organs. So, a defective IL-6 induction may also lead to diminished tissue 
destruction.  
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Figure IV.1.1.- Possible mechanism to explain the role of IFN-β in LPS-induced lethality. 
 
Finally, we also tested the response of SPRET/Ei to other TLR ligands. The response to LPS involves 
the induction of two main signaling pathways, the MyD88-dependent and the MyD88-independent 
pathway. Most TLRs use only one signaling pathway to induce responses to pathogens, which makes 
the response not as complex compared to the LPS response (Moynagh, 2005). We demonstrated that 
the LPS-induced MyD88-dependent signaling events upstream of IκB degradation and MAPK 
phosphorylation are intact, suggesting a normal MyD88-dependent pathway in SPRET/Ei. LPS-induced 
IL-6 gene induction at late time points is TRIF-dependent and was impaired in vivo and in SPRET/Ei 
MEFs. MyD88 is the only adaptor molecule that is recruited after IL-1R and is also recruited by TLR2, 
besides TIRAP. We showed that stimulation with ligands for the IL-1R and TLR2 leads also to a 
defective pro-inflammatory cytokine induction in SPRET/Ei in vitro. In addition, SPRET/Ei mice are also 
hypo-responsive to IL-1 induced IL-6 induction and zymosan-induced swelling of the foot. The defective 
induction of pro-inflammatory genes after different TLR ligands can be explained by a common 
mechanism. As described above, we did not show activation of transcription factors NF-κB and AP-1, 
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and neither did we look at the composition of the NF-κB dimers formed after TLR stimulation or at co-
activators such as CBP/p300 and CITED1/CITED2. Another putative explanation is a defect in IRF-5 
activation. It has recently been demonstrated that all TLRs use not only NF-κB but also IRF-5 to induce 
pro-inflammatory cytokine production, such as TNF, IL-6 and IL-12 (Napolitani et al., 2005). SPRET/Ei is 
also hypo-responsive to poly (I:C) in vitro and can resist poly (I:C)/dGalN-induced lethality. Poly (I:C) 
only activates the TRIF-dependent pathway, which makes the response less complex compared to the 
LPS response. This phenotype makes it possible to use poly (I:C) instead of LPS in future experiments 
to determine the mechanism of the defective IFN-β induction.  
 
In summary, in this work we wanted to map and identify the genes that confer hypo-responsiveness to 
LPS in SPRET/Ei. After describing the LPS resistance of SPRET/Ei in detail we aimed at mapping the 
LPS-resistance genes by a genetic strategy. Using this strategy we were not able to identify regions 
small enough to contain a limited number of candidate genes. Another strategy was to find the 
mechanism of the SPRET/Ei LPS resistance in vitro. Since about half of my time was invested in the 
typing and screening of mice to enlarge the initial backcross and to make consomic mice, the in vitro 
data are not as extensive as we would like them to be. So, the work presented in my thesis, showing 
that IFN- plays a role in the LPS resistance of SPRET/Ei, also still raises a lot of questions about the 
exact cause of this defect in IFN- production. Finally, we realize that also other genes than IFN- are 
involved in the hypo-responsiveness of SPRET/Ei to LPS and other TLR ligands. Future work will have 
to identify these genes and their mechanism of action. 
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Perspectives 
 
In this work we have presented some interesting data concerning the importance of IFN-β in LPS-
induced shock. We have demonstrated that SPRET/Ei mice, which have a defective IFN-β production, 
are resistant against LPS-induced shock, and that (BxS)F1 mice are partially protected against a Gram-
negative infection. However, through our genetic studies and experiments with the IFNAR1-knockout 
mice, we know that IFN-β is not the only gene involved in the LPS-resistance of SPRET/Ei. Thus, the 
project concerning the LPS-resistance of SPRET/Ei will continue at two levels: 
 
1. LPS-resistance genes of SPRET/Ei 
 
 We have set the following perspectives: 
 
• Mechanism of the defective IFN-β production? 
We will investigate if IRF-3 is the cause of the defective IFN-β production in SPRET/Ei mice by 
looking at the sequence, dimerization and phosphorylation of IRF-3. We will also investigate other 
mechanisms or molecules involved in the IFN-β regulation in more detail, namely the degradation of 
IFN-β mRNA and molecules like SHIP, RIP1, CITED1 and CITED2. In addition, we will look at the 
relevance of the  ‘down-regulation’ of IFNAR1. 
 
• Are other genes important in the SPRET/Ei LPS-resistance?   
We will investigate if other genes then IFN-β are important in the SPRET/Ei LPS-resistance. For 
this, we will do a differential expression study of macrophage specific genes after LPS and poly (I:C).      
 
• Gram–negative sepsis? 
SPRET/Ei and/or (BxS)F1 mice will be used in different models of Gram-negative sepsis (Cecal 
Ligation and Puncture’ (CLP), Klebsiella pneumoniae and Salmonella typhimurium, …). However, 
the problem is that not much SPRET/Ei mice are available. So, mostly (BxS)F1 mice will be used. 
 
• Based on preliminary experiments we have seen that the SPRET/Ei phenotype ‘resembles’ a 
constitutive endotoxin tolerant phenotype: will this give us new information? 
 
2. SPRET/Ei has a defective IFN-β production 
 We have set the following perspectives: 
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• Does IFN-β play an important role in sepsis? 
We will investigate this by using different models: CLP, K.pneumiae, S. typhimurium, … In addition, 
Jo et al. showed indeed that blocking type I IFN signalling could have therapeutic application in the 
treatment of endotoxemia. 
 
• Can we protect against LPS and Gram-negative sepsis by inhibiting type I IFNs or their up-stream 
or down-stream mediators? 
We will investigate this by using an IFN-β neutralizing Ab (we are developing this in our lab) in 
C57BL/6 mice. Can we protect C57BL/6 mice against LPS-induced shock and sepsis by 
administration of an IFN-β neutralizing Ab?  Another possibility is the administration of an 
antagonist of IFNAR1. 
However, it is possible that blocking IFN-β will lead to susceptibility to viral infections (IFNAR1 -/- 
mice are highly susceptible to viral infection). 
 
 
Thus, we think that molecules of the type I IFN signalling pathway, like IFN-β and IFNAR1, may be new 
therapeutic targets in endotoxemia and sepsis, providing that septic patients are not hypersensitive for 
viral infections and that the activation of the immune system is not compromised. It may be possible to 
treat septic patients with IFN-blocking agents or agents that block type I IFN signalling over a short time 
interval in strictly contained conditions to prevent viral infection. 
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2. SAMENVATTING VAN HET ONDERZOEK EN BESPREKING 
 
Een eerste deel van dit werk beschrijft gedetailleerd  de LPS-resistentie van SPRET/Ei muizen. Hiervoor 
werden muizen geïnjecteerd met hoge doses LPS. In vergelijking met de veelgebruikte 
laboratoriumstam C57BL/6 kunnen SPRET/Ei muizen 10 keer de LD100 voor C57BL/6 verdragen. 
C57BL/6 muizen sterven aan een dosis van 50 µg LPS. SPRET/Ei en (BxS)F1 muizen overleven zonder 
problemen een dosis van 500 µg LPS, wat ook het dominante karakter van de LPS resistentie aantoont. 
Zelfs met zo een hoge dosis vertonen SPRET/Ei muizen geen enkel teken van ziekte. Een aantal 
pathologische parameters werd onderzocht. LPS induceert in C57BL/6 muizen hypothermie, lever- en 
longinflammatie (aanhechting van leukocyten aan het endotheel in de bloedvaten en migratie van 
leukocyten naar de alveoli) en MMP-9 expressie (progressie van inflammatie). In SPRET/Ei en (BxS)F1 
muizen ontwikkelde zich geen hypothermie en was de expressie van MMP-9 lager dan in C57BL/6 
muizen. In de longen en lever van de SPRET/Ei muizen hechten er zich minder leukocyten vast aan het 
endotheel van de bloedvaten en migreren er geen leukocyten naar de alveoli. Via 
beenmergtransplantaties konden we aantonen dat de LPS resistentie van SPRET/Ei muizen afhangt 
van beenmergafgeleide cellen en meer waarschijnlijk macrofagen. 
In vivo gen-inductie werd gemeten door kwantificatie van IL-6 en TNF-α in het serum na LPS injectie. 
Zowel IL-6 als TNF-α werden inderdaad geïnduceerd in SPRET/Ei, maar in significant mindere mate 
dan in C57BL/6. 3 uur en 9 uur na LPS injectie waren IL-6 niveaus significant verschillend tussen 
C57BL/6 en SPRET/Ei. De IL-6 inductie in (BxS)F1 muizen was even laag als in SPRET/Ei muizen. Om 
aan te tonen dat de LPS resistentie van SPRET/Ei niet specifiek is voor S.a.e. LPS, hebben we ook de 
respons getest op LPS afkomstig van E.coli. (BxS)F1 muizen overleven een dosis van 500 µg E.coli 
LPS, een dosis die 100% letaal is voor C57BL/6 muizen. In (BxS)F1 muizen ontwikkelde zich geen 
hypothermie en werd er significant minder IL-6 geïnduceerd in vergelijking met C57BL/6 muizen. 
In vitro gen inductie werd bepaald in thioglycolaat-gestimuleerde macrofagen en in geïmmortaliseerde 
muis embryonaire fibroblasten (MEFs). Ook hier werd IL-6 gekozen om gen-inductie te bestuderen. 
SPRET/Ei macrofagen en MEFs induceren IL-6 in significant mindere mate dan C57BL/6 macrofagen 
en MEFs. Deze gereduceerde IL-6 niveaus komen overeen met de lagere IL-6 niveaus in vitro na LPS. 
Echter, zowel in peritoneale macrofagen als in MEFs van C57BL/6 en SPRET/Ei werden hoge basale 
IL-6 niveaus gemeten. Waarschijnlijk worden macrofagen en MEFs al aangezet tot de expressie van IL-
6 door respectievelijk thioglycolaat en SV40 LargeT. In BMDMs van SPRET/Ei en C57BL/6 muizen 
werden echter geen basale IL-6 niveaus gemeten. BMDMs zijn dus veel betrouwbaarder om als een in 
vitro model gebruikt te worden. 
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Door de extreme aard van LPS-resistentie van SPRET/Ei muizen, wilden we de LPS-resistentiegenen 
identificeren. We hebben dit op twee verschillende manieren aangepakt: een genetische en een in vitro 
benadering. Gezien de extreme resistentie van SPRET/Ei muizen zouden zeer sterke beschermende 
genen aanwezig moeten zijn. SPRET/Ei is niet alleen gekend voor zijn extreme resistentie tegen LPS 
maar ook voor zijn resistentie tegen artritis, gedeeltelijke resistentie tegen astma en zijn extreme 
resistentie tegen TNF (Staelens et al., 2004; Staelens et al., 2002). Nochtans wordt de LPS-resistentie 
waarschijnlijk niet veroorzaakt door dezelfde genen die TNF resistentie beïnvloeden. Volgende 
argumenten staven deze redenering: 
•  TNF-deficiënte en TNFR-deficiënte muizen vertonen een verhoogde gevoeligheid voor letaliteit 
geïnduceerd door hoge doses LPS (Marino et al., 1997; Rothe et al., 1993).  
• De TNF-resistente muisstam DBA/2 is niet resistent tegen LPS (Dr. Ben Wiellockx en Dr. 
Claude Libert, niet gepubliceerde data). 
• LPS-resistente C3H/HeJ muizen zijn gevoelig voor TNF. 
• De loci die gelinkt worden met de LPS resistentie zijn verschillend van de loci die gelinkt 
worden met de TNF resistentie. 
•  30% van de TNF-resistente backcross muizen zijn gevoelig voor LPS (Dr. Jan Staelens, niet 
gepubliceerde data). 
Deze bevindingen laten vermoeden dat andere genen dan de genen die de TNF-resistentie 
veroorzaken, verantwoordelijk zijn voor de extreme resistentie tegen LPS. 
 
In een eerste fase werd een interspecifieke backcross uitgevoerd (n = 90). Na analyse van de backcross 
data werden er nog 51 extra nakomelingen gegenereerd. Deze muizen werden enkel getypeerd voor 
microsatelliet merkers op de 4 chromosomen die gelinkt werden met de LPS-resistentie in de ‘genome 
scan’ (zie later). Op een leeftijd van 8 weken werden alle nakomelingen uit deze kruising geïnjecteerd 
met 250 µg LPS, een dosis die 100% letaal is voor C57BL/6 muizen maar niet letaal is voor SPRET/Ei 
muizen. Van de 141 muizen die geïnjecteerd werden overleefden er 90 muizen (64%) en stierven er 51 
muizen (36%). Indien we met een monogeen kenmerk te maken zouden hebben, zou 50% van de 
muizen moeten overleven en 50% moeten sterven. Echter, slechts 36% van de nakomelingen is 
gevoelig voor LPS. De LPS- resistentie van SPRET/Ei muizen lijkt dus een complex gegeven te zijn, dat 
door meerdere genen beïnvloed wordt. Overlevingsdata en genotyperingsdata werden ingevoerd in het 
computerprogramma MapManager QTX B17 en een ‘genome scan’ werd uitgevoerd. Na het analyseren 
van de data via de ‘single-locus association’ test en ‘simple interval mapping’ test van MapManager 
konden we besluiten dat de LPS-resistentie gelinkt is met loci op chromosoom 2, 10, 13 en X. Er werd 
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een suggestieve linkage gevonden tussen de LPS-resistentie en eenloci op chromosoom 10 en 13, 
bijna significante linkage met een locus op chromosoom 2 en zeer significante linkage met een locus op 
chromosoom X. Op chromosoom 6 werd er een sensitiserende locus gevonden. 
Via (semi)-consome muizen hebben we getracht de belangrijkheid van de QTLs in de LPS-resistentie 
van SPRET/Ei muizen te bevestigen. Om consome muizen te screenen voor hun respons op LPS, 
hebben we zowel een hoge als een lage dosis LPS gebruikt. Het voordeel van een lage dosis LPS is de 
meer subtiele aanpak dan bij het gebruik van een hoge dosis LPS: kwantitatieve kenmerken, zoals IL-6 
en lichaamstemperatuur, kunnen gemeten worden. Bij een hoge dosis LPS worden muizen enkel als 
dood of levend beschouwd. Een muis die bijvoorbeeld een enorme daling in lichaamstemperatuur 
vertoont na de LPS-injectie maar die toch blijft leven zal als LPS-resistent (levend) beschouwd worden. 
Een nadeel van het gebruik van een lage dosis LPS is dat de IL-6 concentratie en de LPS-respons wat 
betreft letaliteit misschien niet met elkaar gelinkt kunnen worden. 
Het was nodig om onze eigen consome muizen te genereren, omdat STF/Pas en STG/Pas - 2 andere 
inteeltstammen afgeleid van Mus spretus individuen en waarvan er consome muizen beschikbaar zijn in 
het Institut Pasteur, Paris, France -niet resistent zijn tegen LPS-geïnduceerde letaliteit. Met  onze eigen 
consome stammen waren we niet in staat om de LPS-resistentie om te zetten naar een monogeen 
kenmerk door het isoleren van individuele QTLs: we hebben enkel een gebied gevonden rond 
microsatelliet D10Mit186 – een ander gebied dan het gebied op chromosoom 10 gevonden in de initiële 
backcross – dat enigszins gelinkt kan worden met de IL-6 concentratie na injectie van een lage dosis 
LPS. De chromosoom 10 consome muizen overleefden echter niet een hoge dosis van 100 µg LPS , 
een dosis die 5 keer lager ligt dan de dosis die kan verdragen worden door SPRET/Ei en (BxS)F1 
muizen. Misschien ligt er een gen op proximaal chromosoom 10 dat de IL-6 concentratie na LPS positief 
beïnvloedt. Deze regio is nog altijd zeer groot en we vonden geen genen die direct gelinkt worden met 
LPS na het bekijken van het publieke muisgenoom. Als we data van de consome muizen bekijken, lijkt 
het er op dat de aanwezigheid van een enkel resistentiegen niet voldoende is om de extreme LPS-
resistentie van SPRET/Ei te verklaren.  We hebben dus te maken hebben met een geval van complexe 
genetica en bovendien treden er epistatische interacties op tussen verschillende loci. We moet en wel 
bemerken dat we, door de moeilijkheden die we hadden om te kweken, niet in staat waren om een groot 
aantal consome muizen te genereren. In het bijzonder de generatie van chromosoom X consome 
muizen liep niet volgens plan, wat nefast was voor het onderzoek omdat dit precies het chromosoom 
was dat we zoveel mogelijk in detail wilden bestuderen. 
Na het heranalyseren van de ‘genome scan’ werd het duidelijk dat de gecombineerde effecten van 
chromosoom 2, 10, 13 en X oplopen tot ongeveer 30% van de totale variatie (het effect van de 
individuele loci bereikt 4 tot 10%). Dit suggereert dat er epistatische interacties werkzaam zijn tussen de 
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verschillende QTLs, of dat we een aantal QTLs gemist hebben. Het is mogelijk dat 2 of meer loci 
samenwerken op een additieve manier. Dit betekent dat iedere locus bijdraagt aan de graad van 
resistentie en dat een bepaalde drempel moet bereikt worden om volledige LPS-resistentie te bekomen. 
Een andere verklaring zou kunnen zijn dat er epistatische interacties optreden tussen QTLs, wat 
betekent dat de interacties tussen QTLs resulteert in een effect dat niet voorspeld kan worden door de 
som van de individuele effecten. Het is ook mogelijk dat we niet alle QTLs geïdentificeerd hebben in de 
‘genome scan’, aangezien een backcross van minimum 1000 muizen nodig is om een zwak QTL te 
ontdekken. Een uitbreiding van de backcross was echter geen optie, gezien de moeilijkheden die we 
hadden om nakomelingen te genereren. 
Via de ‘interacties’ functie van MapManager QTX hebben we mogelijke epistatische interacties 
opgespoord (Manly et al., 2001) en verschillende loci lijken betrokken te zijn bij epistatische interacties. 
In het bijzonder DXMit135, gelegen op het distale deel van chromosoom X, bleek betrokken te zijn in 
epistatische interacties met loci op chromosoom 2 and 13, die allebei eveneens gedetecteerd werden 
via SIM analyse. Aangezien er waarschijnlijk epistatische interacties zijn tussen loci, voerden we een 
test uit om achtergrond QTLs te detecteren. Deze test heet ‘composite interval mapping’ (CIM). We 
vonden suggestieve linkage met een locus op chromosoom 12. De locus op chromosoom 12 zou een 
sensitiserende locus zijn. De locus op chromosoom 12 zou ook betrokken zijn in epistatische interacties 
met een locus op chromosoom 13. Een tekortkoming in dit werk is het genereren van dubbele consome 
muizen voor chromosoom 2 en chromosoom X. Chromosoom 2 en X zijn immers het sterkst gelinkt met 
de LPS-resistentie en er werden mogelijke epistatische effecten tussen deze chromosomen 
gedetecteerd via MapManager QTX. Echter, na 3,5 jaar te hebben getracht chromosoom X consome 
muizen te genereren, hebben we beslist om het identificeren van de LPS resistentiegenen via deze 
strategie te stoppen en geen 2-X-dubbel consome muizen te genereren. In plaats daarvan hebben we 
ons gefocust op een andere strategie. 
Door de spectaculaire resistentie van SPRET/Ei muizen tegen LPS en de hoge graad van genetisch 
polymorfisme tussen C57BL/6 en SPRET/Ei muizen, waren we van mening dat het identificeren van de 
LPS resistentiegenen redelijk gemakkelijk zou gaan. Op basis van de backcross data veronderstelden 
we dat de QTLs (gelinkt met de LPS-resistentie) gemakkelijk detecteerbaar zouden zijn en dat we 
tenminste gedeeltelijk het LPS-resistente fenotype zouden terugvinden in de consome muizen. In dit 
geval zou het vrij eenvoudig geweest zijn om tot een kritische regio komen met een beperkt aantal 
kandidaat-genen, door een tweede en grotere backcross op te starten tussen een LPS-resistente 
consome muis en een C57BL/6 muis. Desalniettemin was het backcross experiment een interessant 
werk en heeft het ons geleerd dat extreme fenotypes misschien helemaal afhankelijk zijn van interacties 
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tussen loci, zoals ook vroeger al was waargenomen door Dr. Jan Staelens tijdens zijn poging om de 
SPRET/Ei TNF resistentiegenen te klonen. 
 
Via een tweede aanpak trachtten we de moleculaire basis van de LPS-resistentie te identificeren door 
een in vitro model te gebruiken. De verminderde respons van SPRET/Ei muizen op LPS in vitro in 
macrofagen werd gebruikt om het mechanisme van de LPS-resistentie te bestuderen. LPS induceert 
een complex netwerk van signalisatie-moleculen wat leidt tot de inductie van verschillende genen. 
TLR4-stimulatie activeert de MyD88-afhankelijke pathway, wat tot vroege NF-κB and MAPK activatie 
leidt, en de TRIF-afhankelijke pathway, wat tot late NF-κB- en MAPK-activatie leidt alsook tot activatie 
van IRF-3 . LPS-geïnduceerde pro-inflammatoire gen-inductie (bvb. IL-6 en TNF) is afhankelijk van NF-
κB, maar ook van andere transcriptiefactoren zoals AP-1. AP-1 wordt geactiveerd door MAPK p38 en 
JNK. Fosforylatie en daaropvolgende degradatie van IκB resulteert in translocatie van NF-κB naar de 
nucleus. We hebben aangetoond dat de MyD88-afhankelijke pathway leidend tot IκB-degradatie intact 
is in SPRET/Ei BMDMs op vroege tijdstippen. We hebben ook aangetoond dat fosforylatie van de 
MAPK p38 en JNK normaal is. Daarenboven werd de intacte Myd88-afhankelijke signalisatie bevestigd 
doordat er geen significant verschil is tussen SPRET/Ei and C57BL/6 BMDMs in vroege IL-6 and TNF-
α mRNA expressie. Ook de LPS-geïnduceerde mRNA expressie van bvb. Il1a, Il1b, Il12a, Il12b, Bcl2, 
Birc4 (coderend voor XIAP) en Tnfaip3 (coderend voor A20) is niet significant verschillend tussen 
SPRET/Ei and C57BL/6 muizen. Dus, na 1 uur en na 4 uur van LPS-stimulatie is de IL-6 en TNF-α 
mRNA expressie normaal in SPRET/Ei muizen. In tegenstelling tot de normale vroege IL-6 en TNF-α 
mRNA expressie in SPRET/Ei BMDMs, zijn de in vivo niveaus van TNF-α (1 uur na LPS-injectie) en IL-
6 (3 uur na LPS-injectie) significant lager in SPRET/Ei muizen in vergelijking met C57BL/6 muizen. We 
moeten echter benadrukken dat een in vivo model veel complexer is dan een in vitro model. LPS kan 
verschillende celtypes activeren (bvb. macrofagen, DCs, neutrofielen en fibroblasten) om pro-
inflammatoire cytokines zoals TNF-α en IL-6 te produceren. Deze cytokines (bvb. IL-1) kunnen dan op 
hun beurt andere cellen activeren om ook IL-6 en TNF-α te produceren. 
Naast een vroege NF-κB activatie, kan TLR4 ook een late NF-κB en MAPK activatie induceren via de  
TRIF-afhankelijke pathway. De adaptor-molecule TRIF kan zowel TRAF6 als TBK1/IKK-ε naar zijn N-
terminaal domein recruteren. Het recruteren van TRAF6 leidt tot een tweede golf van pro-inflammatoire 
cytokines. TRIF -/- macrofagen vertonen een defecte TNF-α, IL-6 en IL-12p40 productie 24 uur na LPS-
stimulatie. Wij toonden aan dat de IL-6 expressie 24 uur na LPS-stimulatie defect is in SPRET/Ei MEFs 
in vergelijking met de IL-6 expressie in C57BL/6 MEFs. In hetzelfde experiment werd bevestigd dat de 
vroege IL-6 inductie (4 uur na LPS-stimulatie) normaal is. We kunnen dus concluderen dat de vroege 
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pro-inflammatoire gen-inductie intact is in SPRET/Ei cellen, terwijl de late (TRIF-afhankelijke) gen-
inductie defect is. 
We moeten er echter op wijzen dat IκB degradatie en fosforylatie van MAPK p38 en JNK niet 
noodzakelijk betekent dat de NF-κB en AP-1 activatie intact is, maar wel dat de stroomopwaartse 
signalisatiemoleculen in orde zijn. We zijn van plan de activatie van deze moleculen te bekijken via 
EMSA. Een andere mogelijke verklaring voor het defect in late IL-6 inductie zou kunnen zijn dat een 
anti-inflammatoir mechanisme overactief is in SPRET/Ei. In endotoxine-tolerantie, een transiënte staat 
van een verminderde respons op een tweede stimulatie van LPS, worden specifieke anti-inflammatoire 
mechanismen gebruikt, zoals de accumulatie van p50-p50 homodimeren of de inductie van signalisatie 
pathways zoals PI3K. Het zou bijvoorbeeld mogelijk kunnen zijn dat p50-p50 homodimeren worden 
gevormd, die transcriptioneel inactief zijn, in plaats van de transcriptioneel actieve p65-p50 
heterodimeren. Men heeft gezien dat in endotoxine-tolerantie de formatie van p50-p50 homodimeren 
leidt tot een daling van TNF-α niveaus. Een ander mechanisme om endotoxine-tolerantie te reguleren is 
de inductie van PI3K signalisatie. PI3K ligt op chromosoom 13 en kan TLR signalisatie inhiberen. Het 
onderliggende mechanisme hiervan is tot op heden nog niet gekend, maar de onderdrukking van p38, 
JNK1/2 en NF-κB signalisatie blijkt een rol te spelen. Dus kan misschien een of ander anti-inflammatoir 
mechanisme dat de pro-inflammatoire gen-expressie blokkeert, zoals de vorming van p50-p50 
homodimeren of de inductie van de PI3K signalisatie pathway, overactief zijn in SPRET/Ei muizen. Dit 
anti-inflammatoir mechanisme kan door NF-κB of AP-1 zelf geïnduceerd worden, aangezien IL-6 en 
TNF-α perfect wordt geïnduceerd in SPRET/Ei op vroege tijdstippen. 
 
LPS induceert de expressie van het Ifnb gen door middel van een MyD88-onafhankelijke, TRIF-
afhankelijke pathway (Yamamoto et al., 2002). Poly (I:C), een TLR3 ligand, activeert ook de TRIF-
afhankelijke pathway om IFN-β te induceren. Activatie van de TRIF-afhankelijke pathway leidt tot 
activatie van de transcriptie factor IRF-3, wat vervolgens resulteert in IFN-β inductie, STAT1 fosforylatie 
en translocatie, en inductie van STAT1-afhankelijke genen zoals IRF-7 (Yamamoto et al., 2003). We 
hebben aangetoond dat IFN-β mRNA inductie door LPS, maar ook door poly (I:C), grotendeels 
verhinderd was in SPRET/Ei BMDMs. Ten gevolge van deze defectieve IFN-β inductie, werd LPS-
geïnduceerde STAT1 fosforylatie en daaropvolgende nucleaire translocatie verhinderd. Een defect in de 
translocatie van STAT1 verhinderde op zijn beurt IRF-7 expressie. Het defect in IFN-β productie werd 
ook in vivo aangetoond na LPS en Influenza virus. IFN-β is ontdekt als een krachtige antivirale molecule 
(Isaacs and Lindenmann, 1957). Voor een lange tijd werd gedacht dat dit de enige functie was van type 
I IFN, maar in de laatste jaren is er een meer uitgebreide rol voor IFNs in immuniteit aangetoond. We 
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hebben de rol van IFN-β in de SPRET/Ei LPS-resistentie proberen aan te tonen alsook de gevolgen van 
de defectieve IFN-β inductie. Aangezien de LPS-resistentie van SPRET/Ei muizen ongedaan kan 
worden gemaakt door exogeen IFN-β toe te voegen, suggereert dit dat IFN-β een belangrijke rol speelt 
in de LPS-geïnduceerde letaliteit. Verwijdering van het Ifnb gen of van genen betrokken in de inductie 
van of in de respons op IFN-β leidt tot resistentie tegen endotoxemie (Karaghiosoff et al., 2003; 
Sakaguchi et al., 2003). Wijzelf hebben kunnen aantonen dat IFNAR1 knock-out muizen resistent zijn 
tegen een letale dosis LPS (wij zijn de eerste groep die dit konden publiceren), maar dat ze wel wel een 
serieuze daling in lichaamstemperatuur vertonen. In tegenstelling tot IFNAR1 knock-out muizen, 
vertonen SPRET/Ei muizen geen daling in lichaamstemperatuur na eenzelfde dosis LPS. Het lijkt erop 
dat andere genen dan het Ifnb gen nodig zijn om het volledige LPS-resistente fenotype te bekomen. Dit 
bevestigt de data van de ‘genome scan’ analysis die aantoonden dat de LPS-resistentie een complex 
kenmerk is. In samenwerking met Dr. Johan Grooten kunnen we macro-array filters, die ongeveer 500 
macrofaag-specifieke genen bevatten, gebruiken om de differentiële mRNA expressie te bestuderen 
tussen SPRET/Ei BMDMs en C57BL/6 BMDMs. We hebben al in een eerste experiment, 
gebruikmakend van deze filters met macrofaag-specifieke genen, aangetoond dat 6 uur na LPS-
stimulatie ongeveer 50 genen ≥ 2 maal sterker tot expressie komen en dat ongeveer 50 genen ≥ 2 
minder sterk tot expressie komen in SPRET/Ei BMDMs in vergelijking met C57BL/6 BMDMs. Deze 
differentiële expressie-studie zal herhaald worden met LPS, maar zal ook uitgevoerd worden met poly 
(I:C). We hopen tot een kleiner aantal kandidaat genen te komen (genen die differentieel tot expressie 
komen tussen SPRET/Ei en C57BL/6) door de data na LPS- en poly (I:C)-stimulatie te vergelijken en 
door meerdere tijdspunten te bestuderen Via het Bioinformatica programma ‘Difference Distance Matrix 
Analysis’ hopen we transcriptiefactoren/genen  te vinden die verantwoordelijk zouden kunnen zijn voor 
de differentiële expressie van SPRET/Ei genen.  
Het defect in IFN-β heeft zo zijn consequenties. Het is aangetoond dat IFN-β macrofagen kan 
sensitizeren voor celdood geïnduceerd door Listeria monocytogenes en dat het kan beschermen tegen 
progressieve leishmaniasis (Mattner et al., 2004; Stockinger et al., 2002). Waarschijnlijk door het defect 
in IFN-β zijn SPRET/Ei muizen inderdaad compleet resistent tegen Listeria monocytogenes en (BxS)F1 
muizen zijn erg gevoelig voor een Leishmania major infectie. We plannen ook om de respons van 
SPRET/Ei na te gaan voor virale infecties. Aangezien IFN-β een krachtige antivirale molecule is, 
verwachten we dat SPRET/Ei muizen zeer gevoelig zullen zijn voor virale infecties. Verschillende 
studies hebben een rol voor IFN-β gesuggereerd in LPS-geïnduceerde endotoxemie, maar zijn 
belangrijkheid in Gram-negatieve sepsis moet nog worden aangetoond. De eventuele voor- en nadelen 
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van het blokkeren van IFN-β of zijn receptoren in het behandelen van sepsis-patiënten wordt uitvoerig 
besproken in de review: ‘Must we inhibit type I IFNs in endotoxemia and sepsis?’ (Mahieu and Libert).   
 
Een belangrijk deel in dit werk was het ontrafelen van het mechanisme van de defectieve IFN-β 
inductie. Het defect kan op verschillende niveaus gelegen zijn: er kan een defect in de IFN-β promotor 
of in een van zijn regulatoren zijn, in een van de moleculen van de TRIF-afhankelijke pathway of in de 
positieve feedback lus na IFN-β signalisatie. Ten eerste hebben we de sequentie van de IFN-β 
promotor bestudeerd. We vonden echter geen variaties tussen C57BL/6 en SPRET/Ei muizen. Ten 
tweede zijn we de activatie van IRF-3 gaan bestuderen als een eindpunt van de TRIF-afhankelijke 
pathway. IFN-β inductie is afhankelijk van de fosforylatie/activatie van de transcriptie factor IRF-3. 
Daarom hebben we de sekwentie van de serine/threonine-cluster in het C-terminaal domein van IRF-3 
bepaald. Er werden geen variaties gevonden in de belangrijke serines van deze regio, maar we hebben 
wel enkele unieke aminozuur- veranderingen gevonden in SPRET/Ei muizen welke een invloed zouden 
kunnen hebben op de fosforylatie van IRF-3. Echter, ongeveer op hetzelfde moment toonden we aan 
dat IRF-3 gefosforyleerd wordt in SPRET/Ei BMDMs. Meer nog, Jin Mo Park, met wie we samenwerken, 
kon aantonen dat IRF-3 knock-out macrofagen na LPS stimulatie  een breder gendefect hebben (Ifnb, 
Rantes, Isg15 en Cxcl10) dan SPRET/Ei BMDMs  (Ifnb en Ccl5). Natuurlijk betekent een normale 
fosforylatie van IRF-3 niet noodzakelijk dat er IRF-3 dimeren worden gevormd of dat zijn co-factoren 
CBP/p300, of de trans-activatoren van CBP/p300, CITED1 en CITED2, normaal zijn in SPRET/Ei 
muizen. Een interessant gegeven is dat CITED1 en CITED2 respectievelijk op chromosoom X en 10 
liggen, twee chromosomen die gelinkt worden met de LPS-resistentie. Het is mogelijk dat een defecte of 
veranderde activatie van deze co-factoren de IRF-3 afhankelijke inductie van IFN-β kunnen veranderen. 
Meer nog, CBP/p300 blijkt ook een co-factor te zijn van de NF-κB component p65 (Gerritsen et al., 
1997). Misschien veroorzaakt een defect in CBP/p300 of in een van zijn trans-activatoren CITED1 en 
CITED2 zowel een defectieve IL-6 als IFN-β inductie. We zullen dus zeker kijken of er IRF-3 dimeren 
worden gevormd, of NF-κB en AP-1 activatie doorgaat en welke NF-κB dimeren gevormd worden op 
een vroeg en laat tijdstip na LPS-stimulatie. 
 
Een ander interessant gegeven is dat IFN-β mRNA stabiliteit post-transcriptioneel gereguleerd wordt 
door een AU-rijk element in de 3’UTR, en een tweede element (CRID element) in het 3’ eind van de 
coderende regio. Dusver hebben we de volledige sekwentie van het gehele Ifnb gen nog niet bepaald. 
We hebben ook nog niet zijn positieve/negatieve regulatoren bestudeerd zoals YY1, IRF-1 en IRF-2. 
Het spreekt vanzelf dat deze factoren verder onderzocht moeten worden. Verder is het ook interessant 
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om te weten dat de promotors van Ifnb en Ccl5 (coderend voor RANTES)  zowel een NF-κB als een 
IRF-3 PRD element bevatten. In dat geval kan de defectieve inductie van zowel het Ifnb gen als het 
Ccl5 gen te wijten zijn aan een defecte transactivatie van de transcriptiefactoren NF-κB en IRF-3. Dus, 
een anti-inflammatoir mechanisme dat NF-κB activatie verhindert, zoals de formatie van p50-p50 
homodimeren, of een defect in een van de co-factoren zoals CBP/p300 of CITED1/2, kan 
verantwoordelijk zijn voor zowel late pro-inflammatoire gen-inductie als voor defectieve IFN-β inductie. 
Door gebruik te maken van een specifiek Bioinformatica programma, zullen we op zoek gaan naar 
andere genen die ook zowel een NF-κB als een IRF-3 element in hun promotor hebben. Vervolgens 
zullen we hun expressie na LPS-stimulatie onderzoeken. 
 
De verminderde IFN-β inductie kan ook te wijten zijn aan een defect in de positieve feedback lus na 
IFN-β signalisatie. We hebben aangetoond dat OAS mRNA inductie, afhankelijk van de vorming van 
een STAT1/STAT2/IRF-9 complex na IFNAR stimulatie, significant lager is in SPRET/Ei BMDMs na 
IFN- of LPS-stimulatie. We hebben ook aangetoond dat IFNAR1 mRNA snel naar beneden  gereguleerd 
wordt in SPRET/Ei muizen na IFN-β stimulatie. Het mechanisme en de significantie van dit fenomeen is 
nog niet gekend. Hetzelfde werd aangetoond na LPS-stimulatie. Bovendien wordt significant minder IL-6 
geïnduceerd na IFN-stimulatie in SPRET/Ei BMDMs. Of het defect in OAS mRNA en IL-6 inductie na 
stimulatie met IFN-β gemedieerd wordt door regulatie naar beneden van IFNAR1 mRNA moet nog 
worden aangetoond. In de toekomst zullen we onderzoeken welk mechanisme instaat voor de down-
regulatie van IFNAR1. Ook zal de sekwentie en de expressie onderzocht worden van verschillende 
moleculen van de JAK-STAT pathway. Overexpressie van een negatieve regulator zou correleren met 
de dominantie van de LPS-resistentie. Daarom zou het ook interessant zijn om de negatieve regulatoren 
van de JAK-STAT pathway te bestuderen zoals SOCS, SHP en PIAS moleculen. 
 
Zoals gesuggereerd, zijn duidelijk andere genen dan Ifnb betrokken in de LPS-resistentie van SPRET/Ei 
muizen. Het is aangetoond dat IFN-β een brede set van chemokines kan induceren (Coelho et al., 
2005). Expressie van chemokines leidt tot migratie van leukocyten naar de inflammatoire locaties. 
Interessant genoeg hebben we gezien dat in LPS-geïnjecteerde SPRET/Ei muizen geen leukocyten 
migreren naar de alveoli en dat in longen en lever van LPS-geïnjecteerde SPRET/Ei muizen er zich 
minder leukocyten aan het endotheel van de bloedvaten hechten. Tevens hebben we ook in een 
preliminaire differentiële expressie- studie kunnen zien dat chemokines niet of veel minder worden 
geïnduceerd in SPRET/Ei BMDMs in vergelijking met C57BL/6 BMDMs na LPS-stimulatie. Dus, een 
mogelijke hypothese om de rol van IFN-β in LPS-geïnduceerde letaliteit te verklaren is de volgende (zie 
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figuur IV.1.1): Het defect in IFN-β inductie in SPRET/Ei muizen zou kunnen leiden tot een defectieve 
chemokine-productie. Dit defect in chemokine-productie leidt vervolgens tot een defectieve migratie van 
leukocyten naar de inflammatoire sites en tot een verminderde weefseldestructie. Na stimulatie van de 
IFNAR1 receptor door IFN-β wordt ook IL-6 geproduceerd. Het mechanisme van IFN-β-geïnduceerde 
IL-6 productie is nog niet gekend op dit moment. Dus, een combinatie van een defect in de late TRIF-
afhankelijke IL-6 geninductie en een defect in IFN-β-geïnduceerde IL-6 gen inductie leidt tot 
verminderde IL-6 niveaus. Pro-inflammatoire cytokines, zoals IL-6, kunnen ook direct op organen 
inwerken. Een defectieve IL-6 inductie zou dus ook kunnen leiden tot een verminderde 
weefseldestructie. 
 
Tenslotte hebben we ook de respons van SPRET/Ei muizen op andere TLR liganden getest. De LPS 
respons leidt hoofdzakelijk tot activatie van 2 pathways: de MyD88-afhankelijke en de MyD88-
onafhankelijke pathway. De meeste TLRs activeren slechts één pathway om een respons op 
pathogenen op te wekken, wat de respons minder complex maakt als de LPS-respons (Moynagh, 
2005). We hebben aangetoond dat LPS-geïnduceerde MyD88-afhankelijke signalisatie stroomopwaarts 
van IκB degradatie en MAPK activatie intact is. Dit suggereert dat er een normale MyD88-afhankelijke 
pathway is in SPRET/Ei muizen. LPS-geïnduceerde IL-6 gen-inductie op late tijdspunten is TRIF-
afhankelijk en gaat niet door in vitro in SPRET/Ei MEFs. MyD88 is de enige adaptor die door de IL-1R 
gerekruteerd wordt. TLR2 rekruteert de adaptor moleculen MyD88 en TIRAP. We hebben aangetoond 
dat stimulatie met liganden voor de IL-1R en TLR2 ook leidt tot een defectieve pro-inflammatoire gen-
inductie in vitro in SPRET/Ei muizen. Bovendien reageren SPRET/Ei muizen ook minder op IL-1-
geïnduceerde IL-6 inductie en op zymosan-geïnduceerde zwelling van de voetzool. 
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Figuur V.1.1. -  Mogelijk mechanisme om de rol van IFN-β in LPS-geïnduceerde letaliteit te verklaren. 
 
 
De defectieve inductie van pro-inflammatoire genen na verschillende TLR-liganden kan verklaard 
worden door een gemeenschappelijk mechanisme. Zoals hierboven beschreven, hebben we nog niet 
gekeken naar NF-κB en AP-1 activatie noch naar de compositie van de NF-κB dimeren na TLR-
stimulatie of naar co-activatoren zoals CBP/p300 en CITED1 en CITED2. Een andere mogelijke 
verklaring zou misschien een defect in de IRF-5 activatie kunnen zijn. Recent werd aangetoond dat alle 
TLRs niet enkel NF-κB, maar ook IRF-5 nodig hebben om pro-inflammatoire cytokines (bvb. TNF, IL-6 
en IL-12) te induceren (Napolitani et al., 2005). SPRET/Ei muizen reageren ook minder op poly (I:C) in 
vitro en zijn resistent tegen poly (I:C)/dGalN-geïnduceerde letaliteit. Poly (I:C) activeert enkel de TRIF-
afhankelijke pathway, wat het een minder complexe pathway maakt om te analyseren in vergelijking met 
de LPS respons. Hierdoor kunnen we in de toekomst ook poly (I:C) in plaats van LPS gebruiken om het 
mechanisme van de defectieve IFN-β inductie te onderzoeken.  
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Tot besluit wilden we in dit werk de LPS-resistentiegenen van SPRET/Ei muizen mappen en 
identificeren. Na beschrijving van de LPS-resistentie van SPRET/Ei muizen in detail hebben we 
geprobeerd de LPS-resistentiegenen te mappen via een genetische aanpak. Via deze strategie zijn we 
er niet in geslaagd regios te identificeren die klein genoeg zijn om tot een beperkt aantal 
kandidaatgenen te komen. Een andere strategie om het mechanisme van de LPS resistentie te 
onderzoeken was het gebruik van een in vitro model. Aangezien gedurende het onderzoek ongeveer de 
helft van de tijd geïnvesteerd werd in het typeren en screenen van muizen om de initiële backcross te 
vergroten en om consome muizen te maken, zijn de in vitro data in dit werk niet zo uitgebreid als we 
zouden willen. Het onderzoek wat in deze thesis gepresenteerd wordt, suggererend dat IFN-β een rol 
zou spelen in de LPS-resistentie van SPRET/Ei muizen, roept dus ook nog vele vragen op over de 
precieze oorzaak van de defecte IFN-β productie in SPRET/Ei muizen. Tenslotte realiseren we ons ook 
dat andere genen dan IFN-β betrokken zijn bij de verminderde respons van SPRET/Ei muizen op LPS 
en andere TLR-liganden. Het identificeren van deze genen en hun actiemechanisme is werk voor de 
toekomst. 
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Perspectieven 
 
In dit werk hebben we enkele interessante resultaten behaald betreffende de rol van IFN-β in LPS-
geïnduceerde shock. We hebben aangetoond dat SPRET/Ei muizen (met een defecte IFN-β productie) 
resistent zijn tegen LPS-geïnduceerde shock, en dat (BxS)F1 muizen gedeeltelijk beschermd zijn tegen 
een Gram-negatieve infectie. Echter, uit gegevens van onze genetische studies en van de experimenten 
met de IFNAR1 -/- muizen, weten we dat nog andere genen dan IFN-β betrokken zijn in de LPS-
resistentie van SPRET/Ei. Dus, het project over de LPS-resistentie van SPRET/Ei zal op twee niveaus 
worden voortgezet: 
 
1. LPS-resistentie genen van SPRET/Ei 
 
Volgende perspectieven werden bepaald: 
 
• Mechanisme van de defectieve IFN-β productie? 
We zullen onderzoeken of het defect in IFN-β productie veroorzaakt wordt door een defect in IRF-3 
door te kijken naar de sekwentie, dimerisatie en fosforylatie van IRF-3. We zullen ook andere 
mechanismen of moleculen meer in detail gaan onderzoeken, namelijk de afbraak van IFN-β mRNA 
en moleculen zoals SHIP, RIP1, CITED1 en CITED2. Een laatste item in deze context is het 
onderzoek naar de relevantie van de ‘down-regulation’ van IFNAR1. 
 
• Zijn andere genen belangrijk in de SPRET/Ei LPS-resistentie?   
We zullen onderzoeken of andere genen belangrijk zijn in de SPRET/Ei LPS-resistentie. Hiervoor 
zullen we zullen een differentiële expressie-studie van macrofaag specifieke genen na LPS en poly 
(I:C) doen 
 
• Gram–negatieve sepsis? 
We zullen SPRET/Ei en/of (BxS)F1 muizen testen op hun response op verschillende modellen van 
Gram-negatieve sepsis (Cecal Ligation and Puncture’ (CLP), Klebsiella pneumoniae en Salmonella 
typhimurium). Het grote probleem is de beperkte hoeveelheid beschikbare SPRET/Ei muizen, 
waardoor we dus vooral (BxS)F1 muizen zullen gebruiken.  
 
• Preliminaire experimenten doen ons vermoeden dat het SPRET/Ei fenotype ‘vergelijkbaar’ is met 
het constitutieve LPS-tolerante fenotype: kan dit ons nieuwe informatie opleveren? 
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2. SPRET/Ei heeft een defect in de IFN-β productie 
Volgende perspectieven werden bepaald: 
 
• Speelt IFN-β een belangrijke rol in sepsis? 
Dit zullen we onderzoeken door het gebruik van verschillende modellen: CLP, K.pneumiae, S. 
typhimurium, … Bovendien toonden Jo et al. aan dat het blokkeren van de type I IFN signalisatie 
therapeutische toekomst heeft voor de behandeling van endotoxemie. 
 
• Kan het blokkeren van type I IFN, of zijn stroomopwaartse of stroomneerwaartse mediatoren, 
bescherming bieden tegen LPS of Gram- sepsis? 
Dit zullen we onderzoeken via een IFN-β neutraliserend antilichaam in C57BL/6 muizen. Momenteel 
zijn we zo’n antilichaam in ons laboratorium aan het ontwikkelen. De vraag die zich hierbij opdringt 
is: ‘Kunnen we C57BL/6 muizen beschermen tegen LPS-geïnduceerde shock en sepis dmv 
toediening van dit IFN-β neutraliserend antilichaam?’. Een andere mogelijkheid is het toedienen van 
een antagonist van IFNAR1. 
Een nadeel zou echter kunnen zijn dat het blokkeren van IFN-β zal leiden tot een verhoogde 
vatbaarheid voor virale infecties (IFNAR1 -/- muizen  bijvoorbeeld zijn heel vatbaar voor virale 
infecties). 
 
We denken dus dat moleculen betrokken in type I IFN signalisatie, zoals IFN-β en IFNAR1, mogelijks 
nieuwe therapeutische doelwitten zijn in de behandeling van endotoxemie en sepsis. Dit kan echter 
alleen wanneer patiënten met sepsis niet supergevoelig worden voor virale infecties en wanneer de 
activatie van het immuunsysteem niet onderdrukt is. Misschien is het mogelijk om patiënten met sepsis 
te behandelen met agentia die IFN blokkeren of die type I IFN-signalisatie blokkeren gedurende een 
korte tijd onder gelimiteerde omstandigheden om virale infecties te verhinderen. 
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